[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fgdsP14XlSepq2fT_a_KJH7lJSmtHA66BRws2t7HBUJg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":87,"rows":94},"NYU Langone Health",[4],1385,false,303,39,858988,117,966,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Breast Cancer",36,{"name":18,"count":19},"Hypertension",34,{"name":21,"count":22},"Prostate Cancer",28,{"name":24,"count":25},"Multiple Sclerosis",26,{"name":27,"count":28},"Obesity",22,{"name":30,"count":31},"Epilepsy",21,{"name":33,"count":34},"Cardiovascular Diseases",19,{"name":36,"count":37},"Diabetes",16,[39,44,48,53,58,63,68,73,78,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT02621151","Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder","2022-11-10","Pembrolizumab",{"nctId":45,"briefTitle":46,"date":47,"intervention":43},"NCT02752685","Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer","2022-12-29",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03999749","A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma","2023-07-01","Ipilimumab",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT03971461","Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma","2025-04-18","Lutathera",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05678322","Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy","2025-05-08","18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05037123","Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain","2025-05-28","Continuous ketamine",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT03537586","A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction","2025-06-30","Bivalirudin",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT03667846","Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD","2025-08-31","Topiramate",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05984602","A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer","2025-09-01","Canakinumab",{"nctId":84,"briefTitle":85,"date":81,"intervention":86},"NCT04340752","Optimal Dosing of IC-Green for Visualization of Rotator Cuff Vascularity Using Advanced Imaging Modality Arthroscopy","Indocyanine Green",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,193,267,321,371,400,430,468,506,533,551,569,595,613,638,663,689,717,735,753,771,832,897,981,1008,1026,1044,1062,1085,1103,1128,1146,1166,1192,1273,1313,1410,1451,1489,1521,1551,1573,1621,1669,1695,1723,1837,1887,1916,1938,1963,1987,2011,2035,2060,2085,2109,2130,2148,2166,2190,2215,2233,2251,2269,2287,2305,2323,2341,2359,2377,2395,2413,2431,2449,2467,2485,2503,2521,2539,2557,2575,2593,2611,2637,2663,2681,2699,2722,2753,2787,2819,2872,2906,2928,2953,2971,2989,3014,3037,3084,3122,3140,3164,3182,3205,3294,3343,3377,3395,3413,3437,3461,3479,3504,3529,3553,3576,3641,3688,3720,3753,3787,3821,3855,3873,3891,3917,3940,3958,3976,4001,4024,4047,4070,4093,4118,4142,4160,4178,4196,4224,4242,4260,4285,4308,4334,4358,4383,4401,4427,4445,4467,4490,4518,4536,4554,4572,4590,4608,4626,4644,4662,4680,4705,4729,4754,4772,4796,4823,4841,4866,4884,4902,4927,4951,4969,4987,5014,5032,5050,5068,5091,5117,5135,5159,5177,5195,5217,5242,5260,5283,5301,5326,5344,5369,5396,5414,5438,5463,5486,5511,5529,5552,5578,5596,5619,5644,5662,5683,5706,5730,5756,5781,5799,5824,5842,5865,5888,5911,5938,5956,5974,5992,6017,6040,6058,6080,6103,6127,6151,6176,6194,6217,6240,6263,6291,6309,6327,6350,6368,6392,6418,6436,6454,6472,6498,6613,6684,6761,6813,6866,6912,6947,6980,7010,7040,7074,7100,7126,7152,7178,7205,7237,7264,7296,7318,7343,7376,7398,7420,7442,7468,7504,7526,7553,7575,7602,7624,7646,7664,7688,7711,7736,7760,7782,7807,7825,7843,7867,7889,7907,7930,7948,7966,7988,8013,8031,8054,8072,8090,8112,8136,8154,8177,8203,8221,8239,8263,8286,8304,8329,8351,8373,8391,8415,8433,8454,8477,8500,8521,8550,8568,8586,8604,8622,8640,8658,8680,8702,8720,8746,8771,8789,8815,8833,8851,8869,8892,8919,8937,8958,8980,9005,9023,9048,9073,9099,9117,9135,9153,9171,9189,9207,9225,9250,9268,9292,9310,9335,9353,9376,9399,9417,9435,9459,9482,9505,9529,9547,9570,9592,9610,9636,9657,9681,9707,9725,9743,9767,9792,9810,9828,9853,9871,9894,9920,9938,9956,9981,9999,10017,10042,10060,10083,10107,10125,10143,10161,10185,10203,10228,10246,10268,10291,10316,10339,10361,10387,10405,10430,10448,10474,10492,10510,10528,10546,10570,10588,10606,10624,10645,10663,10687,10705,10727,10748,10770,10794,10812,10833,10859,10877,10900,10924,10949,10967,10990,11012,11037,11055,11078,11101,11119,11143,11165,11194,11228,11256,11287,11320,11345,11363,11381,11406,11424,11447,11470,11492,11515,11533,11557,11579,11601,11623,11646,11672,11696,11720,11743,11769,11792,11810,11835,11853,11871,11896,11914,11932,11950,11975,12001,12019,12043,12061,12079,12103,12125,12149,12167,12185,12211,12229,12253,12271,12289,12313,12337,12355,12377,12401,12428,12446,12464,12482,12506,12528,12551,12578,12596,12614],{"intervention":52,"totalTrials":96,"cells":97},7,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":174,"PHASE4":176,"NA":191},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":173,"soonestReadout":51},[105,116,129,140,149,163],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"NCT01689974","Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma","TERMINATED",[90],"2015-03","2013-01",10,[114],"Metastatic Melanoma",[52],{"nctId":117,"briefTitle":118,"status":119,"phases":120,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":127},"NCT02970981","Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma","COMPLETED",[90],"2018-11","2022-05-02","2016-11-29",18,[126],"Melanoma",[128,52],"Nivolumab",{"nctId":130,"briefTitle":131,"status":119,"phases":132,"primaryCompletion":133,"completion":134,"start":135,"enrollment":112,"conditions":136,"interventions":139},"NCT03367715","Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma",[90],"2021-05-20","2022-03-17","2018-02-07",[137,138],"MGMT-unmethylated Glioblastoma (GBM)","GBM",[128,52],{"nctId":49,"briefTitle":50,"status":141,"phases":142,"primaryCompletion":51,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":147},"ACTIVE_NOT_RECRUITING",[90],"2030-04-07","2019-06-11",71,[126],[52,128,148],"Tocilizumab",{"nctId":150,"briefTitle":151,"status":152,"phases":153,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":160},"NCT05428007","Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma","RECRUITING",[90],"2026-08","2028-02","2023-02-02",105,[126,159],"Unresectable Melanoma",[161,52,162],"Sarilumab","Nivolumab\u002FRelatlimab",{"nctId":164,"briefTitle":165,"status":119,"phases":166,"primaryCompletion":167,"completion":168,"start":169,"enrollment":9,"conditions":170,"interventions":172},"NCT02221739","Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)",[89,90],"2015-04-15","2015-10-27","2014-07-01",[171],"Non-small Cell Lung Cancer (NSCLC)",[52],2,{"trials":175,"activeCount":100},[],{"trials":177,"activeCount":190,"soonestReadout":182},[178],{"nctId":179,"briefTitle":180,"status":152,"phases":181,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":188},"NCT07504796","ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab",[92],"2029-05","2031-05","2026-04-13",90,[114,187],"Advanced Melanoma",[128,189,52],"Relatlimab",1,{"trials":192,"activeCount":100},[],{"intervention":194,"totalTrials":195,"cells":196},"Guselkumab",3,{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":238,"PHASE4":240,"NA":253},{"trials":198,"activeCount":100},[],{"trials":200,"activeCount":100},[],{"trials":202,"activeCount":190,"soonestReadout":208},[203],{"nctId":204,"briefTitle":205,"status":206,"phases":207,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":213},"NCT07138898","Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","NOT_YET_RECRUITING",[90],"2027-09","2025-09",80,[212],"Rheumatic Disease",[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],"Methotrexate","Sulfasalazine","Hydroxychloroquine","Leflunomide","Azathioprine","Mycophenolate","Cyclosporine","Tacrolimus","Etanercept","Adalimumab","Golimumab","Certolizumab","Infliximab","Rituximab","Belimumab","Anakinra","Abatacept","Secukinumab","Ixekizumab","Bimekizumab","Ustekinumab","Risankizumab","Tofacitinib","Upadacitinib",{"trials":239,"activeCount":100},[],{"trials":241,"activeCount":190,"soonestReadout":246},[242],{"nctId":243,"briefTitle":244,"status":152,"phases":245,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":252},"NCT05004727","Multi-Center PAMPA Study",[92],"2026-12-31","2028-11-02","2022-02-16",176,[251],"Psoriasis",[194],{"trials":254,"activeCount":190,"soonestReadout":259},[255],{"nctId":256,"briefTitle":257,"status":206,"phases":258,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":266},"NCT07602517","Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis",[],"2028-05-20","2029-05-20","2026-05-20",75,[264,265],"Spondyloarthritis","Inflammatory Bowel Diseases",[194],{"intervention":128,"totalTrials":268,"cells":269},6,{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":285,"PHASE3":311,"PHASE4":313,"NA":319},{"trials":271,"activeCount":100},[],{"trials":273,"activeCount":100},[274],{"nctId":275,"briefTitle":276,"status":119,"phases":277,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":283},"NCT02983006","Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma",[89],"2019-12-23","2021-01-01","2016-10",12,[126],[284,128],"DS-8273a",{"trials":286,"activeCount":190,"soonestReadout":51},[287,291,303,307],{"nctId":117,"briefTitle":118,"status":119,"phases":288,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":289,"interventions":290},[90],[126],[128,52],{"nctId":292,"briefTitle":293,"status":294,"phases":295,"primaryCompletion":296,"completion":297,"start":298,"enrollment":100,"conditions":299,"interventions":301},"NCT03149120","Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas","WITHDRAWN",[90],"2017-08-17","2022-06","2017-08",[300],"Soft Tissue Sarcomas",[128,302],"Pazopanib",{"nctId":130,"briefTitle":131,"status":119,"phases":304,"primaryCompletion":133,"completion":134,"start":135,"enrollment":112,"conditions":305,"interventions":306},[90],[137,138],[128,52],{"nctId":49,"briefTitle":50,"status":141,"phases":308,"primaryCompletion":51,"completion":143,"start":144,"enrollment":145,"conditions":309,"interventions":310},[90],[126],[52,128,148],{"trials":312,"activeCount":100},[],{"trials":314,"activeCount":190,"soonestReadout":182},[315],{"nctId":179,"briefTitle":180,"status":152,"phases":316,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":317,"interventions":318},[92],[114,187],[128,189,52],{"trials":320,"activeCount":100},[],{"intervention":322,"totalTrials":195,"cells":323},"Saline",{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":341,"PHASE3":355,"PHASE4":357,"NA":369},{"trials":325,"activeCount":100},[],{"trials":327,"activeCount":190,"soonestReadout":332},[328],{"nctId":329,"briefTitle":330,"status":152,"phases":331,"primaryCompletion":332,"completion":333,"start":334,"enrollment":335,"conditions":336,"interventions":339},"NCT06455514","Post-CA Neuroprotection With Magnesium",[89],"2026-03-30","2026-06-30","2025-03-25",178,[337,338],"Cardiac Arrest","Return of Spontaneous Circulation",[340,322],"Magnesium Sulfate",{"trials":342,"activeCount":100},[343],{"nctId":344,"briefTitle":345,"status":119,"phases":346,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":353},"NCT03274453","A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion",[90],"2014-11-01","2017-09","2012-11-01",129,[352],"Spinal Fusion",[354,322],"Ketamine",{"trials":356,"activeCount":100},[],{"trials":358,"activeCount":190,"soonestReadout":333},[359],{"nctId":360,"briefTitle":361,"status":141,"phases":362,"primaryCompletion":333,"completion":333,"start":363,"enrollment":364,"conditions":365,"interventions":367},"NCT05391971","Effects of Stellate Ganglion Block in Post-traumatic Stress Disorder",[92],"2022-08-01",79,[366],"Post Traumatic Stress Disorder",[368,322],"Bupivacaine",{"trials":370,"activeCount":100},[],{"intervention":340,"totalTrials":173,"cells":372},{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":381,"PHASE3":383,"PHASE4":385,"NA":398},{"trials":374,"activeCount":100},[],{"trials":376,"activeCount":190,"soonestReadout":332},[377],{"nctId":329,"briefTitle":330,"status":152,"phases":378,"primaryCompletion":332,"completion":333,"start":334,"enrollment":335,"conditions":379,"interventions":380},[89],[337,338],[340,322],{"trials":382,"activeCount":100},[],{"trials":384,"activeCount":100},[],{"trials":386,"activeCount":190,"soonestReadout":391},[387],{"nctId":388,"briefTitle":389,"status":141,"phases":390,"primaryCompletion":391,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":396},"NCT06477133","Magnesium Sulfate as an Adjunctive Analgesic in Prostate Surgery",[92],"2026-06","2024-06-04",68,[395],"Prostatectomy",[397],"Magnesium sulfate",{"trials":399,"activeCount":100},[],{"intervention":368,"totalTrials":173,"cells":401},{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":408,"PHASE4":410,"NA":428},{"trials":403,"activeCount":100},[],{"trials":405,"activeCount":100},[],{"trials":407,"activeCount":100},[],{"trials":409,"activeCount":100},[],{"trials":411,"activeCount":190,"soonestReadout":333},[412,416],{"nctId":360,"briefTitle":361,"status":141,"phases":413,"primaryCompletion":333,"completion":333,"start":363,"enrollment":364,"conditions":414,"interventions":415},[92],[366],[368,322],{"nctId":417,"briefTitle":418,"status":119,"phases":419,"primaryCompletion":420,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":425},"NCT03693404","Effects of a Surgical Site Injection on Pain Scores and Narcotic Use After Orthopaedic Trauma Surgery",[92],"2021-06-05","2018-12-01",190,[424],"Pertrochanteric Fracture",[426,368,427],"Marcaine, Duramorph , ketorolac","General Anesthetics",{"trials":429,"activeCount":100},[],{"intervention":431,"totalTrials":173,"cells":432},"IPACK block",{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":439,"PHASE4":441,"NA":466},{"trials":434,"activeCount":100},[],{"trials":436,"activeCount":100},[],{"trials":438,"activeCount":100},[],{"trials":440,"activeCount":100},[],{"trials":442,"activeCount":190,"soonestReadout":458},[443,454],{"nctId":444,"briefTitle":445,"status":119,"phases":446,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":453},"NCT05286307","Adductor Canal Block and IPACK Block vs. Isolated Adductor Canal Block for Post-Operative Analgesia Following ACL Reconstruction With Bone Patellar Tendon Bone Autograft:",[92],"2023-03-31","2023-12-18","2022-07-11",102,[452],"Anterior Cruciate Ligament Rupture",[431],{"nctId":455,"briefTitle":456,"status":152,"phases":457,"primaryCompletion":458,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":464},"NCT06952556","Adductor Canal Block and IPACK Block vs. Isolated Adductor Canal Block for Post-Operative Analgesia Following HTO\u002FDFO\u002FTTO",[92],"2027-04-28","2027-06-28","2025-04-28",100,[463],"Analgesia",[465,431],"ACB",{"trials":467,"activeCount":100},[],{"intervention":469,"totalTrials":173,"cells":470},"Sublingual Buprenorphine",{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":477,"PHASE4":479,"NA":504},{"trials":472,"activeCount":100},[],{"trials":474,"activeCount":100},[],{"trials":476,"activeCount":100},[],{"trials":478,"activeCount":100},[],{"trials":480,"activeCount":190,"soonestReadout":496},[481,492],{"nctId":482,"briefTitle":483,"status":119,"phases":484,"primaryCompletion":485,"completion":485,"start":486,"enrollment":487,"conditions":488,"interventions":490},"NCT03604159","XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept",[92],"2020-05-04","2019-06-24",52,[489],"Opioid Dependence",[491,469],"Buprenorphine Extended Release",{"nctId":493,"briefTitle":494,"status":152,"phases":495,"primaryCompletion":496,"completion":497,"start":498,"enrollment":499,"conditions":500,"interventions":502},"NCT06051890","Assessing Optimal XRB Initiation Points in Jail",[92],"2026-12-01","2027-03-01","2025-06-02",200,[501],"Opioid Use Disorder",[503,469],"Extended-Release Buprenorphine",{"trials":505,"activeCount":100},[],{"intervention":503,"totalTrials":173,"cells":507},{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":514,"PHASE4":516,"NA":531},{"trials":509,"activeCount":100},[],{"trials":511,"activeCount":100},[],{"trials":513,"activeCount":100},[],{"trials":515,"activeCount":100},[],{"trials":517,"activeCount":190,"soonestReadout":496},[518,522],{"nctId":493,"briefTitle":494,"status":152,"phases":519,"primaryCompletion":496,"completion":497,"start":498,"enrollment":499,"conditions":520,"interventions":521},[92],[501],[503,469],{"nctId":523,"briefTitle":524,"status":294,"phases":525,"primaryCompletion":526,"completion":527,"start":528,"enrollment":100,"conditions":529,"interventions":530},"NCT05481112","Assessing Optimal XR-Buprenorphine Initiation Points in Jail",[92],"2025-11-01","2026-02-01","2023-11-01",[501],[503],{"trials":532,"activeCount":100},[],{"intervention":465,"totalTrials":190,"cells":534},{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":541,"PHASE4":543,"NA":549},{"trials":536,"activeCount":100},[],{"trials":538,"activeCount":100},[],{"trials":540,"activeCount":100},[],{"trials":542,"activeCount":100},[],{"trials":544,"activeCount":190,"soonestReadout":458},[545],{"nctId":455,"briefTitle":456,"status":152,"phases":546,"primaryCompletion":458,"completion":459,"start":460,"enrollment":461,"conditions":547,"interventions":548},[92],[463],[465,431],{"trials":550,"activeCount":100},[],{"intervention":189,"totalTrials":190,"cells":552},{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":559,"PHASE4":561,"NA":567},{"trials":554,"activeCount":100},[],{"trials":556,"activeCount":100},[],{"trials":558,"activeCount":100},[],{"trials":560,"activeCount":100},[],{"trials":562,"activeCount":190,"soonestReadout":182},[563],{"nctId":179,"briefTitle":180,"status":152,"phases":564,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":565,"interventions":566},[92],[114,187],[128,189,52],{"trials":568,"activeCount":100},[],{"intervention":570,"totalTrials":190,"cells":571},"CpG-adjuvanted HBV Vaccine",{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":578,"PHASE4":580,"NA":593},{"trials":573,"activeCount":100},[],{"trials":575,"activeCount":100},[],{"trials":577,"activeCount":100},[],{"trials":579,"activeCount":100},[],{"trials":581,"activeCount":190,"soonestReadout":586},[582],{"nctId":583,"briefTitle":584,"status":141,"phases":585,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":591},"NCT04674462","Understanding Poor Vaccine Responses to Hepatitis B Vaccination",[92],"2026-07","2022-07-07",101,[590],"Vaccine Reaction",[570,592],"Traditional HBV Vaccine",{"trials":594,"activeCount":100},[],{"intervention":592,"totalTrials":190,"cells":596},{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":603,"PHASE4":605,"NA":611},{"trials":598,"activeCount":100},[],{"trials":600,"activeCount":100},[],{"trials":602,"activeCount":100},[],{"trials":604,"activeCount":100},[],{"trials":606,"activeCount":190,"soonestReadout":586},[607],{"nctId":583,"briefTitle":584,"status":141,"phases":608,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":609,"interventions":610},[92],[590],[570,592],{"trials":612,"activeCount":100},[],{"intervention":614,"totalTrials":190,"cells":615},"Methylphenidate Hydrochloride Extended Release",{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":622,"PHASE4":624,"NA":636},{"trials":617,"activeCount":100},[],{"trials":619,"activeCount":100},[],{"trials":621,"activeCount":100},[],{"trials":623,"activeCount":100},[],{"trials":625,"activeCount":190,"soonestReadout":333},[626],{"nctId":627,"briefTitle":628,"status":152,"phases":629,"primaryCompletion":333,"completion":630,"start":631,"enrollment":632,"conditions":633,"interventions":635},"NCT06577779","An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening",[92],"2026-10-30","2025-01-29",30,[634],"Attention-deficit\u002FHyperactivity Disorder",[614],{"trials":637,"activeCount":100},[],{"intervention":639,"totalTrials":190,"cells":640},"Herpes Zoster Subunit (HZ\u002Fsu) Vaccine",{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":647,"PHASE4":649,"NA":661},{"trials":642,"activeCount":100},[],{"trials":644,"activeCount":100},[],{"trials":646,"activeCount":100},[],{"trials":648,"activeCount":100},[],{"trials":650,"activeCount":190,"soonestReadout":655},[651],{"nctId":652,"briefTitle":653,"status":152,"phases":654,"primaryCompletion":655,"completion":655,"start":656,"enrollment":657,"conditions":658,"interventions":660},"NCT05559671","Safety of the Herpes Zoster Subunit Vaccine in Lupus",[92],"2027-07-31","2023-12-21",224,[659],"Systemic Lupus Erythematosus",[639],{"trials":662,"activeCount":100},[],{"intervention":664,"totalTrials":190,"cells":665},"Escitalopram Oxalate",{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":672,"PHASE4":674,"NA":687},{"trials":667,"activeCount":100},[],{"trials":669,"activeCount":100},[],{"trials":671,"activeCount":100},[],{"trials":673,"activeCount":100},[],{"trials":675,"activeCount":190,"soonestReadout":246},[676],{"nctId":677,"briefTitle":678,"status":152,"phases":679,"primaryCompletion":246,"completion":680,"start":681,"enrollment":682,"conditions":683,"interventions":686},"NCT05004987","Aβ Dynamics in LLMD",[92],"2027-06-30","2022-02-04",60,[684,685],"Alzheimer Disease","Major Depressive Disorder",[664],{"trials":688,"activeCount":100},[],{"intervention":690,"totalTrials":190,"cells":691},"Evolocumab Cartridge",{"EARLY_PHASE1":692,"PHASE1":694,"PHASE2":696,"PHASE3":698,"PHASE4":700,"NA":715},{"trials":693,"activeCount":100},[],{"trials":695,"activeCount":100},[],{"trials":697,"activeCount":100},[],{"trials":699,"activeCount":100},[],{"trials":701,"activeCount":190,"soonestReadout":706},[702],{"nctId":703,"briefTitle":704,"status":152,"phases":705,"primaryCompletion":706,"completion":655,"start":707,"enrollment":708,"conditions":709,"interventions":711},"NCT05641753","Cholesterol Lowering and Residual Risk in Diabetes, Type 1",[92],"2027-07-01","2022-12-06",125,[710],"Type 1 Diabetes",[690,712,713,714],"Atorvastatin Calcium","Ezetimibe","18F-FDG",{"trials":716,"activeCount":100},[],{"intervention":712,"totalTrials":190,"cells":718},{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":725,"PHASE4":727,"NA":733},{"trials":720,"activeCount":100},[],{"trials":722,"activeCount":100},[],{"trials":724,"activeCount":100},[],{"trials":726,"activeCount":100},[],{"trials":728,"activeCount":190,"soonestReadout":706},[729],{"nctId":703,"briefTitle":704,"status":152,"phases":730,"primaryCompletion":706,"completion":655,"start":707,"enrollment":708,"conditions":731,"interventions":732},[92],[710],[690,712,713,714],{"trials":734,"activeCount":100},[],{"intervention":713,"totalTrials":190,"cells":736},{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":745,"NA":751},{"trials":738,"activeCount":100},[],{"trials":740,"activeCount":100},[],{"trials":742,"activeCount":100},[],{"trials":744,"activeCount":100},[],{"trials":746,"activeCount":190,"soonestReadout":706},[747],{"nctId":703,"briefTitle":704,"status":152,"phases":748,"primaryCompletion":706,"completion":655,"start":707,"enrollment":708,"conditions":749,"interventions":750},[92],[710],[690,712,713,714],{"trials":752,"activeCount":100},[],{"intervention":714,"totalTrials":190,"cells":754},{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":761,"PHASE4":763,"NA":769},{"trials":756,"activeCount":100},[],{"trials":758,"activeCount":100},[],{"trials":760,"activeCount":100},[],{"trials":762,"activeCount":100},[],{"trials":764,"activeCount":190,"soonestReadout":706},[765],{"nctId":703,"briefTitle":704,"status":152,"phases":766,"primaryCompletion":706,"completion":655,"start":707,"enrollment":708,"conditions":767,"interventions":768},[92],[710],[690,712,713,714],{"trials":770,"activeCount":100},[],{"intervention":216,"totalTrials":772,"cells":773},5,{"EARLY_PHASE1":774,"PHASE1":776,"PHASE2":778,"PHASE3":816,"PHASE4":828,"NA":830},{"trials":775,"activeCount":100},[],{"trials":777,"activeCount":100},[],{"trials":779,"activeCount":190,"soonestReadout":208},[780,790,800,812],{"nctId":781,"briefTitle":782,"status":108,"phases":783,"primaryCompletion":784,"completion":784,"start":785,"enrollment":786,"conditions":787,"interventions":789},"NCT04369742","Treating COVID-19 With Hydroxychloroquine (TEACH)",[90],"2021-04-01","2020-04-15",128,[788],"COVID-19",[216],{"nctId":791,"briefTitle":792,"status":119,"phases":793,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":798,"interventions":799},"NCT04354870","COVID-19 PrEP HCW HCQ Study",[90],"2020-09-15","2020-10-01","2020-04-03",130,[788],[216],{"nctId":801,"briefTitle":802,"status":119,"phases":803,"primaryCompletion":804,"completion":804,"start":805,"enrollment":806,"conditions":807,"interventions":811},"NCT01379573","Preventive Approach to Congenital Heart Block With Hydroxychloroquine",[90],"2020-07-16","2011-01-01",74,[808,809,810],"Congenital Heart Block","Neonatal Lupus","Autoantibody-Associated Heart Block",[216],{"nctId":204,"briefTitle":205,"status":206,"phases":813,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":814,"interventions":815},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":817,"activeCount":190,"soonestReadout":822},[818],{"nctId":819,"briefTitle":820,"status":152,"phases":821,"primaryCompletion":822,"completion":823,"start":824,"enrollment":825,"conditions":826,"interventions":827},"NCT05799378","Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease",[91],"2028-12-31","2029-06-30","2024-06-27",330,[659],[216],{"trials":829,"activeCount":100},[],{"trials":831,"activeCount":100},[],{"intervention":833,"totalTrials":772,"cells":834},"Cannabidiol",{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":882,"PHASE4":893,"NA":895},{"trials":836,"activeCount":100},[],{"trials":838,"activeCount":100},[],{"trials":840,"activeCount":190,"soonestReadout":876},[841,852,862,872],{"nctId":842,"briefTitle":843,"status":119,"phases":844,"primaryCompletion":845,"completion":845,"start":846,"enrollment":847,"conditions":848,"interventions":850},"NCT03248167","Cannabidiol as a Treatment for AUD Comorbid With PTSD",[89,90],"2022-04-20","2019-09-16",95,[849,366],"Alcohol Use Disorder",[833,851],"Placebos",{"nctId":853,"briefTitle":854,"status":119,"phases":855,"primaryCompletion":856,"completion":857,"start":858,"enrollment":682,"conditions":859,"interventions":861},"NCT05571592","Cannabidiol as a Treatment for Social Anxiety Disorder (R61)",[90],"2025-11-26","2025-12-03","2023-01-26",[860],"Social Anxiety Disorder",[833],{"nctId":863,"briefTitle":864,"status":119,"phases":865,"primaryCompletion":866,"completion":866,"start":867,"enrollment":868,"conditions":869,"interventions":871},"NCT04760613","CBD for Chronic Radicular Pain on Chronic Opioid Therapy (COT)",[89,90],"2023-06-07","2022-02-03",14,[870],"Radiculopathy",[833],{"nctId":873,"briefTitle":874,"status":152,"phases":875,"primaryCompletion":876,"completion":391,"start":877,"enrollment":878,"conditions":879,"interventions":881},"NCT04550377","Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI",[90],"2026-03","2021-05-26",120,[366,880],"Traumatic Brain Injury",[833],{"trials":883,"activeCount":190,"soonestReadout":888},[884],{"nctId":885,"briefTitle":886,"status":152,"phases":887,"primaryCompletion":888,"completion":888,"start":889,"enrollment":461,"conditions":890,"interventions":892},"NCT05020028","Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis",[90,91],"2026-09","2022-06-22",[891],"Knee Arthritis",[833],{"trials":894,"activeCount":100},[],{"trials":896,"activeCount":100},[],{"intervention":898,"totalTrials":268,"cells":899},"Dexamethasone",{"EARLY_PHASE1":900,"PHASE1":902,"PHASE2":913,"PHASE3":927,"PHASE4":966,"NA":979},{"trials":901,"activeCount":100},[],{"trials":903,"activeCount":100},[904],{"nctId":905,"briefTitle":906,"status":294,"phases":907,"primaryCompletion":908,"completion":908,"start":909,"enrollment":100,"conditions":910,"interventions":912},"NCT02753166","Dexamethasone as an Immediate Intervention",[89],"2017-12-12","2017-01",[911],"Trauma",[898],{"trials":914,"activeCount":100},[915],{"nctId":916,"briefTitle":917,"status":108,"phases":918,"primaryCompletion":919,"completion":919,"start":920,"enrollment":921,"conditions":922,"interventions":924},"NCT00843310","Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma",[90],"2011-10","2008-11",8,[923],"Multiple Myeloma",[925,926,898],"Lenalidomide","Melphalan",{"trials":928,"activeCount":190,"soonestReadout":822},[929,940,950],{"nctId":930,"briefTitle":931,"status":152,"phases":932,"primaryCompletion":822,"completion":823,"start":933,"enrollment":934,"conditions":935,"interventions":938},"NCT04474223","Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)",[91],"2020-08-01",1300,[936,937],"AVB - Atrioventricular Block","Fetal AVB",[898,939],"IVIG",{"nctId":941,"briefTitle":942,"status":108,"phases":943,"primaryCompletion":944,"completion":944,"start":945,"enrollment":946,"conditions":947,"interventions":949},"NCT02266797","Effect of Intravenous Corticosteroid Injections on Dysphagia After Cervical Spine Surgery",[91],"2015-09-01","2013-11",4,[948],"Dysphagia After Anterior Cervical Decompression and Fusion of the Spine",[898],{"nctId":951,"briefTitle":952,"status":108,"phases":953,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":957,"interventions":964},"NCT02266433","Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders",[91],"2018-07-01","2012-08",245,[958,959,960,961,962,963],"DeQuervains Tenosynovitis","Lateral Epicondylitis","Tennis Elbow","Trigger Finger","Tenosynovitis","Inflammatory Disease",[965,898],"Ketorolac",{"trials":967,"activeCount":100},[968],{"nctId":969,"briefTitle":970,"status":108,"phases":971,"primaryCompletion":972,"completion":973,"start":974,"enrollment":946,"conditions":975,"interventions":977},"NCT04126278","Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection",[92],"2022-08-12","2022-08-23","2020-12-01",[976],"Calcific Tendinitis",[978,898],"Barbotage",{"trials":980,"activeCount":100},[],{"intervention":982,"totalTrials":190,"cells":983},"Nicotine Replacement Therapy Agent - Patches",{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":988,"PHASE3":990,"PHASE4":1004,"NA":1006},{"trials":985,"activeCount":100},[],{"trials":987,"activeCount":100},[],{"trials":989,"activeCount":100},[],{"trials":991,"activeCount":190,"soonestReadout":996},[992],{"nctId":993,"briefTitle":994,"status":152,"phases":995,"primaryCompletion":996,"completion":996,"start":997,"enrollment":998,"conditions":999,"interventions":1001},"NCT05154669","Integrating Financial Coaching and Smoking Cessation Coaching",[91],"2029-12-01","2022-12-08",602,[1000],"Smoking",[982,1002,1003],"Nicotine Replacement Therapy Agent - Lozenges","Nicotine Replacement Therapy Agent - Gum",{"trials":1005,"activeCount":100},[],{"trials":1007,"activeCount":100},[],{"intervention":1002,"totalTrials":190,"cells":1009},{"EARLY_PHASE1":1010,"PHASE1":1012,"PHASE2":1014,"PHASE3":1016,"PHASE4":1022,"NA":1024},{"trials":1011,"activeCount":100},[],{"trials":1013,"activeCount":100},[],{"trials":1015,"activeCount":100},[],{"trials":1017,"activeCount":190,"soonestReadout":996},[1018],{"nctId":993,"briefTitle":994,"status":152,"phases":1019,"primaryCompletion":996,"completion":996,"start":997,"enrollment":998,"conditions":1020,"interventions":1021},[91],[1000],[982,1002,1003],{"trials":1023,"activeCount":100},[],{"trials":1025,"activeCount":100},[],{"intervention":1003,"totalTrials":190,"cells":1027},{"EARLY_PHASE1":1028,"PHASE1":1030,"PHASE2":1032,"PHASE3":1034,"PHASE4":1040,"NA":1042},{"trials":1029,"activeCount":100},[],{"trials":1031,"activeCount":100},[],{"trials":1033,"activeCount":100},[],{"trials":1035,"activeCount":190,"soonestReadout":996},[1036],{"nctId":993,"briefTitle":994,"status":152,"phases":1037,"primaryCompletion":996,"completion":996,"start":997,"enrollment":998,"conditions":1038,"interventions":1039},[91],[1000],[982,1002,1003],{"trials":1041,"activeCount":100},[],{"trials":1043,"activeCount":100},[],{"intervention":939,"totalTrials":190,"cells":1045},{"EARLY_PHASE1":1046,"PHASE1":1048,"PHASE2":1050,"PHASE3":1052,"PHASE4":1058,"NA":1060},{"trials":1047,"activeCount":100},[],{"trials":1049,"activeCount":100},[],{"trials":1051,"activeCount":100},[],{"trials":1053,"activeCount":190,"soonestReadout":822},[1054],{"nctId":930,"briefTitle":931,"status":152,"phases":1055,"primaryCompletion":822,"completion":823,"start":933,"enrollment":934,"conditions":1056,"interventions":1057},[91],[936,937],[898,939],{"trials":1059,"activeCount":100},[],{"trials":1061,"activeCount":100},[],{"intervention":67,"totalTrials":190,"cells":1063},{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1068,"PHASE3":1070,"PHASE4":1081,"NA":1083},{"trials":1065,"activeCount":100},[],{"trials":1067,"activeCount":100},[],{"trials":1069,"activeCount":100},[],{"trials":1071,"activeCount":190,"soonestReadout":66},[1072],{"nctId":64,"briefTitle":65,"status":141,"phases":1073,"primaryCompletion":66,"completion":1074,"start":1075,"enrollment":1076,"conditions":1077,"interventions":1079},[91],"2026-08-31","2022-01-04",765,[1078],"Chronic Postsurgical Pain",[67,1080],"Ketamine + Saline",{"trials":1082,"activeCount":100},[],{"trials":1084,"activeCount":100},[],{"intervention":1080,"totalTrials":190,"cells":1086},{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1093,"PHASE4":1099,"NA":1101},{"trials":1088,"activeCount":100},[],{"trials":1090,"activeCount":100},[],{"trials":1092,"activeCount":100},[],{"trials":1094,"activeCount":190,"soonestReadout":66},[1095],{"nctId":64,"briefTitle":65,"status":141,"phases":1096,"primaryCompletion":66,"completion":1074,"start":1075,"enrollment":1076,"conditions":1097,"interventions":1098},[91],[1078],[67,1080],{"trials":1100,"activeCount":100},[],{"trials":1102,"activeCount":100},[],{"intervention":1104,"totalTrials":190,"cells":1105},"Psilocybin 25 mgs",{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1112,"PHASE4":1124,"NA":1126},{"trials":1107,"activeCount":100},[],{"trials":1109,"activeCount":100},[],{"trials":1111,"activeCount":100},[],{"trials":1113,"activeCount":190,"soonestReadout":1118},[1114],{"nctId":1115,"briefTitle":1116,"status":152,"phases":1117,"primaryCompletion":1118,"completion":1118,"start":1119,"enrollment":499,"conditions":1120,"interventions":1122},"NCT05398484","Psilocybin Therapy in Advanced Cancer",[90,91],"2027-01-01","2023-05-24",[1121],"Advanced Cancer",[1104,1123],"Niacin 100mg",{"trials":1125,"activeCount":100},[],{"trials":1127,"activeCount":100},[],{"intervention":1123,"totalTrials":190,"cells":1129},{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1136,"PHASE4":1142,"NA":1144},{"trials":1131,"activeCount":100},[],{"trials":1133,"activeCount":100},[],{"trials":1135,"activeCount":100},[],{"trials":1137,"activeCount":190,"soonestReadout":1118},[1138],{"nctId":1115,"briefTitle":1116,"status":152,"phases":1139,"primaryCompletion":1118,"completion":1118,"start":1119,"enrollment":499,"conditions":1140,"interventions":1141},[90,91],[1121],[1104,1123],{"trials":1143,"activeCount":100},[],{"trials":1145,"activeCount":100},[],{"intervention":62,"totalTrials":190,"cells":1147},{"EARLY_PHASE1":1148,"PHASE1":1150,"PHASE2":1152,"PHASE3":1154,"PHASE4":1162,"NA":1164},{"trials":1149,"activeCount":100},[],{"trials":1151,"activeCount":100},[],{"trials":1153,"activeCount":100},[],{"trials":1155,"activeCount":190,"soonestReadout":61},[1156],{"nctId":59,"briefTitle":60,"status":141,"phases":1157,"primaryCompletion":61,"completion":1158,"start":1159,"enrollment":25,"conditions":1160,"interventions":1161},[91],"2026-11","2023-01-31",[21],[62],{"trials":1163,"activeCount":100},[],{"trials":1165,"activeCount":100},[],{"intervention":1167,"totalTrials":190,"cells":1168},"Anticoagulant Therapy",{"EARLY_PHASE1":1169,"PHASE1":1171,"PHASE2":1173,"PHASE3":1175,"PHASE4":1188,"NA":1190},{"trials":1170,"activeCount":100},[],{"trials":1172,"activeCount":100},[],{"trials":1174,"activeCount":100},[],{"trials":1176,"activeCount":190,"soonestReadout":1181},[1177],{"nctId":1178,"briefTitle":1179,"status":152,"phases":1180,"primaryCompletion":1181,"completion":1182,"start":1183,"enrollment":1184,"conditions":1185,"interventions":1187},"NCT05591118","Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy",[91],"2027-03-29","2027-08-04","2023-07-17",500,[1186],"Pulmonary Embolism",[1167],{"trials":1189,"activeCount":100},[],{"trials":1191,"activeCount":100},[],{"intervention":1193,"totalTrials":96,"cells":1194},"Psilocybin",{"EARLY_PHASE1":1195,"PHASE1":1208,"PHASE2":1229,"PHASE3":1267,"PHASE4":1269,"NA":1271},{"trials":1196,"activeCount":100},[1197],{"nctId":1198,"briefTitle":1199,"status":119,"phases":1200,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":1203,"conditions":1204,"interventions":1206},"NCT00957359","Psilocybin Cancer Anxiety Study",[88],"2018-09-06","2009-02",29,[1205],"Cancer",[1193,1207],"Niacin",{"trials":1209,"activeCount":190,"soonestReadout":1223},[1210,1219],{"nctId":1211,"briefTitle":1212,"status":119,"phases":1213,"primaryCompletion":1214,"completion":1214,"start":1215,"enrollment":281,"conditions":1216,"interventions":1218},"NCT02421263","The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals",[89],"2020-06-05","2015-04",[1217],"Religious or Spiritual Problem",[1193],{"nctId":1220,"briefTitle":1221,"status":206,"phases":1222,"primaryCompletion":1223,"completion":1224,"start":586,"enrollment":185,"conditions":1225,"interventions":1228},"NCT07607938","Psilocybin as a Novel Therapy for Residual Anhedonia",[89],"2030-08-01","2030-09-30",[1226,1227],"Anhedonia","Emotional Blunting",[1193],{"trials":1230,"activeCount":195,"soonestReadout":1244},[1231,1240,1250,1257],{"nctId":1232,"briefTitle":1233,"status":152,"phases":1234,"primaryCompletion":1235,"completion":1235,"start":1236,"enrollment":1237,"conditions":1238,"interventions":1239},"NCT06796062","Psilocybin for Opioid Use Disorder (OUD)",[90],"2029-02","2025-12-17",480,[501],[1193],{"nctId":1241,"briefTitle":1242,"status":206,"phases":1243,"primaryCompletion":1244,"completion":1244,"start":1245,"enrollment":1246,"conditions":1247,"interventions":1249},"NCT07296328","Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter",[90],"2027-04-01","2026-01-15",25,[1248],"Stuttering",[1193],{"nctId":1251,"briefTitle":1252,"status":152,"phases":1253,"primaryCompletion":182,"completion":182,"start":1254,"enrollment":499,"conditions":1255,"interventions":1256},"NCT06349083","Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD",[90],"2025-08-26",[849],[1193],{"nctId":1258,"briefTitle":1259,"status":119,"phases":1260,"primaryCompletion":1261,"completion":1261,"start":1262,"enrollment":847,"conditions":1263,"interventions":1265},"NCT02061293","A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence",[90],"2021-07-30","2014-06",[1264],"Alcohol Dependence",[1193,1266],"Diphenhydramine",{"trials":1268,"activeCount":100},[],{"trials":1270,"activeCount":100},[],{"trials":1272,"activeCount":100},[],{"intervention":221,"totalTrials":195,"cells":1274},{"EARLY_PHASE1":1275,"PHASE1":1277,"PHASE2":1279,"PHASE3":1307,"PHASE4":1309,"NA":1311},{"trials":1276,"activeCount":100},[],{"trials":1278,"activeCount":100},[],{"trials":1280,"activeCount":195,"soonestReadout":888},[1281,1292,1296],{"nctId":1282,"briefTitle":1283,"status":141,"phases":1284,"primaryCompletion":1285,"completion":1285,"start":1286,"enrollment":1287,"conditions":1288,"interventions":1290},"NCT05621759","Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD",[90],"2027-01-30","2022-09-07",27,[1289],"Graft Vs Host Disease",[1291,230,221],"Cyclophosphamide",{"nctId":204,"briefTitle":205,"status":206,"phases":1293,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":1294,"interventions":1295},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"nctId":1297,"briefTitle":1298,"status":152,"phases":1299,"primaryCompletion":888,"completion":888,"start":1300,"enrollment":281,"conditions":1301,"interventions":1303},"NCT04477629","Belatacept in De Novo Heart Transplantation",[90],"2020-08-06",[1302],"Heart Transplantation",[1304,221,1305,1306],"Belatacept","Mycophenolate Mofetil","Corticosteroid",{"trials":1308,"activeCount":100},[],{"trials":1310,"activeCount":100},[],{"trials":1312,"activeCount":100},[],{"intervention":43,"totalTrials":921,"cells":1314},{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1319,"PHASE3":1393,"PHASE4":1395,"NA":1408},{"trials":1316,"activeCount":100},[],{"trials":1318,"activeCount":100},[],{"trials":1320,"activeCount":173,"soonestReadout":42},[1321,1329,1341,1352,1365,1372,1383],{"nctId":40,"briefTitle":41,"status":141,"phases":1322,"primaryCompletion":42,"completion":1323,"start":1324,"enrollment":682,"conditions":1325,"interventions":1327},[90],"2025-12","2016-08-11",[1326],"Muscle-invasive Urothelial Cancer of the Bladder",[43,1328],"Gemcitabine",{"nctId":1330,"briefTitle":1331,"status":108,"phases":1332,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":772,"conditions":1335,"interventions":1337},"NCT02934503","Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)",[90],"2019-10-01","2017-01-23",[1336],"Small Cell Lung Cancer (SCLC)",[43,1338,1339,1340],"Cisplatin","Carboplatin","Etoposide",{"nctId":1342,"briefTitle":1343,"status":108,"phases":1344,"primaryCompletion":1345,"completion":1346,"start":1347,"enrollment":34,"conditions":1348,"interventions":1350},"NCT05691829","Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC",[90],"2024-06-20","2025-04-21","2023-01-24",[1349],"NSCLC Stage IV",[43,1351],"Chemotherapy",{"nctId":1353,"briefTitle":1354,"status":119,"phases":1355,"primaryCompletion":1356,"completion":1357,"start":1358,"enrollment":1359,"conditions":1360,"interventions":1363},"NCT03321630","A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies",[90],"2023-03-10","2024-01-16","2017-10-24",24,[1361,1362],"GastroEsophageal Cancer","Gastric Cancer",[1364,43],"Lenvatinib",{"nctId":45,"briefTitle":46,"status":141,"phases":1366,"primaryCompletion":47,"completion":1323,"start":1367,"enrollment":1368,"conditions":1369,"interventions":1370},[90],"2016-06",70,[15],[43,1371],"Nab-Paclitaxel",{"nctId":1373,"briefTitle":1374,"status":294,"phases":1375,"primaryCompletion":1376,"completion":1377,"start":1378,"enrollment":100,"conditions":1379,"interventions":1381},"NCT04016116","Dual PD-1 and JAK2 Inhibition in Hematological Malignancies",[90],"2020-12","2021-12","2019-12",[1205,1380],"Hematological Malignancy",[43,1382],"Ruxolitinib",{"nctId":1384,"briefTitle":1385,"status":108,"phases":1386,"primaryCompletion":1387,"completion":1387,"start":1388,"enrollment":268,"conditions":1389,"interventions":1392},"NCT02875067","Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma",[89,90],"2017-10-02","2016-08-29",[1390,1391],"Relapsed Hodgkin Lymphoma","Relapsed Non-Hodgkin Lymphoma",[43,925],{"trials":1394,"activeCount":100},[],{"trials":1396,"activeCount":100},[1397],{"nctId":1398,"briefTitle":1399,"status":294,"phases":1400,"primaryCompletion":1401,"completion":1401,"start":1402,"enrollment":100,"conditions":1403,"interventions":1405},"NCT03891979","Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma",[92],"2020-06-01","2019-06-25",[1404],"Pancreatic Cancer",[43,1406,1407],"Ciprofloxacin 500mg PO BID days 1-29","Metronidazole 500mg PO TID days 1-29",{"trials":1409,"activeCount":100},[],{"intervention":230,"totalTrials":946,"cells":1411},{"EARLY_PHASE1":1412,"PHASE1":1423,"PHASE2":1425,"PHASE3":1435,"PHASE4":1437,"NA":1449},{"trials":1413,"activeCount":100},[1414],{"nctId":1415,"briefTitle":1416,"status":119,"phases":1417,"primaryCompletion":1418,"completion":1418,"start":1419,"enrollment":195,"conditions":1420,"interventions":1422},"NCT01693640","A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome",[88],"2018-12-28","2012-06",[1421],"Female Patients With Behcet's Syndrome",[230],{"trials":1424,"activeCount":100},[],{"trials":1426,"activeCount":173,"soonestReadout":1285},[1427,1431],{"nctId":1282,"briefTitle":1283,"status":141,"phases":1428,"primaryCompletion":1285,"completion":1285,"start":1286,"enrollment":1287,"conditions":1429,"interventions":1430},[90],[1289],[1291,230,221],{"nctId":204,"briefTitle":205,"status":206,"phases":1432,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":1433,"interventions":1434},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":1436,"activeCount":100},[],{"trials":1438,"activeCount":100},[1439],{"nctId":1440,"briefTitle":1441,"status":119,"phases":1442,"primaryCompletion":1443,"completion":1443,"start":1444,"enrollment":1246,"conditions":1445,"interventions":1447},"NCT03652961","Rheumatoid Arthritis Memory B Cells and Abatacept",[92],"2021-09-27","2019-06-02",[1446],"Rheumatoid Arthritis",[230,1448],"DMARDs",{"trials":1450,"activeCount":100},[],{"intervention":1328,"totalTrials":195,"cells":1452},{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1465,"PHASE3":1483,"PHASE4":1485,"NA":1487},{"trials":1454,"activeCount":100},[],{"trials":1456,"activeCount":190,"soonestReadout":81},[1457],{"nctId":79,"briefTitle":80,"status":141,"phases":1458,"primaryCompletion":81,"completion":1459,"start":1460,"enrollment":1461,"conditions":1462,"interventions":1463},[89],"2026-07-01","2023-07-14",9,[1404],[82,1464,1371,1328],"Tislelizumab",{"trials":1466,"activeCount":190,"soonestReadout":42},[1467,1471],{"nctId":40,"briefTitle":41,"status":141,"phases":1468,"primaryCompletion":42,"completion":1323,"start":1324,"enrollment":682,"conditions":1469,"interventions":1470},[90],[1326],[43,1328],{"nctId":1472,"briefTitle":1473,"status":119,"phases":1474,"primaryCompletion":1475,"completion":1476,"start":1477,"enrollment":1478,"conditions":1479,"interventions":1480},"NCT00696696","Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer",[90],"2010-11","2013-06","2007-09",45,[1404],[1328,1481,1482],"Erlotinib","Sorafenib",{"trials":1484,"activeCount":100},[],{"trials":1486,"activeCount":100},[],{"trials":1488,"activeCount":100},[],{"intervention":1371,"totalTrials":195,"cells":1490},{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1499,"PHASE3":1515,"PHASE4":1517,"NA":1519},{"trials":1492,"activeCount":100},[],{"trials":1494,"activeCount":190,"soonestReadout":81},[1495],{"nctId":79,"briefTitle":80,"status":141,"phases":1496,"primaryCompletion":81,"completion":1459,"start":1460,"enrollment":1461,"conditions":1497,"interventions":1498},[89],[1404],[82,1464,1371,1328],{"trials":1500,"activeCount":190,"soonestReadout":47},[1501,1511],{"nctId":1502,"briefTitle":1503,"status":108,"phases":1504,"primaryCompletion":1505,"completion":1505,"start":1506,"enrollment":195,"conditions":1507,"interventions":1509},"NCT02075021","Phase I\u002FII Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed\u002FRefractory Multiple Myeloma",[89,90],"2015-11","2014-03",[1508],"Relapsed or Refractory Multiple Myeloma",[925,1510],"nab-paclitaxel",{"nctId":45,"briefTitle":46,"status":141,"phases":1512,"primaryCompletion":47,"completion":1323,"start":1367,"enrollment":1368,"conditions":1513,"interventions":1514},[90],[15],[43,1371],{"trials":1516,"activeCount":100},[],{"trials":1518,"activeCount":100},[],{"trials":1520,"activeCount":100},[],{"intervention":148,"totalTrials":195,"cells":1522},{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1527,"PHASE3":1545,"PHASE4":1547,"NA":1549},{"trials":1524,"activeCount":100},[],{"trials":1526,"activeCount":100},[],{"trials":1528,"activeCount":173,"soonestReadout":51},[1529,1537,1541],{"nctId":1530,"briefTitle":1531,"status":108,"phases":1532,"primaryCompletion":945,"completion":945,"start":1533,"enrollment":190,"conditions":1534,"interventions":1536},"NCT01693653","Tocilizumab for the Treatment of Behcet's Syndrome",[90],"2012-09",[1535],"Behcet Syndrome",[148],{"nctId":49,"briefTitle":50,"status":141,"phases":1538,"primaryCompletion":51,"completion":143,"start":144,"enrollment":145,"conditions":1539,"interventions":1540},[90],[126],[52,128,148],{"nctId":204,"briefTitle":205,"status":206,"phases":1542,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":1543,"interventions":1544},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":1546,"activeCount":100},[],{"trials":1548,"activeCount":100},[],{"trials":1550,"activeCount":100},[],{"intervention":82,"totalTrials":173,"cells":1552},{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1561,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1554,"activeCount":100},[],{"trials":1556,"activeCount":190,"soonestReadout":81},[1557],{"nctId":79,"briefTitle":80,"status":141,"phases":1558,"primaryCompletion":81,"completion":1459,"start":1460,"enrollment":1461,"conditions":1559,"interventions":1560},[89],[1404],[82,1464,1371,1328],{"trials":1562,"activeCount":190,"soonestReadout":208},[1563],{"nctId":204,"briefTitle":205,"status":206,"phases":1564,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":1565,"interventions":1566},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":1568,"activeCount":100},[],{"trials":1570,"activeCount":100},[],{"trials":1572,"activeCount":100},[],{"intervention":1574,"totalTrials":195,"cells":1575},"Dexmedetomidine",{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1593,"PHASE4":1595,"NA":1619},{"trials":1577,"activeCount":100},[],{"trials":1579,"activeCount":100},[],{"trials":1581,"activeCount":190,"soonestReadout":1118},[1582],{"nctId":1583,"briefTitle":1584,"status":1585,"phases":1586,"primaryCompletion":1118,"completion":1587,"start":1588,"enrollment":1589,"conditions":1590,"interventions":1592},"NCT06148311","Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia","ENROLLING_BY_INVITATION",[90],"2027-09-01","2024-07-01",15,[1591],"Familial Dysautonomia",[1574],{"trials":1594,"activeCount":100},[],{"trials":1596,"activeCount":100},[1597,1609],{"nctId":1598,"briefTitle":1599,"status":119,"phases":1600,"primaryCompletion":1506,"completion":1601,"start":1602,"enrollment":1603,"conditions":1604,"interventions":1608},"NCT01901588","Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery",[92],"2016-05","2012-03",63,[1605,1606,1607],"Strabismus","Delirium on Emergence","Pediatric Disorders",[1574],{"nctId":1610,"briefTitle":1611,"status":119,"phases":1612,"primaryCompletion":1613,"completion":1613,"start":1614,"enrollment":1615,"conditions":1616,"interventions":1618},"NCT03325972","Study on the Effects of Intravenous Dexmedetomidine on Pain in Patients Undergoing Elective Spinal Surgery",[92],"2022-02-22","2016-09-14",83,[1617],"Chronic Pain",[1574],{"trials":1620,"activeCount":100},[],{"intervention":1622,"totalTrials":195,"cells":1623},"XR-NTX",{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1628,"PHASE3":1642,"PHASE4":1644,"NA":1667},{"trials":1625,"activeCount":100},[],{"trials":1627,"activeCount":100},[],{"trials":1629,"activeCount":190,"soonestReadout":246},[1630],{"nctId":1631,"briefTitle":1632,"status":141,"phases":1633,"primaryCompletion":246,"completion":1634,"start":1635,"enrollment":1636,"conditions":1637,"interventions":1639},"NCT04464980","Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)",[90],"2027-01-31","2021-06-08",1516,[1638],"Opioid Use Disorder (OUD)",[1640,1641,1622],"SL-BUP","XR-BUP",{"trials":1643,"activeCount":100},[],{"trials":1645,"activeCount":100},[1646,1658],{"nctId":1647,"briefTitle":1648,"status":119,"phases":1649,"primaryCompletion":1650,"completion":1651,"start":1652,"enrollment":1653,"conditions":1654,"interventions":1656},"NCT04219540","Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults",[92],"2024-08-01","2025-02-28","2021-01-07",675,[1655],"Opioid-use Disorder",[1657,1622],"XR-B",{"nctId":1659,"briefTitle":1660,"status":119,"phases":1661,"primaryCompletion":1662,"completion":1662,"start":1262,"enrollment":1663,"conditions":1664,"interventions":1665},"NCT01893827","Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care",[92],"2018-10-03",237,[1264],[1622,1666],"Oral Naltrexone",{"trials":1668,"activeCount":100},[],{"intervention":234,"totalTrials":173,"cells":1670},{"EARLY_PHASE1":1671,"PHASE1":1673,"PHASE2":1675,"PHASE3":1681,"PHASE4":1683,"NA":1693},{"trials":1672,"activeCount":100},[],{"trials":1674,"activeCount":100},[],{"trials":1676,"activeCount":190,"soonestReadout":208},[1677],{"nctId":204,"briefTitle":205,"status":206,"phases":1678,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":1679,"interventions":1680},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":1682,"activeCount":100},[],{"trials":1684,"activeCount":100},[1685],{"nctId":1686,"briefTitle":1687,"status":108,"phases":1688,"primaryCompletion":1689,"completion":1689,"start":248,"enrollment":281,"conditions":1690,"interventions":1692},"NCT04629196","Induction Optimization With Stelara for Crohn's Disease",[92],"2024-01-17",[1691],"Crohn Disease",[234,234,234],{"trials":1694,"activeCount":100},[],{"intervention":1306,"totalTrials":173,"cells":1696},{"EARLY_PHASE1":1697,"PHASE1":1699,"PHASE2":1701,"PHASE3":1707,"PHASE4":1719,"NA":1721},{"trials":1698,"activeCount":100},[],{"trials":1700,"activeCount":100},[],{"trials":1702,"activeCount":190,"soonestReadout":888},[1703],{"nctId":1297,"briefTitle":1298,"status":152,"phases":1704,"primaryCompletion":888,"completion":888,"start":1300,"enrollment":281,"conditions":1705,"interventions":1706},[90],[1302],[1304,221,1305,1306],{"trials":1708,"activeCount":100},[1709],{"nctId":1710,"briefTitle":1711,"status":108,"phases":1712,"primaryCompletion":1713,"completion":1713,"start":1714,"enrollment":1715,"conditions":1716,"interventions":1718},"NCT02249377","PRP vs Corticosteroid in Baker's Cyst",[91],"2017-04-01","2014-02",50,[1717],"Baker's Cyst",[1306],{"trials":1720,"activeCount":100},[],{"trials":1722,"activeCount":100},[],{"intervention":1291,"totalTrials":1461,"cells":1724},{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1742,"PHASE3":1831,"PHASE4":1833,"NA":1835},{"trials":1726,"activeCount":100},[],{"trials":1728,"activeCount":100},[1729],{"nctId":1730,"briefTitle":1731,"status":119,"phases":1732,"primaryCompletion":1733,"start":1734,"conditions":1735,"interventions":1736},"NCT00009997","Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer",[89],"2004-01","1999-03",[15],[1737,1738,1739,1740,1741],"trastuzumab","cyclophosphamide","doxorubicin hydrochloride","paclitaxel","tamoxifen citrate",{"trials":1743,"activeCount":190,"soonestReadout":1285},[1744,1755,1765,1769,1789,1802,1813,1822],{"nctId":1745,"briefTitle":1746,"status":119,"phases":1747,"primaryCompletion":1748,"completion":1748,"start":1749,"enrollment":1750,"conditions":1751,"interventions":1753},"NCT01963481","Exemestane and Cyclophosphamide for Metastatic Breast Cancer",[90],"2017-10-01","2013-09",23,[1752],"Metastatic Beast Cancer",[1754,1291],"Exemestane",{"nctId":1756,"briefTitle":1757,"status":119,"phases":1758,"primaryCompletion":47,"completion":1759,"start":1760,"enrollment":1750,"conditions":1761,"interventions":1763},"NCT03945591","High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",[90],"2024-01-04","2019-06-20",[1762],"GVHD",[1764,1291],"Bortezomib",{"nctId":1282,"briefTitle":1283,"status":141,"phases":1766,"primaryCompletion":1285,"completion":1285,"start":1286,"enrollment":1287,"conditions":1767,"interventions":1768},[90],[1289],[1291,230,221],{"nctId":1770,"briefTitle":1771,"status":294,"phases":1772,"start":1773,"enrollment":100,"conditions":1774,"interventions":1779},"NCT00003273","Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor",[90],"1997-11",[1775,1776,1777,1778],"Brain and Central Nervous System Tumors","Neuroblastoma","Retinoblastoma","Sarcoma",[1780,1781,1782,1738,1783,1784,1785,1786,1787,1788],"filgrastim","carboplatin","cisplatin","etoposide","leucovorin calcium","methotrexate","temozolomide","thiotepa","vincristine sulfate",{"nctId":1790,"briefTitle":1791,"status":119,"phases":1792,"primaryCompletion":1793,"completion":1794,"start":1795,"enrollment":1796,"conditions":1797,"interventions":1800},"NCT01421017","Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases",[89,90],"2016-07-01","2016-08-06","2011-08-19",31,[15,1798,1799],"Metastatic Breast Cancer","Recurrent Breast Cancer",[1801,1291],"Imiquimod",{"nctId":1803,"briefTitle":1804,"status":108,"phases":1805,"primaryCompletion":1806,"completion":1807,"start":1808,"enrollment":1461,"conditions":1809,"interventions":1811},"NCT00483119","Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus",[90],"2010-02","2011-02","2007-04",[1810],"Pemphigus Vulgaris",[1812,1738],"intravenous immunoglobulin",{"nctId":1814,"briefTitle":1815,"status":108,"phases":1816,"primaryCompletion":1817,"completion":1817,"start":1818,"enrollment":268,"conditions":1819,"interventions":1821},"NCT03187756","Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft",[90],"2018-12-18","2017-06-02",[1820],"Hematopoietic Malignancies",[1291],{"nctId":1823,"briefTitle":1824,"status":108,"phases":1825,"primaryCompletion":1714,"completion":1714,"start":919,"enrollment":1826,"conditions":1827,"interventions":1828},"NCT01438177","Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma",[90],11,[923],[1829,1291,1830],"Velcade","Chloroquine",{"trials":1832,"activeCount":100},[],{"trials":1834,"activeCount":100},[],{"trials":1836,"activeCount":100},[],{"intervention":1737,"totalTrials":946,"cells":1838},{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1847,"PHASE3":1881,"PHASE4":1883,"NA":1885},{"trials":1840,"activeCount":100},[],{"trials":1842,"activeCount":100},[1843],{"nctId":1730,"briefTitle":1731,"status":119,"phases":1844,"primaryCompletion":1733,"start":1734,"conditions":1845,"interventions":1846},[89],[15],[1737,1738,1739,1740,1741],{"trials":1848,"activeCount":190,"soonestReadout":182},[1849,1861,1870],{"nctId":1850,"briefTitle":1851,"status":108,"phases":1852,"primaryCompletion":1853,"completion":1853,"start":1854,"enrollment":1855,"conditions":1856,"interventions":1857},"NCT02297230","Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics",[89,90],"2014-12-02","2002-06",44,[15],[1858,1859,1860],"Capecitabine","Trastuzumab","Paclitaxel",{"nctId":1862,"briefTitle":1863,"status":119,"phases":1864,"primaryCompletion":1865,"start":1866,"conditions":1867,"interventions":1868},"NCT00006825","Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer",[89,90],"2004-07","2000-07",[15],[1737,1869],"pegylated liposomal doxorubicin hydrochloride",{"nctId":1871,"briefTitle":1872,"status":152,"phases":1873,"primaryCompletion":182,"completion":1874,"start":1875,"enrollment":1715,"conditions":1876,"interventions":1878},"NCT07612215","Elacestrant in Advanced Triple Positive Breast Cancer",[89,90],"2030-05","2026-05-13",[1877],"ER Positive, HER2 Positive Breast Cancer",[1879,1859,1880],"Elacestrant","Pertuzumab",{"trials":1882,"activeCount":100},[],{"trials":1884,"activeCount":100},[],{"trials":1886,"activeCount":100},[],{"intervention":223,"totalTrials":173,"cells":1888},{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1893,"PHASE3":1910,"PHASE4":1912,"NA":1914},{"trials":1890,"activeCount":100},[],{"trials":1892,"activeCount":100},[],{"trials":1894,"activeCount":190,"soonestReadout":208},[1895,1906],{"nctId":1896,"briefTitle":1897,"status":119,"phases":1898,"primaryCompletion":1476,"completion":1714,"start":1899,"enrollment":1900,"conditions":1901,"interventions":1903},"NCT00814255","Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial",[90],"2008-12",32,[1902],"Focal Segmental Glomerulosclerosis",[223,1904,1905],"Lisinopril, losartan, and atorvastatin","galactose",{"nctId":204,"briefTitle":205,"status":206,"phases":1907,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":1908,"interventions":1909},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":1911,"activeCount":100},[],{"trials":1913,"activeCount":100},[],{"trials":1915,"activeCount":100},[],{"intervention":1785,"totalTrials":173,"cells":1917},{"EARLY_PHASE1":1918,"PHASE1":1920,"PHASE2":1922,"PHASE3":1932,"PHASE4":1934,"NA":1936},{"trials":1919,"activeCount":100},[],{"trials":1921,"activeCount":100},[],{"trials":1923,"activeCount":190,"soonestReadout":208},[1924,1928],{"nctId":1770,"briefTitle":1771,"status":294,"phases":1925,"start":1773,"enrollment":100,"conditions":1926,"interventions":1927},[90],[1775,1776,1777,1778],[1780,1781,1782,1738,1783,1784,1785,1786,1787,1788],{"nctId":204,"briefTitle":205,"status":206,"phases":1929,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":1930,"interventions":1931},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":1933,"activeCount":100},[],{"trials":1935,"activeCount":100},[],{"trials":1937,"activeCount":100},[],{"intervention":1939,"totalTrials":190,"cells":1940},"Valganciclovir",{"EARLY_PHASE1":1941,"PHASE1":1943,"PHASE2":1945,"PHASE3":1957,"PHASE4":1959,"NA":1961},{"trials":1942,"activeCount":100},[],{"trials":1944,"activeCount":100},[],{"trials":1946,"activeCount":190,"soonestReadout":1951},[1947],{"nctId":1948,"briefTitle":1949,"status":152,"phases":1950,"primaryCompletion":1951,"completion":1952,"start":1953,"enrollment":1715,"conditions":1954,"interventions":1956},"NCT05708755","CMV Immunity Monitoring in Lung Transplant Recipients",[90],"2027-05","2028-05","2024-09-13",[1955],"Lung Transplant; Complications",[1939],{"trials":1958,"activeCount":100},[],{"trials":1960,"activeCount":100},[],{"trials":1962,"activeCount":100},[],{"intervention":1964,"totalTrials":190,"cells":1965},"Dexmedetomidine Sublingual",{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1981,"PHASE4":1983,"NA":1985},{"trials":1967,"activeCount":100},[],{"trials":1969,"activeCount":100},[],{"trials":1971,"activeCount":190,"soonestReadout":1976},[1972],{"nctId":1973,"briefTitle":1974,"status":141,"phases":1975,"primaryCompletion":1976,"completion":1977,"start":1978,"enrollment":772,"conditions":1979,"interventions":1980},"NCT06128356","Pilot Study of Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia",[90],"2028-09","2028-12","2024-06-01",[1591],[1964],{"trials":1982,"activeCount":100},[],{"trials":1984,"activeCount":100},[],{"trials":1986,"activeCount":100},[],{"intervention":1988,"totalTrials":190,"cells":1989},"Empagliflozin 10 MG",{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":2005,"PHASE4":2007,"NA":2009},{"trials":1991,"activeCount":100},[],{"trials":1993,"activeCount":100},[],{"trials":1995,"activeCount":190,"soonestReadout":2000},[1996],{"nctId":1997,"briefTitle":1998,"status":152,"phases":1999,"primaryCompletion":2000,"completion":2000,"start":2001,"enrollment":682,"conditions":2002,"interventions":2004},"NCT05786443","Safety and Efficacy of Empagliflozin in Hemodialysis",[90],"2026-12-30","2024-01-31",[2003],"End Stage Renal Disease",[1988],{"trials":2006,"activeCount":100},[],{"trials":2008,"activeCount":100},[],{"trials":2010,"activeCount":100},[],{"intervention":2012,"totalTrials":190,"cells":2013},"Empagliflozin",{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2018,"PHASE3":2029,"PHASE4":2031,"NA":2033},{"trials":2015,"activeCount":100},[],{"trials":2017,"activeCount":100},[],{"trials":2019,"activeCount":190,"soonestReadout":2024},[2020],{"nctId":2021,"briefTitle":2022,"status":152,"phases":2023,"primaryCompletion":2024,"completion":2025,"start":2026,"enrollment":37,"conditions":2027,"interventions":2028},"NCT05757791","Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)",[90],"2026-04","2026-05","2023-03-17",[685],[2012],{"trials":2030,"activeCount":100},[],{"trials":2032,"activeCount":100},[],{"trials":2034,"activeCount":100},[],{"intervention":2036,"totalTrials":190,"cells":2037},"Leuprolide, Degarelix or Relugolix",{"EARLY_PHASE1":2038,"PHASE1":2040,"PHASE2":2042,"PHASE3":2054,"PHASE4":2056,"NA":2058},{"trials":2039,"activeCount":100},[],{"trials":2041,"activeCount":100},[],{"trials":2043,"activeCount":190,"soonestReadout":2048},[2044],{"nctId":2045,"briefTitle":2046,"status":152,"phases":2047,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":2051,"conditions":2052,"interventions":2053},"NCT06397703","ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer",[90],"2030-04-16","2031-04-16","2024-04-16",392,[21],[2036],{"trials":2055,"activeCount":100},[],{"trials":2057,"activeCount":100},[],{"trials":2059,"activeCount":100},[],{"intervention":2061,"totalTrials":190,"cells":2062},"Nicotine Replacement Product",{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2067,"PHASE3":2079,"PHASE4":2081,"NA":2083},{"trials":2064,"activeCount":100},[],{"trials":2066,"activeCount":100},[],{"trials":2068,"activeCount":190,"soonestReadout":2073},[2069],{"nctId":2070,"briefTitle":2071,"status":152,"phases":2072,"primaryCompletion":2073,"completion":497,"start":2074,"enrollment":2075,"conditions":2076,"interventions":2078},"NCT05722561","E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder",[90],"2026-11-01","2024-08-08",302,[501,2077],"Cigarette Smoking",[2061],{"trials":2080,"activeCount":100},[],{"trials":2082,"activeCount":100},[],{"trials":2084,"activeCount":100},[],{"intervention":2086,"totalTrials":190,"cells":2087},"Caffeine anhydrous 5% added to Lipoderm Cream Base.",{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2103,"PHASE4":2105,"NA":2107},{"trials":2089,"activeCount":100},[],{"trials":2091,"activeCount":100},[],{"trials":2093,"activeCount":190,"soonestReadout":1323},[2094],{"nctId":2095,"briefTitle":2096,"status":141,"phases":2097,"primaryCompletion":1323,"completion":2098,"start":2099,"enrollment":682,"conditions":2100,"interventions":2102},"NCT03768492","Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy",[90],"2027-12","2020-06-29",[2101],"Carcinoma Breast",[2086],{"trials":2104,"activeCount":100},[],{"trials":2106,"activeCount":100},[],{"trials":2108,"activeCount":100},[],{"intervention":57,"totalTrials":190,"cells":2110},{"EARLY_PHASE1":2111,"PHASE1":2113,"PHASE2":2115,"PHASE3":2124,"PHASE4":2126,"NA":2128},{"trials":2112,"activeCount":100},[],{"trials":2114,"activeCount":100},[],{"trials":2116,"activeCount":190,"soonestReadout":56},[2117],{"nctId":54,"briefTitle":55,"status":141,"phases":2118,"primaryCompletion":56,"completion":2119,"start":2120,"enrollment":1900,"conditions":2121,"interventions":2123},[90],"2027-01","2019-05-15",[2122],"Meningioma",[57],{"trials":2125,"activeCount":100},[],{"trials":2127,"activeCount":100},[],{"trials":2129,"activeCount":100},[],{"intervention":161,"totalTrials":190,"cells":2131},{"EARLY_PHASE1":2132,"PHASE1":2134,"PHASE2":2136,"PHASE3":2142,"PHASE4":2144,"NA":2146},{"trials":2133,"activeCount":100},[],{"trials":2135,"activeCount":100},[],{"trials":2137,"activeCount":190,"soonestReadout":154},[2138],{"nctId":150,"briefTitle":151,"status":152,"phases":2139,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":2140,"interventions":2141},[90],[126,159],[161,52,162],{"trials":2143,"activeCount":100},[],{"trials":2145,"activeCount":100},[],{"trials":2147,"activeCount":100},[],{"intervention":162,"totalTrials":190,"cells":2149},{"EARLY_PHASE1":2150,"PHASE1":2152,"PHASE2":2154,"PHASE3":2160,"PHASE4":2162,"NA":2164},{"trials":2151,"activeCount":100},[],{"trials":2153,"activeCount":100},[],{"trials":2155,"activeCount":190,"soonestReadout":154},[2156],{"nctId":150,"briefTitle":151,"status":152,"phases":2157,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":2158,"interventions":2159},[90],[126,159],[161,52,162],{"trials":2161,"activeCount":100},[],{"trials":2163,"activeCount":100},[],{"trials":2165,"activeCount":100},[],{"intervention":2167,"totalTrials":190,"cells":2168},"Cisplatinum",{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2173,"PHASE3":2184,"PHASE4":2186,"NA":2188},{"trials":2170,"activeCount":100},[],{"trials":2172,"activeCount":100},[],{"trials":2174,"activeCount":190,"soonestReadout":1977},[2175],{"nctId":2176,"briefTitle":2177,"status":152,"phases":2178,"primaryCompletion":1977,"completion":1977,"start":2179,"enrollment":878,"conditions":2180,"interventions":2183},"NCT03215719","Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma",[90],"2017-10-18",[2181,2182],"Oropharyngeal Carcinoma","HPV Positive Oropharyngeal Squamous Cell Carcinoma",[2167],{"trials":2185,"activeCount":100},[],{"trials":2187,"activeCount":100},[],{"trials":2189,"activeCount":100},[],{"intervention":2191,"totalTrials":190,"cells":2192},"Emapalumab",{"EARLY_PHASE1":2193,"PHASE1":2195,"PHASE2":2197,"PHASE3":2209,"PHASE4":2211,"NA":2213},{"trials":2194,"activeCount":100},[],{"trials":2196,"activeCount":100},[],{"trials":2198,"activeCount":190,"soonestReadout":2203},[2199],{"nctId":2200,"briefTitle":2201,"status":206,"phases":2202,"primaryCompletion":2203,"completion":2204,"start":2205,"enrollment":682,"conditions":2206,"interventions":2208},"NCT07567014","Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS",[90],"2028-05-31","2029-05-31","2026-05-11",[923,2207],"Large B-cell Lymphoma (LBCL)",[2191],{"trials":2210,"activeCount":100},[],{"trials":2212,"activeCount":100},[],{"trials":2214,"activeCount":100},[],{"intervention":215,"totalTrials":190,"cells":2216},{"EARLY_PHASE1":2217,"PHASE1":2219,"PHASE2":2221,"PHASE3":2227,"PHASE4":2229,"NA":2231},{"trials":2218,"activeCount":100},[],{"trials":2220,"activeCount":100},[],{"trials":2222,"activeCount":190,"soonestReadout":208},[2223],{"nctId":204,"briefTitle":205,"status":206,"phases":2224,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2225,"interventions":2226},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2228,"activeCount":100},[],{"trials":2230,"activeCount":100},[],{"trials":2232,"activeCount":100},[],{"intervention":217,"totalTrials":190,"cells":2234},{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2239,"PHASE3":2245,"PHASE4":2247,"NA":2249},{"trials":2236,"activeCount":100},[],{"trials":2238,"activeCount":100},[],{"trials":2240,"activeCount":190,"soonestReadout":208},[2241],{"nctId":204,"briefTitle":205,"status":206,"phases":2242,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2243,"interventions":2244},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2246,"activeCount":100},[],{"trials":2248,"activeCount":100},[],{"trials":2250,"activeCount":100},[],{"intervention":218,"totalTrials":190,"cells":2252},{"EARLY_PHASE1":2253,"PHASE1":2255,"PHASE2":2257,"PHASE3":2263,"PHASE4":2265,"NA":2267},{"trials":2254,"activeCount":100},[],{"trials":2256,"activeCount":100},[],{"trials":2258,"activeCount":190,"soonestReadout":208},[2259],{"nctId":204,"briefTitle":205,"status":206,"phases":2260,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2261,"interventions":2262},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2264,"activeCount":100},[],{"trials":2266,"activeCount":100},[],{"trials":2268,"activeCount":100},[],{"intervention":219,"totalTrials":190,"cells":2270},{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2275,"PHASE3":2281,"PHASE4":2283,"NA":2285},{"trials":2272,"activeCount":100},[],{"trials":2274,"activeCount":100},[],{"trials":2276,"activeCount":190,"soonestReadout":208},[2277],{"nctId":204,"briefTitle":205,"status":206,"phases":2278,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2279,"interventions":2280},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2282,"activeCount":100},[],{"trials":2284,"activeCount":100},[],{"trials":2286,"activeCount":100},[],{"intervention":220,"totalTrials":190,"cells":2288},{"EARLY_PHASE1":2289,"PHASE1":2291,"PHASE2":2293,"PHASE3":2299,"PHASE4":2301,"NA":2303},{"trials":2290,"activeCount":100},[],{"trials":2292,"activeCount":100},[],{"trials":2294,"activeCount":190,"soonestReadout":208},[2295],{"nctId":204,"briefTitle":205,"status":206,"phases":2296,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2297,"interventions":2298},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2300,"activeCount":100},[],{"trials":2302,"activeCount":100},[],{"trials":2304,"activeCount":100},[],{"intervention":222,"totalTrials":190,"cells":2306},{"EARLY_PHASE1":2307,"PHASE1":2309,"PHASE2":2311,"PHASE3":2317,"PHASE4":2319,"NA":2321},{"trials":2308,"activeCount":100},[],{"trials":2310,"activeCount":100},[],{"trials":2312,"activeCount":190,"soonestReadout":208},[2313],{"nctId":204,"briefTitle":205,"status":206,"phases":2314,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2315,"interventions":2316},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2318,"activeCount":100},[],{"trials":2320,"activeCount":100},[],{"trials":2322,"activeCount":100},[],{"intervention":224,"totalTrials":190,"cells":2324},{"EARLY_PHASE1":2325,"PHASE1":2327,"PHASE2":2329,"PHASE3":2335,"PHASE4":2337,"NA":2339},{"trials":2326,"activeCount":100},[],{"trials":2328,"activeCount":100},[],{"trials":2330,"activeCount":190,"soonestReadout":208},[2331],{"nctId":204,"briefTitle":205,"status":206,"phases":2332,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2333,"interventions":2334},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2336,"activeCount":100},[],{"trials":2338,"activeCount":100},[],{"trials":2340,"activeCount":100},[],{"intervention":225,"totalTrials":190,"cells":2342},{"EARLY_PHASE1":2343,"PHASE1":2345,"PHASE2":2347,"PHASE3":2353,"PHASE4":2355,"NA":2357},{"trials":2344,"activeCount":100},[],{"trials":2346,"activeCount":100},[],{"trials":2348,"activeCount":190,"soonestReadout":208},[2349],{"nctId":204,"briefTitle":205,"status":206,"phases":2350,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2351,"interventions":2352},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2354,"activeCount":100},[],{"trials":2356,"activeCount":100},[],{"trials":2358,"activeCount":100},[],{"intervention":226,"totalTrials":190,"cells":2360},{"EARLY_PHASE1":2361,"PHASE1":2363,"PHASE2":2365,"PHASE3":2371,"PHASE4":2373,"NA":2375},{"trials":2362,"activeCount":100},[],{"trials":2364,"activeCount":100},[],{"trials":2366,"activeCount":190,"soonestReadout":208},[2367],{"nctId":204,"briefTitle":205,"status":206,"phases":2368,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2369,"interventions":2370},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2372,"activeCount":100},[],{"trials":2374,"activeCount":100},[],{"trials":2376,"activeCount":100},[],{"intervention":227,"totalTrials":190,"cells":2378},{"EARLY_PHASE1":2379,"PHASE1":2381,"PHASE2":2383,"PHASE3":2389,"PHASE4":2391,"NA":2393},{"trials":2380,"activeCount":100},[],{"trials":2382,"activeCount":100},[],{"trials":2384,"activeCount":190,"soonestReadout":208},[2385],{"nctId":204,"briefTitle":205,"status":206,"phases":2386,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2387,"interventions":2388},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2390,"activeCount":100},[],{"trials":2392,"activeCount":100},[],{"trials":2394,"activeCount":100},[],{"intervention":228,"totalTrials":190,"cells":2396},{"EARLY_PHASE1":2397,"PHASE1":2399,"PHASE2":2401,"PHASE3":2407,"PHASE4":2409,"NA":2411},{"trials":2398,"activeCount":100},[],{"trials":2400,"activeCount":100},[],{"trials":2402,"activeCount":190,"soonestReadout":208},[2403],{"nctId":204,"briefTitle":205,"status":206,"phases":2404,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2405,"interventions":2406},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2408,"activeCount":100},[],{"trials":2410,"activeCount":100},[],{"trials":2412,"activeCount":100},[],{"intervention":229,"totalTrials":190,"cells":2414},{"EARLY_PHASE1":2415,"PHASE1":2417,"PHASE2":2419,"PHASE3":2425,"PHASE4":2427,"NA":2429},{"trials":2416,"activeCount":100},[],{"trials":2418,"activeCount":100},[],{"trials":2420,"activeCount":190,"soonestReadout":208},[2421],{"nctId":204,"briefTitle":205,"status":206,"phases":2422,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2423,"interventions":2424},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2426,"activeCount":100},[],{"trials":2428,"activeCount":100},[],{"trials":2430,"activeCount":100},[],{"intervention":231,"totalTrials":190,"cells":2432},{"EARLY_PHASE1":2433,"PHASE1":2435,"PHASE2":2437,"PHASE3":2443,"PHASE4":2445,"NA":2447},{"trials":2434,"activeCount":100},[],{"trials":2436,"activeCount":100},[],{"trials":2438,"activeCount":190,"soonestReadout":208},[2439],{"nctId":204,"briefTitle":205,"status":206,"phases":2440,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2441,"interventions":2442},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2444,"activeCount":100},[],{"trials":2446,"activeCount":100},[],{"trials":2448,"activeCount":100},[],{"intervention":232,"totalTrials":190,"cells":2450},{"EARLY_PHASE1":2451,"PHASE1":2453,"PHASE2":2455,"PHASE3":2461,"PHASE4":2463,"NA":2465},{"trials":2452,"activeCount":100},[],{"trials":2454,"activeCount":100},[],{"trials":2456,"activeCount":190,"soonestReadout":208},[2457],{"nctId":204,"briefTitle":205,"status":206,"phases":2458,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2459,"interventions":2460},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2462,"activeCount":100},[],{"trials":2464,"activeCount":100},[],{"trials":2466,"activeCount":100},[],{"intervention":233,"totalTrials":190,"cells":2468},{"EARLY_PHASE1":2469,"PHASE1":2471,"PHASE2":2473,"PHASE3":2479,"PHASE4":2481,"NA":2483},{"trials":2470,"activeCount":100},[],{"trials":2472,"activeCount":100},[],{"trials":2474,"activeCount":190,"soonestReadout":208},[2475],{"nctId":204,"briefTitle":205,"status":206,"phases":2476,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2477,"interventions":2478},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2480,"activeCount":100},[],{"trials":2482,"activeCount":100},[],{"trials":2484,"activeCount":100},[],{"intervention":235,"totalTrials":190,"cells":2486},{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2491,"PHASE3":2497,"PHASE4":2499,"NA":2501},{"trials":2488,"activeCount":100},[],{"trials":2490,"activeCount":100},[],{"trials":2492,"activeCount":190,"soonestReadout":208},[2493],{"nctId":204,"briefTitle":205,"status":206,"phases":2494,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2495,"interventions":2496},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2498,"activeCount":100},[],{"trials":2500,"activeCount":100},[],{"trials":2502,"activeCount":100},[],{"intervention":236,"totalTrials":190,"cells":2504},{"EARLY_PHASE1":2505,"PHASE1":2507,"PHASE2":2509,"PHASE3":2515,"PHASE4":2517,"NA":2519},{"trials":2506,"activeCount":100},[],{"trials":2508,"activeCount":100},[],{"trials":2510,"activeCount":190,"soonestReadout":208},[2511],{"nctId":204,"briefTitle":205,"status":206,"phases":2512,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2513,"interventions":2514},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2516,"activeCount":100},[],{"trials":2518,"activeCount":100},[],{"trials":2520,"activeCount":100},[],{"intervention":237,"totalTrials":190,"cells":2522},{"EARLY_PHASE1":2523,"PHASE1":2525,"PHASE2":2527,"PHASE3":2533,"PHASE4":2535,"NA":2537},{"trials":2524,"activeCount":100},[],{"trials":2526,"activeCount":100},[],{"trials":2528,"activeCount":190,"soonestReadout":208},[2529],{"nctId":204,"briefTitle":205,"status":206,"phases":2530,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":2531,"interventions":2532},[90],[212],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,148,229,82,230,231,232,233,234,194,235,236,237],{"trials":2534,"activeCount":100},[],{"trials":2536,"activeCount":100},[],{"trials":2538,"activeCount":100},[],{"intervention":1640,"totalTrials":190,"cells":2540},{"EARLY_PHASE1":2541,"PHASE1":2543,"PHASE2":2545,"PHASE3":2551,"PHASE4":2553,"NA":2555},{"trials":2542,"activeCount":100},[],{"trials":2544,"activeCount":100},[],{"trials":2546,"activeCount":190,"soonestReadout":246},[2547],{"nctId":1631,"briefTitle":1632,"status":141,"phases":2548,"primaryCompletion":246,"completion":1634,"start":1635,"enrollment":1636,"conditions":2549,"interventions":2550},[90],[1638],[1640,1641,1622],{"trials":2552,"activeCount":100},[],{"trials":2554,"activeCount":100},[],{"trials":2556,"activeCount":100},[],{"intervention":1641,"totalTrials":190,"cells":2558},{"EARLY_PHASE1":2559,"PHASE1":2561,"PHASE2":2563,"PHASE3":2569,"PHASE4":2571,"NA":2573},{"trials":2560,"activeCount":100},[],{"trials":2562,"activeCount":100},[],{"trials":2564,"activeCount":190,"soonestReadout":246},[2565],{"nctId":1631,"briefTitle":1632,"status":141,"phases":2566,"primaryCompletion":246,"completion":1634,"start":1635,"enrollment":1636,"conditions":2567,"interventions":2568},[90],[1638],[1640,1641,1622],{"trials":2570,"activeCount":100},[],{"trials":2572,"activeCount":100},[],{"trials":2574,"activeCount":100},[],{"intervention":1879,"totalTrials":190,"cells":2576},{"EARLY_PHASE1":2577,"PHASE1":2579,"PHASE2":2581,"PHASE3":2587,"PHASE4":2589,"NA":2591},{"trials":2578,"activeCount":100},[],{"trials":2580,"activeCount":100},[],{"trials":2582,"activeCount":190,"soonestReadout":182},[2583],{"nctId":1871,"briefTitle":1872,"status":152,"phases":2584,"primaryCompletion":182,"completion":1874,"start":1875,"enrollment":1715,"conditions":2585,"interventions":2586},[89,90],[1877],[1879,1859,1880],{"trials":2588,"activeCount":100},[],{"trials":2590,"activeCount":100},[],{"trials":2592,"activeCount":100},[],{"intervention":1880,"totalTrials":190,"cells":2594},{"EARLY_PHASE1":2595,"PHASE1":2597,"PHASE2":2599,"PHASE3":2605,"PHASE4":2607,"NA":2609},{"trials":2596,"activeCount":100},[],{"trials":2598,"activeCount":100},[],{"trials":2600,"activeCount":190,"soonestReadout":182},[2601],{"nctId":1871,"briefTitle":1872,"status":152,"phases":2602,"primaryCompletion":182,"completion":1874,"start":1875,"enrollment":1715,"conditions":2603,"interventions":2604},[89,90],[1877],[1879,1859,1880],{"trials":2606,"activeCount":100},[],{"trials":2608,"activeCount":100},[],{"trials":2610,"activeCount":100},[],{"intervention":2612,"totalTrials":190,"cells":2613},"DRP-104",{"EARLY_PHASE1":2614,"PHASE1":2616,"PHASE2":2618,"PHASE3":2631,"PHASE4":2633,"NA":2635},{"trials":2615,"activeCount":100},[],{"trials":2617,"activeCount":100},[],{"trials":2619,"activeCount":190,"soonestReadout":2624},[2620],{"nctId":2621,"briefTitle":2622,"status":152,"phases":2623,"primaryCompletion":2624,"completion":2625,"start":2626,"enrollment":2627,"conditions":2628,"interventions":2630},"NCT07249372","DRP-104 in Patients With NFE2L2\u002FKEAP1-altered Non-Small Cell Lung Cancer",[90],"2027-10-31","2028-10-31","2026-01-14",37,[2629],"Non Small Cell Lung Cancer",[2612],{"trials":2632,"activeCount":100},[],{"trials":2634,"activeCount":100},[],{"trials":2636,"activeCount":100},[],{"intervention":2638,"totalTrials":190,"cells":2639},"18F-MK-6240",{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2657,"PHASE4":2659,"NA":2661},{"trials":2641,"activeCount":100},[],{"trials":2643,"activeCount":100},[],{"trials":2645,"activeCount":190,"soonestReadout":2650},[2646],{"nctId":2647,"briefTitle":2648,"status":141,"phases":2649,"primaryCompletion":2650,"completion":2651,"start":2652,"enrollment":2653,"conditions":2654,"interventions":2656},"NCT04784416","Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)",[90],"2025-10-30","2026-01-31","2021-04-27",196,[2655,684],"Mild Cognitive Impairment",[2638],{"trials":2658,"activeCount":100},[],{"trials":2660,"activeCount":100},[],{"trials":2662,"activeCount":100},[],{"intervention":1304,"totalTrials":190,"cells":2664},{"EARLY_PHASE1":2665,"PHASE1":2667,"PHASE2":2669,"PHASE3":2675,"PHASE4":2677,"NA":2679},{"trials":2666,"activeCount":100},[],{"trials":2668,"activeCount":100},[],{"trials":2670,"activeCount":190,"soonestReadout":888},[2671],{"nctId":1297,"briefTitle":1298,"status":152,"phases":2672,"primaryCompletion":888,"completion":888,"start":1300,"enrollment":281,"conditions":2673,"interventions":2674},[90],[1302],[1304,221,1305,1306],{"trials":2676,"activeCount":100},[],{"trials":2678,"activeCount":100},[],{"trials":2680,"activeCount":100},[],{"intervention":1305,"totalTrials":190,"cells":2682},{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2693,"PHASE4":2695,"NA":2697},{"trials":2684,"activeCount":100},[],{"trials":2686,"activeCount":100},[],{"trials":2688,"activeCount":190,"soonestReadout":888},[2689],{"nctId":1297,"briefTitle":1298,"status":152,"phases":2690,"primaryCompletion":888,"completion":888,"start":1300,"enrollment":281,"conditions":2691,"interventions":2692},[90],[1302],[1304,221,1305,1306],{"trials":2694,"activeCount":100},[],{"trials":2696,"activeCount":100},[],{"trials":2698,"activeCount":100},[],{"intervention":2700,"totalTrials":190,"cells":2701},"Induction Chemo-Immunotherapy",{"EARLY_PHASE1":2702,"PHASE1":2704,"PHASE2":2706,"PHASE3":2716,"PHASE4":2718,"NA":2720},{"trials":2703,"activeCount":100},[],{"trials":2705,"activeCount":100},[],{"trials":2707,"activeCount":190,"soonestReadout":183},[2708],{"nctId":2709,"briefTitle":2710,"status":206,"phases":2711,"primaryCompletion":183,"completion":2712,"start":2025,"enrollment":682,"conditions":2713,"interventions":2715},"NCT07428148","Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma",[89,90],"2033-05",[2714],"Oropharyngeal Squamous Cell Carcinoma",[2700],{"trials":2717,"activeCount":100},[],{"trials":2719,"activeCount":100},[],{"trials":2721,"activeCount":100},[],{"intervention":77,"totalTrials":173,"cells":2723},{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2728,"PHASE3":2736,"PHASE4":2738,"NA":2740},{"trials":2725,"activeCount":100},[],{"trials":2727,"activeCount":100},[],{"trials":2729,"activeCount":190,"soonestReadout":76},[2730],{"nctId":74,"briefTitle":75,"status":152,"phases":2731,"primaryCompletion":76,"completion":76,"start":2732,"enrollment":2733,"conditions":2734,"interventions":2735},[90],"2019-10-10",150,[366,849],[77],{"trials":2737,"activeCount":100},[],{"trials":2739,"activeCount":100},[],{"trials":2741,"activeCount":100},[2742],{"nctId":2743,"briefTitle":2744,"status":294,"phases":2745,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":100,"conditions":2748,"interventions":2750},"NCT02643719","Migraine Treatment in ED",[93],"2017-10","2015-12",[2749],"Migraine",[77,2751,2752],"Standard of Care","Abortive Medication",{"intervention":1351,"totalTrials":195,"cells":2754},{"EARLY_PHASE1":2755,"PHASE1":2757,"PHASE2":2775,"PHASE3":2781,"PHASE4":2783,"NA":2785},{"trials":2756,"activeCount":100},[],{"trials":2758,"activeCount":173,"soonestReadout":2771},[2759,2767],{"nctId":2760,"briefTitle":2761,"status":206,"phases":2762,"primaryCompletion":2763,"completion":2763,"start":2024,"enrollment":632,"conditions":2764,"interventions":2766},"NCT07335380","Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma",[89],"2031-03",[2765],"Oral Cavity Squamous Cell Carcinoma",[1351],{"nctId":2768,"briefTitle":2769,"status":152,"phases":2770,"primaryCompletion":2771,"completion":2772,"start":447,"enrollment":1589,"conditions":2773,"interventions":2774},"NCT05723107","EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)",[89],"2027-11","2028-03",[1404],[1351],{"trials":2776,"activeCount":100},[2777],{"nctId":1342,"briefTitle":1343,"status":108,"phases":2778,"primaryCompletion":1345,"completion":1346,"start":1347,"enrollment":34,"conditions":2779,"interventions":2780},[90],[1349],[43,1351],{"trials":2782,"activeCount":100},[],{"trials":2784,"activeCount":100},[],{"trials":2786,"activeCount":100},[],{"intervention":2788,"totalTrials":173,"cells":2789},"Indocyanine green",{"EARLY_PHASE1":2790,"PHASE1":2792,"PHASE2":2801,"PHASE3":2803,"PHASE4":2805,"NA":2817},{"trials":2791,"activeCount":100},[],{"trials":2793,"activeCount":190,"soonestReadout":81},[2794],{"nctId":84,"briefTitle":85,"status":141,"phases":2795,"primaryCompletion":81,"completion":81,"start":2796,"enrollment":2797,"conditions":2798,"interventions":2800},[89],"2021-01-27",20,[2799],"Rotator Cuff Tears",[86],{"trials":2802,"activeCount":100},[],{"trials":2804,"activeCount":100},[],{"trials":2806,"activeCount":100},[2807],{"nctId":2808,"briefTitle":2809,"status":294,"phases":2810,"primaryCompletion":2811,"completion":2812,"start":2813,"enrollment":100,"conditions":2814,"interventions":2816},"NCT05332405","SPY Angiography To Assist With Ulnar Nerve Transposition at the Elbow",[92],"2023-10-01","2024-04-01","2022-05-26",[2815],"Cubital Tunnel Syndrome",[2788],{"trials":2818,"activeCount":100},[],{"intervention":1786,"totalTrials":772,"cells":2820},{"EARLY_PHASE1":2821,"PHASE1":2823,"PHASE2":2843,"PHASE3":2866,"PHASE4":2868,"NA":2870},{"trials":2822,"activeCount":100},[],{"trials":2824,"activeCount":190,"soonestReadout":2829},[2825,2835],{"nctId":2826,"briefTitle":2827,"status":206,"phases":2828,"primaryCompletion":2829,"completion":2830,"start":391,"enrollment":2797,"conditions":2831,"interventions":2833},"NCT07457307","Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac",[89],"2028-06","2029-06",[2832],"High-grade Glioma",[2834],"Temozolomide",{"nctId":2836,"briefTitle":2837,"status":119,"phases":2838,"primaryCompletion":2839,"start":2840,"conditions":2841,"interventions":2842},"NCT00025558","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer",[89],"2007-05","2000-10",[1775],[1780,1781,1786,1787],{"trials":2844,"activeCount":100},[2845,2849,2860],{"nctId":1770,"briefTitle":1771,"status":294,"phases":2846,"start":1773,"enrollment":100,"conditions":2847,"interventions":2848},[90],[1775,1776,1777,1778],[1780,1781,1782,1738,1783,1784,1785,1786,1787,1788],{"nctId":2850,"briefTitle":2851,"status":108,"phases":2852,"primaryCompletion":2853,"completion":1215,"start":2854,"enrollment":22,"conditions":2855,"interventions":2857},"NCT01105702","Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma",[90],"2014-04","2010-05",[2856],"Brain Cancer",[2834,2858,2859],"Bevacizumab","Lithium Carbonate",{"nctId":2861,"briefTitle":2862,"status":294,"phases":2863,"start":1773,"enrollment":100,"conditions":2864,"interventions":2865},"NCT00006263","Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma",[90],[1775],[1780,1781,1786],{"trials":2867,"activeCount":100},[],{"trials":2869,"activeCount":100},[],{"trials":2871,"activeCount":100},[],{"intervention":2873,"totalTrials":173,"cells":2874},"Sotorasib",{"EARLY_PHASE1":2875,"PHASE1":2877,"PHASE2":2890,"PHASE3":2900,"PHASE4":2902,"NA":2904},{"trials":2876,"activeCount":100},[],{"trials":2878,"activeCount":190,"soonestReadout":2883},[2879],{"nctId":2880,"briefTitle":2881,"status":152,"phases":2882,"primaryCompletion":2883,"completion":2883,"start":2884,"enrollment":2885,"conditions":2886,"interventions":2888},"NCT05815173","Ladarixin With Sotorasib in Advanced NSCLC",[89],"2027-08","2023-08-01",40,[2887],"Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation",[2873,2889],"Ladarixin",{"trials":2891,"activeCount":100},[2892],{"nctId":2893,"briefTitle":2894,"status":294,"phases":2895,"primaryCompletion":2896,"completion":2024,"start":2897,"enrollment":100,"conditions":2898,"interventions":2899},"NCT05815186","Ladarixin With Sotorasib in Advanced NSCLC - Phase II",[90],"2025-04","2024-04",[2887],[2873,2889],{"trials":2901,"activeCount":100},[],{"trials":2903,"activeCount":100},[],{"trials":2905,"activeCount":100},[],{"intervention":2889,"totalTrials":173,"cells":2907},{"EARLY_PHASE1":2908,"PHASE1":2910,"PHASE2":2916,"PHASE3":2922,"PHASE4":2924,"NA":2926},{"trials":2909,"activeCount":100},[],{"trials":2911,"activeCount":190,"soonestReadout":2883},[2912],{"nctId":2880,"briefTitle":2881,"status":152,"phases":2913,"primaryCompletion":2883,"completion":2883,"start":2884,"enrollment":2885,"conditions":2914,"interventions":2915},[89],[2887],[2873,2889],{"trials":2917,"activeCount":100},[2918],{"nctId":2893,"briefTitle":2894,"status":294,"phases":2919,"primaryCompletion":2896,"completion":2024,"start":2897,"enrollment":100,"conditions":2920,"interventions":2921},[90],[2887],[2873,2889],{"trials":2923,"activeCount":100},[],{"trials":2925,"activeCount":100},[],{"trials":2927,"activeCount":100},[],{"intervention":2929,"totalTrials":190,"cells":2930},"Belzutifan",{"EARLY_PHASE1":2931,"PHASE1":2933,"PHASE2":2945,"PHASE3":2947,"PHASE4":2949,"NA":2951},{"trials":2932,"activeCount":100},[],{"trials":2934,"activeCount":190,"soonestReadout":1587},[2935],{"nctId":2936,"briefTitle":2937,"status":152,"phases":2938,"primaryCompletion":1587,"completion":2939,"start":2940,"enrollment":281,"conditions":2941,"interventions":2943},"NCT07179770","Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)",[89],"2027-10-01","2025-09-15",[2942],"Metastatic Clear Cell Renal Cell Carcinoma",[2929,2944],"89Zr-DFO-girentuximab",{"trials":2946,"activeCount":100},[],{"trials":2948,"activeCount":100},[],{"trials":2950,"activeCount":100},[],{"trials":2952,"activeCount":100},[],{"intervention":2944,"totalTrials":190,"cells":2954},{"EARLY_PHASE1":2955,"PHASE1":2957,"PHASE2":2963,"PHASE3":2965,"PHASE4":2967,"NA":2969},{"trials":2956,"activeCount":100},[],{"trials":2958,"activeCount":190,"soonestReadout":1587},[2959],{"nctId":2936,"briefTitle":2937,"status":152,"phases":2960,"primaryCompletion":1587,"completion":2939,"start":2940,"enrollment":281,"conditions":2961,"interventions":2962},[89],[2942],[2929,2944],{"trials":2964,"activeCount":100},[],{"trials":2966,"activeCount":100},[],{"trials":2968,"activeCount":100},[],{"trials":2970,"activeCount":100},[],{"intervention":1464,"totalTrials":190,"cells":2972},{"EARLY_PHASE1":2973,"PHASE1":2975,"PHASE2":2981,"PHASE3":2983,"PHASE4":2985,"NA":2987},{"trials":2974,"activeCount":100},[],{"trials":2976,"activeCount":190,"soonestReadout":81},[2977],{"nctId":79,"briefTitle":80,"status":141,"phases":2978,"primaryCompletion":81,"completion":1459,"start":1460,"enrollment":1461,"conditions":2979,"interventions":2980},[89],[1404],[82,1464,1371,1328],{"trials":2982,"activeCount":100},[],{"trials":2984,"activeCount":100},[],{"trials":2986,"activeCount":100},[],{"trials":2988,"activeCount":100},[],{"intervention":2990,"totalTrials":190,"cells":2991},"Azeliragon",{"EARLY_PHASE1":2992,"PHASE1":2994,"PHASE2":3006,"PHASE3":3008,"PHASE4":3010,"NA":3012},{"trials":2993,"activeCount":100},[],{"trials":2995,"activeCount":190,"soonestReadout":2119},[2996],{"nctId":2997,"briefTitle":2998,"status":141,"phases":2999,"primaryCompletion":2119,"completion":3000,"start":3001,"enrollment":31,"conditions":3002,"interventions":3005},"NCT06724926","Concurrent Azeliragon With Craniospinal Irradiation",[89],"2031-01","2025-02-18",[3003,2832,3004],"Solid Tumor","Leptomeningeal Metastasis",[2990],{"trials":3007,"activeCount":100},[],{"trials":3009,"activeCount":100},[],{"trials":3011,"activeCount":100},[],{"trials":3013,"activeCount":100},[],{"intervention":3015,"totalTrials":190,"cells":3016},"CpG1018",{"EARLY_PHASE1":3017,"PHASE1":3019,"PHASE2":3029,"PHASE3":3031,"PHASE4":3033,"NA":3035},{"trials":3018,"activeCount":100},[],{"trials":3020,"activeCount":190,"soonestReadout":1158},[3021],{"nctId":3022,"briefTitle":3023,"status":152,"phases":3024,"primaryCompletion":1158,"completion":1158,"start":3025,"enrollment":124,"conditions":3026,"interventions":3028},"NCT05606341","Innate Immunity Stimulation Via TLR9 in Early AD",[89],"2023-03-13",[2655,3027],"Alzheimer Dementia",[3015,3015,3015],{"trials":3030,"activeCount":100},[],{"trials":3032,"activeCount":100},[],{"trials":3034,"activeCount":100},[],{"trials":3036,"activeCount":100},[],{"intervention":3038,"totalTrials":195,"cells":3039},"Atorvastatin",{"EARLY_PHASE1":3040,"PHASE1":3052,"PHASE2":3054,"PHASE3":3066,"PHASE4":3068,"NA":3082},{"trials":3041,"activeCount":190,"soonestReadout":3046},[3042],{"nctId":3043,"briefTitle":3044,"status":152,"phases":3045,"primaryCompletion":3046,"completion":3046,"start":3047,"enrollment":1715,"conditions":3048,"interventions":3050},"NCT06961630","Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction",[88],"2027-03-31","2025-10-07",[3049],"Myocardial Injury After Noncardiac Surgery",[3051,3038],"Rivaroxaban",{"trials":3053,"activeCount":100},[],{"trials":3055,"activeCount":100},[3056],{"nctId":3057,"briefTitle":3058,"status":108,"phases":3059,"primaryCompletion":3060,"completion":3060,"start":3061,"enrollment":3062,"conditions":3063,"interventions":3065},"NCT00412841","Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus",[90],"2008-01","2002-11",43,[3064],"Avascular Necrosis",[3038],{"trials":3067,"activeCount":100},[],{"trials":3069,"activeCount":100},[3070],{"nctId":3071,"briefTitle":3072,"status":108,"phases":3073,"primaryCompletion":3074,"completion":3074,"start":1714,"enrollment":3075,"conditions":3076,"interventions":3079},"NCT01837069","Risk Factor Control Before Orthopedic Surgery",[92],"2018-04-02",198,[3077,3078],"Osteoarthritis","Cardiovascular Disease",[3080,3081,3038],"Metoprolol","Lisinopril",{"trials":3083,"activeCount":100},[],{"intervention":3085,"totalTrials":173,"cells":3086},"Aspirin",{"EARLY_PHASE1":3087,"PHASE1":3099,"PHASE2":3101,"PHASE3":3116,"PHASE4":3118,"NA":3120},{"trials":3088,"activeCount":190,"soonestReadout":3093},[3089],{"nctId":3090,"briefTitle":3091,"status":152,"phases":3092,"primaryCompletion":3093,"completion":3094,"start":3095,"enrollment":632,"conditions":3096,"interventions":3098},"NCT07525635","Aspirin Dosing in Pregnancy",[88],"2027-08-01","2028-02-20","2026-04-27",[3097],"Preeclampsia Possible",[3085],{"trials":3100,"activeCount":100},[],{"trials":3102,"activeCount":100},[3103],{"nctId":3104,"briefTitle":3105,"status":119,"phases":3106,"primaryCompletion":3107,"completion":3108,"start":3109,"enrollment":3110,"conditions":3111,"interventions":3114},"NCT02559414","Antiplatelet Therapy in HIV",[90],"2016-04","2017-02","2015-02",55,[3112,33,3113],"HIV","Inflammation",[3085,3115],"Clopidogrel",{"trials":3117,"activeCount":100},[],{"trials":3119,"activeCount":100},[],{"trials":3121,"activeCount":100},[],{"intervention":3051,"totalTrials":190,"cells":3123},{"EARLY_PHASE1":3124,"PHASE1":3130,"PHASE2":3132,"PHASE3":3134,"PHASE4":3136,"NA":3138},{"trials":3125,"activeCount":190,"soonestReadout":3046},[3126],{"nctId":3043,"briefTitle":3044,"status":152,"phases":3127,"primaryCompletion":3046,"completion":3046,"start":3047,"enrollment":1715,"conditions":3128,"interventions":3129},[88],[3049],[3051,3038],{"trials":3131,"activeCount":100},[],{"trials":3133,"activeCount":100},[],{"trials":3135,"activeCount":100},[],{"trials":3137,"activeCount":100},[],{"trials":3139,"activeCount":100},[],{"intervention":3141,"totalTrials":190,"cells":3142},"Psilocybin 25 mg",{"EARLY_PHASE1":3143,"PHASE1":3154,"PHASE2":3156,"PHASE3":3158,"PHASE4":3160,"NA":3162},{"trials":3144,"activeCount":190,"soonestReadout":3149},[3145],{"nctId":3146,"briefTitle":3147,"status":206,"phases":3148,"primaryCompletion":3149,"completion":3149,"start":154,"enrollment":112,"conditions":3150,"interventions":3152},"NCT06760533","Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)",[88],"2026-12",[3151],"IBS - Irritable Bowel Syndrome",[3141,3153],"Niacin 100 mg",{"trials":3155,"activeCount":100},[],{"trials":3157,"activeCount":100},[],{"trials":3159,"activeCount":100},[],{"trials":3161,"activeCount":100},[],{"trials":3163,"activeCount":100},[],{"intervention":3153,"totalTrials":190,"cells":3165},{"EARLY_PHASE1":3166,"PHASE1":3172,"PHASE2":3174,"PHASE3":3176,"PHASE4":3178,"NA":3180},{"trials":3167,"activeCount":190,"soonestReadout":3149},[3168],{"nctId":3146,"briefTitle":3147,"status":206,"phases":3169,"primaryCompletion":3149,"completion":3149,"start":154,"enrollment":112,"conditions":3170,"interventions":3171},[88],[3151],[3141,3153],{"trials":3173,"activeCount":100},[],{"trials":3175,"activeCount":100},[],{"trials":3177,"activeCount":100},[],{"trials":3179,"activeCount":100},[],{"trials":3181,"activeCount":100},[],{"intervention":3183,"totalTrials":190,"cells":3184},"XRD-0394",{"EARLY_PHASE1":3185,"PHASE1":3195,"PHASE2":3197,"PHASE3":3199,"PHASE4":3201,"NA":3203},{"trials":3186,"activeCount":190,"soonestReadout":1951},[3187],{"nctId":3188,"briefTitle":3189,"status":152,"phases":3190,"primaryCompletion":1951,"completion":183,"start":3191,"enrollment":9,"conditions":3192,"interventions":3194},"NCT06829173","Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas",[88],"2025-11-05",[3193],"High-Grade Glioma",[3183],{"trials":3196,"activeCount":100},[],{"trials":3198,"activeCount":100},[],{"trials":3200,"activeCount":100},[],{"trials":3202,"activeCount":100},[],{"trials":3204,"activeCount":100},[],{"intervention":3206,"totalTrials":96,"cells":3207},"Tranexamic Acid",{"EARLY_PHASE1":3208,"PHASE1":3210,"PHASE2":3212,"PHASE3":3214,"PHASE4":3216,"NA":3282},{"trials":3209,"activeCount":100},[],{"trials":3211,"activeCount":100},[],{"trials":3213,"activeCount":100},[],{"trials":3215,"activeCount":100},[],{"trials":3217,"activeCount":100},[3218,3228,3238,3253,3263,3273],{"nctId":3219,"briefTitle":3220,"status":119,"phases":3221,"primaryCompletion":3222,"completion":3222,"start":3223,"enrollment":3224,"conditions":3225,"interventions":3227},"NCT03606109","Reducing Hemarthrosis in Tibial Tubercle Osteotomy by the Administration of Intravenous Tranexamic Acid",[92],"2021-06-02","2018-06-26",58,[3226],"Tibial Tubercle Osteotomy",[3206],{"nctId":3229,"briefTitle":3230,"status":119,"phases":3231,"primaryCompletion":3232,"completion":3232,"start":3233,"enrollment":3234,"conditions":3235,"interventions":3237},"NCT03631355","Reducing Hemarthrosis in ACL Reconstruction With BTB Autograft by the Administration of Intravenous TXA",[92],"2020-03-01","2018-06-06",110,[3236],"Anterior Cruciate Ligament Reconstruction",[3206],{"nctId":3239,"briefTitle":3240,"status":108,"phases":3241,"primaryCompletion":3242,"completion":3242,"start":3243,"enrollment":3244,"conditions":3245,"interventions":3247},"NCT04814433","Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation",[92],"2023-07-10","2021-03-24",46,[3246],"Opioid Pain Medication",[3248,3249,3250,3251,3252],"Tranexamic acid","Aminocaproic acid","Recombinant Human Thrombin","Lidocaine Hydrochloride with Epinephrine","Bupivacaine Hydrochloride with Epinephrine",{"nctId":3254,"briefTitle":3255,"status":108,"phases":3256,"primaryCompletion":3257,"completion":3257,"start":3258,"enrollment":3259,"conditions":3260,"interventions":3262},"NCT04560010","TXA in Anticoagulated Patients Study",[92],"2023-03-11","2020-10-06",17,[3261],"Total Shoulder Athroplasty",[3206],{"nctId":3264,"briefTitle":3265,"status":119,"phases":3266,"primaryCompletion":1533,"completion":1533,"start":1899,"enrollment":3267,"conditions":3268,"interventions":3270},"NCT00958581","Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery",[92],177,[3269],"Scoliosis",[3206,3271,3272],"Normal Saline","Epsilon aminocaproic acid",{"nctId":3274,"briefTitle":3275,"status":108,"phases":3276,"primaryCompletion":3277,"completion":3277,"start":1652,"enrollment":34,"conditions":3278,"interventions":3280},"NCT04650698","TXA in Revision Total Shoulder Arthroplasty",[92],"2023-03-12",[3279],"Arthropathy Shoulder",[3281],"Tranexamic acid (TXA)",{"trials":3283,"activeCount":190,"soonestReadout":3288},[3284],{"nctId":3285,"briefTitle":3286,"status":206,"phases":3287,"primaryCompletion":3288,"completion":3288,"start":3289,"enrollment":3290,"conditions":3291,"interventions":3293},"NCT07494032","Extended Oral Tranexamic Acid After Primary Total Knee Arthroplasty",[93],"2029-05-01","2026-05-01",350,[3292],"Knee Arthropathy",[3248],{"intervention":3295,"totalTrials":195,"cells":3296},"Medication",{"EARLY_PHASE1":3297,"PHASE1":3299,"PHASE2":3301,"PHASE3":3303,"PHASE4":3305,"NA":3322},{"trials":3298,"activeCount":100},[],{"trials":3300,"activeCount":100},[],{"trials":3302,"activeCount":100},[],{"trials":3304,"activeCount":100},[],{"trials":3306,"activeCount":100},[3307],{"nctId":3308,"briefTitle":3309,"status":119,"phases":3310,"primaryCompletion":3311,"completion":3312,"start":3313,"enrollment":3314,"conditions":3315,"interventions":3321},"NCT01985360","ISCHEMIA-Chronic Kidney Disease Trial",[92],"2019-06","2020-07","2014-01",777,[33,3316,3317,3318,3319,3320],"Coronary Artery Disease","Heart Diseases","Myocardial Ischemia","Kidney Disease","End Stage Renal Failure on Dialysis",[3295],{"trials":3323,"activeCount":190,"soonestReadout":3339},[3324,3335],{"nctId":3325,"briefTitle":3326,"status":119,"phases":3327,"primaryCompletion":3328,"completion":3329,"start":3330,"enrollment":3331,"conditions":3332,"interventions":3334},"NCT01471522","International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)",[93],"2019-06-30","2023-05-30","2012-07",5179,[33,3333,3316,3317,3318],"Coronary Disease",[3295],{"nctId":3336,"briefTitle":3337,"status":141,"phases":3338,"primaryCompletion":3339,"completion":3339,"start":3330,"enrollment":3340,"conditions":3341,"interventions":3342},"NCT04894877","ISCHEMIA-EXTEND (Extended Follow-up)",[],"2026-03-31",5391,[33,3333,3316,3317,3318],[3295],{"intervention":72,"totalTrials":173,"cells":3344},{"EARLY_PHASE1":3345,"PHASE1":3347,"PHASE2":3349,"PHASE3":3351,"PHASE4":3353,"NA":3365},{"trials":3346,"activeCount":100},[],{"trials":3348,"activeCount":100},[],{"trials":3350,"activeCount":100},[],{"trials":3352,"activeCount":100},[],{"trials":3354,"activeCount":100},[3355],{"nctId":3356,"briefTitle":3357,"status":119,"phases":3358,"primaryCompletion":945,"completion":3359,"start":3360,"enrollment":461,"conditions":3361,"interventions":3362},"NCT01848899","Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography",[92],"2014-11","2013-02",[3316],[3363,3364,72],"Iodixanol","Ioxaglate",{"trials":3366,"activeCount":190,"soonestReadout":71},[3367],{"nctId":69,"briefTitle":70,"status":141,"phases":3368,"primaryCompletion":71,"completion":333,"start":3369,"enrollment":3370,"conditions":3371,"interventions":3374},[93],"2018-06-29",206,[3372,3373,3318],"Coronary Microvascular Disease","Ischemic Heart Disease",[72,3375,3376],"Adenosine","Heparin",{"intervention":3375,"totalTrials":190,"cells":3378},{"EARLY_PHASE1":3379,"PHASE1":3381,"PHASE2":3383,"PHASE3":3385,"PHASE4":3387,"NA":3389},{"trials":3380,"activeCount":100},[],{"trials":3382,"activeCount":100},[],{"trials":3384,"activeCount":100},[],{"trials":3386,"activeCount":100},[],{"trials":3388,"activeCount":100},[],{"trials":3390,"activeCount":190,"soonestReadout":71},[3391],{"nctId":69,"briefTitle":70,"status":141,"phases":3392,"primaryCompletion":71,"completion":333,"start":3369,"enrollment":3370,"conditions":3393,"interventions":3394},[93],[3372,3373,3318],[72,3375,3376],{"intervention":3376,"totalTrials":190,"cells":3396},{"EARLY_PHASE1":3397,"PHASE1":3399,"PHASE2":3401,"PHASE3":3403,"PHASE4":3405,"NA":3407},{"trials":3398,"activeCount":100},[],{"trials":3400,"activeCount":100},[],{"trials":3402,"activeCount":100},[],{"trials":3404,"activeCount":100},[],{"trials":3406,"activeCount":100},[],{"trials":3408,"activeCount":190,"soonestReadout":71},[3409],{"nctId":69,"briefTitle":70,"status":141,"phases":3410,"primaryCompletion":71,"completion":333,"start":3369,"enrollment":3370,"conditions":3411,"interventions":3412},[93],[3372,3373,3318],[72,3375,3376],{"intervention":3414,"totalTrials":190,"cells":3415},"Tc-99m Pentetate",{"EARLY_PHASE1":3416,"PHASE1":3418,"PHASE2":3420,"PHASE3":3422,"PHASE4":3424,"NA":3426},{"trials":3417,"activeCount":100},[],{"trials":3419,"activeCount":100},[],{"trials":3421,"activeCount":100},[],{"trials":3423,"activeCount":100},[],{"trials":3425,"activeCount":100},[],{"trials":3427,"activeCount":190,"soonestReadout":3432},[3428],{"nctId":3429,"briefTitle":3430,"status":141,"phases":3431,"primaryCompletion":3432,"completion":3432,"start":3433,"enrollment":9,"conditions":3434,"interventions":3436},"NCT06116253","Advanced Diffusion Imaging in Renal Cancer Patients",[93],"2028-12-01","2022-12-01",[3435],"Renal Cancer",[3414],{"intervention":3438,"totalTrials":190,"cells":3439},"PET Tracer",{"EARLY_PHASE1":3440,"PHASE1":3442,"PHASE2":3444,"PHASE3":3446,"PHASE4":3448,"NA":3450},{"trials":3441,"activeCount":100},[],{"trials":3443,"activeCount":100},[],{"trials":3445,"activeCount":100},[],{"trials":3447,"activeCount":100},[],{"trials":3449,"activeCount":100},[],{"trials":3451,"activeCount":190,"soonestReadout":246},[3452],{"nctId":3453,"briefTitle":3454,"status":141,"phases":3455,"primaryCompletion":246,"completion":246,"start":3456,"enrollment":632,"conditions":3457,"interventions":3459},"NCT05615415","Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI",[],"2022-02-15",[3458],"Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection",[3438,3460],"MRI Tracer",{"intervention":3460,"totalTrials":190,"cells":3462},{"EARLY_PHASE1":3463,"PHASE1":3465,"PHASE2":3467,"PHASE3":3469,"PHASE4":3471,"NA":3473},{"trials":3464,"activeCount":100},[],{"trials":3466,"activeCount":100},[],{"trials":3468,"activeCount":100},[],{"trials":3470,"activeCount":100},[],{"trials":3472,"activeCount":100},[],{"trials":3474,"activeCount":190,"soonestReadout":246},[3475],{"nctId":3453,"briefTitle":3454,"status":141,"phases":3476,"primaryCompletion":246,"completion":246,"start":3456,"enrollment":632,"conditions":3477,"interventions":3478},[],[3458],[3438,3460],{"intervention":3480,"totalTrials":190,"cells":3481},"Natera® Empower™ hereditary cancer panel test",{"EARLY_PHASE1":3482,"PHASE1":3484,"PHASE2":3486,"PHASE3":3488,"PHASE4":3490,"NA":3492},{"trials":3483,"activeCount":100},[],{"trials":3485,"activeCount":100},[],{"trials":3487,"activeCount":100},[],{"trials":3489,"activeCount":100},[],{"trials":3491,"activeCount":100},[],{"trials":3493,"activeCount":190,"soonestReadout":246},[3494],{"nctId":3495,"briefTitle":3496,"status":152,"phases":3497,"primaryCompletion":246,"completion":3498,"start":3499,"enrollment":3500,"conditions":3501,"interventions":3503},"NCT06926816","Universal Genetic Testing for Cancer Risk Reduction",[93],"2027-12-31","2025-03-04",600,[3502],"Genetic Testing",[3480],{"intervention":3505,"totalTrials":190,"cells":3506},"Bacteriophage Treatment",{"EARLY_PHASE1":3507,"PHASE1":3509,"PHASE2":3511,"PHASE3":3513,"PHASE4":3515,"NA":3517},{"trials":3508,"activeCount":100},[],{"trials":3510,"activeCount":100},[],{"trials":3512,"activeCount":100},[],{"trials":3514,"activeCount":100},[],{"trials":3516,"activeCount":100},[],{"trials":3518,"activeCount":190,"soonestReadout":3523},[3519],{"nctId":3520,"briefTitle":3521,"status":152,"phases":3522,"primaryCompletion":3523,"completion":3524,"start":3525,"enrollment":461,"conditions":3526,"interventions":3528},"NCT07076238","Biomarkers of Phage Treatment Response in NTM and Other Infections",[],"2030-06-25","2032-06-25","2025-06-25",[3527],"Nontuberculous Mycobacterial Lung Disease",[3505],{"intervention":3530,"totalTrials":190,"cells":3531},"Androgen Deprivation Therapy",{"EARLY_PHASE1":3532,"PHASE1":3534,"PHASE2":3536,"PHASE3":3538,"PHASE4":3540,"NA":3542},{"trials":3533,"activeCount":100},[],{"trials":3535,"activeCount":100},[],{"trials":3537,"activeCount":100},[],{"trials":3539,"activeCount":100},[],{"trials":3541,"activeCount":100},[],{"trials":3543,"activeCount":190,"soonestReadout":3093},[3544],{"nctId":3545,"briefTitle":3546,"status":152,"phases":3547,"primaryCompletion":3093,"completion":3548,"start":3549,"enrollment":22,"conditions":3550,"interventions":3552},"NCT07142967","Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)",[93],"2029-08-02","2025-08-15",[3551],"Intraprostatic Prostate Cancer",[3530],{"intervention":3554,"totalTrials":190,"cells":3555},"contrast agent, Gadolinium",{"EARLY_PHASE1":3556,"PHASE1":3558,"PHASE2":3560,"PHASE3":3562,"PHASE4":3564,"NA":3566},{"trials":3557,"activeCount":100},[],{"trials":3559,"activeCount":100},[],{"trials":3561,"activeCount":100},[],{"trials":3563,"activeCount":100},[],{"trials":3565,"activeCount":100},[],{"trials":3567,"activeCount":190,"soonestReadout":3572},[3568],{"nctId":3569,"briefTitle":3570,"status":141,"phases":3571,"primaryCompletion":3572,"completion":3572,"start":2853,"enrollment":1589,"conditions":3573,"interventions":3575},"NCT02270359","Research on Infarction With Open Arteries Using OCT and CMR",[93],"2025-10-31",[3574],"Myocardial Infarction",[3554],{"intervention":354,"totalTrials":268,"cells":3577},{"EARLY_PHASE1":3578,"PHASE1":3580,"PHASE2":3592,"PHASE3":3608,"PHASE4":3620,"NA":3639},{"trials":3579,"activeCount":100},[],{"trials":3581,"activeCount":100},[3582],{"nctId":3583,"briefTitle":3584,"status":108,"phases":3585,"primaryCompletion":3586,"completion":3586,"start":3587,"enrollment":190,"conditions":3588,"interventions":3591},"NCT05229653","The Using Postoperative Ketamine and Exploring the Effect on Endometriosis Pain (UPKEEEP) Study",[89],"2022-10-21","2022-04-12",[3589,3590],"Endometriosis","Post Operative Pain",[354],{"trials":3593,"activeCount":100},[3594,3598],{"nctId":344,"briefTitle":345,"status":119,"phases":3595,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":3596,"interventions":3597},[90],[352],[354,322],{"nctId":3599,"briefTitle":3600,"status":119,"phases":3601,"primaryCompletion":3602,"completion":3603,"start":3604,"enrollment":31,"conditions":3605,"interventions":3607},"NCT02106325","Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients",[90],"2016-02","2017-03","2013-12",[3606],"Depression",[354,1266],{"trials":3609,"activeCount":100},[3610],{"nctId":3611,"briefTitle":3612,"status":119,"phases":3613,"primaryCompletion":3614,"completion":3614,"start":3615,"enrollment":185,"conditions":3616,"interventions":3619},"NCT02452060","Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy",[90,91],"2017-04-13","2014-10",[3617,3618],"Pain","Postoperative Depression",[354],{"trials":3621,"activeCount":100},[3622,3631],{"nctId":3623,"briefTitle":3624,"status":119,"phases":3625,"primaryCompletion":3626,"completion":280,"start":3627,"enrollment":3244,"conditions":3628,"interventions":3630},"NCT02424591","A Comparison of Intra-op Ketamine vs Placebo in Patients Having Spinal Fusion",[92],"2016-01","2014-08",[3629],"Postoperative Pain",[354],{"nctId":3632,"briefTitle":3633,"status":119,"phases":3634,"primaryCompletion":3635,"completion":3635,"start":3636,"enrollment":1796,"conditions":3637,"interventions":3638},"NCT04831736","Effect of Postoperative Single Dose of Ketamine on Pain After Mastectomy",[92],"2022-03-29","2021-04-26",[3629],[354],{"trials":3640,"activeCount":100},[],{"intervention":3642,"totalTrials":195,"cells":3643},"Extended-Release Naltrexone",{"EARLY_PHASE1":3644,"PHASE1":3646,"PHASE2":3648,"PHASE3":3650,"PHASE4":3661,"NA":3686},{"trials":3645,"activeCount":100},[],{"trials":3647,"activeCount":100},[],{"trials":3649,"activeCount":100},[],{"trials":3651,"activeCount":100},[3652],{"nctId":3653,"briefTitle":3654,"status":119,"phases":3655,"primaryCompletion":3656,"completion":3656,"start":2854,"enrollment":3657,"conditions":3658,"interventions":3660},"NCT01180647","Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail",[91],"2013-07",48,[3659],"Opiate Dependence",[3642],{"trials":3662,"activeCount":100},[3663,3675],{"nctId":3664,"briefTitle":3665,"status":119,"phases":3666,"primaryCompletion":3667,"completion":3668,"start":3669,"enrollment":3670,"conditions":3671,"interventions":3674},"NCT01999946","Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry",[92],"2019-05-28","2020-12-24","2014-06-27",217,[3672,3673],"Heroin Dependence","Opioid-Related Disorders",[3642],{"nctId":3676,"briefTitle":3677,"status":119,"phases":3678,"primaryCompletion":3679,"completion":3680,"start":3681,"enrollment":3682,"conditions":3683,"interventions":3684},"NCT02032433","Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment",[92],"2017-01-25","2017-01-31","2014-01-29",570,[501],[3642,3685],"Buprenorphine-Naloxone",{"trials":3687,"activeCount":100},[],{"intervention":3689,"totalTrials":173,"cells":3690},"Losartan",{"EARLY_PHASE1":3691,"PHASE1":3693,"PHASE2":3695,"PHASE3":3697,"PHASE4":3699,"NA":3718},{"trials":3692,"activeCount":100},[],{"trials":3694,"activeCount":100},[],{"trials":3696,"activeCount":100},[],{"trials":3698,"activeCount":100},[],{"trials":3700,"activeCount":100},[3701,3710],{"nctId":3702,"briefTitle":3703,"status":294,"phases":3704,"primaryCompletion":3705,"completion":3705,"start":3706,"enrollment":100,"conditions":3707,"interventions":3709},"NCT05157464","Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty",[92],"2024-12-31","2023-09-01",[3708],"Arthrofibrosis",[3689],{"nctId":3711,"briefTitle":3712,"status":294,"phases":3713,"primaryCompletion":3714,"completion":3714,"start":1588,"enrollment":100,"conditions":3715,"interventions":3717},"NCT06333522","Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty",[92],"2026-01-01",[3716],"Arthrofibrosis of Knee",[3689],{"trials":3719,"activeCount":100},[],{"intervention":3721,"totalTrials":173,"cells":3722},"Memantine",{"EARLY_PHASE1":3723,"PHASE1":3725,"PHASE2":3727,"PHASE3":3729,"PHASE4":3731,"NA":3751},{"trials":3724,"activeCount":100},[],{"trials":3726,"activeCount":100},[],{"trials":3728,"activeCount":100},[],{"trials":3730,"activeCount":100},[],{"trials":3732,"activeCount":100},[3733,3742],{"nctId":3734,"briefTitle":3735,"status":119,"phases":3736,"primaryCompletion":3737,"completion":3737,"start":3738,"enrollment":2797,"conditions":3739,"interventions":3741},"NCT00120874","Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training",[92],"2011-11","2006-08",[3740],"Alzheimer's Disease",[3721],{"nctId":3743,"briefTitle":3744,"status":119,"phases":3745,"primaryCompletion":3746,"completion":3746,"start":3747,"enrollment":3259,"conditions":3748,"interventions":3749},"NCT00933608","Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease",[92],"2011-09","2009-07",[3740],[3750],"memantine",{"trials":3752,"activeCount":100},[],{"intervention":3754,"totalTrials":173,"cells":3755},"Oxytocin",{"EARLY_PHASE1":3756,"PHASE1":3758,"PHASE2":3760,"PHASE3":3762,"PHASE4":3774,"NA":3785},{"trials":3757,"activeCount":100},[],{"trials":3759,"activeCount":100},[],{"trials":3761,"activeCount":100},[],{"trials":3763,"activeCount":100},[3764],{"nctId":3765,"briefTitle":3766,"status":108,"phases":3767,"primaryCompletion":3768,"completion":3768,"start":3769,"enrollment":3770,"conditions":3771,"interventions":3773},"NCT04210310","High Dose Oxytocin Nasal Spray for Treatment of Tinnitus",[91],"2022-05-10","2020-01-15",33,[3772],"Tinnitus",[3754],{"trials":3775,"activeCount":100},[3776],{"nctId":3777,"briefTitle":3778,"status":294,"phases":3779,"primaryCompletion":3780,"completion":3780,"start":1505,"enrollment":100,"conditions":3781,"interventions":3784},"NCT02410655","An Evidence Based Protocol for Oxytocin Administration in Vaginal Delivery",[92],"2017-07-27",[3782,3783],"Uterine Atony","Postpartum Hemorrhage",[3754,3754],{"trials":3786,"activeCount":100},[],{"intervention":3788,"totalTrials":173,"cells":3789},"Colchicine",{"EARLY_PHASE1":3790,"PHASE1":3792,"PHASE2":3794,"PHASE3":3796,"PHASE4":3798,"NA":3819},{"trials":3791,"activeCount":100},[],{"trials":3793,"activeCount":100},[],{"trials":3795,"activeCount":100},[],{"trials":3797,"activeCount":100},[],{"trials":3799,"activeCount":100},[3800,3809],{"nctId":3801,"briefTitle":3802,"status":119,"phases":3803,"primaryCompletion":3804,"completion":3804,"start":3805,"enrollment":112,"conditions":3806,"interventions":3808},"NCT02140372","Anti-platelet Effects of Colchicine in Healthy Volunteers",[92],"2015-01","2014-05",[3807],"Healthy",[3788],{"nctId":3810,"briefTitle":3811,"status":119,"phases":3812,"primaryCompletion":3813,"completion":3814,"start":3815,"enrollment":3816,"conditions":3817,"interventions":3818},"NCT01709981","Anti-inflammatory Effects of Colchicine in PCI",[92],"2019-08-30","2021-12-13","2013-05-30",280,[3316],[3788],{"trials":3820,"activeCount":100},[],{"intervention":3822,"totalTrials":173,"cells":3823},"Acetaminophen",{"EARLY_PHASE1":3824,"PHASE1":3826,"PHASE2":3828,"PHASE3":3830,"PHASE4":3841,"NA":3853},{"trials":3825,"activeCount":100},[],{"trials":3827,"activeCount":100},[],{"trials":3829,"activeCount":100},[],{"trials":3831,"activeCount":100},[3832],{"nctId":3833,"briefTitle":3834,"status":294,"phases":3835,"primaryCompletion":3836,"completion":3837,"start":3838,"enrollment":100,"conditions":3839,"interventions":3840},"NCT02737124","Acetaminophen Randomized Controlled Trial",[91],"2018-03-01","2018-03-19","2017-02-16",[3590],[3822],{"trials":3842,"activeCount":100},[3843],{"nctId":3844,"briefTitle":3845,"status":119,"phases":3846,"primaryCompletion":3847,"completion":3847,"start":3848,"enrollment":461,"conditions":3849,"interventions":3851},"NCT03510910","Multimodal Analgesia With Acetaminophen vs. Narcotics Alone After Hip Arthroscopy",[92],"2019-12-01","2018-04-10",[3850],"Hip Arthroscopy",[3822,3852],"Percocet",{"trials":3854,"activeCount":100},[],{"intervention":3363,"totalTrials":190,"cells":3856},{"EARLY_PHASE1":3857,"PHASE1":3859,"PHASE2":3861,"PHASE3":3863,"PHASE4":3865,"NA":3871},{"trials":3858,"activeCount":100},[],{"trials":3860,"activeCount":100},[],{"trials":3862,"activeCount":100},[],{"trials":3864,"activeCount":100},[],{"trials":3866,"activeCount":100},[3867],{"nctId":3356,"briefTitle":3357,"status":119,"phases":3868,"primaryCompletion":945,"completion":3359,"start":3360,"enrollment":461,"conditions":3869,"interventions":3870},[92],[3316],[3363,3364,72],{"trials":3872,"activeCount":100},[],{"intervention":3364,"totalTrials":190,"cells":3874},{"EARLY_PHASE1":3875,"PHASE1":3877,"PHASE2":3879,"PHASE3":3881,"PHASE4":3883,"NA":3889},{"trials":3876,"activeCount":100},[],{"trials":3878,"activeCount":100},[],{"trials":3880,"activeCount":100},[],{"trials":3882,"activeCount":100},[],{"trials":3884,"activeCount":100},[3885],{"nctId":3356,"briefTitle":3357,"status":119,"phases":3886,"primaryCompletion":945,"completion":3359,"start":3360,"enrollment":461,"conditions":3887,"interventions":3888},[92],[3316],[3363,3364,72],{"trials":3890,"activeCount":100},[],{"intervention":3892,"totalTrials":190,"cells":3893},"Anti-ADHD medication",{"EARLY_PHASE1":3894,"PHASE1":3896,"PHASE2":3898,"PHASE3":3900,"PHASE4":3902,"NA":3915},{"trials":3895,"activeCount":100},[],{"trials":3897,"activeCount":100},[],{"trials":3899,"activeCount":100},[],{"trials":3901,"activeCount":100},[],{"trials":3903,"activeCount":100},[3904],{"nctId":3905,"briefTitle":3906,"status":119,"phases":3907,"completion":3908,"start":3909,"conditions":3910,"interventions":3914},"NCT00000388","Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA)",[92],"1999-11","1998-09",[3911,3912,3913],"Attention Deficit Disorder With Hyperactivity","Substance-related Disorders","Dyssocial Behavior",[3892],{"trials":3916,"activeCount":100},[],{"intervention":3918,"totalTrials":190,"cells":3919},"Colchicine 0.8 mg or 0.6 mg orally once daily",{"EARLY_PHASE1":3920,"PHASE1":3922,"PHASE2":3924,"PHASE3":3926,"PHASE4":3928,"NA":3938},{"trials":3921,"activeCount":100},[],{"trials":3923,"activeCount":100},[],{"trials":3925,"activeCount":100},[],{"trials":3927,"activeCount":100},[],{"trials":3929,"activeCount":100},[3930],{"nctId":3931,"briefTitle":3932,"status":119,"phases":3933,"primaryCompletion":3934,"completion":3934,"start":2120,"enrollment":878,"conditions":3935,"interventions":3937},"NCT03913442","Colchicine for the Treatment of Osteoarthritis of the Knee",[92],"2024-01-11",[3077,3936],"Osteo Arthritis Knee",[3918],{"trials":3939,"activeCount":100},[],{"intervention":1406,"totalTrials":190,"cells":3941},{"EARLY_PHASE1":3942,"PHASE1":3944,"PHASE2":3946,"PHASE3":3948,"PHASE4":3950,"NA":3956},{"trials":3943,"activeCount":100},[],{"trials":3945,"activeCount":100},[],{"trials":3947,"activeCount":100},[],{"trials":3949,"activeCount":100},[],{"trials":3951,"activeCount":100},[3952],{"nctId":1398,"briefTitle":1399,"status":294,"phases":3953,"primaryCompletion":1401,"completion":1401,"start":1402,"enrollment":100,"conditions":3954,"interventions":3955},[92],[1404],[43,1406,1407],{"trials":3957,"activeCount":100},[],{"intervention":1407,"totalTrials":190,"cells":3959},{"EARLY_PHASE1":3960,"PHASE1":3962,"PHASE2":3964,"PHASE3":3966,"PHASE4":3968,"NA":3974},{"trials":3961,"activeCount":100},[],{"trials":3963,"activeCount":100},[],{"trials":3965,"activeCount":100},[],{"trials":3967,"activeCount":100},[],{"trials":3969,"activeCount":100},[3970],{"nctId":1398,"briefTitle":1399,"status":294,"phases":3971,"primaryCompletion":1401,"completion":1401,"start":1402,"enrollment":100,"conditions":3972,"interventions":3973},[92],[1404],[43,1406,1407],{"trials":3975,"activeCount":100},[],{"intervention":3977,"totalTrials":190,"cells":3978},"Rivastigmine Patch",{"EARLY_PHASE1":3979,"PHASE1":3981,"PHASE2":3983,"PHASE3":3985,"PHASE4":3987,"NA":3999},{"trials":3980,"activeCount":100},[],{"trials":3982,"activeCount":100},[],{"trials":3984,"activeCount":100},[],{"trials":3986,"activeCount":100},[],{"trials":3988,"activeCount":100},[3989],{"nctId":3990,"briefTitle":3991,"status":119,"phases":3992,"primaryCompletion":3993,"completion":3994,"start":1899,"enrollment":632,"conditions":3995,"interventions":3998},"NCT00835159","Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial",[92],"2010-07","2010-10",[3996,3997],"Delirium","Postoperative Cognitive Dysfunction",[3977],{"trials":4000,"activeCount":100},[],{"intervention":4002,"totalTrials":190,"cells":4003},"Guanfacine extended release",{"EARLY_PHASE1":4004,"PHASE1":4006,"PHASE2":4008,"PHASE3":4010,"PHASE4":4012,"NA":4022},{"trials":4005,"activeCount":100},[],{"trials":4007,"activeCount":100},[],{"trials":4009,"activeCount":100},[],{"trials":4011,"activeCount":100},[],{"trials":4013,"activeCount":100},[4014],{"nctId":4015,"briefTitle":4016,"status":294,"phases":4017,"primaryCompletion":4018,"completion":4018,"start":3847,"enrollment":100,"conditions":4019,"interventions":4021},"NCT04066088","Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome",[92],"2020-08-21",[4020],"Prader-Willi Syndrome",[4002],{"trials":4023,"activeCount":100},[],{"intervention":4025,"totalTrials":190,"cells":4026},"Buprenorphine Naloxone",{"EARLY_PHASE1":4027,"PHASE1":4029,"PHASE2":4031,"PHASE3":4033,"PHASE4":4035,"NA":4045},{"trials":4028,"activeCount":100},[],{"trials":4030,"activeCount":100},[],{"trials":4032,"activeCount":100},[],{"trials":4034,"activeCount":100},[],{"trials":4036,"activeCount":100},[4037],{"nctId":4038,"briefTitle":4039,"status":119,"phases":4040,"primaryCompletion":4041,"completion":4041,"start":4042,"enrollment":1589,"conditions":4043,"interventions":4044},"NCT04283500","Buprenorphine Loading in the Emergency Department",[92],"2023-02-25","2020-11-01",[1655],[4025],{"trials":4046,"activeCount":100},[],{"intervention":4048,"totalTrials":190,"cells":4049},"Clevidipine",{"EARLY_PHASE1":4050,"PHASE1":4052,"PHASE2":4054,"PHASE3":4056,"PHASE4":4058,"NA":4068},{"trials":4051,"activeCount":100},[],{"trials":4053,"activeCount":100},[],{"trials":4055,"activeCount":100},[],{"trials":4057,"activeCount":100},[],{"trials":4059,"activeCount":100},[4060],{"nctId":4061,"briefTitle":4062,"status":119,"phases":4063,"primaryCompletion":4064,"completion":1806,"start":3747,"enrollment":28,"conditions":4065,"interventions":4067},"NCT00952081","A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients",[92],"2009-12",[18,4066,30],"Brain Tumor",[4048],{"trials":4069,"activeCount":100},[],{"intervention":4071,"totalTrials":190,"cells":4072},"XR-NTX+CM",{"EARLY_PHASE1":4073,"PHASE1":4075,"PHASE2":4077,"PHASE3":4079,"PHASE4":4081,"NA":4091},{"trials":4074,"activeCount":100},[],{"trials":4076,"activeCount":100},[],{"trials":4078,"activeCount":100},[],{"trials":4080,"activeCount":100},[],{"trials":4082,"activeCount":100},[4083],{"nctId":4084,"briefTitle":4085,"status":119,"phases":4086,"primaryCompletion":4087,"completion":4087,"start":4088,"enrollment":1715,"conditions":4089,"interventions":4090},"NCT02445339","Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users",[92],"2019-02-08","2015-07",[1264,849],[4071],{"trials":4092,"activeCount":100},[],{"intervention":4094,"totalTrials":190,"cells":4095},"Ursodiol",{"EARLY_PHASE1":4096,"PHASE1":4098,"PHASE2":4100,"PHASE3":4102,"PHASE4":4104,"NA":4116},{"trials":4097,"activeCount":100},[],{"trials":4099,"activeCount":100},[],{"trials":4101,"activeCount":100},[],{"trials":4103,"activeCount":100},[],{"trials":4105,"activeCount":100},[4106],{"nctId":4107,"briefTitle":4108,"status":119,"phases":4109,"primaryCompletion":4110,"completion":4111,"start":4112,"enrollment":1461,"conditions":4113,"interventions":4115},"NCT02748616","C. Difficile and Ursodiol",[92],"2019-11-01","2020-01-31","2017-03-01",[4114],"Diarrhea",[4094],{"trials":4117,"activeCount":100},[],{"intervention":4119,"totalTrials":190,"cells":4120},"Tolvaptan",{"EARLY_PHASE1":4121,"PHASE1":4123,"PHASE2":4125,"PHASE3":4127,"PHASE4":4129,"NA":4140},{"trials":4122,"activeCount":100},[],{"trials":4124,"activeCount":100},[],{"trials":4126,"activeCount":100},[],{"trials":4128,"activeCount":100},[],{"trials":4130,"activeCount":100},[4131],{"nctId":4132,"briefTitle":4133,"status":108,"phases":4134,"primaryCompletion":110,"completion":110,"start":1602,"enrollment":173,"conditions":4135,"interventions":4137},"NCT01890694","Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia",[92],[4136],"Hyponatremia",[4119,4138,4139],"Vital signs","Blood laboratory tests",{"trials":4141,"activeCount":100},[],{"intervention":4138,"totalTrials":190,"cells":4143},{"EARLY_PHASE1":4144,"PHASE1":4146,"PHASE2":4148,"PHASE3":4150,"PHASE4":4152,"NA":4158},{"trials":4145,"activeCount":100},[],{"trials":4147,"activeCount":100},[],{"trials":4149,"activeCount":100},[],{"trials":4151,"activeCount":100},[],{"trials":4153,"activeCount":100},[4154],{"nctId":4132,"briefTitle":4133,"status":108,"phases":4155,"primaryCompletion":110,"completion":110,"start":1602,"enrollment":173,"conditions":4156,"interventions":4157},[92],[4136],[4119,4138,4139],{"trials":4159,"activeCount":100},[],{"intervention":4139,"totalTrials":190,"cells":4161},{"EARLY_PHASE1":4162,"PHASE1":4164,"PHASE2":4166,"PHASE3":4168,"PHASE4":4170,"NA":4176},{"trials":4163,"activeCount":100},[],{"trials":4165,"activeCount":100},[],{"trials":4167,"activeCount":100},[],{"trials":4169,"activeCount":100},[],{"trials":4171,"activeCount":100},[4172],{"nctId":4132,"briefTitle":4133,"status":108,"phases":4173,"primaryCompletion":110,"completion":110,"start":1602,"enrollment":173,"conditions":4174,"interventions":4175},[92],[4136],[4119,4138,4139],{"trials":4177,"activeCount":100},[],{"intervention":491,"totalTrials":190,"cells":4179},{"EARLY_PHASE1":4180,"PHASE1":4182,"PHASE2":4184,"PHASE3":4186,"PHASE4":4188,"NA":4194},{"trials":4181,"activeCount":100},[],{"trials":4183,"activeCount":100},[],{"trials":4185,"activeCount":100},[],{"trials":4187,"activeCount":100},[],{"trials":4189,"activeCount":100},[4190],{"nctId":482,"briefTitle":483,"status":119,"phases":4191,"primaryCompletion":485,"completion":485,"start":486,"enrollment":487,"conditions":4192,"interventions":4193},[92],[489],[491,469],{"trials":4195,"activeCount":100},[],{"intervention":4197,"totalTrials":190,"cells":4198},"Bupivacaine 20mL 0.5%",{"EARLY_PHASE1":4199,"PHASE1":4201,"PHASE2":4203,"PHASE3":4205,"PHASE4":4207,"NA":4222},{"trials":4200,"activeCount":100},[],{"trials":4202,"activeCount":100},[],{"trials":4204,"activeCount":100},[],{"trials":4206,"activeCount":100},[],{"trials":4208,"activeCount":100},[4209],{"nctId":4210,"briefTitle":4211,"status":119,"phases":4212,"primaryCompletion":4213,"completion":4214,"start":4215,"enrollment":4216,"conditions":4217,"interventions":4219},"NCT04867369","Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis",[92],"2023-11-08","2023-11-11","2021-07-14",160,[4218],"Tendonitis",[4197,4220,4221],"Bupivacaine 20mL 0.25%","Bupivacaine up to 15mL 0.25%",{"trials":4223,"activeCount":100},[],{"intervention":4220,"totalTrials":190,"cells":4225},{"EARLY_PHASE1":4226,"PHASE1":4228,"PHASE2":4230,"PHASE3":4232,"PHASE4":4234,"NA":4240},{"trials":4227,"activeCount":100},[],{"trials":4229,"activeCount":100},[],{"trials":4231,"activeCount":100},[],{"trials":4233,"activeCount":100},[],{"trials":4235,"activeCount":100},[4236],{"nctId":4210,"briefTitle":4211,"status":119,"phases":4237,"primaryCompletion":4213,"completion":4214,"start":4215,"enrollment":4216,"conditions":4238,"interventions":4239},[92],[4218],[4197,4220,4221],{"trials":4241,"activeCount":100},[],{"intervention":4221,"totalTrials":190,"cells":4243},{"EARLY_PHASE1":4244,"PHASE1":4246,"PHASE2":4248,"PHASE3":4250,"PHASE4":4252,"NA":4258},{"trials":4245,"activeCount":100},[],{"trials":4247,"activeCount":100},[],{"trials":4249,"activeCount":100},[],{"trials":4251,"activeCount":100},[],{"trials":4253,"activeCount":100},[4254],{"nctId":4210,"briefTitle":4211,"status":119,"phases":4255,"primaryCompletion":4213,"completion":4214,"start":4215,"enrollment":4216,"conditions":4256,"interventions":4257},[92],[4218],[4197,4220,4221],{"trials":4259,"activeCount":100},[],{"intervention":4261,"totalTrials":190,"cells":4262},"Bupivacaine Hydrochloride",{"EARLY_PHASE1":4263,"PHASE1":4265,"PHASE2":4267,"PHASE3":4269,"PHASE4":4271,"NA":4283},{"trials":4264,"activeCount":100},[],{"trials":4266,"activeCount":100},[],{"trials":4268,"activeCount":100},[],{"trials":4270,"activeCount":100},[],{"trials":4272,"activeCount":100},[4273],{"nctId":4274,"briefTitle":4275,"status":119,"phases":4276,"primaryCompletion":4277,"completion":4278,"start":933,"enrollment":4279,"conditions":4280,"interventions":4282},"NCT04353414","Transmuscular Quadratus Lumborum Block Plus Pericapsular Injection vs Pericapsular Injection",[92],"2022-02-17","2022-02-23",104,[4281],"Hip Pain Chronic",[4261],{"trials":4284,"activeCount":100},[],{"intervention":4286,"totalTrials":190,"cells":4287},"Colchicine 0.6 mg",{"EARLY_PHASE1":4288,"PHASE1":4290,"PHASE2":4292,"PHASE3":4294,"PHASE4":4296,"NA":4306},{"trials":4289,"activeCount":100},[],{"trials":4291,"activeCount":100},[],{"trials":4293,"activeCount":100},[],{"trials":4295,"activeCount":100},[],{"trials":4297,"activeCount":100},[4298],{"nctId":4299,"briefTitle":4300,"status":294,"phases":4301,"primaryCompletion":4302,"completion":4302,"start":4303,"enrollment":100,"conditions":4304,"interventions":4305},"NCT02995512","Mechanistic Effects of Colchicine in Patients With Myocardial Infarction",[92],"2018-09-12","2017-05-01",[3574],[4286],{"trials":4307,"activeCount":100},[],{"intervention":4309,"totalTrials":190,"cells":4310},"Citalopram",{"EARLY_PHASE1":4311,"PHASE1":4313,"PHASE2":4315,"PHASE3":4317,"PHASE4":4319,"NA":4332},{"trials":4312,"activeCount":100},[],{"trials":4314,"activeCount":100},[],{"trials":4316,"activeCount":100},[],{"trials":4318,"activeCount":100},[],{"trials":4320,"activeCount":100},[4321],{"nctId":4322,"briefTitle":4323,"status":119,"phases":4324,"primaryCompletion":4325,"completion":4326,"start":4327,"enrollment":847,"conditions":4328,"interventions":4331},"NCT01041274","DECIFER: Depression and Citalopram In First Episode Recovery",[92],"2014-12","2018-03-26","2010-01",[4329,4330],"Schizophrenia","Schizophreniform Disorder",[4309],{"trials":4333,"activeCount":100},[],{"intervention":4335,"totalTrials":190,"cells":4336},"Saxenda",{"EARLY_PHASE1":4337,"PHASE1":4339,"PHASE2":4341,"PHASE3":4343,"PHASE4":4345,"NA":4356},{"trials":4338,"activeCount":100},[],{"trials":4340,"activeCount":100},[],{"trials":4342,"activeCount":100},[],{"trials":4344,"activeCount":100},[],{"trials":4346,"activeCount":100},[4347],{"nctId":4348,"briefTitle":4349,"status":119,"phases":4350,"primaryCompletion":4351,"completion":4351,"start":4352,"enrollment":4353,"conditions":4354,"interventions":4355},"NCT03048578","Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery",[92],"2021-03-02","2017-05-22",132,[27],[4335],{"trials":4357,"activeCount":100},[],{"intervention":4359,"totalTrials":190,"cells":4360},"Aspirin 81mg",{"EARLY_PHASE1":4361,"PHASE1":4363,"PHASE2":4365,"PHASE3":4367,"PHASE4":4369,"NA":4381},{"trials":4362,"activeCount":100},[],{"trials":4364,"activeCount":100},[],{"trials":4366,"activeCount":100},[],{"trials":4368,"activeCount":100},[],{"trials":4370,"activeCount":100},[4371],{"nctId":4372,"briefTitle":4373,"status":119,"phases":4374,"primaryCompletion":631,"completion":631,"start":4375,"enrollment":4376,"conditions":4377,"interventions":4379},"NCT04697719","Body Weight, Aspirin Dose and Pro-resolving Mediators",[92],"2021-11-04",103,[4378],"Body Weight",[4359,4380],"Aspirin 325mg",{"trials":4382,"activeCount":100},[],{"intervention":4380,"totalTrials":190,"cells":4384},{"EARLY_PHASE1":4385,"PHASE1":4387,"PHASE2":4389,"PHASE3":4391,"PHASE4":4393,"NA":4399},{"trials":4386,"activeCount":100},[],{"trials":4388,"activeCount":100},[],{"trials":4390,"activeCount":100},[],{"trials":4392,"activeCount":100},[],{"trials":4394,"activeCount":100},[4395],{"nctId":4372,"briefTitle":4373,"status":119,"phases":4396,"primaryCompletion":631,"completion":631,"start":4375,"enrollment":4376,"conditions":4397,"interventions":4398},[92],[4378],[4359,4380],{"trials":4400,"activeCount":100},[],{"intervention":4402,"totalTrials":190,"cells":4403},"Intravenous Placebo",{"EARLY_PHASE1":4404,"PHASE1":4406,"PHASE2":4408,"PHASE3":4410,"PHASE4":4412,"NA":4425},{"trials":4405,"activeCount":100},[],{"trials":4407,"activeCount":100},[],{"trials":4409,"activeCount":100},[],{"trials":4411,"activeCount":100},[],{"trials":4413,"activeCount":100},[4414],{"nctId":4415,"briefTitle":4416,"status":108,"phases":4417,"primaryCompletion":4418,"completion":4419,"start":4420,"enrollment":487,"conditions":4421,"interventions":4423},"NCT03825939","Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty",[92],"2016-07-26","2016-09-06","2015-04-21",[4422],"Blood Loss",[4402,4424],"Intravenous Tranexamic Acid",{"trials":4426,"activeCount":100},[],{"intervention":4424,"totalTrials":190,"cells":4428},{"EARLY_PHASE1":4429,"PHASE1":4431,"PHASE2":4433,"PHASE3":4435,"PHASE4":4437,"NA":4443},{"trials":4430,"activeCount":100},[],{"trials":4432,"activeCount":100},[],{"trials":4434,"activeCount":100},[],{"trials":4436,"activeCount":100},[],{"trials":4438,"activeCount":100},[4439],{"nctId":4415,"briefTitle":4416,"status":108,"phases":4440,"primaryCompletion":4418,"completion":4419,"start":4420,"enrollment":487,"conditions":4441,"interventions":4442},[92],[4422],[4402,4424],{"trials":4444,"activeCount":100},[],{"intervention":4446,"totalTrials":190,"cells":4447},"Topical Preparation H arm",{"EARLY_PHASE1":4448,"PHASE1":4450,"PHASE2":4452,"PHASE3":4454,"PHASE4":4456,"NA":4465},{"trials":4449,"activeCount":100},[],{"trials":4451,"activeCount":100},[],{"trials":4453,"activeCount":100},[],{"trials":4455,"activeCount":100},[],{"trials":4457,"activeCount":100},[4458],{"nctId":4459,"briefTitle":4460,"status":108,"phases":4461,"primaryCompletion":4462,"completion":4462,"start":4088,"enrollment":632,"conditions":4463,"interventions":4464},"NCT02665221","Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY",[92],"2016-09",[24],[4446],{"trials":4466,"activeCount":100},[],{"intervention":4468,"totalTrials":190,"cells":4469},"Ferumoxytol",{"EARLY_PHASE1":4470,"PHASE1":4472,"PHASE2":4474,"PHASE3":4476,"PHASE4":4478,"NA":4488},{"trials":4471,"activeCount":100},[],{"trials":4473,"activeCount":100},[],{"trials":4475,"activeCount":100},[],{"trials":4477,"activeCount":100},[],{"trials":4479,"activeCount":100},[4480],{"nctId":4481,"briefTitle":4482,"status":108,"phases":4483,"primaryCompletion":4484,"completion":4484,"start":3769,"enrollment":190,"conditions":4485,"interventions":4487},"NCT04080908","Study to Assess Feasibility and Safety of Iron Repletion With Feraheme in Iron Deficient Patients With Durable Ventricular Assist Device Support",[92],"2021-10-19",[4486],"Anemia",[4468],{"trials":4489,"activeCount":100},[],{"intervention":4491,"totalTrials":190,"cells":4492},"Statin",{"EARLY_PHASE1":4493,"PHASE1":4495,"PHASE2":4497,"PHASE3":4499,"PHASE4":4501,"NA":4516},{"trials":4494,"activeCount":100},[],{"trials":4496,"activeCount":100},[],{"trials":4498,"activeCount":100},[],{"trials":4500,"activeCount":100},[],{"trials":4502,"activeCount":100},[4503],{"nctId":4504,"briefTitle":4505,"status":119,"phases":4506,"primaryCompletion":4507,"completion":4508,"start":4509,"enrollment":4510,"conditions":4511,"interventions":4513},"NCT04369664","CHOlesterol Lowering and Residual Risk in Type 2 Diabetes",[92],"2023-09-25","2023-10-19","2020-08-12",151,[4512],"Type 2 Diabetes",[4491,4514,4515],"PCSK9 inhibitor","Ezetimibe 10mg",{"trials":4517,"activeCount":100},[],{"intervention":4514,"totalTrials":190,"cells":4519},{"EARLY_PHASE1":4520,"PHASE1":4522,"PHASE2":4524,"PHASE3":4526,"PHASE4":4528,"NA":4534},{"trials":4521,"activeCount":100},[],{"trials":4523,"activeCount":100},[],{"trials":4525,"activeCount":100},[],{"trials":4527,"activeCount":100},[],{"trials":4529,"activeCount":100},[4530],{"nctId":4504,"briefTitle":4505,"status":119,"phases":4531,"primaryCompletion":4507,"completion":4508,"start":4509,"enrollment":4510,"conditions":4532,"interventions":4533},[92],[4512],[4491,4514,4515],{"trials":4535,"activeCount":100},[],{"intervention":4515,"totalTrials":190,"cells":4537},{"EARLY_PHASE1":4538,"PHASE1":4540,"PHASE2":4542,"PHASE3":4544,"PHASE4":4546,"NA":4552},{"trials":4539,"activeCount":100},[],{"trials":4541,"activeCount":100},[],{"trials":4543,"activeCount":100},[],{"trials":4545,"activeCount":100},[],{"trials":4547,"activeCount":100},[4548],{"nctId":4504,"briefTitle":4505,"status":119,"phases":4549,"primaryCompletion":4507,"completion":4508,"start":4509,"enrollment":4510,"conditions":4550,"interventions":4551},[92],[4512],[4491,4514,4515],{"trials":4553,"activeCount":100},[],{"intervention":3685,"totalTrials":190,"cells":4555},{"EARLY_PHASE1":4556,"PHASE1":4558,"PHASE2":4560,"PHASE3":4562,"PHASE4":4564,"NA":4570},{"trials":4557,"activeCount":100},[],{"trials":4559,"activeCount":100},[],{"trials":4561,"activeCount":100},[],{"trials":4563,"activeCount":100},[],{"trials":4565,"activeCount":100},[4566],{"nctId":3676,"briefTitle":3677,"status":119,"phases":4567,"primaryCompletion":3679,"completion":3680,"start":3681,"enrollment":3682,"conditions":4568,"interventions":4569},[92],[501],[3642,3685],{"trials":4571,"activeCount":100},[],{"intervention":426,"totalTrials":190,"cells":4573},{"EARLY_PHASE1":4574,"PHASE1":4576,"PHASE2":4578,"PHASE3":4580,"PHASE4":4582,"NA":4588},{"trials":4575,"activeCount":100},[],{"trials":4577,"activeCount":100},[],{"trials":4579,"activeCount":100},[],{"trials":4581,"activeCount":100},[],{"trials":4583,"activeCount":100},[4584],{"nctId":417,"briefTitle":418,"status":119,"phases":4585,"primaryCompletion":420,"completion":420,"start":421,"enrollment":422,"conditions":4586,"interventions":4587},[92],[424],[426,368,427],{"trials":4589,"activeCount":100},[],{"intervention":427,"totalTrials":190,"cells":4591},{"EARLY_PHASE1":4592,"PHASE1":4594,"PHASE2":4596,"PHASE3":4598,"PHASE4":4600,"NA":4606},{"trials":4593,"activeCount":100},[],{"trials":4595,"activeCount":100},[],{"trials":4597,"activeCount":100},[],{"trials":4599,"activeCount":100},[],{"trials":4601,"activeCount":100},[4602],{"nctId":417,"briefTitle":418,"status":119,"phases":4603,"primaryCompletion":420,"completion":420,"start":421,"enrollment":422,"conditions":4604,"interventions":4605},[92],[424],[426,368,427],{"trials":4607,"activeCount":100},[],{"intervention":3249,"totalTrials":190,"cells":4609},{"EARLY_PHASE1":4610,"PHASE1":4612,"PHASE2":4614,"PHASE3":4616,"PHASE4":4618,"NA":4624},{"trials":4611,"activeCount":100},[],{"trials":4613,"activeCount":100},[],{"trials":4615,"activeCount":100},[],{"trials":4617,"activeCount":100},[],{"trials":4619,"activeCount":100},[4620],{"nctId":3239,"briefTitle":3240,"status":108,"phases":4621,"primaryCompletion":3242,"completion":3242,"start":3243,"enrollment":3244,"conditions":4622,"interventions":4623},[92],[3246],[3248,3249,3250,3251,3252],{"trials":4625,"activeCount":100},[],{"intervention":3250,"totalTrials":190,"cells":4627},{"EARLY_PHASE1":4628,"PHASE1":4630,"PHASE2":4632,"PHASE3":4634,"PHASE4":4636,"NA":4642},{"trials":4629,"activeCount":100},[],{"trials":4631,"activeCount":100},[],{"trials":4633,"activeCount":100},[],{"trials":4635,"activeCount":100},[],{"trials":4637,"activeCount":100},[4638],{"nctId":3239,"briefTitle":3240,"status":108,"phases":4639,"primaryCompletion":3242,"completion":3242,"start":3243,"enrollment":3244,"conditions":4640,"interventions":4641},[92],[3246],[3248,3249,3250,3251,3252],{"trials":4643,"activeCount":100},[],{"intervention":3251,"totalTrials":190,"cells":4645},{"EARLY_PHASE1":4646,"PHASE1":4648,"PHASE2":4650,"PHASE3":4652,"PHASE4":4654,"NA":4660},{"trials":4647,"activeCount":100},[],{"trials":4649,"activeCount":100},[],{"trials":4651,"activeCount":100},[],{"trials":4653,"activeCount":100},[],{"trials":4655,"activeCount":100},[4656],{"nctId":3239,"briefTitle":3240,"status":108,"phases":4657,"primaryCompletion":3242,"completion":3242,"start":3243,"enrollment":3244,"conditions":4658,"interventions":4659},[92],[3246],[3248,3249,3250,3251,3252],{"trials":4661,"activeCount":100},[],{"intervention":3252,"totalTrials":190,"cells":4663},{"EARLY_PHASE1":4664,"PHASE1":4666,"PHASE2":4668,"PHASE3":4670,"PHASE4":4672,"NA":4678},{"trials":4665,"activeCount":100},[],{"trials":4667,"activeCount":100},[],{"trials":4669,"activeCount":100},[],{"trials":4671,"activeCount":100},[],{"trials":4673,"activeCount":100},[4674],{"nctId":3239,"briefTitle":3240,"status":108,"phases":4675,"primaryCompletion":3242,"completion":3242,"start":3243,"enrollment":3244,"conditions":4676,"interventions":4677},[92],[3246],[3248,3249,3250,3251,3252],{"trials":4679,"activeCount":100},[],{"intervention":4681,"totalTrials":190,"cells":4682},"Patiromer",{"EARLY_PHASE1":4683,"PHASE1":4685,"PHASE2":4687,"PHASE3":4689,"PHASE4":4691,"NA":4703},{"trials":4684,"activeCount":100},[],{"trials":4686,"activeCount":100},[],{"trials":4688,"activeCount":100},[],{"trials":4690,"activeCount":100},[],{"trials":4692,"activeCount":100},[4693],{"nctId":4694,"briefTitle":4695,"status":119,"phases":4696,"primaryCompletion":4697,"completion":4697,"start":4698,"enrollment":195,"conditions":4699,"interventions":4702},"NCT03183778","Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.",[92],"2019-08-01","2018-03-12",[4700,4701],"Chronic Kidney Diseases","Hyperkalemia",[4681],{"trials":4704,"activeCount":100},[],{"intervention":4706,"totalTrials":190,"cells":4707},"Transplant with HCV positive donor, followed by surveillance and treatment of viremia",{"EARLY_PHASE1":4708,"PHASE1":4710,"PHASE2":4712,"PHASE3":4714,"PHASE4":4716,"NA":4727},{"trials":4709,"activeCount":100},[],{"trials":4711,"activeCount":100},[],{"trials":4713,"activeCount":100},[],{"trials":4715,"activeCount":100},[],{"trials":4717,"activeCount":100},[4718],{"nctId":4719,"briefTitle":4720,"status":119,"phases":4721,"primaryCompletion":4722,"completion":4722,"start":4723,"enrollment":1246,"conditions":4724,"interventions":4726},"NCT03382847","HCV Positive Heart Donors",[92],"2020-05-06","2018-01-05",[4725],"Heart Failure",[4706],{"trials":4728,"activeCount":100},[],{"intervention":4730,"totalTrials":190,"cells":4731},"Aspirin and\u002For Atorvastatin",{"EARLY_PHASE1":4732,"PHASE1":4734,"PHASE2":4736,"PHASE3":4738,"PHASE4":4740,"NA":4752},{"trials":4733,"activeCount":100},[],{"trials":4735,"activeCount":100},[],{"trials":4737,"activeCount":100},[],{"trials":4739,"activeCount":100},[],{"trials":4741,"activeCount":100},[4742],{"nctId":4743,"briefTitle":4744,"status":119,"phases":4745,"primaryCompletion":4746,"completion":4746,"start":4747,"enrollment":1603,"conditions":4748,"interventions":4751},"NCT03228017","Subclinical Cardiovascular Disease in Psoriatic Disease",[92],"2019-04-01","2017-08-01",[33,3574,4749,4750],"Atherosclerotic Cardiovascular Disease","Thrombotic Vascular Disease",[4730],{"trials":4753,"activeCount":100},[],{"intervention":978,"totalTrials":190,"cells":4755},{"EARLY_PHASE1":4756,"PHASE1":4758,"PHASE2":4760,"PHASE3":4762,"PHASE4":4764,"NA":4770},{"trials":4757,"activeCount":100},[],{"trials":4759,"activeCount":100},[],{"trials":4761,"activeCount":100},[],{"trials":4763,"activeCount":100},[],{"trials":4765,"activeCount":100},[4766],{"nctId":969,"briefTitle":970,"status":108,"phases":4767,"primaryCompletion":972,"completion":973,"start":974,"enrollment":946,"conditions":4768,"interventions":4769},[92],[976],[978,898],{"trials":4771,"activeCount":100},[],{"intervention":4773,"totalTrials":190,"cells":4774},"Nebulized 3% sodium chloride solution",{"EARLY_PHASE1":4775,"PHASE1":4777,"PHASE2":4779,"PHASE3":4781,"PHASE4":4783,"NA":4794},{"trials":4776,"activeCount":100},[],{"trials":4778,"activeCount":100},[],{"trials":4780,"activeCount":100},[],{"trials":4782,"activeCount":100},[],{"trials":4784,"activeCount":100},[4785],{"nctId":4786,"briefTitle":4787,"status":108,"phases":4788,"primaryCompletion":4789,"completion":4789,"start":4790,"enrollment":262,"conditions":4791,"interventions":4793},"NCT06441162","Efficacy Of Combined Nebulized Hypertonic Saline and Chest Percussion Therapy in Acute Viral Bronchiolitis",[92],"2025-05-15","2024-07-15",[4792],"Acute Bronchiolitis",[4773],{"trials":4795,"activeCount":100},[],{"intervention":4797,"totalTrials":190,"cells":4798},"Norco",{"EARLY_PHASE1":4799,"PHASE1":4801,"PHASE2":4803,"PHASE3":4805,"PHASE4":4807,"NA":4821},{"trials":4800,"activeCount":100},[],{"trials":4802,"activeCount":100},[],{"trials":4804,"activeCount":100},[],{"trials":4806,"activeCount":100},[],{"trials":4808,"activeCount":100},[4809],{"nctId":4810,"briefTitle":4811,"status":119,"phases":4812,"primaryCompletion":4813,"completion":4813,"start":4814,"enrollment":1368,"conditions":4815,"interventions":4819},"NCT03457116","Narcotics vs NSAIDs for Post-operative Analgesia in Outpatient Rhinoplasty",[92],"2020-11-02","2018-01-30",[4816,4817,4818],"Rhinoplasty","Non-steroidal Ant Inflammatory Drugs","Opioid Use",[4797,4820],"NSAID",{"trials":4822,"activeCount":100},[],{"intervention":4820,"totalTrials":190,"cells":4824},{"EARLY_PHASE1":4825,"PHASE1":4827,"PHASE2":4829,"PHASE3":4831,"PHASE4":4833,"NA":4839},{"trials":4826,"activeCount":100},[],{"trials":4828,"activeCount":100},[],{"trials":4830,"activeCount":100},[],{"trials":4832,"activeCount":100},[],{"trials":4834,"activeCount":100},[4835],{"nctId":4810,"briefTitle":4811,"status":119,"phases":4836,"primaryCompletion":4813,"completion":4813,"start":4814,"enrollment":1368,"conditions":4837,"interventions":4838},[92],[4816,4817,4818],[4797,4820],{"trials":4840,"activeCount":100},[],{"intervention":4842,"totalTrials":190,"cells":4843},"Tiopronin 1g per day",{"EARLY_PHASE1":4844,"PHASE1":4846,"PHASE2":4848,"PHASE3":4850,"PHASE4":4852,"NA":4864},{"trials":4845,"activeCount":100},[],{"trials":4847,"activeCount":100},[],{"trials":4849,"activeCount":100},[],{"trials":4851,"activeCount":100},[],{"trials":4853,"activeCount":100},[4854],{"nctId":4855,"briefTitle":4856,"status":119,"phases":4857,"primaryCompletion":4858,"completion":4858,"start":1419,"enrollment":112,"conditions":4859,"interventions":4861},"NCT02125721","Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria",[92],"2017-12",[4860],"Cystinuria",[4842,4862,4863],"Tiopronin 2g per day","Tiopronin 3g per day",{"trials":4865,"activeCount":100},[],{"intervention":4862,"totalTrials":190,"cells":4867},{"EARLY_PHASE1":4868,"PHASE1":4870,"PHASE2":4872,"PHASE3":4874,"PHASE4":4876,"NA":4882},{"trials":4869,"activeCount":100},[],{"trials":4871,"activeCount":100},[],{"trials":4873,"activeCount":100},[],{"trials":4875,"activeCount":100},[],{"trials":4877,"activeCount":100},[4878],{"nctId":4855,"briefTitle":4856,"status":119,"phases":4879,"primaryCompletion":4858,"completion":4858,"start":1419,"enrollment":112,"conditions":4880,"interventions":4881},[92],[4860],[4842,4862,4863],{"trials":4883,"activeCount":100},[],{"intervention":4863,"totalTrials":190,"cells":4885},{"EARLY_PHASE1":4886,"PHASE1":4888,"PHASE2":4890,"PHASE3":4892,"PHASE4":4894,"NA":4900},{"trials":4887,"activeCount":100},[],{"trials":4889,"activeCount":100},[],{"trials":4891,"activeCount":100},[],{"trials":4893,"activeCount":100},[],{"trials":4895,"activeCount":100},[4896],{"nctId":4855,"briefTitle":4856,"status":119,"phases":4897,"primaryCompletion":4858,"completion":4858,"start":1419,"enrollment":112,"conditions":4898,"interventions":4899},[92],[4860],[4842,4862,4863],{"trials":4901,"activeCount":100},[],{"intervention":4903,"totalTrials":190,"cells":4904},"Aripiprazole",{"EARLY_PHASE1":4905,"PHASE1":4907,"PHASE2":4909,"PHASE3":4911,"PHASE4":4913,"NA":4925},{"trials":4906,"activeCount":100},[],{"trials":4908,"activeCount":100},[],{"trials":4910,"activeCount":100},[],{"trials":4912,"activeCount":100},[],{"trials":4914,"activeCount":100},[4915],{"nctId":4916,"briefTitle":4917,"status":119,"phases":4918,"primaryCompletion":4919,"completion":1806,"start":4920,"enrollment":1826,"conditions":4921,"interventions":4924},"NCT00241176","Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder",[92],"2008-08","2005-09",[4922,4923],"Tourette's Syndrome","Tic Disorders",[4903],{"trials":4926,"activeCount":100},[],{"intervention":4928,"totalTrials":190,"cells":4929},"D-Cycloserine",{"EARLY_PHASE1":4930,"PHASE1":4932,"PHASE2":4934,"PHASE3":4936,"PHASE4":4938,"NA":4949},{"trials":4931,"activeCount":100},[],{"trials":4933,"activeCount":100},[],{"trials":4935,"activeCount":100},[],{"trials":4937,"activeCount":100},[],{"trials":4939,"activeCount":100},[4940],{"nctId":4941,"briefTitle":4942,"status":119,"phases":4943,"primaryCompletion":4944,"completion":2746,"start":1714,"enrollment":3224,"conditions":4945,"interventions":4948},"NCT01981759","D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions",[92],"2017-05",[4329,4946,4947],"Schizoaffective Disorder","Delusional Disorder",[4928],{"trials":4950,"activeCount":100},[],{"intervention":3081,"totalTrials":190,"cells":4952},{"EARLY_PHASE1":4953,"PHASE1":4955,"PHASE2":4957,"PHASE3":4959,"PHASE4":4961,"NA":4967},{"trials":4954,"activeCount":100},[],{"trials":4956,"activeCount":100},[],{"trials":4958,"activeCount":100},[],{"trials":4960,"activeCount":100},[],{"trials":4962,"activeCount":100},[4963],{"nctId":3071,"briefTitle":3072,"status":108,"phases":4964,"primaryCompletion":3074,"completion":3074,"start":1714,"enrollment":3075,"conditions":4965,"interventions":4966},[92],[3077,3078],[3080,3081,3038],{"trials":4968,"activeCount":100},[],{"intervention":1657,"totalTrials":190,"cells":4970},{"EARLY_PHASE1":4971,"PHASE1":4973,"PHASE2":4975,"PHASE3":4977,"PHASE4":4979,"NA":4985},{"trials":4972,"activeCount":100},[],{"trials":4974,"activeCount":100},[],{"trials":4976,"activeCount":100},[],{"trials":4978,"activeCount":100},[],{"trials":4980,"activeCount":100},[4981],{"nctId":1647,"briefTitle":1648,"status":119,"phases":4982,"primaryCompletion":1650,"completion":1651,"start":1652,"enrollment":1653,"conditions":4983,"interventions":4984},[92],[1655],[1657,1622],{"trials":4986,"activeCount":100},[],{"intervention":4988,"totalTrials":190,"cells":4989},"Masked Placebo",{"EARLY_PHASE1":4990,"PHASE1":4992,"PHASE2":4994,"PHASE3":4996,"PHASE4":4998,"NA":5012},{"trials":4991,"activeCount":100},[],{"trials":4993,"activeCount":100},[],{"trials":4995,"activeCount":100},[],{"trials":4997,"activeCount":100},[],{"trials":4999,"activeCount":100},[5000],{"nctId":5001,"briefTitle":5002,"status":119,"phases":5003,"primaryCompletion":5004,"completion":5005,"start":5006,"enrollment":5007,"conditions":5008,"interventions":5010},"NCT03134196","Zoster Eye Disease Study",[92],"2023-12-31","2024-07-22","2017-08-23",527,[5009],"Herpes Zoster Ophthalmicus",[4988,5011],"Masked Oral Valacyclovir",{"trials":5013,"activeCount":100},[],{"intervention":5011,"totalTrials":190,"cells":5015},{"EARLY_PHASE1":5016,"PHASE1":5018,"PHASE2":5020,"PHASE3":5022,"PHASE4":5024,"NA":5030},{"trials":5017,"activeCount":100},[],{"trials":5019,"activeCount":100},[],{"trials":5021,"activeCount":100},[],{"trials":5023,"activeCount":100},[],{"trials":5025,"activeCount":100},[5026],{"nctId":5001,"briefTitle":5002,"status":119,"phases":5027,"primaryCompletion":5004,"completion":5005,"start":5006,"enrollment":5007,"conditions":5028,"interventions":5029},[92],[5009],[4988,5011],{"trials":5031,"activeCount":100},[],{"intervention":1666,"totalTrials":190,"cells":5033},{"EARLY_PHASE1":5034,"PHASE1":5036,"PHASE2":5038,"PHASE3":5040,"PHASE4":5042,"NA":5048},{"trials":5035,"activeCount":100},[],{"trials":5037,"activeCount":100},[],{"trials":5039,"activeCount":100},[],{"trials":5041,"activeCount":100},[],{"trials":5043,"activeCount":100},[5044],{"nctId":1659,"briefTitle":1660,"status":119,"phases":5045,"primaryCompletion":1662,"completion":1662,"start":1262,"enrollment":1663,"conditions":5046,"interventions":5047},[92],[1264],[1622,1666],{"trials":5049,"activeCount":100},[],{"intervention":1448,"totalTrials":190,"cells":5051},{"EARLY_PHASE1":5052,"PHASE1":5054,"PHASE2":5056,"PHASE3":5058,"PHASE4":5060,"NA":5066},{"trials":5053,"activeCount":100},[],{"trials":5055,"activeCount":100},[],{"trials":5057,"activeCount":100},[],{"trials":5059,"activeCount":100},[],{"trials":5061,"activeCount":100},[5062],{"nctId":1440,"briefTitle":1441,"status":119,"phases":5063,"primaryCompletion":1443,"completion":1443,"start":1444,"enrollment":1246,"conditions":5064,"interventions":5065},[92],[1446],[230,1448],{"trials":5067,"activeCount":100},[],{"intervention":5069,"totalTrials":190,"cells":5070},"Sertraline",{"EARLY_PHASE1":5071,"PHASE1":5073,"PHASE2":5075,"PHASE3":5077,"PHASE4":5079,"NA":5089},{"trials":5072,"activeCount":100},[],{"trials":5074,"activeCount":100},[],{"trials":5076,"activeCount":100},[],{"trials":5078,"activeCount":100},[],{"trials":5080,"activeCount":100},[5081],{"nctId":5082,"briefTitle":5083,"status":108,"phases":5084,"primaryCompletion":3747,"completion":3747,"start":5085,"enrollment":9,"conditions":5086,"interventions":5088},"NCT00391430","Cognitive Behavioral Therapy Versus Sertraline in the Treatment of Post-Traumatic Stress Disorder",[92],"2005-05",[5087],"Post-Traumatic Stress Disorder",[5069],{"trials":5090,"activeCount":100},[],{"intervention":5092,"totalTrials":190,"cells":5093},"Liposomal Bupivacaine",{"EARLY_PHASE1":5094,"PHASE1":5096,"PHASE2":5098,"PHASE3":5100,"PHASE4":5102,"NA":5115},{"trials":5095,"activeCount":100},[],{"trials":5097,"activeCount":100},[],{"trials":5099,"activeCount":100},[],{"trials":5101,"activeCount":100},[],{"trials":5103,"activeCount":100},[5104],{"nctId":5105,"briefTitle":5106,"status":119,"phases":5107,"primaryCompletion":5108,"completion":5108,"start":5109,"enrollment":5110,"conditions":5111,"interventions":5113},"NCT03913091","Liposomal Bupivacaine (Exparel ® ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA)",[92],"2021-01-19","2019-03-01",184,[5112],"Shoulder Pain",[5092,5114],"0.5% Bupivacaine HCL",{"trials":5116,"activeCount":100},[],{"intervention":5114,"totalTrials":190,"cells":5118},{"EARLY_PHASE1":5119,"PHASE1":5121,"PHASE2":5123,"PHASE3":5125,"PHASE4":5127,"NA":5133},{"trials":5120,"activeCount":100},[],{"trials":5122,"activeCount":100},[],{"trials":5124,"activeCount":100},[],{"trials":5126,"activeCount":100},[],{"trials":5128,"activeCount":100},[5129],{"nctId":5105,"briefTitle":5106,"status":119,"phases":5130,"primaryCompletion":5108,"completion":5108,"start":5109,"enrollment":5110,"conditions":5131,"interventions":5132},[92],[5112],[5092,5114],{"trials":5134,"activeCount":100},[],{"intervention":5136,"totalTrials":190,"cells":5137},"Donepezil Hydrochloride",{"EARLY_PHASE1":5138,"PHASE1":5140,"PHASE2":5142,"PHASE3":5144,"PHASE4":5146,"NA":5157},{"trials":5139,"activeCount":100},[],{"trials":5141,"activeCount":100},[],{"trials":5143,"activeCount":100},[],{"trials":5145,"activeCount":100},[],{"trials":5147,"activeCount":100},[5148],{"nctId":5149,"briefTitle":5150,"status":119,"phases":5151,"primaryCompletion":5152,"completion":5153,"start":5154,"enrollment":1246,"conditions":5155,"interventions":5156},"NCT03073876","Detecting an Early Response to Donepezil With Measures of Visual Attention",[92],"2009-07-31","2021-01-13","2005-12-01",[684],[5136],{"trials":5158,"activeCount":100},[],{"intervention":3271,"totalTrials":190,"cells":5160},{"EARLY_PHASE1":5161,"PHASE1":5163,"PHASE2":5165,"PHASE3":5167,"PHASE4":5169,"NA":5175},{"trials":5162,"activeCount":100},[],{"trials":5164,"activeCount":100},[],{"trials":5166,"activeCount":100},[],{"trials":5168,"activeCount":100},[],{"trials":5170,"activeCount":100},[5171],{"nctId":3264,"briefTitle":3265,"status":119,"phases":5172,"primaryCompletion":1533,"completion":1533,"start":1899,"enrollment":3267,"conditions":5173,"interventions":5174},[92],[3269],[3206,3271,3272],{"trials":5176,"activeCount":100},[],{"intervention":3272,"totalTrials":190,"cells":5178},{"EARLY_PHASE1":5179,"PHASE1":5181,"PHASE2":5183,"PHASE3":5185,"PHASE4":5187,"NA":5193},{"trials":5180,"activeCount":100},[],{"trials":5182,"activeCount":100},[],{"trials":5184,"activeCount":100},[],{"trials":5186,"activeCount":100},[],{"trials":5188,"activeCount":100},[5189],{"nctId":3264,"briefTitle":3265,"status":119,"phases":5190,"primaryCompletion":1533,"completion":1533,"start":1899,"enrollment":3267,"conditions":5191,"interventions":5192},[92],[3269],[3206,3271,3272],{"trials":5194,"activeCount":100},[],{"intervention":5196,"totalTrials":190,"cells":5197},"Preventative Medication",{"EARLY_PHASE1":5198,"PHASE1":5200,"PHASE2":5202,"PHASE3":5204,"PHASE4":5206,"NA":5215},{"trials":5199,"activeCount":100},[],{"trials":5201,"activeCount":100},[],{"trials":5203,"activeCount":100},[],{"trials":5205,"activeCount":100},[],{"trials":5207,"activeCount":100},[5208],{"nctId":5209,"briefTitle":5210,"status":294,"phases":5211,"primaryCompletion":1378,"completion":1378,"start":5212,"enrollment":100,"conditions":5213,"interventions":5214},"NCT02945839","Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department",[92],"2016-12-28",[2749],[5196],{"trials":5216,"activeCount":100},[],{"intervention":5218,"totalTrials":190,"cells":5219},"Fospropofol",{"EARLY_PHASE1":5220,"PHASE1":5222,"PHASE2":5224,"PHASE3":5226,"PHASE4":5228,"NA":5240},{"trials":5221,"activeCount":100},[],{"trials":5223,"activeCount":100},[],{"trials":5225,"activeCount":100},[],{"trials":5227,"activeCount":100},[],{"trials":5229,"activeCount":100},[5230],{"nctId":5231,"briefTitle":5232,"status":119,"phases":5233,"primaryCompletion":3330,"completion":111,"start":5234,"enrollment":5235,"conditions":5236,"interventions":5238},"NCT01401049","Preventing Propofol Injection Pain: Prospective Randomized Trial Comparing Propofol Versus Fospropofol",[92],"2010-08",116,[5237,3617],"Complication of Injection",[5218,5239],"Propofol\u002FLidocaine",{"trials":5241,"activeCount":100},[],{"intervention":5239,"totalTrials":190,"cells":5243},{"EARLY_PHASE1":5244,"PHASE1":5246,"PHASE2":5248,"PHASE3":5250,"PHASE4":5252,"NA":5258},{"trials":5245,"activeCount":100},[],{"trials":5247,"activeCount":100},[],{"trials":5249,"activeCount":100},[],{"trials":5251,"activeCount":100},[],{"trials":5253,"activeCount":100},[5254],{"nctId":5231,"briefTitle":5232,"status":119,"phases":5255,"primaryCompletion":3330,"completion":111,"start":5234,"enrollment":5235,"conditions":5256,"interventions":5257},[92],[5237,3617],[5218,5239],{"trials":5259,"activeCount":100},[],{"intervention":5261,"totalTrials":190,"cells":5262},"Omalizumab",{"EARLY_PHASE1":5263,"PHASE1":5265,"PHASE2":5267,"PHASE3":5269,"PHASE4":5271,"NA":5281},{"trials":5264,"activeCount":100},[],{"trials":5266,"activeCount":100},[],{"trials":5268,"activeCount":100},[],{"trials":5270,"activeCount":100},[],{"trials":5272,"activeCount":100},[5273],{"nctId":5274,"briefTitle":5275,"status":108,"phases":5276,"primaryCompletion":5277,"completion":5277,"start":3626,"enrollment":195,"conditions":5278,"interventions":5280},"NCT02658877","Sputum-derived Cellular Targets After Xolair (Omalizumab)",[92],"2018-07-19",[5279],"Asthma",[5261],{"trials":5282,"activeCount":100},[],{"intervention":3852,"totalTrials":190,"cells":5284},{"EARLY_PHASE1":5285,"PHASE1":5287,"PHASE2":5289,"PHASE3":5291,"PHASE4":5293,"NA":5299},{"trials":5286,"activeCount":100},[],{"trials":5288,"activeCount":100},[],{"trials":5290,"activeCount":100},[],{"trials":5292,"activeCount":100},[],{"trials":5294,"activeCount":100},[5295],{"nctId":3844,"briefTitle":3845,"status":119,"phases":5296,"primaryCompletion":3847,"completion":3847,"start":3848,"enrollment":461,"conditions":5297,"interventions":5298},[92],[3850],[3822,3852],{"trials":5300,"activeCount":100},[],{"intervention":5302,"totalTrials":190,"cells":5303},"Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil",{"EARLY_PHASE1":5304,"PHASE1":5306,"PHASE2":5308,"PHASE3":5310,"PHASE4":5312,"NA":5324},{"trials":5305,"activeCount":100},[],{"trials":5307,"activeCount":100},[],{"trials":5309,"activeCount":100},[],{"trials":5311,"activeCount":100},[],{"trials":5313,"activeCount":100},[5314],{"nctId":5315,"briefTitle":5316,"status":119,"phases":5317,"primaryCompletion":5318,"completion":5318,"start":5319,"enrollment":2797,"conditions":5320,"interventions":5322},"NCT04786210","Treatment of Keloids With Fractional Erbium Laser-Assisted 5-Fluorouracil Versus Laser-Assisted Corticosteroid",[92],"2022-12-16","2021-01-30",[5321],"Keloid Scar",[5302,5323],"Fractional erbium:YAG-assisted drug delivery of triamcinolone acetonide",{"trials":5325,"activeCount":100},[],{"intervention":5323,"totalTrials":190,"cells":5327},{"EARLY_PHASE1":5328,"PHASE1":5330,"PHASE2":5332,"PHASE3":5334,"PHASE4":5336,"NA":5342},{"trials":5329,"activeCount":100},[],{"trials":5331,"activeCount":100},[],{"trials":5333,"activeCount":100},[],{"trials":5335,"activeCount":100},[],{"trials":5337,"activeCount":100},[5338],{"nctId":5315,"briefTitle":5316,"status":119,"phases":5339,"primaryCompletion":5318,"completion":5318,"start":5319,"enrollment":2797,"conditions":5340,"interventions":5341},[92],[5321],[5302,5323],{"trials":5343,"activeCount":100},[],{"intervention":5345,"totalTrials":190,"cells":5346},"Ondansetron",{"EARLY_PHASE1":5347,"PHASE1":5349,"PHASE2":5351,"PHASE3":5353,"PHASE4":5355,"NA":5367},{"trials":5348,"activeCount":100},[],{"trials":5350,"activeCount":100},[],{"trials":5352,"activeCount":100},[],{"trials":5354,"activeCount":100},[],{"trials":5356,"activeCount":100},[5357],{"nctId":5358,"briefTitle":5359,"status":119,"phases":5360,"primaryCompletion":5361,"completion":5361,"start":5362,"enrollment":3234,"conditions":5363,"interventions":5366},"NCT03239210","Effects of Ondansetron in Obsessive-compulsive and Tic Disorders",[92],"2022-05-16","2017-06-16",[5364,4923,5365],"Obsessive-Compulsive Disorder","Tourette Syndrome",[5345],{"trials":5368,"activeCount":100},[],{"intervention":5370,"totalTrials":190,"cells":5371},"ACB within true AC with bupivacaine 0.5% 20cc",{"EARLY_PHASE1":5372,"PHASE1":5374,"PHASE2":5376,"PHASE3":5378,"PHASE4":5380,"NA":5394},{"trials":5373,"activeCount":100},[],{"trials":5375,"activeCount":100},[],{"trials":5377,"activeCount":100},[],{"trials":5379,"activeCount":100},[],{"trials":5381,"activeCount":100},[5382],{"nctId":5383,"briefTitle":5384,"status":119,"phases":5385,"primaryCompletion":5386,"completion":5387,"start":5388,"enrollment":5389,"conditions":5390,"interventions":5392},"NCT03401450","Optimal Location of Nerve Block to Minimize Perioperative Opioid Administration in ACL Surgery: Comparing True Adductor Canal to Proximal Block",[92],"2019-01-25","2021-06-29","2018-02-01",69,[5391],"ACL Surgery",[5370,5393],"ACB proximal to true AC with bupivacaine 0.5% 20cc",{"trials":5395,"activeCount":100},[],{"intervention":5393,"totalTrials":190,"cells":5397},{"EARLY_PHASE1":5398,"PHASE1":5400,"PHASE2":5402,"PHASE3":5404,"PHASE4":5406,"NA":5412},{"trials":5399,"activeCount":100},[],{"trials":5401,"activeCount":100},[],{"trials":5403,"activeCount":100},[],{"trials":5405,"activeCount":100},[],{"trials":5407,"activeCount":100},[5408],{"nctId":5383,"briefTitle":5384,"status":119,"phases":5409,"primaryCompletion":5386,"completion":5387,"start":5388,"enrollment":5389,"conditions":5410,"interventions":5411},[92],[5391],[5370,5393],{"trials":5413,"activeCount":100},[],{"intervention":5415,"totalTrials":190,"cells":5416},"Evolocumab",{"EARLY_PHASE1":5417,"PHASE1":5419,"PHASE2":5421,"PHASE3":5423,"PHASE4":5425,"NA":5436},{"trials":5418,"activeCount":100},[],{"trials":5420,"activeCount":100},[],{"trials":5422,"activeCount":100},[],{"trials":5424,"activeCount":100},[],{"trials":5426,"activeCount":100},[5427],{"nctId":5428,"briefTitle":5429,"status":294,"phases":5430,"primaryCompletion":5431,"completion":5431,"start":5432,"enrollment":100,"conditions":5433,"interventions":5435},"NCT04510844","Evolocumab In Advanced Chronic Kidney Disease Trial",[92],"2021-10-01","2021-03-01",[4700,5434],"High Cholesterol",[5415],{"trials":5437,"activeCount":100},[],{"intervention":5439,"totalTrials":190,"cells":5440},"Octreotide LAR",{"EARLY_PHASE1":5441,"PHASE1":5443,"PHASE2":5445,"PHASE3":5447,"PHASE4":5449,"NA":5461},{"trials":5442,"activeCount":100},[],{"trials":5444,"activeCount":100},[],{"trials":5446,"activeCount":100},[],{"trials":5448,"activeCount":100},[],{"trials":5450,"activeCount":100},[5451],{"nctId":5452,"briefTitle":5453,"status":119,"phases":5454,"primaryCompletion":3993,"completion":5455,"start":5456,"enrollment":5457,"conditions":5458,"interventions":5460},"NCT01371643","Surgical Debulking of Pituitary Adenomas",[92],"2011-12","2004-04",41,[5459],"Pituitary Adenoma",[5439],{"trials":5462,"activeCount":100},[],{"intervention":5464,"totalTrials":190,"cells":5465},"4% Lidocaine",{"EARLY_PHASE1":5466,"PHASE1":5468,"PHASE2":5470,"PHASE3":5472,"PHASE4":5474,"NA":5484},{"trials":5467,"activeCount":100},[],{"trials":5469,"activeCount":100},[],{"trials":5471,"activeCount":100},[],{"trials":5473,"activeCount":100},[],{"trials":5475,"activeCount":100},[5476],{"nctId":5477,"briefTitle":5478,"status":294,"phases":5479,"primaryCompletion":5480,"completion":5480,"start":5481,"enrollment":100,"conditions":5482,"interventions":5483},"NCT02809755","Sphenopalatine Ganglion Block to Prevent Shoulder Pain After Laparoscopic Bariatric Surgery",[92],"2017-04-03","2016-08-08",[27],[5464],{"trials":5485,"activeCount":100},[],{"intervention":5487,"totalTrials":190,"cells":5488},"Ticagrelor",{"EARLY_PHASE1":5489,"PHASE1":5491,"PHASE2":5493,"PHASE3":5495,"PHASE4":5497,"NA":5509},{"trials":5490,"activeCount":100},[],{"trials":5492,"activeCount":100},[],{"trials":5494,"activeCount":100},[],{"trials":5496,"activeCount":100},[],{"trials":5498,"activeCount":100},[5499],{"nctId":5500,"briefTitle":5501,"status":119,"phases":5502,"primaryCompletion":5503,"completion":5504,"start":5505,"enrollment":1461,"conditions":5506,"interventions":5507},"NCT02874092","Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis",[92],"2019-04-19","2019-06-19","2016-11-15",[1446],[5487,5508],"MTX therapy",{"trials":5510,"activeCount":100},[],{"intervention":5508,"totalTrials":190,"cells":5512},{"EARLY_PHASE1":5513,"PHASE1":5515,"PHASE2":5517,"PHASE3":5519,"PHASE4":5521,"NA":5527},{"trials":5514,"activeCount":100},[],{"trials":5516,"activeCount":100},[],{"trials":5518,"activeCount":100},[],{"trials":5520,"activeCount":100},[],{"trials":5522,"activeCount":100},[5523],{"nctId":5500,"briefTitle":5501,"status":119,"phases":5524,"primaryCompletion":5503,"completion":5504,"start":5505,"enrollment":1461,"conditions":5525,"interventions":5526},[92],[1446],[5487,5508],{"trials":5528,"activeCount":100},[],{"intervention":5530,"totalTrials":190,"cells":5531},"Solifenacin",{"EARLY_PHASE1":5532,"PHASE1":5534,"PHASE2":5536,"PHASE3":5538,"PHASE4":5540,"NA":5550},{"trials":5533,"activeCount":100},[],{"trials":5535,"activeCount":100},[],{"trials":5537,"activeCount":100},[],{"trials":5539,"activeCount":100},[],{"trials":5541,"activeCount":100},[5542],{"nctId":5543,"briefTitle":5544,"status":108,"phases":5545,"primaryCompletion":2854,"completion":2854,"start":5546,"enrollment":16,"conditions":5547,"interventions":5549},"NCT00759577","Feasibility of \"At-home\" Titration of Solifenacin",[92],"2008-09",[5548],"Overactive Bladder",[5530],{"trials":5551,"activeCount":100},[],{"intervention":5553,"totalTrials":190,"cells":5554},"Adderall ® Immediate Release",{"EARLY_PHASE1":5555,"PHASE1":5557,"PHASE2":5559,"PHASE3":5561,"PHASE4":5563,"NA":5576},{"trials":5556,"activeCount":100},[],{"trials":5558,"activeCount":100},[],{"trials":5560,"activeCount":100},[],{"trials":5562,"activeCount":100},[],{"trials":5564,"activeCount":100},[5565],{"nctId":5566,"briefTitle":5567,"status":119,"phases":5568,"primaryCompletion":5569,"completion":5569,"start":5570,"enrollment":5571,"conditions":5572,"interventions":5574},"NCT00468143","A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall",[92],"2009-01","2007-08",62,[5573],"Attention Deficit Hyperactivity Disorder",[5553,5575],"Adderall XR ®",{"trials":5577,"activeCount":100},[],{"intervention":5575,"totalTrials":190,"cells":5579},{"EARLY_PHASE1":5580,"PHASE1":5582,"PHASE2":5584,"PHASE3":5586,"PHASE4":5588,"NA":5594},{"trials":5581,"activeCount":100},[],{"trials":5583,"activeCount":100},[],{"trials":5585,"activeCount":100},[],{"trials":5587,"activeCount":100},[],{"trials":5589,"activeCount":100},[5590],{"nctId":5566,"briefTitle":5567,"status":119,"phases":5591,"primaryCompletion":5569,"completion":5569,"start":5570,"enrollment":5571,"conditions":5592,"interventions":5593},[92],[5573],[5553,5575],{"trials":5595,"activeCount":100},[],{"intervention":5597,"totalTrials":190,"cells":5598},"Extended release injectable naltrexone",{"EARLY_PHASE1":5599,"PHASE1":5601,"PHASE2":5603,"PHASE3":5605,"PHASE4":5607,"NA":5617},{"trials":5600,"activeCount":100},[],{"trials":5602,"activeCount":100},[],{"trials":5604,"activeCount":100},[],{"trials":5606,"activeCount":100},[],{"trials":5608,"activeCount":100},[5609],{"nctId":5610,"briefTitle":5611,"status":119,"phases":5612,"primaryCompletion":920,"completion":1806,"start":5613,"enrollment":5614,"conditions":5615,"interventions":5616},"NCT00620750","Extended-release Naltrexone for Alcohol Dependence in Primary Care",[92],"2007-07",72,[1264],[5597],{"trials":5618,"activeCount":100},[],{"intervention":5620,"totalTrials":190,"cells":5621},"Palonosetron only",{"EARLY_PHASE1":5622,"PHASE1":5624,"PHASE2":5626,"PHASE3":5628,"PHASE4":5630,"NA":5642},{"trials":5623,"activeCount":100},[],{"trials":5625,"activeCount":100},[],{"trials":5627,"activeCount":100},[],{"trials":5629,"activeCount":100},[],{"trials":5631,"activeCount":100},[5632],{"nctId":5633,"briefTitle":5634,"status":119,"phases":5635,"primaryCompletion":3993,"completion":5636,"start":3747,"enrollment":5637,"conditions":5638,"interventions":5640},"NCT00952133","Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV",[92],"2011-04",118,[5639],"PONV",[5620,5641],"Palonosetron with Dexamethasone",{"trials":5643,"activeCount":100},[],{"intervention":5641,"totalTrials":190,"cells":5645},{"EARLY_PHASE1":5646,"PHASE1":5648,"PHASE2":5650,"PHASE3":5652,"PHASE4":5654,"NA":5660},{"trials":5647,"activeCount":100},[],{"trials":5649,"activeCount":100},[],{"trials":5651,"activeCount":100},[],{"trials":5653,"activeCount":100},[],{"trials":5655,"activeCount":100},[5656],{"nctId":5633,"briefTitle":5634,"status":119,"phases":5657,"primaryCompletion":3993,"completion":5636,"start":3747,"enrollment":5637,"conditions":5658,"interventions":5659},[92],[5639],[5620,5641],{"trials":5661,"activeCount":100},[],{"intervention":5663,"totalTrials":190,"cells":5664},"LDX Treatment",{"EARLY_PHASE1":5665,"PHASE1":5667,"PHASE2":5669,"PHASE3":5671,"PHASE4":5673,"NA":5681},{"trials":5666,"activeCount":100},[],{"trials":5668,"activeCount":100},[],{"trials":5670,"activeCount":100},[],{"trials":5672,"activeCount":100},[],{"trials":5674,"activeCount":100},[5675],{"nctId":5676,"briefTitle":5677,"status":119,"phases":5678,"primaryCompletion":3330,"completion":3330,"start":1806,"enrollment":2885,"conditions":5679,"interventions":5680},"NCT01070394","Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)",[92],[5573],[5663],{"trials":5682,"activeCount":100},[],{"intervention":5684,"totalTrials":190,"cells":5685},"Ibuprofen",{"EARLY_PHASE1":5686,"PHASE1":5688,"PHASE2":5690,"PHASE3":5692,"PHASE4":5694,"NA":5704},{"trials":5687,"activeCount":100},[],{"trials":5689,"activeCount":100},[],{"trials":5691,"activeCount":100},[],{"trials":5693,"activeCount":100},[],{"trials":5695,"activeCount":100},[5696],{"nctId":5697,"briefTitle":5698,"status":108,"phases":5699,"primaryCompletion":5700,"completion":5700,"start":3746,"enrollment":268,"conditions":5701,"interventions":5703},"NCT01377441","Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia.",[92],"2013-05",[5702],"Inflammatory Response",[5684],{"trials":5705,"activeCount":100},[],{"intervention":5707,"totalTrials":190,"cells":5708},"Remifentanil",{"EARLY_PHASE1":5709,"PHASE1":5711,"PHASE2":5713,"PHASE3":5715,"PHASE4":5717,"NA":5728},{"trials":5710,"activeCount":100},[],{"trials":5712,"activeCount":100},[],{"trials":5714,"activeCount":100},[],{"trials":5716,"activeCount":100},[],{"trials":5718,"activeCount":100},[5719],{"nctId":5720,"briefTitle":5721,"status":119,"phases":5722,"primaryCompletion":5723,"completion":5723,"start":5724,"enrollment":37,"conditions":5725,"interventions":5727},"NCT01901575","Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia",[92],"2013-04","2011-07",[5726],"Tachycardia, Ventricular",[5707],{"trials":5729,"activeCount":100},[],{"intervention":5731,"totalTrials":190,"cells":5732},"Pre-op Multimodal analgesia (MMA) regimen + standard post-op oxycodone",{"EARLY_PHASE1":5733,"PHASE1":5735,"PHASE2":5737,"PHASE3":5739,"PHASE4":5741,"NA":5754},{"trials":5734,"activeCount":100},[],{"trials":5736,"activeCount":100},[],{"trials":5738,"activeCount":100},[],{"trials":5740,"activeCount":100},[],{"trials":5742,"activeCount":100},[5743],{"nctId":5744,"briefTitle":5745,"status":119,"phases":5746,"primaryCompletion":5747,"completion":5747,"start":5748,"enrollment":1855,"conditions":5749,"interventions":5753},"NCT04522206","An Analysis of the Efficacy of a Pre-Emptive Multimodal Pain Regimen in Reducing Acute Post-Operative Pain and Narcotic Pain Medication Requirements in Spine Surgery",[92],"2021-06-10","2020-08-20",[5750,5751,5752],"Pain, Postoperative","Spine Injuries and Disorders","Narcotic Use",[5731],{"trials":5755,"activeCount":100},[],{"intervention":5757,"totalTrials":190,"cells":5758},"oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily",{"EARLY_PHASE1":5759,"PHASE1":5761,"PHASE2":5763,"PHASE3":5765,"PHASE4":5767,"NA":5779},{"trials":5760,"activeCount":100},[],{"trials":5762,"activeCount":100},[],{"trials":5764,"activeCount":100},[],{"trials":5766,"activeCount":100},[],{"trials":5768,"activeCount":100},[5769],{"nctId":5770,"briefTitle":5771,"status":294,"phases":5772,"primaryCompletion":4351,"completion":5773,"start":5774,"enrollment":100,"conditions":5775,"interventions":5777},"NCT03626376","Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis",[92],"2022-03-02","2019-12-10",[5776],"Herpes Simplex Virus Keratitis",[5757,5778],"oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops",{"trials":5780,"activeCount":100},[],{"intervention":5778,"totalTrials":190,"cells":5782},{"EARLY_PHASE1":5783,"PHASE1":5785,"PHASE2":5787,"PHASE3":5789,"PHASE4":5791,"NA":5797},{"trials":5784,"activeCount":100},[],{"trials":5786,"activeCount":100},[],{"trials":5788,"activeCount":100},[],{"trials":5790,"activeCount":100},[],{"trials":5792,"activeCount":100},[5793],{"nctId":5770,"briefTitle":5771,"status":294,"phases":5794,"primaryCompletion":4351,"completion":5773,"start":5774,"enrollment":100,"conditions":5795,"interventions":5796},[92],[5776],[5757,5778],{"trials":5798,"activeCount":100},[],{"intervention":5800,"totalTrials":190,"cells":5801},"Acthar low dose",{"EARLY_PHASE1":5802,"PHASE1":5804,"PHASE2":5806,"PHASE3":5808,"PHASE4":5810,"NA":5822},{"trials":5803,"activeCount":100},[],{"trials":5805,"activeCount":100},[],{"trials":5807,"activeCount":100},[],{"trials":5809,"activeCount":100},[],{"trials":5811,"activeCount":100},[5812],{"nctId":5813,"briefTitle":5814,"status":294,"phases":5815,"primaryCompletion":5816,"completion":5816,"start":280,"enrollment":100,"conditions":5817,"interventions":5820},"NCT02779153","Acthar SLE (Systemic Lupus Erythematosus)",[92],"2019-05-22",[5818,5819],"Systemic Lupus Erythematosus (SLE)","Repository Corticotropin Injection",[5800,5821],"Acthar high dose",{"trials":5823,"activeCount":100},[],{"intervention":5821,"totalTrials":190,"cells":5825},{"EARLY_PHASE1":5826,"PHASE1":5828,"PHASE2":5830,"PHASE3":5832,"PHASE4":5834,"NA":5840},{"trials":5827,"activeCount":100},[],{"trials":5829,"activeCount":100},[],{"trials":5831,"activeCount":100},[],{"trials":5833,"activeCount":100},[],{"trials":5835,"activeCount":100},[5836],{"nctId":5813,"briefTitle":5814,"status":294,"phases":5837,"primaryCompletion":5816,"completion":5816,"start":280,"enrollment":100,"conditions":5838,"interventions":5839},[92],[5818,5819],[5800,5821],{"trials":5841,"activeCount":100},[],{"intervention":5843,"totalTrials":190,"cells":5844},"Piperacillin\u002FTazobactam",{"EARLY_PHASE1":5845,"PHASE1":5847,"PHASE2":5849,"PHASE3":5851,"PHASE4":5853,"NA":5863},{"trials":5846,"activeCount":100},[],{"trials":5848,"activeCount":100},[],{"trials":5850,"activeCount":100},[],{"trials":5852,"activeCount":100},[],{"trials":5854,"activeCount":100},[5855],{"nctId":5856,"briefTitle":5857,"status":119,"phases":5858,"primaryCompletion":974,"completion":974,"start":5859,"enrollment":9,"conditions":5860,"interventions":5862},"NCT02991937","Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children",[92],"2016-12",[5861],"Appendicitis",[5843],{"trials":5864,"activeCount":100},[],{"intervention":5866,"totalTrials":190,"cells":5867},"Steroid",{"EARLY_PHASE1":5868,"PHASE1":5870,"PHASE2":5872,"PHASE3":5874,"PHASE4":5876,"NA":5886},{"trials":5869,"activeCount":100},[],{"trials":5871,"activeCount":100},[],{"trials":5873,"activeCount":100},[],{"trials":5875,"activeCount":100},[],{"trials":5877,"activeCount":100},[5878],{"nctId":5879,"briefTitle":5880,"status":119,"phases":5881,"primaryCompletion":5882,"completion":5882,"start":3656,"enrollment":16,"conditions":5883,"interventions":5885},"NCT02286960","Investigation of the Role of Steroids in Enhancing Voice Therapy Outcomes",[92],"2018-12",[5884],"Dysphonia",[5866],{"trials":5887,"activeCount":100},[],{"intervention":5889,"totalTrials":190,"cells":5890},"CBD",{"EARLY_PHASE1":5891,"PHASE1":5893,"PHASE2":5895,"PHASE3":5897,"PHASE4":5899,"NA":5909},{"trials":5892,"activeCount":100},[],{"trials":5894,"activeCount":100},[],{"trials":5896,"activeCount":100},[],{"trials":5898,"activeCount":100},[],{"trials":5900,"activeCount":100},[5901],{"nctId":5902,"briefTitle":5903,"status":294,"phases":5904,"primaryCompletion":2811,"completion":5004,"start":5431,"enrollment":100,"conditions":5905,"interventions":5908},"NCT04768478","CBD for Pain Reduction and Opioid Use After Ankle and Tibia Fracture ORIF",[92],[5906,5907],"Ankle Fractures","Tibia Fracture",[5889],{"trials":5910,"activeCount":100},[],{"intervention":5912,"totalTrials":190,"cells":5913},"Ankle SSB",{"EARLY_PHASE1":5914,"PHASE1":5916,"PHASE2":5918,"PHASE3":5920,"PHASE4":5922,"NA":5936},{"trials":5915,"activeCount":100},[],{"trials":5917,"activeCount":100},[],{"trials":5919,"activeCount":100},[],{"trials":5921,"activeCount":100},[],{"trials":5923,"activeCount":100},[5924],{"nctId":5925,"briefTitle":5926,"status":119,"phases":5927,"primaryCompletion":5928,"completion":5928,"start":5929,"enrollment":461,"conditions":5930,"interventions":5932},"NCT02280291","Single Shot Versus OnQ Pump in Extremity Fractures",[92],"2018-12-13","2013-08",[3617,5931],"Fracture",[5912,5933,5934,5935],"Ankle OnQ","DR SSB","DR OnQ",{"trials":5937,"activeCount":100},[],{"intervention":5933,"totalTrials":190,"cells":5939},{"EARLY_PHASE1":5940,"PHASE1":5942,"PHASE2":5944,"PHASE3":5946,"PHASE4":5948,"NA":5954},{"trials":5941,"activeCount":100},[],{"trials":5943,"activeCount":100},[],{"trials":5945,"activeCount":100},[],{"trials":5947,"activeCount":100},[],{"trials":5949,"activeCount":100},[5950],{"nctId":5925,"briefTitle":5926,"status":119,"phases":5951,"primaryCompletion":5928,"completion":5928,"start":5929,"enrollment":461,"conditions":5952,"interventions":5953},[92],[3617,5931],[5912,5933,5934,5935],{"trials":5955,"activeCount":100},[],{"intervention":5934,"totalTrials":190,"cells":5957},{"EARLY_PHASE1":5958,"PHASE1":5960,"PHASE2":5962,"PHASE3":5964,"PHASE4":5966,"NA":5972},{"trials":5959,"activeCount":100},[],{"trials":5961,"activeCount":100},[],{"trials":5963,"activeCount":100},[],{"trials":5965,"activeCount":100},[],{"trials":5967,"activeCount":100},[5968],{"nctId":5925,"briefTitle":5926,"status":119,"phases":5969,"primaryCompletion":5928,"completion":5928,"start":5929,"enrollment":461,"conditions":5970,"interventions":5971},[92],[3617,5931],[5912,5933,5934,5935],{"trials":5973,"activeCount":100},[],{"intervention":5935,"totalTrials":190,"cells":5975},{"EARLY_PHASE1":5976,"PHASE1":5978,"PHASE2":5980,"PHASE3":5982,"PHASE4":5984,"NA":5990},{"trials":5977,"activeCount":100},[],{"trials":5979,"activeCount":100},[],{"trials":5981,"activeCount":100},[],{"trials":5983,"activeCount":100},[],{"trials":5985,"activeCount":100},[5986],{"nctId":5925,"briefTitle":5926,"status":119,"phases":5987,"primaryCompletion":5928,"completion":5928,"start":5929,"enrollment":461,"conditions":5988,"interventions":5989},[92],[3617,5931],[5912,5933,5934,5935],{"trials":5991,"activeCount":100},[],{"intervention":5993,"totalTrials":190,"cells":5994},"Serdexmethylphenidate\u002Fdexmethylphenidate",{"EARLY_PHASE1":5995,"PHASE1":5997,"PHASE2":5999,"PHASE3":6001,"PHASE4":6003,"NA":6015},{"trials":5996,"activeCount":100},[],{"trials":5998,"activeCount":100},[],{"trials":6000,"activeCount":100},[],{"trials":6002,"activeCount":100},[],{"trials":6004,"activeCount":100},[6005],{"nctId":6006,"briefTitle":6007,"status":119,"phases":6008,"primaryCompletion":6009,"completion":6010,"start":6011,"enrollment":1203,"conditions":6012,"interventions":6014},"NCT06000501","Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening",[92],"2024-07-03","2024-07-17","2023-11-13",[6013],"Adult Attention Deficit Hyperactivity Disorder",[5993],{"trials":6016,"activeCount":100},[],{"intervention":6018,"totalTrials":190,"cells":6019},"Albuterol-sulphate",{"EARLY_PHASE1":6020,"PHASE1":6022,"PHASE2":6024,"PHASE3":6026,"PHASE4":6036,"NA":6038},{"trials":6021,"activeCount":100},[],{"trials":6023,"activeCount":100},[],{"trials":6025,"activeCount":100},[],{"trials":6027,"activeCount":100},[6028],{"nctId":6029,"briefTitle":6030,"status":119,"phases":6031,"primaryCompletion":4325,"completion":4325,"start":6032,"enrollment":1589,"conditions":6033,"interventions":6034},"NCT01987219","The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia",[91],"2013-03",[1591],[6018,6035],"Ipratropium-bromide",{"trials":6037,"activeCount":100},[],{"trials":6039,"activeCount":100},[],{"intervention":6035,"totalTrials":190,"cells":6041},{"EARLY_PHASE1":6042,"PHASE1":6044,"PHASE2":6046,"PHASE3":6048,"PHASE4":6054,"NA":6056},{"trials":6043,"activeCount":100},[],{"trials":6045,"activeCount":100},[],{"trials":6047,"activeCount":100},[],{"trials":6049,"activeCount":100},[6050],{"nctId":6029,"briefTitle":6030,"status":119,"phases":6051,"primaryCompletion":4325,"completion":4325,"start":6032,"enrollment":1589,"conditions":6052,"interventions":6053},[91],[1591],[6018,6035],{"trials":6055,"activeCount":100},[],{"trials":6057,"activeCount":100},[],{"intervention":6059,"totalTrials":190,"cells":6060},"CBD Oral Disintegrating",{"EARLY_PHASE1":6061,"PHASE1":6063,"PHASE2":6065,"PHASE3":6067,"PHASE4":6076,"NA":6078},{"trials":6062,"activeCount":100},[],{"trials":6064,"activeCount":100},[],{"trials":6066,"activeCount":100},[],{"trials":6068,"activeCount":100},[6069],{"nctId":6070,"briefTitle":6071,"status":119,"phases":6072,"primaryCompletion":6073,"completion":5318,"start":974,"enrollment":461,"conditions":6074,"interventions":6075},"NCT04672252","The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy",[90,91],"2021-12-16",[5750],[6059],{"trials":6077,"activeCount":100},[],{"trials":6079,"activeCount":100},[],{"intervention":6081,"totalTrials":190,"cells":6082},"Premarin and Provera",{"EARLY_PHASE1":6083,"PHASE1":6085,"PHASE2":6087,"PHASE3":6089,"PHASE4":6099,"NA":6101},{"trials":6084,"activeCount":100},[],{"trials":6086,"activeCount":100},[],{"trials":6088,"activeCount":100},[],{"trials":6090,"activeCount":100},[6091],{"nctId":6092,"briefTitle":6093,"status":108,"phases":6094,"completion":6095,"start":6096,"enrollment":3290,"conditions":6097,"interventions":6098},"NCT00000419","Safety of Estrogens in Lupus: Hormone Replacement Therapy",[91],"2002-08","1996-04",[659],[6081],{"trials":6100,"activeCount":100},[],{"trials":6102,"activeCount":100},[],{"intervention":6104,"totalTrials":190,"cells":6105},"Botulinum Toxin commonly known as BOTOX®",{"EARLY_PHASE1":6106,"PHASE1":6108,"PHASE2":6110,"PHASE3":6112,"PHASE4":6123,"NA":6125},{"trials":6107,"activeCount":100},[],{"trials":6109,"activeCount":100},[],{"trials":6111,"activeCount":100},[],{"trials":6113,"activeCount":100},[6114],{"nctId":6115,"briefTitle":6116,"status":119,"phases":6117,"primaryCompletion":6118,"completion":6118,"start":6119,"enrollment":37,"conditions":6120,"interventions":6122},"NCT01422161","Study of Botulinum Toxin and Recovery of Hand Function After Stroke",[91],"2015-10","2010-04",[6121],"Stroke With Hemiparesis",[6104],{"trials":6124,"activeCount":100},[],{"trials":6126,"activeCount":100},[],{"intervention":6128,"totalTrials":190,"cells":6129},"MYDAYIS",{"EARLY_PHASE1":6130,"PHASE1":6132,"PHASE2":6134,"PHASE3":6136,"PHASE4":6147,"NA":6149},{"trials":6131,"activeCount":100},[],{"trials":6133,"activeCount":100},[],{"trials":6135,"activeCount":100},[],{"trials":6137,"activeCount":100},[6138],{"nctId":6139,"briefTitle":6140,"status":119,"phases":6141,"primaryCompletion":6142,"completion":6142,"start":6143,"enrollment":487,"conditions":6144,"interventions":6146},"NCT03945175","Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening",[91],"2022-05-11","2020-07-15",[6145],"Attention Deficit-Hyperactivity",[6128],{"trials":6148,"activeCount":100},[],{"trials":6150,"activeCount":100},[],{"intervention":6152,"totalTrials":190,"cells":6153},"SAM-e",{"EARLY_PHASE1":6154,"PHASE1":6156,"PHASE2":6158,"PHASE3":6160,"PHASE4":6172,"NA":6174},{"trials":6155,"activeCount":100},[],{"trials":6157,"activeCount":100},[],{"trials":6159,"activeCount":100},[],{"trials":6161,"activeCount":100},[6162],{"nctId":6163,"briefTitle":6164,"status":119,"phases":6165,"primaryCompletion":6166,"completion":3994,"start":6167,"enrollment":1203,"conditions":6168,"interventions":6170},"NCT00070941","SAM-e for the Treatment of Depression in Patients With Parkinson's Disease",[90,91],"2010-06","2003-07",[6169,3606],"Parkinson's Disease",[6152,6171],"oral escitalopram",{"trials":6173,"activeCount":100},[],{"trials":6175,"activeCount":100},[],{"intervention":6171,"totalTrials":190,"cells":6177},{"EARLY_PHASE1":6178,"PHASE1":6180,"PHASE2":6182,"PHASE3":6184,"PHASE4":6190,"NA":6192},{"trials":6179,"activeCount":100},[],{"trials":6181,"activeCount":100},[],{"trials":6183,"activeCount":100},[],{"trials":6185,"activeCount":100},[6186],{"nctId":6163,"briefTitle":6164,"status":119,"phases":6187,"primaryCompletion":6166,"completion":3994,"start":6167,"enrollment":1203,"conditions":6188,"interventions":6189},[90,91],[6169,3606],[6152,6171],{"trials":6191,"activeCount":100},[],{"trials":6193,"activeCount":100},[],{"intervention":6195,"totalTrials":190,"cells":6196},"Ortho-Novum 777",{"EARLY_PHASE1":6197,"PHASE1":6199,"PHASE2":6201,"PHASE3":6203,"PHASE4":6213,"NA":6215},{"trials":6198,"activeCount":100},[],{"trials":6200,"activeCount":100},[],{"trials":6202,"activeCount":100},[],{"trials":6204,"activeCount":100},[6205],{"nctId":6206,"briefTitle":6207,"status":119,"phases":6208,"completion":6209,"start":6210,"enrollment":3290,"conditions":6211,"interventions":6212},"NCT00000420","Safety of Estrogens in Lupus: Birth Control Pills",[91],"2003-08","1997-06",[659],[6195],{"trials":6214,"activeCount":100},[],{"trials":6216,"activeCount":100},[],{"intervention":6218,"totalTrials":190,"cells":6219},"Carbidopa",{"EARLY_PHASE1":6220,"PHASE1":6222,"PHASE2":6224,"PHASE3":6226,"PHASE4":6236,"NA":6238},{"trials":6221,"activeCount":100},[],{"trials":6223,"activeCount":100},[],{"trials":6225,"activeCount":100},[],{"trials":6227,"activeCount":100},[6228],{"nctId":6229,"briefTitle":6230,"status":119,"phases":6231,"primaryCompletion":6232,"completion":6233,"start":4064,"enrollment":281,"conditions":6234,"interventions":6235},"NCT01212484","Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia",[91],"2012-02","2012-10",[1591],[6218],{"trials":6237,"activeCount":100},[],{"trials":6239,"activeCount":100},[],{"intervention":6241,"totalTrials":190,"cells":6242},"fibrinolytic therapy or combination reduced fibrinolytic therapy",{"EARLY_PHASE1":6243,"PHASE1":6245,"PHASE2":6247,"PHASE3":6249,"PHASE4":6259,"NA":6261},{"trials":6244,"activeCount":100},[],{"trials":6246,"activeCount":100},[],{"trials":6248,"activeCount":100},[],{"trials":6250,"activeCount":100},[6251],{"nctId":6252,"briefTitle":6253,"status":119,"phases":6254,"primaryCompletion":6255,"completion":6255,"start":6256,"conditions":6257,"interventions":6258},"NCT00245648","Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI",[91],"2007-10","2001-06",[3574],[6241],{"trials":6260,"activeCount":100},[],{"trials":6262,"activeCount":100},[],{"intervention":6264,"totalTrials":190,"cells":6265},"Beta adrenergic blockers",{"EARLY_PHASE1":6266,"PHASE1":6268,"PHASE2":6270,"PHASE3":6272,"PHASE4":6287,"NA":6289},{"trials":6267,"activeCount":100},[],{"trials":6269,"activeCount":100},[],{"trials":6271,"activeCount":100},[],{"trials":6273,"activeCount":100},[6274],{"nctId":6275,"briefTitle":6276,"status":119,"phases":6277,"primaryCompletion":6278,"completion":6279,"start":6280,"enrollment":6281,"conditions":6282,"interventions":6284},"NCT00004562","Occluded Artery Trial (OAT)",[91],"2010-03","2011-06","1999-09",2201,[33,3317,3574,6283,4725],"Heart Failure, Congestive",[6264,6285,6286],"Platelet inhibitors","ACE Inhibitors",{"trials":6288,"activeCount":100},[],{"trials":6290,"activeCount":100},[],{"intervention":6285,"totalTrials":190,"cells":6292},{"EARLY_PHASE1":6293,"PHASE1":6295,"PHASE2":6297,"PHASE3":6299,"PHASE4":6305,"NA":6307},{"trials":6294,"activeCount":100},[],{"trials":6296,"activeCount":100},[],{"trials":6298,"activeCount":100},[],{"trials":6300,"activeCount":100},[6301],{"nctId":6275,"briefTitle":6276,"status":119,"phases":6302,"primaryCompletion":6278,"completion":6279,"start":6280,"enrollment":6281,"conditions":6303,"interventions":6304},[91],[33,3317,3574,6283,4725],[6264,6285,6286],{"trials":6306,"activeCount":100},[],{"trials":6308,"activeCount":100},[],{"intervention":6286,"totalTrials":190,"cells":6310},{"EARLY_PHASE1":6311,"PHASE1":6313,"PHASE2":6315,"PHASE3":6317,"PHASE4":6323,"NA":6325},{"trials":6312,"activeCount":100},[],{"trials":6314,"activeCount":100},[],{"trials":6316,"activeCount":100},[],{"trials":6318,"activeCount":100},[6319],{"nctId":6275,"briefTitle":6276,"status":119,"phases":6320,"primaryCompletion":6278,"completion":6279,"start":6280,"enrollment":6281,"conditions":6321,"interventions":6322},[91],[33,3317,3574,6283,4725],[6264,6285,6286],{"trials":6324,"activeCount":100},[],{"trials":6326,"activeCount":100},[],{"intervention":6328,"totalTrials":190,"cells":6329},"Rifaximin",{"EARLY_PHASE1":6330,"PHASE1":6332,"PHASE2":6334,"PHASE3":6336,"PHASE4":6346,"NA":6348},{"trials":6331,"activeCount":100},[],{"trials":6333,"activeCount":100},[],{"trials":6335,"activeCount":100},[],{"trials":6337,"activeCount":100},[6338],{"nctId":6339,"briefTitle":6340,"status":294,"phases":6341,"primaryCompletion":5859,"start":6118,"enrollment":100,"conditions":6342,"interventions":6344},"NCT02086825","A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure",[91],[6343],"Hepatic Encephalopathy",[6328,6345],"Lactulose",{"trials":6347,"activeCount":100},[],{"trials":6349,"activeCount":100},[],{"intervention":6345,"totalTrials":190,"cells":6351},{"EARLY_PHASE1":6352,"PHASE1":6354,"PHASE2":6356,"PHASE3":6358,"PHASE4":6364,"NA":6366},{"trials":6353,"activeCount":100},[],{"trials":6355,"activeCount":100},[],{"trials":6357,"activeCount":100},[],{"trials":6359,"activeCount":100},[6360],{"nctId":6339,"briefTitle":6340,"status":294,"phases":6361,"primaryCompletion":5859,"start":6118,"enrollment":100,"conditions":6362,"interventions":6363},[91],[6343],[6328,6345],{"trials":6365,"activeCount":100},[],{"trials":6367,"activeCount":100},[],{"intervention":6369,"totalTrials":190,"cells":6370},"Antimicrobial Barrier Dressing",{"EARLY_PHASE1":6371,"PHASE1":6373,"PHASE2":6375,"PHASE3":6377,"PHASE4":6388,"NA":6390},{"trials":6372,"activeCount":100},[],{"trials":6374,"activeCount":100},[],{"trials":6376,"activeCount":100},[],{"trials":6378,"activeCount":100},[6379],{"nctId":6380,"briefTitle":6381,"status":119,"phases":6382,"primaryCompletion":784,"completion":6383,"start":6384,"enrollment":6385,"conditions":6386,"interventions":6387},"NCT03345771","Antimicrobial Barrier Dressing Versus Closed-incision Negative Pressure Therapy in the Obese Primary Total Joint Arthroplasty",[91],"2021-06-01","2017-11-13",230,[3077],[6369],{"trials":6389,"activeCount":100},[],{"trials":6391,"activeCount":100},[],{"intervention":6393,"totalTrials":190,"cells":6394},"Infliximab at weeks 0,2, and 6",{"EARLY_PHASE1":6395,"PHASE1":6397,"PHASE2":6399,"PHASE3":6401,"PHASE4":6414,"NA":6416},{"trials":6396,"activeCount":100},[],{"trials":6398,"activeCount":100},[],{"trials":6400,"activeCount":100},[],{"trials":6402,"activeCount":100},[6403],{"nctId":6404,"briefTitle":6405,"status":294,"phases":6406,"primaryCompletion":6407,"completion":6407,"start":6408,"enrollment":100,"conditions":6409,"interventions":6411},"NCT02771457","Managing Infliximab Reinduction After Temporary Discontinuation of Drug",[91],"2019-07","2016-07",[6410],"Inflammatory Bowel Disease",[6393,6412,6413],"Infliximab at weeks 0,4, and 8","Infliximab at weeks 0 and 8",{"trials":6415,"activeCount":100},[],{"trials":6417,"activeCount":100},[],{"intervention":6412,"totalTrials":190,"cells":6419},{"EARLY_PHASE1":6420,"PHASE1":6422,"PHASE2":6424,"PHASE3":6426,"PHASE4":6432,"NA":6434},{"trials":6421,"activeCount":100},[],{"trials":6423,"activeCount":100},[],{"trials":6425,"activeCount":100},[],{"trials":6427,"activeCount":100},[6428],{"nctId":6404,"briefTitle":6405,"status":294,"phases":6429,"primaryCompletion":6407,"completion":6407,"start":6408,"enrollment":100,"conditions":6430,"interventions":6431},[91],[6410],[6393,6412,6413],{"trials":6433,"activeCount":100},[],{"trials":6435,"activeCount":100},[],{"intervention":6413,"totalTrials":190,"cells":6437},{"EARLY_PHASE1":6438,"PHASE1":6440,"PHASE2":6442,"PHASE3":6444,"PHASE4":6450,"NA":6452},{"trials":6439,"activeCount":100},[],{"trials":6441,"activeCount":100},[],{"trials":6443,"activeCount":100},[],{"trials":6445,"activeCount":100},[6446],{"nctId":6404,"briefTitle":6405,"status":294,"phases":6447,"primaryCompletion":6407,"completion":6407,"start":6408,"enrollment":100,"conditions":6448,"interventions":6449},[91],[6410],[6393,6412,6413],{"trials":6451,"activeCount":100},[],{"trials":6453,"activeCount":100},[],{"intervention":965,"totalTrials":190,"cells":6455},{"EARLY_PHASE1":6456,"PHASE1":6458,"PHASE2":6460,"PHASE3":6462,"PHASE4":6468,"NA":6470},{"trials":6457,"activeCount":100},[],{"trials":6459,"activeCount":100},[],{"trials":6461,"activeCount":100},[],{"trials":6463,"activeCount":100},[6464],{"nctId":951,"briefTitle":952,"status":108,"phases":6465,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":6466,"interventions":6467},[91],[958,959,960,961,962,963],[965,898],{"trials":6469,"activeCount":100},[],{"trials":6471,"activeCount":100},[],{"intervention":6473,"totalTrials":190,"cells":6474},"Retapamulin",{"EARLY_PHASE1":6475,"PHASE1":6477,"PHASE2":6479,"PHASE3":6481,"PHASE4":6494,"NA":6496},{"trials":6476,"activeCount":100},[],{"trials":6478,"activeCount":100},[],{"trials":6480,"activeCount":100},[],{"trials":6482,"activeCount":100},[6483],{"nctId":6484,"briefTitle":6485,"status":119,"phases":6486,"primaryCompletion":6487,"completion":6488,"start":6489,"enrollment":6490,"conditions":6491,"interventions":6493},"NCT03304873","Retapamulin as a Decolonizing Agent for MRSA",[91],"2019-02-13","2019-03-18","2017-12-01",47,[6492],"MRSA",[6473],{"trials":6495,"activeCount":100},[],{"trials":6497,"activeCount":100},[],{"intervention":1782,"totalTrials":1826,"cells":6499},{"EARLY_PHASE1":6500,"PHASE1":6502,"PHASE2":6533,"PHASE3":6607,"PHASE4":6609,"NA":6611},{"trials":6501,"activeCount":100},[],{"trials":6503,"activeCount":100},[6504,6512,6522],{"nctId":6505,"briefTitle":6506,"status":119,"phases":6507,"primaryCompletion":5570,"start":6508,"conditions":6509,"interventions":6510},"NCT00010023","Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors",[89],"2000-08",[1205],[6511,1782],"capecitabine",{"nctId":6513,"briefTitle":6514,"status":119,"phases":6515,"primaryCompletion":6516,"start":6517,"conditions":6518,"interventions":6520},"NCT00003132","Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable Cancer",[89],"2001-11","1998-01",[6519],"Unspecified Adult Solid Tumor, Protocol Specific",[6521,1782],"bryostatin 1",{"nctId":6523,"briefTitle":6524,"status":119,"phases":6525,"primaryCompletion":6526,"start":6527,"enrollment":1855,"conditions":6528,"interventions":6530},"NCT00003144","Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors",[89],"2001-04","1997-08",[6529,6519],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan",[6531,1782,6532],"amifostine trihydrate","gemcitabine hydrochloride",{"trials":6534,"activeCount":100},[6535,6539,6554,6562,6572,6576,6585,6596],{"nctId":1330,"briefTitle":1331,"status":108,"phases":6536,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":772,"conditions":6537,"interventions":6538},[90],[1336],[43,1338,1339,1340],{"nctId":6540,"briefTitle":6541,"status":119,"phases":6542,"primaryCompletion":6543,"start":6544,"enrollment":1478,"conditions":6545,"interventions":6552},"NCT00005049","Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer",[90],"2006-11","1997-05",[6546,1362,6547,6548,6549,6550,6551],"Colorectal Cancer","Gastrointestinal Carcinoid Tumor","Gastrointestinal Stromal Tumor","Ovarian Cancer","Peritoneal Cavity Cancer","Small Intestine Cancer",[1781,1782,6553],"floxuridine",{"nctId":6555,"briefTitle":6556,"status":119,"phases":6557,"primaryCompletion":6558,"start":6559,"enrollment":16,"conditions":6560,"interventions":6561},"NCT00003332","Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and\u002For Surgery in Treating Patients Who Have Pancreatic Cancer",[89,90],"2004-10","1997-07",[1404],[1782,6532],{"nctId":6563,"briefTitle":6564,"status":119,"phases":6565,"primaryCompletion":6566,"completion":6567,"start":6568,"conditions":6569,"interventions":6570},"NCT00004103","Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer",[90],"2007-03","2009-06","1998-07",[1362],[1782,6553,6571],"irinotecan hydrochloride",{"nctId":1770,"briefTitle":1771,"status":294,"phases":6573,"start":1773,"enrollment":100,"conditions":6574,"interventions":6575},[90],[1775,1776,1777,1778],[1780,1781,1782,1738,1783,1784,1785,1786,1787,1788],{"nctId":6577,"briefTitle":6578,"status":119,"phases":6579,"primaryCompletion":6580,"start":6581,"conditions":6582,"interventions":6583},"NCT00005051","Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer",[90],"2003-03","1999-08",[6549],[1781,1782,1740,6584],"topotecan hydrochloride",{"nctId":6586,"briefTitle":6587,"status":119,"phases":6588,"primaryCompletion":3746,"completion":6118,"start":6589,"enrollment":632,"conditions":6590,"interventions":6592},"NCT00857246","Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer",[90],"2005-07",[1362,6591],"Stomach Cancer",[6593,6594,1338,6595],"Cetuximab","Irinotecan","5-FU",{"nctId":6597,"briefTitle":6598,"status":108,"phases":6599,"primaryCompletion":6600,"completion":1533,"start":6601,"enrollment":921,"conditions":6602,"interventions":6605},"NCT00848783","Irinotecan\u002FCisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers",[90],"2011-08","2008-05",[1362,6603,6604],"Gastric Adenocarcinoma","Esophageal Cancer",[6594,1338,6606,1858],"Floxuridine",{"trials":6608,"activeCount":100},[],{"trials":6610,"activeCount":100},[],{"trials":6612,"activeCount":100},[],{"intervention":1781,"totalTrials":112,"cells":6614},{"EARLY_PHASE1":6615,"PHASE1":6617,"PHASE2":6623,"PHASE3":6678,"PHASE4":6680,"NA":6682},{"trials":6616,"activeCount":100},[],{"trials":6618,"activeCount":100},[6619],{"nctId":2836,"briefTitle":2837,"status":119,"phases":6620,"primaryCompletion":2839,"start":2840,"conditions":6621,"interventions":6622},[89],[1775],[1780,1781,1786,1787],{"trials":6624,"activeCount":100},[6625,6633,6637,6641,6645,6653,6657,6661,6669],{"nctId":6626,"briefTitle":6627,"status":119,"phases":6628,"primaryCompletion":6629,"completion":6032,"start":6166,"enrollment":1246,"conditions":6630,"interventions":6631},"NCT01127763","RAD001 Plus Carboplatin in Breast Cancer Patients",[90],"2012-11",[15],[6632,1339],"RAD001",{"nctId":1330,"briefTitle":1331,"status":108,"phases":6634,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":772,"conditions":6635,"interventions":6636},[90],[1336],[43,1338,1339,1340],{"nctId":6540,"briefTitle":6541,"status":119,"phases":6638,"primaryCompletion":6543,"start":6544,"enrollment":1478,"conditions":6639,"interventions":6640},[90],[6546,1362,6547,6548,6549,6550,6551],[1781,1782,6553],{"nctId":1770,"briefTitle":1771,"status":294,"phases":6642,"start":1773,"enrollment":100,"conditions":6643,"interventions":6644},[90],[1775,1776,1777,1778],[1780,1781,1782,1738,1783,1784,1785,1786,1787,1788],{"nctId":6646,"briefTitle":6647,"status":119,"phases":6648,"primaryCompletion":6649,"start":6650,"conditions":6651,"interventions":6652},"NCT00010036","Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme",[90],"2001-10","1999-05",[1775],[1781,6571],{"nctId":2861,"briefTitle":2862,"status":294,"phases":6654,"start":1773,"enrollment":100,"conditions":6655,"interventions":6656},[90],[1775],[1780,1781,1786],{"nctId":6577,"briefTitle":6578,"status":119,"phases":6658,"primaryCompletion":6580,"start":6581,"conditions":6659,"interventions":6660},[90],[6549],[1781,1782,1740,6584],{"nctId":6662,"briefTitle":6663,"status":119,"phases":6664,"primaryCompletion":6665,"start":6666,"enrollment":682,"conditions":6667,"interventions":6668},"NCT00002619","Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors",[90],"2000-04","1994-09",[1775],[1780,1781,1787],{"nctId":6670,"briefTitle":6671,"status":119,"phases":6672,"primaryCompletion":6673,"completion":6673,"start":6674,"enrollment":6675,"conditions":6676,"interventions":6677},"NCT01289353","Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer",[89,90],"2019-07-08","2009-03-06",92,[15],[1339],{"trials":6679,"activeCount":100},[],{"trials":6681,"activeCount":100},[],{"trials":6683,"activeCount":100},[],{"intervention":1740,"totalTrials":1461,"cells":6685},{"EARLY_PHASE1":6686,"PHASE1":6688,"PHASE2":6710,"PHASE3":6755,"PHASE4":6757,"NA":6759},{"trials":6687,"activeCount":100},[],{"trials":6689,"activeCount":100},[6690,6694,6702],{"nctId":1730,"briefTitle":1731,"status":119,"phases":6691,"primaryCompletion":1733,"start":1734,"conditions":6692,"interventions":6693},[89],[15],[1737,1738,1739,1740,1741],{"nctId":6695,"briefTitle":6696,"status":119,"phases":6697,"primaryCompletion":5859,"completion":5859,"start":6698,"enrollment":1750,"conditions":6699,"interventions":6700},"NCT02911350","Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer",[89],"2000-05",[21],[6701,1860],"Hormone Suppressors",{"nctId":6703,"briefTitle":6704,"status":119,"phases":6705,"primaryCompletion":6508,"start":6706,"conditions":6707,"interventions":6708},"NCT00005048","Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy",[89],"1997-04",[21],[6709,1740],"estramustine phosphate sodium",{"trials":6711,"activeCount":100},[6712,6720,6724,6734,6738,6748],{"nctId":6713,"briefTitle":6714,"status":119,"phases":6715,"primaryCompletion":6716,"completion":6716,"start":6717,"enrollment":5389,"conditions":6718,"interventions":6719},"NCT02280252","Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response",[90],"2018-12-20","2005-03",[15],[1860],{"nctId":1850,"briefTitle":1851,"status":108,"phases":6721,"primaryCompletion":1853,"completion":1853,"start":1854,"enrollment":1855,"conditions":6722,"interventions":6723},[89,90],[15],[1858,1859,1860],{"nctId":6725,"briefTitle":6726,"status":119,"phases":6727,"primaryCompletion":6728,"start":6729,"conditions":6730,"interventions":6733},"NCT00003334","Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract",[90],"2001-12","1997-03",[6731,6732,6549,1778],"Endometrial Cancer","Fallopian Tube Cancer",[1740,1869],{"nctId":6577,"briefTitle":6578,"status":119,"phases":6735,"primaryCompletion":6580,"start":6581,"conditions":6736,"interventions":6737},[90],[6549],[1781,1782,1740,6584],{"nctId":6739,"briefTitle":6740,"status":119,"phases":6741,"primaryCompletion":6742,"start":3909,"conditions":6743,"interventions":6746},"NCT00004105","Combination Chemotherapy in Treating Patients With Advanced Cancer",[89,90],"2003-04",[6744,6745,1778,6519],"Leukemia","Lymphoma",[6709,1740,6747],"vinorelbine ditartrate",{"nctId":6749,"briefTitle":6750,"status":119,"phases":6751,"primaryCompletion":4088,"completion":4088,"start":6742,"enrollment":5457,"conditions":6752,"interventions":6753},"NCT02474186","Phase II Study for Solid Metastatic Tumors",[90],[15,1798,3003],[6754,1740],"Xeloda",{"trials":6756,"activeCount":100},[],{"trials":6758,"activeCount":100},[],{"trials":6760,"activeCount":100},[],{"intervention":6584,"totalTrials":772,"cells":6762},{"EARLY_PHASE1":6763,"PHASE1":6765,"PHASE2":6801,"PHASE3":6807,"PHASE4":6809,"NA":6811},{"trials":6764,"activeCount":100},[],{"trials":6766,"activeCount":100},[6767,6775,6783,6791],{"nctId":6768,"briefTitle":6769,"status":119,"phases":6770,"primaryCompletion":6771,"start":6772,"conditions":6773,"interventions":6774},"NCT00025311","Topotecan in Treating Patients With Recurrent, Progressive, or Refractory Cancer That is Metastatic to the Lining Around the Brain",[89],"2003-10","2001-05",[1775],[6584],{"nctId":6776,"briefTitle":6777,"status":119,"phases":6778,"primaryCompletion":6779,"start":6508,"conditions":6780,"interventions":6781},"NCT00006391","Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",[89],"2004-11",[6732,6549,6550],[6782,6584],"oxaliplatin",{"nctId":6784,"briefTitle":6785,"status":119,"phases":6786,"primaryCompletion":6787,"start":6508,"conditions":6788,"interventions":6789},"NCT00005990","R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors",[89],"2006-09",[6519],[6790,6584],"tipifarnib",{"nctId":6792,"briefTitle":6740,"status":119,"phases":6793,"primaryCompletion":6516,"start":6517,"enrollment":632,"conditions":6794,"interventions":6799},"NCT00003331",[89],[6795,6744,6745,6796,6797,6798,6519],"Chronic Myeloproliferative Disorders","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes","Precancerous Condition",[6800,1784,6584],"fluorouracil",{"trials":6802,"activeCount":100},[6803],{"nctId":6577,"briefTitle":6578,"status":119,"phases":6804,"primaryCompletion":6580,"start":6581,"conditions":6805,"interventions":6806},[90],[6549],[1781,1782,1740,6584],{"trials":6808,"activeCount":100},[],{"trials":6810,"activeCount":100},[],{"trials":6812,"activeCount":100},[],{"intervention":6782,"totalTrials":772,"cells":6814},{"EARLY_PHASE1":6815,"PHASE1":6817,"PHASE2":6823,"PHASE3":6860,"PHASE4":6862,"NA":6864},{"trials":6816,"activeCount":100},[],{"trials":6818,"activeCount":100},[6819],{"nctId":6776,"briefTitle":6777,"status":119,"phases":6820,"primaryCompletion":6779,"start":6508,"conditions":6821,"interventions":6822},[89],[6732,6549,6550],[6782,6584],{"trials":6824,"activeCount":100},[6825,6835,6843,6850],{"nctId":6826,"briefTitle":6827,"status":108,"phases":6828,"primaryCompletion":3993,"completion":6118,"start":6829,"enrollment":1359,"conditions":6830,"interventions":6831},"NCT00463840","Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer",[89,90],"2004-06",[1404],[6832,6833,6834],"Oxaliplatin","5FU","FOLFOX 6",{"nctId":6836,"briefTitle":6837,"status":119,"phases":6838,"primaryCompletion":6516,"start":6839,"conditions":6840,"interventions":6841},"NCT00004102","Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer",[90],"1999-01",[6546],[6842,6800,1784,6782],"FOLFOX regimen",{"nctId":6844,"briefTitle":6845,"status":119,"phases":6846,"primaryCompletion":6256,"start":6581,"conditions":6847,"interventions":6848},"NCT00005050","Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer",[89,90],[6546],[6849,6800,6782],"ethynyluracil",{"nctId":6851,"briefTitle":6852,"status":119,"phases":6853,"primaryCompletion":6854,"completion":6855,"start":6856,"enrollment":16,"conditions":6857,"interventions":6859},"NCT00444678","Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer",[90],"2012-08-01","2015-06-01","2004-06-01",[6546,6858],"Neoplasm Metastasis",[6593,6832,1858],{"trials":6861,"activeCount":100},[],{"trials":6863,"activeCount":100},[],{"trials":6865,"activeCount":100},[],{"intervention":2858,"totalTrials":946,"cells":6867},{"EARLY_PHASE1":6868,"PHASE1":6870,"PHASE2":6880,"PHASE3":6906,"PHASE4":6908,"NA":6910},{"trials":6869,"activeCount":100},[],{"trials":6871,"activeCount":100},[6872],{"nctId":6873,"briefTitle":6874,"status":119,"phases":6875,"primaryCompletion":6876,"completion":1419,"start":3060,"enrollment":1589,"conditions":6877,"interventions":6878},"NCT00846612","Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer",[89],"2010-09",[6549],[6879,2858],"Doxil",{"trials":6881,"activeCount":100},[6882,6890,6902],{"nctId":6883,"briefTitle":6884,"status":119,"phases":6885,"primaryCompletion":1714,"completion":6886,"start":6278,"enrollment":1203,"conditions":6887,"interventions":6889},"NCT01091259","Irinotecan and Bevacizumab for Recurrent Ovarian Cancer",[90],"2015-05",[6549,6732,6888],"Primary Peritoneal Carcinoma",[6594,2858],{"nctId":6891,"briefTitle":6892,"status":294,"phases":6893,"primaryCompletion":3311,"completion":3311,"start":6894,"enrollment":100,"conditions":6895,"interventions":6898},"NCT02754362","A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma",[90],"2016-11",[6896,6897],"Glioblastoma","Glioma",[2858,6899,6900,6901],"Peptide Vaccine","Poly-ICLC as immune adjuvant","Keyhole limpet hemocyanin",{"nctId":2850,"briefTitle":2851,"status":108,"phases":6903,"primaryCompletion":2853,"completion":1215,"start":2854,"enrollment":22,"conditions":6904,"interventions":6905},[90],[2856],[2834,2858,2859],{"trials":6907,"activeCount":100},[],{"trials":6909,"activeCount":100},[],{"trials":6911,"activeCount":100},[],{"intervention":6594,"totalTrials":946,"cells":6913},{"EARLY_PHASE1":6914,"PHASE1":6916,"PHASE2":6927,"PHASE3":6941,"PHASE4":6943,"NA":6945},{"trials":6915,"activeCount":100},[],{"trials":6917,"activeCount":100},[6918],{"nctId":6919,"briefTitle":6920,"status":119,"phases":6921,"primaryCompletion":6922,"completion":6922,"start":4462,"enrollment":96,"conditions":6923,"interventions":6925},"NCT02906059","Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer",[89],"2020-03-12",[6924],"Metastatic Colorectal Cancer",[6926,6594],"AZD1775",{"trials":6928,"activeCount":100},[6929,6933,6937],{"nctId":6883,"briefTitle":6884,"status":119,"phases":6930,"primaryCompletion":1714,"completion":6886,"start":6278,"enrollment":1203,"conditions":6931,"interventions":6932},[90],[6549,6732,6888],[6594,2858],{"nctId":6586,"briefTitle":6587,"status":119,"phases":6934,"primaryCompletion":3746,"completion":6118,"start":6589,"enrollment":632,"conditions":6935,"interventions":6936},[90],[1362,6591],[6593,6594,1338,6595],{"nctId":6597,"briefTitle":6598,"status":108,"phases":6938,"primaryCompletion":6600,"completion":1533,"start":6601,"enrollment":921,"conditions":6939,"interventions":6940},[90],[1362,6603,6604],[6594,1338,6606,1858],{"trials":6942,"activeCount":100},[],{"trials":6944,"activeCount":100},[],{"trials":6946,"activeCount":100},[],{"intervention":6553,"totalTrials":946,"cells":6948},{"EARLY_PHASE1":6949,"PHASE1":6951,"PHASE2":6953,"PHASE3":6974,"PHASE4":6976,"NA":6978},{"trials":6950,"activeCount":100},[],{"trials":6952,"activeCount":100},[],{"trials":6954,"activeCount":100},[6955,6959,6966,6970],{"nctId":6540,"briefTitle":6541,"status":119,"phases":6956,"primaryCompletion":6543,"start":6544,"enrollment":1478,"conditions":6957,"interventions":6958},[90],[6546,1362,6547,6548,6549,6550,6551],[1781,1782,6553],{"nctId":6960,"briefTitle":6961,"status":119,"phases":6962,"primaryCompletion":6566,"completion":6232,"start":6963,"enrollment":22,"conditions":6964,"interventions":6965},"NCT00858338","Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer",[90],"2002-12",[1362,6591],[6606],{"nctId":6563,"briefTitle":6564,"status":119,"phases":6967,"primaryCompletion":6566,"completion":6567,"start":6568,"conditions":6968,"interventions":6969},[90],[1362],[1782,6553,6571],{"nctId":6597,"briefTitle":6598,"status":108,"phases":6971,"primaryCompletion":6600,"completion":1533,"start":6601,"enrollment":921,"conditions":6972,"interventions":6973},[90],[1362,6603,6604],[6594,1338,6606,1858],{"trials":6975,"activeCount":100},[],{"trials":6977,"activeCount":100},[],{"trials":6979,"activeCount":100},[],{"intervention":1858,"totalTrials":946,"cells":6981},{"EARLY_PHASE1":6982,"PHASE1":6984,"PHASE2":6990,"PHASE3":7004,"PHASE4":7006,"NA":7008},{"trials":6983,"activeCount":100},[],{"trials":6985,"activeCount":100},[6986],{"nctId":6505,"briefTitle":6506,"status":119,"phases":6987,"primaryCompletion":5570,"start":6508,"conditions":6988,"interventions":6989},[89],[1205],[6511,1782],{"trials":6991,"activeCount":100},[6992,6996,7000],{"nctId":1850,"briefTitle":1851,"status":108,"phases":6993,"primaryCompletion":1853,"completion":1853,"start":1854,"enrollment":1855,"conditions":6994,"interventions":6995},[89,90],[15],[1858,1859,1860],{"nctId":6851,"briefTitle":6852,"status":119,"phases":6997,"primaryCompletion":6854,"completion":6855,"start":6856,"enrollment":16,"conditions":6998,"interventions":6999},[90],[6546,6858],[6593,6832,1858],{"nctId":6597,"briefTitle":6598,"status":108,"phases":7001,"primaryCompletion":6600,"completion":1533,"start":6601,"enrollment":921,"conditions":7002,"interventions":7003},[90],[1362,6603,6604],[6594,1338,6606,1858],{"trials":7005,"activeCount":100},[],{"trials":7007,"activeCount":100},[],{"trials":7009,"activeCount":100},[],{"intervention":1780,"totalTrials":946,"cells":7011},{"EARLY_PHASE1":7012,"PHASE1":7014,"PHASE2":7020,"PHASE3":7034,"PHASE4":7036,"NA":7038},{"trials":7013,"activeCount":100},[],{"trials":7015,"activeCount":100},[7016],{"nctId":2836,"briefTitle":2837,"status":119,"phases":7017,"primaryCompletion":2839,"start":2840,"conditions":7018,"interventions":7019},[89],[1775],[1780,1781,1786,1787],{"trials":7021,"activeCount":100},[7022,7026,7030],{"nctId":1770,"briefTitle":1771,"status":294,"phases":7023,"start":1773,"enrollment":100,"conditions":7024,"interventions":7025},[90],[1775,1776,1777,1778],[1780,1781,1782,1738,1783,1784,1785,1786,1787,1788],{"nctId":2861,"briefTitle":2862,"status":294,"phases":7027,"start":1773,"enrollment":100,"conditions":7028,"interventions":7029},[90],[1775],[1780,1781,1786],{"nctId":6662,"briefTitle":6663,"status":119,"phases":7031,"primaryCompletion":6665,"start":6666,"enrollment":682,"conditions":7032,"interventions":7033},[90],[1775],[1780,1781,1787],{"trials":7035,"activeCount":100},[],{"trials":7037,"activeCount":100},[],{"trials":7039,"activeCount":100},[],{"intervention":1764,"totalTrials":195,"cells":7041},{"EARLY_PHASE1":7042,"PHASE1":7044,"PHASE2":7054,"PHASE3":7068,"PHASE4":7070,"NA":7072},{"trials":7043,"activeCount":100},[],{"trials":7045,"activeCount":100},[7046],{"nctId":7047,"briefTitle":7048,"status":119,"phases":7049,"primaryCompletion":6649,"start":7050,"conditions":7051,"interventions":7052},"NCT00004002","PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma",[89],"1999-07",[6745,6551,6519],[7053],"bortezomib",{"trials":7055,"activeCount":100},[7056,7060],{"nctId":1756,"briefTitle":1757,"status":119,"phases":7057,"primaryCompletion":47,"completion":1759,"start":1760,"enrollment":1750,"conditions":7058,"interventions":7059},[90],[1762],[1764,1291],{"nctId":7061,"briefTitle":7062,"status":108,"phases":7063,"primaryCompletion":1714,"completion":7064,"start":3746,"enrollment":1359,"conditions":7065,"interventions":7066},"NCT01315873","Bortezomib and Bendamustine to Treat Relapsed\u002FRefractory Myeloma",[90],"2015-09",[923],[7067,1764],"Bendamustine",{"trials":7069,"activeCount":100},[],{"trials":7071,"activeCount":100},[],{"trials":7073,"activeCount":100},[],{"intervention":1787,"totalTrials":195,"cells":7075},{"EARLY_PHASE1":7076,"PHASE1":7078,"PHASE2":7084,"PHASE3":7094,"PHASE4":7096,"NA":7098},{"trials":7077,"activeCount":100},[],{"trials":7079,"activeCount":100},[7080],{"nctId":2836,"briefTitle":2837,"status":119,"phases":7081,"primaryCompletion":2839,"start":2840,"conditions":7082,"interventions":7083},[89],[1775],[1780,1781,1786,1787],{"trials":7085,"activeCount":100},[7086,7090],{"nctId":1770,"briefTitle":1771,"status":294,"phases":7087,"start":1773,"enrollment":100,"conditions":7088,"interventions":7089},[90],[1775,1776,1777,1778],[1780,1781,1782,1738,1783,1784,1785,1786,1787,1788],{"nctId":6662,"briefTitle":6663,"status":119,"phases":7091,"primaryCompletion":6665,"start":6666,"enrollment":682,"conditions":7092,"interventions":7093},[90],[1775],[1780,1781,1787],{"trials":7095,"activeCount":100},[],{"trials":7097,"activeCount":100},[],{"trials":7099,"activeCount":100},[],{"intervention":925,"totalTrials":195,"cells":7101},{"EARLY_PHASE1":7102,"PHASE1":7104,"PHASE2":7106,"PHASE3":7120,"PHASE4":7122,"NA":7124},{"trials":7103,"activeCount":100},[],{"trials":7105,"activeCount":100},[],{"trials":7107,"activeCount":100},[7108,7112,7116],{"nctId":1502,"briefTitle":1503,"status":108,"phases":7109,"primaryCompletion":1505,"completion":1505,"start":1506,"enrollment":195,"conditions":7110,"interventions":7111},[89,90],[1508],[925,1510],{"nctId":916,"briefTitle":917,"status":108,"phases":7113,"primaryCompletion":919,"completion":919,"start":920,"enrollment":921,"conditions":7114,"interventions":7115},[90],[923],[925,926,898],{"nctId":1384,"briefTitle":1385,"status":108,"phases":7117,"primaryCompletion":1387,"completion":1387,"start":1388,"enrollment":268,"conditions":7118,"interventions":7119},[89,90],[1390,1391],[43,925],{"trials":7121,"activeCount":100},[],{"trials":7123,"activeCount":100},[],{"trials":7125,"activeCount":100},[],{"intervention":6800,"totalTrials":195,"cells":7127},{"EARLY_PHASE1":7128,"PHASE1":7130,"PHASE2":7136,"PHASE3":7146,"PHASE4":7148,"NA":7150},{"trials":7129,"activeCount":100},[],{"trials":7131,"activeCount":100},[7132],{"nctId":6792,"briefTitle":6740,"status":119,"phases":7133,"primaryCompletion":6516,"start":6517,"enrollment":632,"conditions":7134,"interventions":7135},[89],[6795,6744,6745,6796,6797,6798,6519],[6800,1784,6584],{"trials":7137,"activeCount":100},[7138,7142],{"nctId":6836,"briefTitle":6837,"status":119,"phases":7139,"primaryCompletion":6516,"start":6839,"conditions":7140,"interventions":7141},[90],[6546],[6842,6800,1784,6782],{"nctId":6844,"briefTitle":6845,"status":119,"phases":7143,"primaryCompletion":6256,"start":6581,"conditions":7144,"interventions":7145},[89,90],[6546],[6849,6800,6782],{"trials":7147,"activeCount":100},[],{"trials":7149,"activeCount":100},[],{"trials":7151,"activeCount":100},[],{"intervention":1784,"totalTrials":195,"cells":7153},{"EARLY_PHASE1":7154,"PHASE1":7156,"PHASE2":7162,"PHASE3":7172,"PHASE4":7174,"NA":7176},{"trials":7155,"activeCount":100},[],{"trials":7157,"activeCount":100},[7158],{"nctId":6792,"briefTitle":6740,"status":119,"phases":7159,"primaryCompletion":6516,"start":6517,"enrollment":632,"conditions":7160,"interventions":7161},[89],[6795,6744,6745,6796,6797,6798,6519],[6800,1784,6584],{"trials":7163,"activeCount":100},[7164,7168],{"nctId":6836,"briefTitle":6837,"status":119,"phases":7165,"primaryCompletion":6516,"start":6839,"conditions":7166,"interventions":7167},[90],[6546],[6842,6800,1784,6782],{"nctId":1770,"briefTitle":1771,"status":294,"phases":7169,"start":1773,"enrollment":100,"conditions":7170,"interventions":7171},[90],[1775,1776,1777,1778],[1780,1781,1782,1738,1783,1784,1785,1786,1787,1788],{"trials":7173,"activeCount":100},[],{"trials":7175,"activeCount":100},[],{"trials":7177,"activeCount":100},[],{"intervention":1754,"totalTrials":173,"cells":7179},{"EARLY_PHASE1":7180,"PHASE1":7182,"PHASE2":7184,"PHASE3":7199,"PHASE4":7201,"NA":7203},{"trials":7181,"activeCount":100},[],{"trials":7183,"activeCount":100},[],{"trials":7185,"activeCount":100},[7186,7190],{"nctId":1745,"briefTitle":1746,"status":119,"phases":7187,"primaryCompletion":1748,"completion":1748,"start":1749,"enrollment":1750,"conditions":7188,"interventions":7189},[90],[1752],[1754,1291],{"nctId":7191,"briefTitle":7192,"status":119,"phases":7193,"primaryCompletion":6772,"start":7194,"conditions":7195,"interventions":7196},"NCT00010010","Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer",[90],"2000-06",[15],[7197,7198],"exemestane","goserelin acetate",{"trials":7200,"activeCount":100},[],{"trials":7202,"activeCount":100},[],{"trials":7204,"activeCount":100},[],{"intervention":7206,"totalTrials":173,"cells":7207},"Docetaxel",{"EARLY_PHASE1":7208,"PHASE1":7210,"PHASE2":7212,"PHASE3":7231,"PHASE4":7233,"NA":7235},{"trials":7209,"activeCount":100},[],{"trials":7211,"activeCount":100},[],{"trials":7213,"activeCount":100},[7214,7222],{"nctId":7215,"briefTitle":7216,"status":108,"phases":7217,"primaryCompletion":2854,"completion":2854,"start":5085,"enrollment":1359,"conditions":7218,"interventions":7220},"NCT00861471","Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer",[89,90],[21,7219],"Prostatic Neoplasms",[7206,7221],"Imatinib Mesylate",{"nctId":7223,"briefTitle":7224,"status":108,"phases":7225,"primaryCompletion":7226,"completion":7227,"start":4746,"enrollment":124,"conditions":7228,"interventions":7229},"NCT03837353","A Parallel Arm Phase 1b\u002F2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1",[89,90],"2022-07-19","2022-09-20",[21],[7230,7206],"DKN-01",{"trials":7232,"activeCount":100},[],{"trials":7234,"activeCount":100},[],{"trials":7236,"activeCount":100},[],{"intervention":6632,"totalTrials":173,"cells":7238},{"EARLY_PHASE1":7239,"PHASE1":7250,"PHASE2":7252,"PHASE3":7258,"PHASE4":7260,"NA":7262},{"trials":7240,"activeCount":100},[7241],{"nctId":7242,"briefTitle":7243,"status":119,"phases":7244,"primaryCompletion":1378,"completion":1378,"start":1476,"enrollment":772,"conditions":7245,"interventions":7249},"NCT01880749","Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas",[88],[7246,7247,7248],"Neurofibromatosis Type 2","Vestibular Schwannomas","Meningiomas",[6632],{"trials":7251,"activeCount":100},[],{"trials":7253,"activeCount":100},[7254],{"nctId":6626,"briefTitle":6627,"status":119,"phases":7255,"primaryCompletion":6629,"completion":6032,"start":6166,"enrollment":1246,"conditions":7256,"interventions":7257},[90],[15],[6632,1339],{"trials":7259,"activeCount":100},[],{"trials":7261,"activeCount":100},[],{"trials":7263,"activeCount":100},[],{"intervention":7265,"totalTrials":173,"cells":7266},"Ferric carboxymaltose",{"EARLY_PHASE1":7267,"PHASE1":7269,"PHASE2":7278,"PHASE3":7290,"PHASE4":7292,"NA":7294},{"trials":7268,"activeCount":100},[],{"trials":7270,"activeCount":100},[7271],{"nctId":7272,"briefTitle":7273,"status":119,"phases":7274,"primaryCompletion":3626,"start":6886,"enrollment":921,"conditions":7275,"interventions":7277},"NCT02737995","Iron Stores and Skeletal Muscle Metabolism in Chronic Heart Failure",[89],[7276],"Chronic Heart Failure",[7265],{"trials":7279,"activeCount":100},[7280],{"nctId":7281,"briefTitle":7282,"status":108,"phases":7283,"primaryCompletion":7284,"completion":7284,"start":7285,"enrollment":2797,"conditions":7286,"interventions":7288},"NCT03218384","Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency",[90],"2022-04-04","2017-09-07",[7287],"Iron-deficiency",[7289],"Ferric Carboxymaltose",{"trials":7291,"activeCount":100},[],{"trials":7293,"activeCount":100},[],{"trials":7295,"activeCount":100},[],{"intervention":1340,"totalTrials":173,"cells":7297},{"EARLY_PHASE1":7298,"PHASE1":7300,"PHASE2":7302,"PHASE3":7312,"PHASE4":7314,"NA":7316},{"trials":7299,"activeCount":100},[],{"trials":7301,"activeCount":100},[],{"trials":7303,"activeCount":100},[7304,7308],{"nctId":1330,"briefTitle":1331,"status":108,"phases":7305,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":772,"conditions":7306,"interventions":7307},[90],[1336],[43,1338,1339,1340],{"nctId":1770,"briefTitle":1771,"status":294,"phases":7309,"start":1773,"enrollment":100,"conditions":7310,"interventions":7311},[90],[1775,1776,1777,1778],[1780,1781,1782,1738,1783,1784,1785,1786,1787,1788],{"trials":7313,"activeCount":100},[],{"trials":7315,"activeCount":100},[],{"trials":7317,"activeCount":100},[],{"intervention":6790,"totalTrials":173,"cells":7319},{"EARLY_PHASE1":7320,"PHASE1":7322,"PHASE2":7328,"PHASE3":7337,"PHASE4":7339,"NA":7341},{"trials":7321,"activeCount":100},[],{"trials":7323,"activeCount":100},[7324],{"nctId":6784,"briefTitle":6785,"status":119,"phases":7325,"primaryCompletion":6787,"start":6508,"conditions":7326,"interventions":7327},[89],[6519],[6790,6584],{"trials":7329,"activeCount":100},[7330],{"nctId":7331,"briefTitle":7332,"status":119,"phases":7333,"primaryCompletion":6698,"start":6280,"conditions":7334,"interventions":7336},"NCT00005041","R115777 in Treating Patients With Relapsed Small Cell Lung Cancer",[90],[7335],"Lung Cancer",[6790],{"trials":7338,"activeCount":100},[],{"trials":7340,"activeCount":100},[],{"trials":7342,"activeCount":100},[],{"intervention":7344,"totalTrials":173,"cells":7345},"SOM 230 \u002F Pasireotide",{"EARLY_PHASE1":7346,"PHASE1":7348,"PHASE2":7361,"PHASE3":7370,"PHASE4":7372,"NA":7374},{"trials":7347,"activeCount":100},[],{"trials":7349,"activeCount":100},[7350],{"nctId":7351,"briefTitle":7352,"status":119,"phases":7353,"primaryCompletion":7354,"completion":945,"start":7355,"enrollment":1589,"conditions":7356,"interventions":7360},"NCT01372644","Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial",[89],"2010-12","2007-11",[7357,7358,7359],"Atypical Ductal Breast Hyperplasia","Lobular Carcinoma in Situ (LCIS)","Atypical Lobular Hyperplasia (ALH) of Breast",[7344],{"trials":7362,"activeCount":100},[7363],{"nctId":7364,"briefTitle":7365,"status":108,"phases":7366,"primaryCompletion":6118,"completion":6118,"start":6279,"enrollment":1461,"conditions":7367,"interventions":7369},"NCT01372618","Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor",[89,90],[7368],"Ductal Carcinoma in Situ",[7344],{"trials":7371,"activeCount":100},[],{"trials":7373,"activeCount":100},[],{"trials":7375,"activeCount":100},[],{"intervention":1869,"totalTrials":173,"cells":7377},{"EARLY_PHASE1":7378,"PHASE1":7380,"PHASE2":7382,"PHASE3":7392,"PHASE4":7394,"NA":7396},{"trials":7379,"activeCount":100},[],{"trials":7381,"activeCount":100},[],{"trials":7383,"activeCount":100},[7384,7388],{"nctId":6725,"briefTitle":6726,"status":119,"phases":7385,"primaryCompletion":6728,"start":6729,"conditions":7386,"interventions":7387},[90],[6731,6732,6549,1778],[1740,1869],{"nctId":1862,"briefTitle":1863,"status":119,"phases":7389,"primaryCompletion":1865,"start":1866,"conditions":7390,"interventions":7391},[89,90],[15],[1737,1869],{"trials":7393,"activeCount":100},[],{"trials":7395,"activeCount":100},[],{"trials":7397,"activeCount":100},[],{"intervention":6532,"totalTrials":173,"cells":7399},{"EARLY_PHASE1":7400,"PHASE1":7402,"PHASE2":7408,"PHASE3":7414,"PHASE4":7416,"NA":7418},{"trials":7401,"activeCount":100},[],{"trials":7403,"activeCount":100},[7404],{"nctId":6523,"briefTitle":6524,"status":119,"phases":7405,"primaryCompletion":6526,"start":6527,"enrollment":1855,"conditions":7406,"interventions":7407},[89],[6529,6519],[6531,1782,6532],{"trials":7409,"activeCount":100},[7410],{"nctId":6555,"briefTitle":6556,"status":119,"phases":7411,"primaryCompletion":6558,"start":6559,"enrollment":16,"conditions":7412,"interventions":7413},[89,90],[1404],[1782,6532],{"trials":7415,"activeCount":100},[],{"trials":7417,"activeCount":100},[],{"trials":7419,"activeCount":100},[],{"intervention":6571,"totalTrials":173,"cells":7421},{"EARLY_PHASE1":7422,"PHASE1":7424,"PHASE2":7426,"PHASE3":7436,"PHASE4":7438,"NA":7440},{"trials":7423,"activeCount":100},[],{"trials":7425,"activeCount":100},[],{"trials":7427,"activeCount":100},[7428,7432],{"nctId":6563,"briefTitle":6564,"status":119,"phases":7429,"primaryCompletion":6566,"completion":6567,"start":6568,"conditions":7430,"interventions":7431},[90],[1362],[1782,6553,6571],{"nctId":6646,"briefTitle":6647,"status":119,"phases":7433,"primaryCompletion":6649,"start":6650,"conditions":7434,"interventions":7435},[90],[1775],[1781,6571],{"trials":7437,"activeCount":100},[],{"trials":7439,"activeCount":100},[],{"trials":7441,"activeCount":100},[],{"intervention":1801,"totalTrials":173,"cells":7443},{"EARLY_PHASE1":7444,"PHASE1":7446,"PHASE2":7448,"PHASE3":7462,"PHASE4":7464,"NA":7466},{"trials":7445,"activeCount":100},[],{"trials":7447,"activeCount":100},[],{"trials":7449,"activeCount":100},[7450,7458],{"nctId":7451,"briefTitle":7452,"status":119,"phases":7453,"primaryCompletion":5636,"completion":1476,"start":7454,"enrollment":112,"conditions":7455,"interventions":7457},"NCT00899574","Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases",[90],"2009-05",[15,7456],"Breast Neoplasms",[1801],{"nctId":1790,"briefTitle":1791,"status":119,"phases":7459,"primaryCompletion":1793,"completion":1794,"start":1795,"enrollment":1796,"conditions":7460,"interventions":7461},[89,90],[15,1798,1799],[1801,1291],{"trials":7463,"activeCount":100},[],{"trials":7465,"activeCount":100},[],{"trials":7467,"activeCount":100},[],{"intervention":7469,"totalTrials":173,"cells":7470},"aerosol interferon-gamma",{"EARLY_PHASE1":7471,"PHASE1":7473,"PHASE2":7484,"PHASE3":7498,"PHASE4":7500,"NA":7502},{"trials":7472,"activeCount":100},[],{"trials":7474,"activeCount":100},[7475],{"nctId":7476,"briefTitle":7477,"status":119,"phases":7478,"primaryCompletion":7479,"completion":421,"start":7480,"enrollment":281,"conditions":7481,"interventions":7483},"NCT00563212","A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis",[89],"2010-06-01","2007-01",[7482],"Pulmonary Fibrosis",[7469],{"trials":7485,"activeCount":100},[7486],{"nctId":7487,"briefTitle":7488,"status":119,"phases":7489,"primaryCompletion":7480,"completion":5570,"start":7490,"enrollment":7491,"conditions":7492,"interventions":7495},"NCT00201123","Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs",[90],"2005-04",89,[7493,7494],"Tuberculosis","AIDS-related Complex",[7496,7497],"Aerosol Interferon-Gamma","Subcutaneous interferon-gamma",{"trials":7499,"activeCount":100},[],{"trials":7501,"activeCount":100},[],{"trials":7503,"activeCount":100},[],{"intervention":6593,"totalTrials":173,"cells":7505},{"EARLY_PHASE1":7506,"PHASE1":7508,"PHASE2":7510,"PHASE3":7520,"PHASE4":7522,"NA":7524},{"trials":7507,"activeCount":100},[],{"trials":7509,"activeCount":100},[],{"trials":7511,"activeCount":100},[7512,7516],{"nctId":6851,"briefTitle":6852,"status":119,"phases":7513,"primaryCompletion":6854,"completion":6855,"start":6856,"enrollment":16,"conditions":7514,"interventions":7515},[90],[6546,6858],[6593,6832,1858],{"nctId":6586,"briefTitle":6587,"status":119,"phases":7517,"primaryCompletion":3746,"completion":6118,"start":6589,"enrollment":632,"conditions":7518,"interventions":7519},[90],[1362,6591],[6593,6594,1338,6595],{"trials":7521,"activeCount":100},[],{"trials":7523,"activeCount":100},[],{"trials":7525,"activeCount":100},[],{"intervention":1481,"totalTrials":173,"cells":7527},{"EARLY_PHASE1":7528,"PHASE1":7530,"PHASE2":7532,"PHASE3":7547,"PHASE4":7549,"NA":7551},{"trials":7529,"activeCount":100},[],{"trials":7531,"activeCount":100},[],{"trials":7533,"activeCount":100},[7534,7543],{"nctId":7535,"briefTitle":7536,"status":108,"phases":7537,"primaryCompletion":1533,"completion":7538,"start":7539,"enrollment":268,"conditions":7540,"interventions":7541},"NCT01003938","Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer",[90],"2012-12","2009-08",[6549],[7542,1481],"Topotecan",{"nctId":1472,"briefTitle":1473,"status":119,"phases":7544,"primaryCompletion":1475,"completion":1476,"start":1477,"enrollment":1478,"conditions":7545,"interventions":7546},[90],[1404],[1328,1481,1482],{"trials":7548,"activeCount":100},[],{"trials":7550,"activeCount":100},[],{"trials":7552,"activeCount":100},[],{"intervention":6709,"totalTrials":173,"cells":7554},{"EARLY_PHASE1":7555,"PHASE1":7557,"PHASE2":7563,"PHASE3":7569,"PHASE4":7571,"NA":7573},{"trials":7556,"activeCount":100},[],{"trials":7558,"activeCount":100},[7559],{"nctId":6703,"briefTitle":6704,"status":119,"phases":7560,"primaryCompletion":6508,"start":6706,"conditions":7561,"interventions":7562},[89],[21],[6709,1740],{"trials":7564,"activeCount":100},[7565],{"nctId":6739,"briefTitle":6740,"status":119,"phases":7566,"primaryCompletion":6742,"start":3909,"conditions":7567,"interventions":7568},[89,90],[6744,6745,1778,6519],[6709,1740,6747],{"trials":7570,"activeCount":100},[],{"trials":7572,"activeCount":100},[],{"trials":7574,"activeCount":100},[],{"intervention":1482,"totalTrials":173,"cells":7576},{"EARLY_PHASE1":7577,"PHASE1":7579,"PHASE2":7581,"PHASE3":7596,"PHASE4":7598,"NA":7600},{"trials":7578,"activeCount":100},[],{"trials":7580,"activeCount":100},[],{"trials":7582,"activeCount":100},[7583,7587],{"nctId":1472,"briefTitle":1473,"status":119,"phases":7584,"primaryCompletion":1475,"completion":1476,"start":1477,"enrollment":1478,"conditions":7585,"interventions":7586},[90],[1404],[1328,1481,1482],{"nctId":7588,"briefTitle":7589,"status":108,"phases":7590,"primaryCompletion":6032,"completion":6032,"start":5636,"enrollment":281,"conditions":7591,"interventions":7595},"NCT01338857","Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas",[90],[7592,7593,7594],"neurofibromatosis1 (NF1)","Recurrent or Progressive Optic Pathway Gliomas (OPG)","Recurrent or Progressive Low-grade Glioma",[1482],{"trials":7597,"activeCount":100},[],{"trials":7599,"activeCount":100},[],{"trials":7601,"activeCount":100},[],{"intervention":1266,"totalTrials":173,"cells":7603},{"EARLY_PHASE1":7604,"PHASE1":7606,"PHASE2":7608,"PHASE3":7618,"PHASE4":7620,"NA":7622},{"trials":7605,"activeCount":100},[],{"trials":7607,"activeCount":100},[],{"trials":7609,"activeCount":100},[7610,7614],{"nctId":1258,"briefTitle":1259,"status":119,"phases":7611,"primaryCompletion":1261,"completion":1261,"start":1262,"enrollment":847,"conditions":7612,"interventions":7613},[90],[1264],[1193,1266],{"nctId":3599,"briefTitle":3600,"status":119,"phases":7615,"primaryCompletion":3602,"completion":3603,"start":3604,"enrollment":31,"conditions":7616,"interventions":7617},[90],[3606],[354,1266],{"trials":7619,"activeCount":100},[],{"trials":7621,"activeCount":100},[],{"trials":7623,"activeCount":100},[],{"intervention":7625,"totalTrials":190,"cells":7626},"TBL12",{"EARLY_PHASE1":7627,"PHASE1":7629,"PHASE2":7631,"PHASE3":7640,"PHASE4":7642,"NA":7644},{"trials":7628,"activeCount":100},[],{"trials":7630,"activeCount":100},[],{"trials":7632,"activeCount":100},[7633],{"nctId":7634,"briefTitle":7635,"status":108,"phases":7636,"primaryCompletion":3604,"completion":3604,"start":1807,"enrollment":2797,"conditions":7637,"interventions":7639},"NCT01302366","A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma",[90],[7638],"Myeloma",[7625],{"trials":7641,"activeCount":100},[],{"trials":7643,"activeCount":100},[],{"trials":7645,"activeCount":100},[],{"intervention":7221,"totalTrials":190,"cells":7647},{"EARLY_PHASE1":7648,"PHASE1":7650,"PHASE2":7652,"PHASE3":7658,"PHASE4":7660,"NA":7662},{"trials":7649,"activeCount":100},[],{"trials":7651,"activeCount":100},[],{"trials":7653,"activeCount":100},[7654],{"nctId":7215,"briefTitle":7216,"status":108,"phases":7655,"primaryCompletion":2854,"completion":2854,"start":5085,"enrollment":1359,"conditions":7656,"interventions":7657},[89,90],[21,7219],[7206,7221],{"trials":7659,"activeCount":100},[],{"trials":7661,"activeCount":100},[],{"trials":7663,"activeCount":100},[],{"intervention":7665,"totalTrials":190,"cells":7666},"Dronabinol",{"EARLY_PHASE1":7667,"PHASE1":7669,"PHASE2":7671,"PHASE3":7682,"PHASE4":7684,"NA":7686},{"trials":7668,"activeCount":100},[],{"trials":7670,"activeCount":100},[],{"trials":7672,"activeCount":100},[7673],{"nctId":7674,"briefTitle":7675,"status":294,"phases":7676,"primaryCompletion":7677,"completion":7677,"start":1505,"enrollment":100,"conditions":7678,"interventions":7681},"NCT02608931","The Safety, Tolerability and Efficacy of Dronabinol, for the Treatment of Nausea and Vomiting in Familial Dysautonomia",[90],"2019-03-22",[7679,7680,1591],"Nausea","Vomiting",[7665],{"trials":7683,"activeCount":100},[],{"trials":7685,"activeCount":100},[],{"trials":7687,"activeCount":100},[],{"intervention":7689,"totalTrials":190,"cells":7690},"cisplatin liposomal",{"EARLY_PHASE1":7691,"PHASE1":7693,"PHASE2":7695,"PHASE3":7705,"PHASE4":7707,"NA":7709},{"trials":7692,"activeCount":100},[],{"trials":7694,"activeCount":100},[],{"trials":7696,"activeCount":100},[7697],{"nctId":7698,"briefTitle":7699,"status":119,"phases":7700,"primaryCompletion":7701,"start":7702,"conditions":7703,"interventions":7704},"NCT00004083","Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer",[90],"1999-12","1999-02",[6549],[7689],{"trials":7706,"activeCount":100},[],{"trials":7708,"activeCount":100},[],{"trials":7710,"activeCount":100},[],{"intervention":7712,"totalTrials":190,"cells":7713},"Everolimus",{"EARLY_PHASE1":7714,"PHASE1":7716,"PHASE2":7718,"PHASE3":7730,"PHASE4":7732,"NA":7734},{"trials":7715,"activeCount":100},[],{"trials":7717,"activeCount":100},[],{"trials":7719,"activeCount":100},[7720],{"nctId":7721,"briefTitle":7722,"status":119,"phases":7723,"primaryCompletion":7724,"completion":7725,"start":3313,"enrollment":1589,"conditions":7726,"interventions":7729},"NCT02451696","A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD",[90],"2017-12-08","2017-12-28",[30,7727,7728],"Tuberous Sclerosis Complex","Focal Cortical Dysplasia",[7712],{"trials":7731,"activeCount":100},[],{"trials":7733,"activeCount":100},[],{"trials":7735,"activeCount":100},[],{"intervention":7737,"totalTrials":190,"cells":7738},"Lapatinib",{"EARLY_PHASE1":7739,"PHASE1":7741,"PHASE2":7743,"PHASE3":7754,"PHASE4":7756,"NA":7758},{"trials":7740,"activeCount":100},[],{"trials":7742,"activeCount":100},[],{"trials":7744,"activeCount":100},[7745],{"nctId":7746,"briefTitle":7747,"status":119,"phases":7748,"primaryCompletion":6233,"completion":6629,"start":7749,"enrollment":31,"conditions":7750,"interventions":7753},"NCT00973739","Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors",[90],"2009-09",[7751,7752],"Neurofibromatosis 2","Vestibular Schwannoma",[7737],{"trials":7755,"activeCount":100},[],{"trials":7757,"activeCount":100},[],{"trials":7759,"activeCount":100},[],{"intervention":7761,"totalTrials":190,"cells":7762},"NRX-1074",{"EARLY_PHASE1":7763,"PHASE1":7765,"PHASE2":7767,"PHASE3":7776,"PHASE4":7778,"NA":7780},{"trials":7764,"activeCount":100},[],{"trials":7766,"activeCount":100},[],{"trials":7768,"activeCount":100},[7769],{"nctId":7770,"briefTitle":7771,"status":294,"phases":7772,"primaryCompletion":7773,"enrollment":100,"conditions":7774,"interventions":7775},"NCT02603458","NRX-1074 in Early Course Schizophrenia",[90],"2020-08",[4329],[7761],{"trials":7777,"activeCount":100},[],{"trials":7779,"activeCount":100},[],{"trials":7781,"activeCount":100},[],{"intervention":7783,"totalTrials":190,"cells":7784},"Clazakizumab 25 mg",{"EARLY_PHASE1":7785,"PHASE1":7787,"PHASE2":7789,"PHASE3":7801,"PHASE4":7803,"NA":7805},{"trials":7786,"activeCount":100},[],{"trials":7788,"activeCount":100},[],{"trials":7790,"activeCount":100},[7791],{"nctId":7792,"briefTitle":7793,"status":119,"phases":7794,"primaryCompletion":7795,"completion":7796,"start":7797,"enrollment":335,"conditions":7798,"interventions":7799},"NCT04343989","A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection",[90],"2021-02-03","2021-03-12","2020-03-31",[788],[7783,7800],"Clazakizumab 12.5 mg",{"trials":7802,"activeCount":100},[],{"trials":7804,"activeCount":100},[],{"trials":7806,"activeCount":100},[],{"intervention":7800,"totalTrials":190,"cells":7808},{"EARLY_PHASE1":7809,"PHASE1":7811,"PHASE2":7813,"PHASE3":7819,"PHASE4":7821,"NA":7823},{"trials":7810,"activeCount":100},[],{"trials":7812,"activeCount":100},[],{"trials":7814,"activeCount":100},[7815],{"nctId":7792,"briefTitle":7793,"status":119,"phases":7816,"primaryCompletion":7795,"completion":7796,"start":7797,"enrollment":335,"conditions":7817,"interventions":7818},[90],[788],[7783,7800],{"trials":7820,"activeCount":100},[],{"trials":7822,"activeCount":100},[],{"trials":7824,"activeCount":100},[],{"intervention":851,"totalTrials":190,"cells":7826},{"EARLY_PHASE1":7827,"PHASE1":7829,"PHASE2":7831,"PHASE3":7837,"PHASE4":7839,"NA":7841},{"trials":7828,"activeCount":100},[],{"trials":7830,"activeCount":100},[],{"trials":7832,"activeCount":100},[7833],{"nctId":842,"briefTitle":843,"status":119,"phases":7834,"primaryCompletion":845,"completion":845,"start":846,"enrollment":847,"conditions":7835,"interventions":7836},[89,90],[849,366],[833,851],{"trials":7838,"activeCount":100},[],{"trials":7840,"activeCount":100},[],{"trials":7842,"activeCount":100},[],{"intervention":7844,"totalTrials":190,"cells":7845},"Lisdexamfetamine",{"EARLY_PHASE1":7846,"PHASE1":7848,"PHASE2":7850,"PHASE3":7861,"PHASE4":7863,"NA":7865},{"trials":7847,"activeCount":100},[],{"trials":7849,"activeCount":100},[],{"trials":7851,"activeCount":100},[7852],{"nctId":7853,"briefTitle":7854,"status":119,"phases":7855,"primaryCompletion":7856,"completion":7856,"start":1505,"enrollment":7857,"conditions":7858,"interventions":7860},"NCT02635035","Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT",[90],"2019-01-09",38,[7859,5573],"Attention Deficit Disorder",[7844],{"trials":7862,"activeCount":100},[],{"trials":7864,"activeCount":100},[],{"trials":7866,"activeCount":100},[],{"intervention":7868,"totalTrials":190,"cells":7869},"Panobinostat",{"EARLY_PHASE1":7870,"PHASE1":7872,"PHASE2":7874,"PHASE3":7883,"PHASE4":7885,"NA":7887},{"trials":7871,"activeCount":100},[],{"trials":7873,"activeCount":100},[],{"trials":7875,"activeCount":100},[7876],{"nctId":7877,"briefTitle":7878,"status":119,"phases":7879,"primaryCompletion":110,"completion":4088,"start":6567,"enrollment":487,"conditions":7880,"interventions":7881},"NCT00878436","Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration",[89,90],[21,7219],[7868,7882],"Bicalutamide",{"trials":7884,"activeCount":100},[],{"trials":7886,"activeCount":100},[],{"trials":7888,"activeCount":100},[],{"intervention":7882,"totalTrials":190,"cells":7890},{"EARLY_PHASE1":7891,"PHASE1":7893,"PHASE2":7895,"PHASE3":7901,"PHASE4":7903,"NA":7905},{"trials":7892,"activeCount":100},[],{"trials":7894,"activeCount":100},[],{"trials":7896,"activeCount":100},[7897],{"nctId":7877,"briefTitle":7878,"status":119,"phases":7898,"primaryCompletion":110,"completion":4088,"start":6567,"enrollment":487,"conditions":7899,"interventions":7900},[89,90],[21,7219],[7868,7882],{"trials":7902,"activeCount":100},[],{"trials":7904,"activeCount":100},[],{"trials":7906,"activeCount":100},[],{"intervention":7908,"totalTrials":190,"cells":7909},"C1-INH",{"EARLY_PHASE1":7910,"PHASE1":7912,"PHASE2":7914,"PHASE3":7924,"PHASE4":7926,"NA":7928},{"trials":7911,"activeCount":100},[],{"trials":7913,"activeCount":100},[],{"trials":7915,"activeCount":100},[7916],{"nctId":7917,"briefTitle":7918,"status":119,"phases":7919,"primaryCompletion":7920,"completion":7920,"start":280,"enrollment":190,"conditions":7921,"interventions":7923},"NCT02936479","C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection",[90],"2018-10-30",[7922],"Antibody Mediated Rejection of Kidney Transplant",[7908],{"trials":7925,"activeCount":100},[],{"trials":7927,"activeCount":100},[],{"trials":7929,"activeCount":100},[],{"intervention":1904,"totalTrials":190,"cells":7931},{"EARLY_PHASE1":7932,"PHASE1":7934,"PHASE2":7936,"PHASE3":7942,"PHASE4":7944,"NA":7946},{"trials":7933,"activeCount":100},[],{"trials":7935,"activeCount":100},[],{"trials":7937,"activeCount":100},[7938],{"nctId":1896,"briefTitle":1897,"status":119,"phases":7939,"primaryCompletion":1476,"completion":1714,"start":1899,"enrollment":1900,"conditions":7940,"interventions":7941},[90],[1902],[223,1904,1905],{"trials":7943,"activeCount":100},[],{"trials":7945,"activeCount":100},[],{"trials":7947,"activeCount":100},[],{"intervention":1905,"totalTrials":190,"cells":7949},{"EARLY_PHASE1":7950,"PHASE1":7952,"PHASE2":7954,"PHASE3":7960,"PHASE4":7962,"NA":7964},{"trials":7951,"activeCount":100},[],{"trials":7953,"activeCount":100},[],{"trials":7955,"activeCount":100},[7956],{"nctId":1896,"briefTitle":1897,"status":119,"phases":7957,"primaryCompletion":1476,"completion":1714,"start":1899,"enrollment":1900,"conditions":7958,"interventions":7959},[90],[1902],[223,1904,1905],{"trials":7961,"activeCount":100},[],{"trials":7963,"activeCount":100},[],{"trials":7965,"activeCount":100},[],{"intervention":7967,"totalTrials":190,"cells":7968},"Everolimus (RAD001) , Afinitor®",{"EARLY_PHASE1":7969,"PHASE1":7971,"PHASE2":7973,"PHASE3":7982,"PHASE4":7984,"NA":7986},{"trials":7970,"activeCount":100},[],{"trials":7972,"activeCount":100},[],{"trials":7974,"activeCount":100},[7975],{"nctId":7976,"briefTitle":7977,"status":119,"phases":7978,"primaryCompletion":7538,"completion":3604,"start":919,"enrollment":112,"conditions":7979,"interventions":7981},"NCT01419639","Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2",[90],[7980],"Neurofibromatosis Type II",[7967],{"trials":7983,"activeCount":100},[],{"trials":7985,"activeCount":100},[],{"trials":7987,"activeCount":100},[],{"intervention":7989,"totalTrials":190,"cells":7990},"Carbidopa Low-Dose",{"EARLY_PHASE1":7991,"PHASE1":7993,"PHASE2":7995,"PHASE3":8007,"PHASE4":8009,"NA":8011},{"trials":7992,"activeCount":100},[],{"trials":7994,"activeCount":100},[],{"trials":7996,"activeCount":100},[7997],{"nctId":7998,"briefTitle":7999,"status":119,"phases":8000,"primaryCompletion":8001,"completion":8001,"start":7064,"enrollment":28,"conditions":8002,"interventions":8005},"NCT02553265","Carbidopa for the Treatment of Excessive Blood Pressure Variability",[90],"2019-05-10",[8003,8004],"Dysautonomia, Familial","Baroreflex Failure Syndrome",[7989,8006],"Carbidopa High-Dose",{"trials":8008,"activeCount":100},[],{"trials":8010,"activeCount":100},[],{"trials":8012,"activeCount":100},[],{"intervention":8006,"totalTrials":190,"cells":8014},{"EARLY_PHASE1":8015,"PHASE1":8017,"PHASE2":8019,"PHASE3":8025,"PHASE4":8027,"NA":8029},{"trials":8016,"activeCount":100},[],{"trials":8018,"activeCount":100},[],{"trials":8020,"activeCount":100},[8021],{"nctId":7998,"briefTitle":7999,"status":119,"phases":8022,"primaryCompletion":8001,"completion":8001,"start":7064,"enrollment":28,"conditions":8023,"interventions":8024},[90],[8003,8004],[7989,8006],{"trials":8026,"activeCount":100},[],{"trials":8028,"activeCount":100},[],{"trials":8030,"activeCount":100},[],{"intervention":8032,"totalTrials":190,"cells":8033},"Nivolumab + Cabiralizumab",{"EARLY_PHASE1":8034,"PHASE1":8036,"PHASE2":8038,"PHASE3":8048,"PHASE4":8050,"NA":8052},{"trials":8035,"activeCount":100},[],{"trials":8037,"activeCount":100},[],{"trials":8039,"activeCount":100},[8040],{"nctId":8041,"briefTitle":8042,"status":108,"phases":8043,"primaryCompletion":8044,"completion":8044,"start":8045,"enrollment":96,"conditions":8046,"interventions":8047},"NCT03599362","Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer",[90],"2020-06-15","2018-07-31",[1404],[8032],{"trials":8049,"activeCount":100},[],{"trials":8051,"activeCount":100},[],{"trials":8053,"activeCount":100},[],{"intervention":6833,"totalTrials":190,"cells":8055},{"EARLY_PHASE1":8056,"PHASE1":8058,"PHASE2":8060,"PHASE3":8066,"PHASE4":8068,"NA":8070},{"trials":8057,"activeCount":100},[],{"trials":8059,"activeCount":100},[],{"trials":8061,"activeCount":100},[8062],{"nctId":6826,"briefTitle":6827,"status":108,"phases":8063,"primaryCompletion":3993,"completion":6118,"start":6829,"enrollment":1359,"conditions":8064,"interventions":8065},[89,90],[1404],[6832,6833,6834],{"trials":8067,"activeCount":100},[],{"trials":8069,"activeCount":100},[],{"trials":8071,"activeCount":100},[],{"intervention":6834,"totalTrials":190,"cells":8073},{"EARLY_PHASE1":8074,"PHASE1":8076,"PHASE2":8078,"PHASE3":8084,"PHASE4":8086,"NA":8088},{"trials":8075,"activeCount":100},[],{"trials":8077,"activeCount":100},[],{"trials":8079,"activeCount":100},[8080],{"nctId":6826,"briefTitle":6827,"status":108,"phases":8081,"primaryCompletion":3993,"completion":6118,"start":6829,"enrollment":1359,"conditions":8082,"interventions":8083},[89,90],[1404],[6832,6833,6834],{"trials":8085,"activeCount":100},[],{"trials":8087,"activeCount":100},[],{"trials":8089,"activeCount":100},[],{"intervention":8091,"totalTrials":190,"cells":8092},"Acamprosate",{"EARLY_PHASE1":8093,"PHASE1":8095,"PHASE2":8097,"PHASE3":8106,"PHASE4":8108,"NA":8110},{"trials":8094,"activeCount":100},[],{"trials":8096,"activeCount":100},[],{"trials":8098,"activeCount":100},[8099],{"nctId":8100,"briefTitle":8101,"status":119,"phases":8102,"primaryCompletion":920,"completion":920,"start":5613,"enrollment":5614,"conditions":8103,"interventions":8105},"NCT00571922","A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction",[89,90],[8104],"Methamphetamine Dependence, Treatment Seeking",[8091],{"trials":8107,"activeCount":100},[],{"trials":8109,"activeCount":100},[],{"trials":8111,"activeCount":100},[],{"intervention":8113,"totalTrials":190,"cells":8114},"Metformin Hydrochloride Extended Release 750mg",{"EARLY_PHASE1":8115,"PHASE1":8117,"PHASE2":8119,"PHASE3":8130,"PHASE4":8132,"NA":8134},{"trials":8116,"activeCount":100},[],{"trials":8118,"activeCount":100},[],{"trials":8120,"activeCount":100},[8121],{"nctId":8122,"briefTitle":8123,"status":119,"phases":8124,"primaryCompletion":8125,"completion":8125,"start":1262,"enrollment":8126,"conditions":8127,"interventions":8129},"NCT02176161","Metformin Prostate Cancer Adjuvant Trial",[90],"2021-07-21",59,[21,8128],"Prostate Cancer Recurrent",[8113],{"trials":8131,"activeCount":100},[],{"trials":8133,"activeCount":100},[],{"trials":8135,"activeCount":100},[],{"intervention":302,"totalTrials":190,"cells":8137},{"EARLY_PHASE1":8138,"PHASE1":8140,"PHASE2":8142,"PHASE3":8148,"PHASE4":8150,"NA":8152},{"trials":8139,"activeCount":100},[],{"trials":8141,"activeCount":100},[],{"trials":8143,"activeCount":100},[8144],{"nctId":292,"briefTitle":293,"status":294,"phases":8145,"primaryCompletion":296,"completion":297,"start":298,"enrollment":100,"conditions":8146,"interventions":8147},[90],[300],[128,302],{"trials":8149,"activeCount":100},[],{"trials":8151,"activeCount":100},[],{"trials":8153,"activeCount":100},[],{"intervention":8155,"totalTrials":190,"cells":8156},"Phytocannabinoid cannabidiol",{"EARLY_PHASE1":8157,"PHASE1":8159,"PHASE2":8161,"PHASE3":8171,"PHASE4":8173,"NA":8175},{"trials":8158,"activeCount":100},[],{"trials":8160,"activeCount":100},[],{"trials":8162,"activeCount":100},[8163],{"nctId":8164,"briefTitle":8165,"status":119,"phases":8166,"primaryCompletion":8167,"completion":8167,"start":8168,"enrollment":1287,"conditions":8169,"interventions":8170},"NCT03252756","Effects of Cannabidiol in Alcohol Use Disorder",[89,90],"2022-03-16","2019-09-01",[849],[8155],{"trials":8172,"activeCount":100},[],{"trials":8174,"activeCount":100},[],{"trials":8176,"activeCount":100},[],{"intervention":8178,"totalTrials":190,"cells":8179},"Daratumumab and Hyaluronidase-fihj",{"EARLY_PHASE1":8180,"PHASE1":8182,"PHASE2":8184,"PHASE3":8197,"PHASE4":8199,"NA":8201},{"trials":8181,"activeCount":100},[],{"trials":8183,"activeCount":100},[],{"trials":8185,"activeCount":100},[8186],{"nctId":8187,"briefTitle":8188,"status":119,"phases":8189,"primaryCompletion":8190,"completion":8190,"start":8191,"enrollment":921,"conditions":8192,"interventions":8194},"NCT05807048","Daratumumab in STK11 Mutated NSCLC",[90],"2025-11-11","2023-06-01",[8193],"Non-small Cell Lung Cancer With STK11\u002FLKB1 Mutation",[8178,8195,8196],"Pre-Intervention Medication","Post-Intervention Medication",{"trials":8198,"activeCount":100},[],{"trials":8200,"activeCount":100},[],{"trials":8202,"activeCount":100},[],{"intervention":8195,"totalTrials":190,"cells":8204},{"EARLY_PHASE1":8205,"PHASE1":8207,"PHASE2":8209,"PHASE3":8215,"PHASE4":8217,"NA":8219},{"trials":8206,"activeCount":100},[],{"trials":8208,"activeCount":100},[],{"trials":8210,"activeCount":100},[8211],{"nctId":8187,"briefTitle":8188,"status":119,"phases":8212,"primaryCompletion":8190,"completion":8190,"start":8191,"enrollment":921,"conditions":8213,"interventions":8214},[90],[8193],[8178,8195,8196],{"trials":8216,"activeCount":100},[],{"trials":8218,"activeCount":100},[],{"trials":8220,"activeCount":100},[],{"intervention":8196,"totalTrials":190,"cells":8222},{"EARLY_PHASE1":8223,"PHASE1":8225,"PHASE2":8227,"PHASE3":8233,"PHASE4":8235,"NA":8237},{"trials":8224,"activeCount":100},[],{"trials":8226,"activeCount":100},[],{"trials":8228,"activeCount":100},[8229],{"nctId":8187,"briefTitle":8188,"status":119,"phases":8230,"primaryCompletion":8190,"completion":8190,"start":8191,"enrollment":921,"conditions":8231,"interventions":8232},[90],[8193],[8178,8195,8196],{"trials":8234,"activeCount":100},[],{"trials":8236,"activeCount":100},[],{"trials":8238,"activeCount":100},[],{"intervention":8240,"totalTrials":190,"cells":8241},"AT-001",{"EARLY_PHASE1":8242,"PHASE1":8244,"PHASE2":8246,"PHASE3":8257,"PHASE4":8259,"NA":8261},{"trials":8243,"activeCount":100},[],{"trials":8245,"activeCount":100},[],{"trials":8247,"activeCount":100},[8248],{"nctId":8249,"briefTitle":8250,"status":119,"phases":8251,"primaryCompletion":8252,"completion":8252,"start":8253,"enrollment":8254,"conditions":8255,"interventions":8256},"NCT04365699","Cardiovascular Effects of COVID-19",[90],"2021-01-31","2020-04-08",81,[788],[8240],{"trials":8258,"activeCount":100},[],{"trials":8260,"activeCount":100},[],{"trials":8262,"activeCount":100},[],{"intervention":8264,"totalTrials":190,"cells":8265},"Axitinib",{"EARLY_PHASE1":8266,"PHASE1":8268,"PHASE2":8270,"PHASE3":8280,"PHASE4":8282,"NA":8284},{"trials":8267,"activeCount":100},[],{"trials":8269,"activeCount":100},[],{"trials":8271,"activeCount":100},[8272],{"nctId":8273,"briefTitle":8274,"status":119,"phases":8275,"primaryCompletion":8276,"completion":8276,"start":2853,"enrollment":8277,"conditions":8278,"interventions":8279},"NCT02129647","Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas",[90],"2019-02-05",13,[7246,7247],[8264],{"trials":8281,"activeCount":100},[],{"trials":8283,"activeCount":100},[],{"trials":8285,"activeCount":100},[],{"intervention":7230,"totalTrials":190,"cells":8287},{"EARLY_PHASE1":8288,"PHASE1":8290,"PHASE2":8292,"PHASE3":8298,"PHASE4":8300,"NA":8302},{"trials":8289,"activeCount":100},[],{"trials":8291,"activeCount":100},[],{"trials":8293,"activeCount":100},[8294],{"nctId":7223,"briefTitle":7224,"status":108,"phases":8295,"primaryCompletion":7226,"completion":7227,"start":4746,"enrollment":124,"conditions":8296,"interventions":8297},[89,90],[21],[7230,7206],{"trials":8299,"activeCount":100},[],{"trials":8301,"activeCount":100},[],{"trials":8303,"activeCount":100},[],{"intervention":8305,"totalTrials":190,"cells":8306},"Megestrol Acetate",{"EARLY_PHASE1":8307,"PHASE1":8309,"PHASE2":8311,"PHASE3":8323,"PHASE4":8325,"NA":8327},{"trials":8308,"activeCount":100},[],{"trials":8310,"activeCount":100},[],{"trials":8312,"activeCount":100},[8313],{"nctId":8314,"briefTitle":8315,"status":119,"phases":8316,"primaryCompletion":8317,"completion":8317,"start":8318,"enrollment":1796,"conditions":8319,"interventions":8322},"NCT00483327","Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate",[90],"2013-10","2007-06",[8320,8321],"Atypical Endometrial Hyperplasia","Endometrial Carcinoma",[8305],{"trials":8324,"activeCount":100},[],{"trials":8326,"activeCount":100},[],{"trials":8328,"activeCount":100},[],{"intervention":8330,"totalTrials":190,"cells":8331},"Vigabatrin",{"EARLY_PHASE1":8332,"PHASE1":8334,"PHASE2":8336,"PHASE3":8345,"PHASE4":8347,"NA":8349},{"trials":8333,"activeCount":100},[],{"trials":8335,"activeCount":100},[],{"trials":8337,"activeCount":100},[8338],{"nctId":8339,"briefTitle":8340,"status":119,"phases":8341,"primaryCompletion":7355,"completion":7355,"start":1808,"enrollment":461,"conditions":8342,"interventions":8344},"NCT00527683","Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence",[90],[8343],"Cocaine Dependence",[8330],{"trials":8346,"activeCount":100},[],{"trials":8348,"activeCount":100},[],{"trials":8350,"activeCount":100},[],{"intervention":8352,"totalTrials":190,"cells":8353},"Precedex",{"EARLY_PHASE1":8354,"PHASE1":8356,"PHASE2":8358,"PHASE3":8367,"PHASE4":8369,"NA":8371},{"trials":8355,"activeCount":100},[],{"trials":8357,"activeCount":100},[],{"trials":8359,"activeCount":100},[8360],{"nctId":8361,"briefTitle":8362,"status":294,"phases":8363,"primaryCompletion":3359,"completion":3359,"start":3359,"enrollment":100,"conditions":8364,"interventions":8366},"NCT01969903","Study of Use of Dexmedetomidine for Regional Anesthesia",[90],[8365],"Anesthesia",[8352],{"trials":8368,"activeCount":100},[],{"trials":8370,"activeCount":100},[],{"trials":8372,"activeCount":100},[],{"intervention":7067,"totalTrials":190,"cells":8374},{"EARLY_PHASE1":8375,"PHASE1":8377,"PHASE2":8379,"PHASE3":8385,"PHASE4":8387,"NA":8389},{"trials":8376,"activeCount":100},[],{"trials":8378,"activeCount":100},[],{"trials":8380,"activeCount":100},[8381],{"nctId":7061,"briefTitle":7062,"status":108,"phases":8382,"primaryCompletion":1714,"completion":7064,"start":3746,"enrollment":1359,"conditions":8383,"interventions":8384},[90],[923],[7067,1764],{"trials":8386,"activeCount":100},[],{"trials":8388,"activeCount":100},[],{"trials":8390,"activeCount":100},[],{"intervention":8392,"totalTrials":190,"cells":8393},"Trametinib daily Until PD",{"EARLY_PHASE1":8394,"PHASE1":8396,"PHASE2":8398,"PHASE3":8409,"PHASE4":8411,"NA":8413},{"trials":8395,"activeCount":100},[],{"trials":8397,"activeCount":100},[],{"trials":8399,"activeCount":100},[8400],{"nctId":8401,"briefTitle":8402,"status":108,"phases":8403,"primaryCompletion":8404,"completion":8404,"start":8405,"enrollment":195,"conditions":8406,"interventions":8407},"NCT03580382","Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF\u002FNRAS Wildtype (WT) Melanoma",[89,90],"2018-09-26","2018-07-06",[126],[8392,8408],"CDX-3379",{"trials":8410,"activeCount":100},[],{"trials":8412,"activeCount":100},[],{"trials":8414,"activeCount":100},[],{"intervention":8408,"totalTrials":190,"cells":8416},{"EARLY_PHASE1":8417,"PHASE1":8419,"PHASE2":8421,"PHASE3":8427,"PHASE4":8429,"NA":8431},{"trials":8418,"activeCount":100},[],{"trials":8420,"activeCount":100},[],{"trials":8422,"activeCount":100},[8423],{"nctId":8401,"briefTitle":8402,"status":108,"phases":8424,"primaryCompletion":8404,"completion":8404,"start":8405,"enrollment":195,"conditions":8425,"interventions":8426},[89,90],[126],[8392,8408],{"trials":8428,"activeCount":100},[],{"trials":8430,"activeCount":100},[],{"trials":8432,"activeCount":100},[],{"intervention":8434,"totalTrials":190,"cells":8435},"Gleevec\u002FPaclitaxel",{"EARLY_PHASE1":8436,"PHASE1":8438,"PHASE2":8440,"PHASE3":8448,"PHASE4":8450,"NA":8452},{"trials":8437,"activeCount":100},[],{"trials":8439,"activeCount":100},[],{"trials":8441,"activeCount":100},[8442],{"nctId":8443,"briefTitle":8444,"status":108,"phases":8445,"primaryCompletion":6119,"completion":6233,"start":1808,"enrollment":868,"conditions":8446,"interventions":8447},"NCT00840450","Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin",[90],[6549],[8434],{"trials":8449,"activeCount":100},[],{"trials":8451,"activeCount":100},[],{"trials":8453,"activeCount":100},[],{"intervention":8455,"totalTrials":190,"cells":8456},"Tiopronin",{"EARLY_PHASE1":8457,"PHASE1":8459,"PHASE2":8461,"PHASE3":8471,"PHASE4":8473,"NA":8475},{"trials":8458,"activeCount":100},[],{"trials":8460,"activeCount":100},[],{"trials":8462,"activeCount":100},[8463],{"nctId":8464,"briefTitle":8465,"status":119,"phases":8466,"primaryCompletion":8467,"completion":8467,"start":8468,"enrollment":112,"conditions":8469,"interventions":8470},"NCT03663855","Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria",[90],"2019-09-10","2018-11-01",[4860],[8455],{"trials":8472,"activeCount":100},[],{"trials":8474,"activeCount":100},[],{"trials":8476,"activeCount":100},[],{"intervention":8478,"totalTrials":190,"cells":8479},"CC-10004",{"EARLY_PHASE1":8480,"PHASE1":8482,"PHASE2":8484,"PHASE3":8494,"PHASE4":8496,"NA":8498},{"trials":8481,"activeCount":100},[],{"trials":8483,"activeCount":100},[],{"trials":8485,"activeCount":100},[8486],{"nctId":8487,"briefTitle":8488,"status":119,"phases":8489,"primaryCompletion":5234,"completion":5234,"start":8490,"enrollment":921,"conditions":8491,"interventions":8493},"NCT00708916","Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients",[89,90],"2008-06",[8492],"Discoid Lupus Erythematosus",[8478],{"trials":8495,"activeCount":100},[],{"trials":8497,"activeCount":100},[],{"trials":8499,"activeCount":100},[],{"intervention":8501,"totalTrials":190,"cells":8502},"Cholecalciferol",{"EARLY_PHASE1":8503,"PHASE1":8505,"PHASE2":8507,"PHASE3":8515,"PHASE4":8517,"NA":8519},{"trials":8504,"activeCount":100},[],{"trials":8506,"activeCount":100},[],{"trials":8508,"activeCount":100},[8509],{"nctId":8510,"briefTitle":8511,"status":294,"phases":8512,"primaryCompletion":4858,"start":3109,"enrollment":100,"conditions":8513,"interventions":8514},"NCT02197286","Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia",[90],[4329,4946],[8501],{"trials":8516,"activeCount":100},[],{"trials":8518,"activeCount":100},[],{"trials":8520,"activeCount":100},[],{"intervention":8522,"totalTrials":190,"cells":8523},"Nivolumab 360mg",{"EARLY_PHASE1":8524,"PHASE1":8526,"PHASE2":8528,"PHASE3":8544,"PHASE4":8546,"NA":8548},{"trials":8525,"activeCount":100},[],{"trials":8527,"activeCount":100},[],{"trials":8529,"activeCount":100},[8530],{"nctId":8531,"briefTitle":8532,"status":119,"phases":8533,"primaryCompletion":8534,"completion":8534,"start":8535,"enrollment":921,"conditions":8536,"interventions":8537},"NCT03742986","Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)",[90],"2023-06-12","2019-05-02",[15],[8522,8538,8539,8540,8541,8542,8543],"Paclitaxel 80mg\u002Fm^2","Doxorubicin 60mg\u002Fm^2","Cyclophosphamide 600mg\u002Fm^2","Paclitaxel 80mg\u002Fm^2 or Docetaxel 75mg\u002Fm^2","Trastuzumab 8mg\u002Fkg and 6 mg\u002Fkg","Pertuzumab 840mg and 420mg",{"trials":8545,"activeCount":100},[],{"trials":8547,"activeCount":100},[],{"trials":8549,"activeCount":100},[],{"intervention":8538,"totalTrials":190,"cells":8551},{"EARLY_PHASE1":8552,"PHASE1":8554,"PHASE2":8556,"PHASE3":8562,"PHASE4":8564,"NA":8566},{"trials":8553,"activeCount":100},[],{"trials":8555,"activeCount":100},[],{"trials":8557,"activeCount":100},[8558],{"nctId":8531,"briefTitle":8532,"status":119,"phases":8559,"primaryCompletion":8534,"completion":8534,"start":8535,"enrollment":921,"conditions":8560,"interventions":8561},[90],[15],[8522,8538,8539,8540,8541,8542,8543],{"trials":8563,"activeCount":100},[],{"trials":8565,"activeCount":100},[],{"trials":8567,"activeCount":100},[],{"intervention":8539,"totalTrials":190,"cells":8569},{"EARLY_PHASE1":8570,"PHASE1":8572,"PHASE2":8574,"PHASE3":8580,"PHASE4":8582,"NA":8584},{"trials":8571,"activeCount":100},[],{"trials":8573,"activeCount":100},[],{"trials":8575,"activeCount":100},[8576],{"nctId":8531,"briefTitle":8532,"status":119,"phases":8577,"primaryCompletion":8534,"completion":8534,"start":8535,"enrollment":921,"conditions":8578,"interventions":8579},[90],[15],[8522,8538,8539,8540,8541,8542,8543],{"trials":8581,"activeCount":100},[],{"trials":8583,"activeCount":100},[],{"trials":8585,"activeCount":100},[],{"intervention":8540,"totalTrials":190,"cells":8587},{"EARLY_PHASE1":8588,"PHASE1":8590,"PHASE2":8592,"PHASE3":8598,"PHASE4":8600,"NA":8602},{"trials":8589,"activeCount":100},[],{"trials":8591,"activeCount":100},[],{"trials":8593,"activeCount":100},[8594],{"nctId":8531,"briefTitle":8532,"status":119,"phases":8595,"primaryCompletion":8534,"completion":8534,"start":8535,"enrollment":921,"conditions":8596,"interventions":8597},[90],[15],[8522,8538,8539,8540,8541,8542,8543],{"trials":8599,"activeCount":100},[],{"trials":8601,"activeCount":100},[],{"trials":8603,"activeCount":100},[],{"intervention":8541,"totalTrials":190,"cells":8605},{"EARLY_PHASE1":8606,"PHASE1":8608,"PHASE2":8610,"PHASE3":8616,"PHASE4":8618,"NA":8620},{"trials":8607,"activeCount":100},[],{"trials":8609,"activeCount":100},[],{"trials":8611,"activeCount":100},[8612],{"nctId":8531,"briefTitle":8532,"status":119,"phases":8613,"primaryCompletion":8534,"completion":8534,"start":8535,"enrollment":921,"conditions":8614,"interventions":8615},[90],[15],[8522,8538,8539,8540,8541,8542,8543],{"trials":8617,"activeCount":100},[],{"trials":8619,"activeCount":100},[],{"trials":8621,"activeCount":100},[],{"intervention":8542,"totalTrials":190,"cells":8623},{"EARLY_PHASE1":8624,"PHASE1":8626,"PHASE2":8628,"PHASE3":8634,"PHASE4":8636,"NA":8638},{"trials":8625,"activeCount":100},[],{"trials":8627,"activeCount":100},[],{"trials":8629,"activeCount":100},[8630],{"nctId":8531,"briefTitle":8532,"status":119,"phases":8631,"primaryCompletion":8534,"completion":8534,"start":8535,"enrollment":921,"conditions":8632,"interventions":8633},[90],[15],[8522,8538,8539,8540,8541,8542,8543],{"trials":8635,"activeCount":100},[],{"trials":8637,"activeCount":100},[],{"trials":8639,"activeCount":100},[],{"intervention":8543,"totalTrials":190,"cells":8641},{"EARLY_PHASE1":8642,"PHASE1":8644,"PHASE2":8646,"PHASE3":8652,"PHASE4":8654,"NA":8656},{"trials":8643,"activeCount":100},[],{"trials":8645,"activeCount":100},[],{"trials":8647,"activeCount":100},[8648],{"nctId":8531,"briefTitle":8532,"status":119,"phases":8649,"primaryCompletion":8534,"completion":8534,"start":8535,"enrollment":921,"conditions":8650,"interventions":8651},[90],[15],[8522,8538,8539,8540,8541,8542,8543],{"trials":8653,"activeCount":100},[],{"trials":8655,"activeCount":100},[],{"trials":8657,"activeCount":100},[],{"intervention":8659,"totalTrials":190,"cells":8660},"liposomal NDDP",{"EARLY_PHASE1":8661,"PHASE1":8663,"PHASE2":8665,"PHASE3":8674,"PHASE4":8676,"NA":8678},{"trials":8662,"activeCount":100},[],{"trials":8664,"activeCount":100},[],{"trials":8666,"activeCount":100},[8667],{"nctId":8668,"briefTitle":8669,"status":119,"phases":8670,"primaryCompletion":6772,"start":3909,"enrollment":632,"conditions":8671,"interventions":8673},"NCT00004033","Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma",[90],[8672],"Malignant Mesothelioma",[8659],{"trials":8675,"activeCount":100},[],{"trials":8677,"activeCount":100},[],{"trials":8679,"activeCount":100},[],{"intervention":8681,"totalTrials":190,"cells":8682},"ataluren",{"EARLY_PHASE1":8683,"PHASE1":8685,"PHASE2":8687,"PHASE3":8696,"PHASE4":8698,"NA":8700},{"trials":8684,"activeCount":100},[],{"trials":8686,"activeCount":100},[],{"trials":8688,"activeCount":100},[8689],{"nctId":8690,"briefTitle":8691,"status":119,"phases":8692,"primaryCompletion":8693,"completion":8693,"start":6894,"enrollment":1589,"conditions":8694,"interventions":8695},"NCT02758626","Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome",[90],"2021-02-27",[30],[8681],{"trials":8697,"activeCount":100},[],{"trials":8699,"activeCount":100},[],{"trials":8701,"activeCount":100},[],{"intervention":926,"totalTrials":190,"cells":8703},{"EARLY_PHASE1":8704,"PHASE1":8706,"PHASE2":8708,"PHASE3":8714,"PHASE4":8716,"NA":8718},{"trials":8705,"activeCount":100},[],{"trials":8707,"activeCount":100},[],{"trials":8709,"activeCount":100},[8710],{"nctId":916,"briefTitle":917,"status":108,"phases":8711,"primaryCompletion":919,"completion":919,"start":920,"enrollment":921,"conditions":8712,"interventions":8713},[90],[923],[925,926,898],{"trials":8715,"activeCount":100},[],{"trials":8717,"activeCount":100},[],{"trials":8719,"activeCount":100},[],{"intervention":8721,"totalTrials":190,"cells":8722},"Levetiracetam Pill",{"EARLY_PHASE1":8723,"PHASE1":8725,"PHASE2":8727,"PHASE3":8740,"PHASE4":8742,"NA":8744},{"trials":8724,"activeCount":100},[],{"trials":8726,"activeCount":100},[],{"trials":8728,"activeCount":100},[8729],{"nctId":8730,"briefTitle":8731,"status":119,"phases":8732,"primaryCompletion":8733,"completion":8734,"start":8735,"enrollment":8736,"conditions":8737,"interventions":8739},"NCT04317807","R33: Levetiracetam in Early Psychosis",[90],"2025-04-01","2025-04-10","2020-08-27",65,[8738],"Early Psychosis",[8721],{"trials":8741,"activeCount":100},[],{"trials":8743,"activeCount":100},[],{"trials":8745,"activeCount":100},[],{"intervention":8747,"totalTrials":190,"cells":8748},"GIK solution",{"EARLY_PHASE1":8749,"PHASE1":8751,"PHASE2":8753,"PHASE3":8765,"PHASE4":8767,"NA":8769},{"trials":8750,"activeCount":100},[],{"trials":8752,"activeCount":100},[],{"trials":8754,"activeCount":100},[8755],{"nctId":8756,"briefTitle":8757,"status":294,"phases":8758,"primaryCompletion":3714,"completion":1118,"start":8759,"enrollment":100,"conditions":8760,"interventions":8763},"NCT05627479","MAGIK for Femoral\u002FTibial Shaft Fractures",[90],"2024-12-01",[8761,8762],"Femoral Shaft Fracture","Tibial Shaft Fracture",[8747,8764],"Isotonic Normal Saline Solution",{"trials":8766,"activeCount":100},[],{"trials":8768,"activeCount":100},[],{"trials":8770,"activeCount":100},[],{"intervention":8764,"totalTrials":190,"cells":8772},{"EARLY_PHASE1":8773,"PHASE1":8775,"PHASE2":8777,"PHASE3":8783,"PHASE4":8785,"NA":8787},{"trials":8774,"activeCount":100},[],{"trials":8776,"activeCount":100},[],{"trials":8778,"activeCount":100},[8779],{"nctId":8756,"briefTitle":8757,"status":294,"phases":8780,"primaryCompletion":3714,"completion":1118,"start":8759,"enrollment":100,"conditions":8781,"interventions":8782},[90],[8761,8762],[8747,8764],{"trials":8784,"activeCount":100},[],{"trials":8786,"activeCount":100},[],{"trials":8788,"activeCount":100},[],{"intervention":8790,"totalTrials":190,"cells":8791},"Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg\u002Fkg IV every 2 weeks",{"EARLY_PHASE1":8792,"PHASE1":8794,"PHASE2":8796,"PHASE3":8809,"PHASE4":8811,"NA":8813},{"trials":8793,"activeCount":100},[],{"trials":8795,"activeCount":100},[],{"trials":8797,"activeCount":100},[8798],{"nctId":8799,"briefTitle":8800,"status":108,"phases":8801,"primaryCompletion":8802,"completion":8802,"start":8803,"enrollment":8277,"conditions":8804,"interventions":8806},"NCT04050462","Nivolumab Combined With BMS-986253 in HCC Patients",[90],"2025-01-31","2019-09-12",[8805],"Hepatocellular Carcinoma",[8790,8807,8808],"Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks","Nivolumab 240 mg IV every 2 weeks",{"trials":8810,"activeCount":100},[],{"trials":8812,"activeCount":100},[],{"trials":8814,"activeCount":100},[],{"intervention":8807,"totalTrials":190,"cells":8816},{"EARLY_PHASE1":8817,"PHASE1":8819,"PHASE2":8821,"PHASE3":8827,"PHASE4":8829,"NA":8831},{"trials":8818,"activeCount":100},[],{"trials":8820,"activeCount":100},[],{"trials":8822,"activeCount":100},[8823],{"nctId":8799,"briefTitle":8800,"status":108,"phases":8824,"primaryCompletion":8802,"completion":8802,"start":8803,"enrollment":8277,"conditions":8825,"interventions":8826},[90],[8805],[8790,8807,8808],{"trials":8828,"activeCount":100},[],{"trials":8830,"activeCount":100},[],{"trials":8832,"activeCount":100},[],{"intervention":8808,"totalTrials":190,"cells":8834},{"EARLY_PHASE1":8835,"PHASE1":8837,"PHASE2":8839,"PHASE3":8845,"PHASE4":8847,"NA":8849},{"trials":8836,"activeCount":100},[],{"trials":8838,"activeCount":100},[],{"trials":8840,"activeCount":100},[8841],{"nctId":8799,"briefTitle":8800,"status":108,"phases":8842,"primaryCompletion":8802,"completion":8802,"start":8803,"enrollment":8277,"conditions":8843,"interventions":8844},[90],[8805],[8790,8807,8808],{"trials":8846,"activeCount":100},[],{"trials":8848,"activeCount":100},[],{"trials":8850,"activeCount":100},[],{"intervention":3115,"totalTrials":190,"cells":8852},{"EARLY_PHASE1":8853,"PHASE1":8855,"PHASE2":8857,"PHASE3":8863,"PHASE4":8865,"NA":8867},{"trials":8854,"activeCount":100},[],{"trials":8856,"activeCount":100},[],{"trials":8858,"activeCount":100},[8859],{"nctId":3104,"briefTitle":3105,"status":119,"phases":8860,"primaryCompletion":3107,"completion":3108,"start":3109,"enrollment":3110,"conditions":8861,"interventions":8862},[90],[3112,33,3113],[3085,3115],{"trials":8864,"activeCount":100},[],{"trials":8866,"activeCount":100},[],{"trials":8868,"activeCount":100},[],{"intervention":8870,"totalTrials":190,"cells":8871},"Avelumab",{"EARLY_PHASE1":8872,"PHASE1":8874,"PHASE2":8876,"PHASE3":8886,"PHASE4":8888,"NA":8890},{"trials":8873,"activeCount":100},[],{"trials":8875,"activeCount":100},[],{"trials":8877,"activeCount":100},[8878],{"nctId":8879,"briefTitle":8880,"status":119,"phases":8881,"primaryCompletion":8882,"completion":8882,"start":8883,"enrollment":268,"conditions":8884,"interventions":8885},"NCT02968940","Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma",[90],"2019-08-29","2017-03-17",[6896],[8870],{"trials":8887,"activeCount":100},[],{"trials":8889,"activeCount":100},[],{"trials":8891,"activeCount":100},[],{"intervention":8893,"totalTrials":190,"cells":8894},"Convalescent Plasma",{"EARLY_PHASE1":8895,"PHASE1":8897,"PHASE2":8899,"PHASE3":8913,"PHASE4":8915,"NA":8917},{"trials":8896,"activeCount":100},[],{"trials":8898,"activeCount":100},[],{"trials":8900,"activeCount":100},[8901],{"nctId":8902,"briefTitle":8903,"status":119,"phases":8904,"primaryCompletion":8905,"completion":8906,"start":8907,"enrollment":8908,"conditions":8909,"interventions":8912},"NCT04364737","CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients",[90],"2021-03-29","2022-12-12","2020-04-17",941,[788,8910,8911],"Coronavirus","Coronavirus Infection",[8893],{"trials":8914,"activeCount":100},[],{"trials":8916,"activeCount":100},[],{"trials":8918,"activeCount":100},[],{"intervention":6842,"totalTrials":190,"cells":8920},{"EARLY_PHASE1":8921,"PHASE1":8923,"PHASE2":8925,"PHASE3":8931,"PHASE4":8933,"NA":8935},{"trials":8922,"activeCount":100},[],{"trials":8924,"activeCount":100},[],{"trials":8926,"activeCount":100},[8927],{"nctId":6836,"briefTitle":6837,"status":119,"phases":8928,"primaryCompletion":6516,"start":6839,"conditions":8929,"interventions":8930},[90],[6546],[6842,6800,1784,6782],{"trials":8932,"activeCount":100},[],{"trials":8934,"activeCount":100},[],{"trials":8936,"activeCount":100},[],{"intervention":8938,"totalTrials":190,"cells":8939},"liposomal annamycin",{"EARLY_PHASE1":8940,"PHASE1":8942,"PHASE2":8944,"PHASE3":8952,"PHASE4":8954,"NA":8956},{"trials":8941,"activeCount":100},[],{"trials":8943,"activeCount":100},[],{"trials":8945,"activeCount":100},[8946],{"nctId":8947,"briefTitle":8948,"status":119,"phases":8949,"primaryCompletion":6772,"start":3909,"conditions":8950,"interventions":8951},"NCT00012129","Chemotherapy in Treating Patients With Breast Cancer",[89,90],[15],[8938],{"trials":8953,"activeCount":100},[],{"trials":8955,"activeCount":100},[],{"trials":8957,"activeCount":100},[],{"intervention":8959,"totalTrials":190,"cells":8960},"Fluticasone propionate HFA 220",{"EARLY_PHASE1":8961,"PHASE1":8963,"PHASE2":8965,"PHASE3":8974,"PHASE4":8976,"NA":8978},{"trials":8962,"activeCount":100},[],{"trials":8964,"activeCount":100},[],{"trials":8966,"activeCount":100},[8967],{"nctId":8968,"briefTitle":8969,"status":119,"phases":8970,"primaryCompletion":8971,"completion":8971,"start":3604,"enrollment":124,"conditions":8972,"interventions":8973},"NCT02740543","Biomarkers of Irritant-Induced and Allergic Asthma",[90],"2019-10-23",[5279],[8959],{"trials":8975,"activeCount":100},[],{"trials":8977,"activeCount":100},[],{"trials":8979,"activeCount":100},[],{"intervention":8981,"totalTrials":190,"cells":8982},"Fenfluramine Hydrochloride",{"EARLY_PHASE1":8983,"PHASE1":8985,"PHASE2":8987,"PHASE3":8999,"PHASE4":9001,"NA":9003},{"trials":8984,"activeCount":100},[],{"trials":8986,"activeCount":100},[],{"trials":8988,"activeCount":100},[8989],{"nctId":8990,"briefTitle":8991,"status":119,"phases":8992,"primaryCompletion":8993,"completion":8994,"start":8995,"enrollment":96,"conditions":8996,"interventions":8998},"NCT03861871","Fenfluramine in CDKL5 Deficiency Disorder (CDD)",[90],"2022-08-30","2022-10-24","2019-10-29",[8997],"CDD",[8981],{"trials":9000,"activeCount":100},[],{"trials":9002,"activeCount":100},[],{"trials":9004,"activeCount":100},[],{"intervention":6849,"totalTrials":190,"cells":9006},{"EARLY_PHASE1":9007,"PHASE1":9009,"PHASE2":9011,"PHASE3":9017,"PHASE4":9019,"NA":9021},{"trials":9008,"activeCount":100},[],{"trials":9010,"activeCount":100},[],{"trials":9012,"activeCount":100},[9013],{"nctId":6844,"briefTitle":6845,"status":119,"phases":9014,"primaryCompletion":6256,"start":6581,"conditions":9015,"interventions":9016},[89,90],[6546],[6849,6800,6782],{"trials":9018,"activeCount":100},[],{"trials":9020,"activeCount":100},[],{"trials":9022,"activeCount":100},[],{"intervention":9024,"totalTrials":190,"cells":9025},"temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid",{"EARLY_PHASE1":9026,"PHASE1":9028,"PHASE2":9030,"PHASE3":9042,"PHASE4":9044,"NA":9046},{"trials":9027,"activeCount":100},[],{"trials":9029,"activeCount":100},[],{"trials":9031,"activeCount":100},[9032],{"nctId":9033,"briefTitle":9034,"status":119,"phases":9035,"primaryCompletion":9036,"completion":9037,"start":9038,"enrollment":3244,"conditions":9039,"interventions":9041},"NCT00528437","Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent\u002FRefractory Malignant Brain Tumors",[90],"2017-06-30","2017-12-30","2005-10",[9040],"Brain Tumors",[9024],{"trials":9043,"activeCount":100},[],{"trials":9045,"activeCount":100},[],{"trials":9047,"activeCount":100},[],{"intervention":9049,"totalTrials":190,"cells":9050},"Platelet Rich Plasma",{"EARLY_PHASE1":9051,"PHASE1":9053,"PHASE2":9055,"PHASE3":9067,"PHASE4":9069,"NA":9071},{"trials":9052,"activeCount":100},[],{"trials":9054,"activeCount":100},[],{"trials":9056,"activeCount":100},[9057],{"nctId":9058,"briefTitle":9059,"status":294,"phases":9060,"primaryCompletion":9061,"completion":9061,"start":9062,"enrollment":100,"conditions":9063,"interventions":9066},"NCT03389685","Can PRP Reduce Pro-Inflammatory Biomarkers Following ACL Injury",[90],"2024-02","2018-09-09",[9064,9065],"ACL - Anterior Cruciate Ligament Rupture","ACL Injury",[9049],{"trials":9068,"activeCount":100},[],{"trials":9070,"activeCount":100},[],{"trials":9072,"activeCount":100},[],{"intervention":9074,"totalTrials":190,"cells":9075},"romiplostim",{"EARLY_PHASE1":9076,"PHASE1":9078,"PHASE2":9080,"PHASE3":9093,"PHASE4":9095,"NA":9097},{"trials":9077,"activeCount":100},[],{"trials":9079,"activeCount":100},[],{"trials":9081,"activeCount":100},[9082],{"nctId":9083,"briefTitle":9084,"status":108,"phases":9085,"primaryCompletion":1505,"completion":1505,"start":111,"enrollment":772,"conditions":9086,"interventions":9092},"NCT01676961","Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy",[90],[9087,9088,9089,9090,9091],"Refractory Multiple Myeloma","Stage I Multiple Myeloma","Stage II Multiple Myeloma","Stage III Multiple Myeloma","Thrombocytopenia",[9074],{"trials":9094,"activeCount":100},[],{"trials":9096,"activeCount":100},[],{"trials":9098,"activeCount":100},[],{"intervention":1788,"totalTrials":190,"cells":9100},{"EARLY_PHASE1":9101,"PHASE1":9103,"PHASE2":9105,"PHASE3":9111,"PHASE4":9113,"NA":9115},{"trials":9102,"activeCount":100},[],{"trials":9104,"activeCount":100},[],{"trials":9106,"activeCount":100},[9107],{"nctId":1770,"briefTitle":1771,"status":294,"phases":9108,"start":1773,"enrollment":100,"conditions":9109,"interventions":9110},[90],[1775,1776,1777,1778],[1780,1781,1782,1738,1783,1784,1785,1786,1787,1788],{"trials":9112,"activeCount":100},[],{"trials":9114,"activeCount":100},[],{"trials":9116,"activeCount":100},[],{"intervention":1364,"totalTrials":190,"cells":9118},{"EARLY_PHASE1":9119,"PHASE1":9121,"PHASE2":9123,"PHASE3":9129,"PHASE4":9131,"NA":9133},{"trials":9120,"activeCount":100},[],{"trials":9122,"activeCount":100},[],{"trials":9124,"activeCount":100},[9125],{"nctId":1353,"briefTitle":1354,"status":119,"phases":9126,"primaryCompletion":1356,"completion":1357,"start":1358,"enrollment":1359,"conditions":9127,"interventions":9128},[90],[1361,1362],[1364,43],{"trials":9130,"activeCount":100},[],{"trials":9132,"activeCount":100},[],{"trials":9134,"activeCount":100},[],{"intervention":6899,"totalTrials":190,"cells":9136},{"EARLY_PHASE1":9137,"PHASE1":9139,"PHASE2":9141,"PHASE3":9147,"PHASE4":9149,"NA":9151},{"trials":9138,"activeCount":100},[],{"trials":9140,"activeCount":100},[],{"trials":9142,"activeCount":100},[9143],{"nctId":6891,"briefTitle":6892,"status":294,"phases":9144,"primaryCompletion":3311,"completion":3311,"start":6894,"enrollment":100,"conditions":9145,"interventions":9146},[90],[6896,6897],[2858,6899,6900,6901],{"trials":9148,"activeCount":100},[],{"trials":9150,"activeCount":100},[],{"trials":9152,"activeCount":100},[],{"intervention":6900,"totalTrials":190,"cells":9154},{"EARLY_PHASE1":9155,"PHASE1":9157,"PHASE2":9159,"PHASE3":9165,"PHASE4":9167,"NA":9169},{"trials":9156,"activeCount":100},[],{"trials":9158,"activeCount":100},[],{"trials":9160,"activeCount":100},[9161],{"nctId":6891,"briefTitle":6892,"status":294,"phases":9162,"primaryCompletion":3311,"completion":3311,"start":6894,"enrollment":100,"conditions":9163,"interventions":9164},[90],[6896,6897],[2858,6899,6900,6901],{"trials":9166,"activeCount":100},[],{"trials":9168,"activeCount":100},[],{"trials":9170,"activeCount":100},[],{"intervention":6901,"totalTrials":190,"cells":9172},{"EARLY_PHASE1":9173,"PHASE1":9175,"PHASE2":9177,"PHASE3":9183,"PHASE4":9185,"NA":9187},{"trials":9174,"activeCount":100},[],{"trials":9176,"activeCount":100},[],{"trials":9178,"activeCount":100},[9179],{"nctId":6891,"briefTitle":6892,"status":294,"phases":9180,"primaryCompletion":3311,"completion":3311,"start":6894,"enrollment":100,"conditions":9181,"interventions":9182},[90],[6896,6897],[2858,6899,6900,6901],{"trials":9184,"activeCount":100},[],{"trials":9186,"activeCount":100},[],{"trials":9188,"activeCount":100},[],{"intervention":2859,"totalTrials":190,"cells":9190},{"EARLY_PHASE1":9191,"PHASE1":9193,"PHASE2":9195,"PHASE3":9201,"PHASE4":9203,"NA":9205},{"trials":9192,"activeCount":100},[],{"trials":9194,"activeCount":100},[],{"trials":9196,"activeCount":100},[9197],{"nctId":2850,"briefTitle":2851,"status":108,"phases":9198,"primaryCompletion":2853,"completion":1215,"start":2854,"enrollment":22,"conditions":9199,"interventions":9200},[90],[2856],[2834,2858,2859],{"trials":9202,"activeCount":100},[],{"trials":9204,"activeCount":100},[],{"trials":9206,"activeCount":100},[],{"intervention":7497,"totalTrials":190,"cells":9208},{"EARLY_PHASE1":9209,"PHASE1":9211,"PHASE2":9213,"PHASE3":9219,"PHASE4":9221,"NA":9223},{"trials":9210,"activeCount":100},[],{"trials":9212,"activeCount":100},[],{"trials":9214,"activeCount":100},[9215],{"nctId":7487,"briefTitle":7488,"status":119,"phases":9216,"primaryCompletion":7480,"completion":5570,"start":7490,"enrollment":7491,"conditions":9217,"interventions":9218},[90],[7493,7494],[7496,7497],{"trials":9220,"activeCount":100},[],{"trials":9222,"activeCount":100},[],{"trials":9224,"activeCount":100},[],{"intervention":9226,"totalTrials":190,"cells":9227},"98% pure CBD",{"EARLY_PHASE1":9228,"PHASE1":9230,"PHASE2":9232,"PHASE3":9244,"PHASE4":9246,"NA":9248},{"trials":9229,"activeCount":100},[],{"trials":9231,"activeCount":100},[],{"trials":9233,"activeCount":100},[9234],{"nctId":9235,"briefTitle":9236,"status":119,"phases":9237,"primaryCompletion":9238,"completion":9238,"start":9239,"enrollment":1203,"conditions":9240,"interventions":9243},"NCT03900923","Cannabidiol for ASD Open Trial",[90],"2023-05-04","2019-03-12",[9241,9242],"ASD","Autism Spectrum Disorder",[9226],{"trials":9245,"activeCount":100},[],{"trials":9247,"activeCount":100},[],{"trials":9249,"activeCount":100},[],{"intervention":7198,"totalTrials":190,"cells":9251},{"EARLY_PHASE1":9252,"PHASE1":9254,"PHASE2":9256,"PHASE3":9262,"PHASE4":9264,"NA":9266},{"trials":9253,"activeCount":100},[],{"trials":9255,"activeCount":100},[],{"trials":9257,"activeCount":100},[9258],{"nctId":7191,"briefTitle":7192,"status":119,"phases":9259,"primaryCompletion":6772,"start":7194,"conditions":9260,"interventions":9261},[90],[15],[7197,7198],{"trials":9263,"activeCount":100},[],{"trials":9265,"activeCount":100},[],{"trials":9267,"activeCount":100},[],{"intervention":9269,"totalTrials":190,"cells":9270},"Sirolimus 2 MG",{"EARLY_PHASE1":9271,"PHASE1":9273,"PHASE2":9275,"PHASE3":9286,"PHASE4":9288,"NA":9290},{"trials":9272,"activeCount":100},[],{"trials":9274,"activeCount":100},[],{"trials":9276,"activeCount":100},[9277],{"nctId":9278,"briefTitle":9279,"status":108,"phases":9280,"primaryCompletion":9281,"completion":279,"start":9282,"enrollment":6490,"conditions":9283,"interventions":9285},"NCT03589976","A Futility Trial of Sirolimus in Multiple System Atrophy",[90],"2020-11-20","2018-09-01",[9284],"Multiple System Atrophy",[9269],{"trials":9287,"activeCount":100},[],{"trials":9289,"activeCount":100},[],{"trials":9291,"activeCount":100},[],{"intervention":6595,"totalTrials":190,"cells":9293},{"EARLY_PHASE1":9294,"PHASE1":9296,"PHASE2":9298,"PHASE3":9304,"PHASE4":9306,"NA":9308},{"trials":9295,"activeCount":100},[],{"trials":9297,"activeCount":100},[],{"trials":9299,"activeCount":100},[9300],{"nctId":6586,"briefTitle":6587,"status":119,"phases":9301,"primaryCompletion":3746,"completion":6118,"start":6589,"enrollment":632,"conditions":9302,"interventions":9303},[90],[1362,6591],[6593,6594,1338,6595],{"trials":9305,"activeCount":100},[],{"trials":9307,"activeCount":100},[],{"trials":9309,"activeCount":100},[],{"intervention":9311,"totalTrials":190,"cells":9312},"Nivolimumab+Carboplatin\u002Fpaclitaxel+Radiation",{"EARLY_PHASE1":9313,"PHASE1":9315,"PHASE2":9317,"PHASE3":9329,"PHASE4":9331,"NA":9333},{"trials":9314,"activeCount":100},[],{"trials":9316,"activeCount":100},[],{"trials":9318,"activeCount":100},[9319],{"nctId":9320,"briefTitle":9321,"status":108,"phases":9322,"primaryCompletion":9323,"completion":9324,"start":9325,"enrollment":281,"conditions":9326,"interventions":9328},"NCT03278626","Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma",[89,90],"2019-11-07","2021-05-31","2017-06-27",[9327],"Esophageal Squamous Cell Carcinoma",[9311],{"trials":9330,"activeCount":100},[],{"trials":9332,"activeCount":100},[],{"trials":9334,"activeCount":100},[],{"intervention":1382,"totalTrials":190,"cells":9336},{"EARLY_PHASE1":9337,"PHASE1":9339,"PHASE2":9341,"PHASE3":9347,"PHASE4":9349,"NA":9351},{"trials":9338,"activeCount":100},[],{"trials":9340,"activeCount":100},[],{"trials":9342,"activeCount":100},[9343],{"nctId":1373,"briefTitle":1374,"status":294,"phases":9344,"primaryCompletion":1376,"completion":1377,"start":1378,"enrollment":100,"conditions":9345,"interventions":9346},[90],[1205,1380],[43,1382],{"trials":9348,"activeCount":100},[],{"trials":9350,"activeCount":100},[],{"trials":9352,"activeCount":100},[],{"intervention":9354,"totalTrials":190,"cells":9355},"IDH305",{"EARLY_PHASE1":9356,"PHASE1":9358,"PHASE2":9360,"PHASE3":9370,"PHASE4":9372,"NA":9374},{"trials":9357,"activeCount":100},[],{"trials":9359,"activeCount":100},[],{"trials":9361,"activeCount":100},[9362],{"nctId":9363,"briefTitle":9364,"status":294,"phases":9365,"primaryCompletion":9366,"completion":9366,"start":9367,"enrollment":100,"conditions":9368,"interventions":9369},"NCT02977689","Trial of IDH305 in IDH1 Mutant Grade II or III Glioma",[90],"2020-04","2018-04",[6897],[9354],{"trials":9371,"activeCount":100},[],{"trials":9373,"activeCount":100},[],{"trials":9375,"activeCount":100},[],{"intervention":9377,"totalTrials":190,"cells":9378},"Carboplatin AUC",{"EARLY_PHASE1":9379,"PHASE1":9381,"PHASE2":9383,"PHASE3":9393,"PHASE4":9395,"NA":9397},{"trials":9380,"activeCount":100},[],{"trials":9382,"activeCount":100},[],{"trials":9384,"activeCount":100},[9385],{"nctId":9386,"briefTitle":9387,"status":119,"phases":9388,"primaryCompletion":9389,"completion":3232,"start":6408,"enrollment":1750,"conditions":9390,"interventions":9391},"NCT02744898","A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus",[90],"2018-08-17",[6731],[9377,9392],"Abraxane",{"trials":9394,"activeCount":100},[],{"trials":9396,"activeCount":100},[],{"trials":9398,"activeCount":100},[],{"intervention":9392,"totalTrials":190,"cells":9400},{"EARLY_PHASE1":9401,"PHASE1":9403,"PHASE2":9405,"PHASE3":9411,"PHASE4":9413,"NA":9415},{"trials":9402,"activeCount":100},[],{"trials":9404,"activeCount":100},[],{"trials":9406,"activeCount":100},[9407],{"nctId":9386,"briefTitle":9387,"status":119,"phases":9408,"primaryCompletion":9389,"completion":3232,"start":6408,"enrollment":1750,"conditions":9409,"interventions":9410},[90],[6731],[9377,9392],{"trials":9412,"activeCount":100},[],{"trials":9414,"activeCount":100},[],{"trials":9416,"activeCount":100},[],{"intervention":7542,"totalTrials":190,"cells":9418},{"EARLY_PHASE1":9419,"PHASE1":9421,"PHASE2":9423,"PHASE3":9429,"PHASE4":9431,"NA":9433},{"trials":9420,"activeCount":100},[],{"trials":9422,"activeCount":100},[],{"trials":9424,"activeCount":100},[9425],{"nctId":7535,"briefTitle":7536,"status":108,"phases":9426,"primaryCompletion":1533,"completion":7538,"start":7539,"enrollment":268,"conditions":9427,"interventions":9428},[90],[6549],[7542,1481],{"trials":9430,"activeCount":100},[],{"trials":9432,"activeCount":100},[],{"trials":9434,"activeCount":100},[],{"intervention":9436,"totalTrials":190,"cells":9437},"Mavyret",{"EARLY_PHASE1":9438,"PHASE1":9440,"PHASE2":9442,"PHASE3":9453,"PHASE4":9455,"NA":9457},{"trials":9439,"activeCount":100},[],{"trials":9441,"activeCount":100},[],{"trials":9443,"activeCount":100},[9444],{"nctId":9445,"briefTitle":9446,"status":119,"phases":9447,"primaryCompletion":9448,"completion":9448,"start":9449,"enrollment":2797,"conditions":9450,"interventions":9452},"NCT03523871","A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret",[90],"2020-09-01","2018-05-12",[9451],"Hepatitis C",[9436],{"trials":9454,"activeCount":100},[],{"trials":9456,"activeCount":100},[],{"trials":9458,"activeCount":100},[],{"intervention":9460,"totalTrials":190,"cells":9461},"Droxidopa",{"EARLY_PHASE1":9462,"PHASE1":9464,"PHASE2":9466,"PHASE3":9476,"PHASE4":9478,"NA":9480},{"trials":9463,"activeCount":100},[],{"trials":9465,"activeCount":100},[],{"trials":9467,"activeCount":100},[9468],{"nctId":9469,"briefTitle":9470,"status":294,"phases":9471,"primaryCompletion":9472,"completion":9472,"start":3626,"enrollment":100,"conditions":9473,"interventions":9475},"NCT02624310","A Study of Norepinephrine in Patients With Congenital Insensitivity to Pain and Anhidrosis",[90],"2019-01",[9474],"HSAN Type IV",[9460],{"trials":9477,"activeCount":100},[],{"trials":9479,"activeCount":100},[],{"trials":9481,"activeCount":100},[],{"intervention":9483,"totalTrials":190,"cells":9484},"Ecallantide subcutaneous dosing",{"EARLY_PHASE1":9485,"PHASE1":9487,"PHASE2":9489,"PHASE3":9499,"PHASE4":9501,"NA":9503},{"trials":9486,"activeCount":100},[],{"trials":9488,"activeCount":100},[],{"trials":9490,"activeCount":100},[9491],{"nctId":9492,"briefTitle":9493,"status":294,"phases":9494,"primaryCompletion":9495,"completion":4858,"start":5929,"enrollment":100,"conditions":9496,"interventions":9498},"NCT01832896","Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema",[90],"2017-07",[9497],"Hereditary Angioedema Types I and II",[9483],{"trials":9500,"activeCount":100},[],{"trials":9502,"activeCount":100},[],{"trials":9504,"activeCount":100},[],{"intervention":9506,"totalTrials":190,"cells":9507},"Vitamin C",{"EARLY_PHASE1":9508,"PHASE1":9510,"PHASE2":9512,"PHASE3":9523,"PHASE4":9525,"NA":9527},{"trials":9509,"activeCount":100},[],{"trials":9511,"activeCount":100},[],{"trials":9513,"activeCount":100},[9514],{"nctId":9515,"briefTitle":9516,"status":119,"phases":9517,"primaryCompletion":9518,"completion":9519,"start":9520,"enrollment":946,"conditions":9521,"interventions":9522},"NCT03433781","A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations",[89,90],"2022-11-06","2023-05-16","2018-05-01",[6797],[9506],{"trials":9524,"activeCount":100},[],{"trials":9526,"activeCount":100},[],{"trials":9528,"activeCount":100},[],{"intervention":1812,"totalTrials":190,"cells":9530},{"EARLY_PHASE1":9531,"PHASE1":9533,"PHASE2":9535,"PHASE3":9541,"PHASE4":9543,"NA":9545},{"trials":9532,"activeCount":100},[],{"trials":9534,"activeCount":100},[],{"trials":9536,"activeCount":100},[9537],{"nctId":1803,"briefTitle":1804,"status":108,"phases":9538,"primaryCompletion":1806,"completion":1807,"start":1808,"enrollment":1461,"conditions":9539,"interventions":9540},[90],[1810],[1812,1738],{"trials":9542,"activeCount":100},[],{"trials":9544,"activeCount":100},[],{"trials":9546,"activeCount":100},[],{"intervention":9548,"totalTrials":190,"cells":9549},"aminocamptothecin",{"EARLY_PHASE1":9550,"PHASE1":9552,"PHASE2":9554,"PHASE3":9564,"PHASE4":9566,"NA":9568},{"trials":9551,"activeCount":100},[],{"trials":9553,"activeCount":100},[],{"trials":9555,"activeCount":100},[9556],{"nctId":9557,"briefTitle":9558,"status":119,"phases":9559,"primaryCompletion":9560,"start":9561,"conditions":9562,"interventions":9563},"NCT00002671","Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer",[90],"2001-02","1995-12",[6549],[9548],{"trials":9565,"activeCount":100},[],{"trials":9567,"activeCount":100},[],{"trials":9569,"activeCount":100},[],{"intervention":9571,"totalTrials":190,"cells":9572},"varencline",{"EARLY_PHASE1":9573,"PHASE1":9575,"PHASE2":9577,"PHASE3":9586,"PHASE4":9588,"NA":9590},{"trials":9574,"activeCount":100},[],{"trials":9576,"activeCount":100},[],{"trials":9578,"activeCount":100},[9579],{"nctId":9580,"briefTitle":9581,"status":294,"phases":9582,"start":1477,"enrollment":100,"conditions":9583,"interventions":9585},"NCT00571805","Study of Varencline Effects on Cigarette Smoking Reward and Craving During a Model of Brief Quit Attempt",[89,90],[9584],"Nicotine Dependence",[9571],{"trials":9587,"activeCount":100},[],{"trials":9589,"activeCount":100},[],{"trials":9591,"activeCount":100},[],{"intervention":6747,"totalTrials":190,"cells":9593},{"EARLY_PHASE1":9594,"PHASE1":9596,"PHASE2":9598,"PHASE3":9604,"PHASE4":9606,"NA":9608},{"trials":9595,"activeCount":100},[],{"trials":9597,"activeCount":100},[],{"trials":9599,"activeCount":100},[9600],{"nctId":6739,"briefTitle":6740,"status":119,"phases":9601,"primaryCompletion":6742,"start":3909,"conditions":9602,"interventions":9603},[89,90],[6744,6745,1778,6519],[6709,1740,6747],{"trials":9605,"activeCount":100},[],{"trials":9607,"activeCount":100},[],{"trials":9609,"activeCount":100},[],{"intervention":9611,"totalTrials":190,"cells":9612},"Levetiracetam",{"EARLY_PHASE1":9613,"PHASE1":9615,"PHASE2":9617,"PHASE3":9630,"PHASE4":9632,"NA":9634},{"trials":9614,"activeCount":100},[],{"trials":9616,"activeCount":100},[],{"trials":9618,"activeCount":100},[9619],{"nctId":9620,"briefTitle":9621,"status":119,"phases":9622,"primaryCompletion":9623,"completion":9623,"start":9624,"enrollment":3657,"conditions":9625,"interventions":9629},"NCT03129360","Levetiracetam in Early Psychosis",[90],"2021-11-03","2017-08-18",[9626,4329,9627,9628],"Psychosis","Schizo Affective Disorder","Schizophreniform",[9611],{"trials":9631,"activeCount":100},[],{"trials":9633,"activeCount":100},[],{"trials":9635,"activeCount":100},[],{"intervention":9637,"totalTrials":190,"cells":9638},"Pyridostigmine Bromide",{"EARLY_PHASE1":9639,"PHASE1":9641,"PHASE2":9643,"PHASE3":9651,"PHASE4":9653,"NA":9655},{"trials":9640,"activeCount":100},[],{"trials":9642,"activeCount":100},[],{"trials":9644,"activeCount":100},[9645],{"nctId":9646,"briefTitle":9647,"status":119,"phases":9648,"primaryCompletion":4088,"completion":4088,"start":919,"enrollment":3770,"conditions":9649,"interventions":9650},"NCT01415921","Safety Study of Pyridostigmine in Heart Failure",[90],[4725],[9637],{"trials":9652,"activeCount":100},[],{"trials":9654,"activeCount":100},[],{"trials":9656,"activeCount":100},[],{"intervention":9658,"totalTrials":190,"cells":9659},"Bardoxolone Methyl",{"EARLY_PHASE1":9660,"PHASE1":9662,"PHASE2":9664,"PHASE3":9675,"PHASE4":9677,"NA":9679},{"trials":9661,"activeCount":100},[],{"trials":9663,"activeCount":100},[],{"trials":9665,"activeCount":100},[9666],{"nctId":9667,"briefTitle":9668,"status":119,"phases":9669,"primaryCompletion":9670,"completion":9670,"start":9671,"enrollment":2885,"conditions":9672,"interventions":9674},"NCT04494646","BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)",[90],"2021-01-08","2020-09-08",[9673],"Covid19",[9658],{"trials":9676,"activeCount":100},[],{"trials":9678,"activeCount":100},[],{"trials":9680,"activeCount":100},[],{"intervention":9682,"totalTrials":190,"cells":9683},"Saline oral\u002Fnasal rinse",{"EARLY_PHASE1":9684,"PHASE1":9686,"PHASE2":9688,"PHASE3":9701,"PHASE4":9703,"NA":9705},{"trials":9685,"activeCount":100},[],{"trials":9687,"activeCount":100},[],{"trials":9689,"activeCount":100},[9690],{"nctId":9691,"briefTitle":9692,"status":294,"phases":9693,"primaryCompletion":9694,"completion":9695,"start":9696,"enrollment":100,"conditions":9697,"interventions":9698},"NCT04344236","Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19",[90],"2020-05-01","2020-05-09","2020-04-09",[788],[9682,9699,9700],"0.5% Povidone\u002FIodine oral\u002Fnasal rinse","0.12% Chlorhexidine oral\u002Fnasal rinse",{"trials":9702,"activeCount":100},[],{"trials":9704,"activeCount":100},[],{"trials":9706,"activeCount":100},[],{"intervention":9699,"totalTrials":190,"cells":9708},{"EARLY_PHASE1":9709,"PHASE1":9711,"PHASE2":9713,"PHASE3":9719,"PHASE4":9721,"NA":9723},{"trials":9710,"activeCount":100},[],{"trials":9712,"activeCount":100},[],{"trials":9714,"activeCount":100},[9715],{"nctId":9691,"briefTitle":9692,"status":294,"phases":9716,"primaryCompletion":9694,"completion":9695,"start":9696,"enrollment":100,"conditions":9717,"interventions":9718},[90],[788],[9682,9699,9700],{"trials":9720,"activeCount":100},[],{"trials":9722,"activeCount":100},[],{"trials":9724,"activeCount":100},[],{"intervention":9700,"totalTrials":190,"cells":9726},{"EARLY_PHASE1":9727,"PHASE1":9729,"PHASE2":9731,"PHASE3":9737,"PHASE4":9739,"NA":9741},{"trials":9728,"activeCount":100},[],{"trials":9730,"activeCount":100},[],{"trials":9732,"activeCount":100},[9733],{"nctId":9691,"briefTitle":9692,"status":294,"phases":9734,"primaryCompletion":9694,"completion":9695,"start":9696,"enrollment":100,"conditions":9735,"interventions":9736},[90],[788],[9682,9699,9700],{"trials":9738,"activeCount":100},[],{"trials":9740,"activeCount":100},[],{"trials":9742,"activeCount":100},[],{"intervention":9744,"totalTrials":190,"cells":9745},"Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention",{"EARLY_PHASE1":9746,"PHASE1":9748,"PHASE2":9750,"PHASE3":9761,"PHASE4":9763,"NA":9765},{"trials":9747,"activeCount":100},[],{"trials":9749,"activeCount":100},[],{"trials":9751,"activeCount":100},[9752],{"nctId":9753,"briefTitle":9744,"status":119,"phases":9754,"primaryCompletion":9755,"completion":9756,"start":9757,"enrollment":3244,"conditions":9758,"interventions":9760},"NCT04503616",[89,90],"2022-12-14","2024-08-15","2020-09-16",[9759],"Graft-versus-host Disease",[9744],{"trials":9762,"activeCount":100},[],{"trials":9764,"activeCount":100},[],{"trials":9766,"activeCount":100},[],{"intervention":9768,"totalTrials":190,"cells":9769},"liposomal interleukin-2",{"EARLY_PHASE1":9770,"PHASE1":9772,"PHASE2":9774,"PHASE3":9786,"PHASE4":9788,"NA":9790},{"trials":9771,"activeCount":100},[],{"trials":9773,"activeCount":100},[],{"trials":9775,"activeCount":100},[9776],{"nctId":9777,"briefTitle":9778,"status":119,"phases":9779,"primaryCompletion":1866,"start":9780,"conditions":9781,"interventions":9783},"NCT00004104","Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma",[90],"1998-06",[9782],"Melanoma (Skin)",[9768,9784,9785],"polyvalent melanoma vaccine","recombinant interferon alfa",{"trials":9787,"activeCount":100},[],{"trials":9789,"activeCount":100},[],{"trials":9791,"activeCount":100},[],{"intervention":9784,"totalTrials":190,"cells":9793},{"EARLY_PHASE1":9794,"PHASE1":9796,"PHASE2":9798,"PHASE3":9804,"PHASE4":9806,"NA":9808},{"trials":9795,"activeCount":100},[],{"trials":9797,"activeCount":100},[],{"trials":9799,"activeCount":100},[9800],{"nctId":9777,"briefTitle":9778,"status":119,"phases":9801,"primaryCompletion":1866,"start":9780,"conditions":9802,"interventions":9803},[90],[9782],[9768,9784,9785],{"trials":9805,"activeCount":100},[],{"trials":9807,"activeCount":100},[],{"trials":9809,"activeCount":100},[],{"intervention":9785,"totalTrials":190,"cells":9811},{"EARLY_PHASE1":9812,"PHASE1":9814,"PHASE2":9816,"PHASE3":9822,"PHASE4":9824,"NA":9826},{"trials":9813,"activeCount":100},[],{"trials":9815,"activeCount":100},[],{"trials":9817,"activeCount":100},[9818],{"nctId":9777,"briefTitle":9778,"status":119,"phases":9819,"primaryCompletion":1866,"start":9780,"conditions":9820,"interventions":9821},[90],[9782],[9768,9784,9785],{"trials":9823,"activeCount":100},[],{"trials":9825,"activeCount":100},[],{"trials":9827,"activeCount":100},[],{"intervention":9829,"totalTrials":190,"cells":9830},"Micro-Fragmented Adipose Tissue",{"EARLY_PHASE1":9831,"PHASE1":9833,"PHASE2":9835,"PHASE3":9847,"PHASE4":9849,"NA":9851},{"trials":9832,"activeCount":100},[],{"trials":9834,"activeCount":100},[],{"trials":9836,"activeCount":100},[9837],{"nctId":9838,"briefTitle":9839,"status":294,"phases":9840,"primaryCompletion":9841,"completion":9841,"start":9842,"enrollment":100,"conditions":9843,"interventions":9845},"NCT05005000","Autologous Intra-Articular Micro-Fragmented Adipose Transfer for the Treatment of Thumb Carpometacarpal Joint Arthritis",[90],"2023-05-25","2022-05-12",[9844],"Arthritis",[9829,9846],"Triamcinolone Acetonide 10mg\u002FmL",{"trials":9848,"activeCount":100},[],{"trials":9850,"activeCount":100},[],{"trials":9852,"activeCount":100},[],{"intervention":9846,"totalTrials":190,"cells":9854},{"EARLY_PHASE1":9855,"PHASE1":9857,"PHASE2":9859,"PHASE3":9865,"PHASE4":9867,"NA":9869},{"trials":9856,"activeCount":100},[],{"trials":9858,"activeCount":100},[],{"trials":9860,"activeCount":100},[9861],{"nctId":9838,"briefTitle":9839,"status":294,"phases":9862,"primaryCompletion":9841,"completion":9841,"start":9842,"enrollment":100,"conditions":9863,"interventions":9864},[90],[9844],[9829,9846],{"trials":9866,"activeCount":100},[],{"trials":9868,"activeCount":100},[],{"trials":9870,"activeCount":100},[],{"intervention":9872,"totalTrials":190,"cells":9873},"Prednisone",{"EARLY_PHASE1":9874,"PHASE1":9876,"PHASE2":9878,"PHASE3":9888,"PHASE4":9890,"NA":9892},{"trials":9875,"activeCount":100},[],{"trials":9877,"activeCount":100},[],{"trials":9879,"activeCount":100},[9880],{"nctId":9881,"briefTitle":9882,"status":119,"phases":9883,"primaryCompletion":6095,"completion":6209,"start":9884,"enrollment":9885,"conditions":9886,"interventions":9887},"NCT00000421","Serologically Active, Clinically Stable Systemic Lupus Erythematosus",[90],"1997-09",154,[659],[9872],{"trials":9889,"activeCount":100},[],{"trials":9891,"activeCount":100},[],{"trials":9893,"activeCount":100},[],{"intervention":9895,"totalTrials":190,"cells":9896},"Combination AZD1775 with AraC",{"EARLY_PHASE1":9897,"PHASE1":9899,"PHASE2":9901,"PHASE3":9914,"PHASE4":9916,"NA":9918},{"trials":9898,"activeCount":100},[],{"trials":9900,"activeCount":100},[],{"trials":9902,"activeCount":100},[9903],{"nctId":9904,"briefTitle":9905,"status":108,"phases":9906,"primaryCompletion":9907,"completion":9907,"start":9908,"enrollment":268,"conditions":9909,"interventions":9912},"NCT03718143","AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis",[90],"2019-09-27","2019-05-08",[9910,9911,6797],"Myelofibroses","Acute Myeloid Leukemia",[9895,9913],"AZD1775 only",{"trials":9915,"activeCount":100},[],{"trials":9917,"activeCount":100},[],{"trials":9919,"activeCount":100},[],{"intervention":9913,"totalTrials":190,"cells":9921},{"EARLY_PHASE1":9922,"PHASE1":9924,"PHASE2":9926,"PHASE3":9932,"PHASE4":9934,"NA":9936},{"trials":9923,"activeCount":100},[],{"trials":9925,"activeCount":100},[],{"trials":9927,"activeCount":100},[9928],{"nctId":9904,"briefTitle":9905,"status":108,"phases":9929,"primaryCompletion":9907,"completion":9907,"start":9908,"enrollment":268,"conditions":9930,"interventions":9931},[90],[9910,9911,6797],[9895,9913],{"trials":9933,"activeCount":100},[],{"trials":9935,"activeCount":100},[],{"trials":9937,"activeCount":100},[],{"intervention":6754,"totalTrials":190,"cells":9939},{"EARLY_PHASE1":9940,"PHASE1":9942,"PHASE2":9944,"PHASE3":9950,"PHASE4":9952,"NA":9954},{"trials":9941,"activeCount":100},[],{"trials":9943,"activeCount":100},[],{"trials":9945,"activeCount":100},[9946],{"nctId":6749,"briefTitle":6750,"status":119,"phases":9947,"primaryCompletion":4088,"completion":4088,"start":6742,"enrollment":5457,"conditions":9948,"interventions":9949},[90],[15,1798,3003],[6754,1740],{"trials":9951,"activeCount":100},[],{"trials":9953,"activeCount":100},[],{"trials":9955,"activeCount":100},[],{"intervention":9957,"totalTrials":190,"cells":9958},"FGF-2",{"EARLY_PHASE1":9959,"PHASE1":9961,"PHASE2":9963,"PHASE3":9975,"PHASE4":9977,"NA":9979},{"trials":9960,"activeCount":100},[],{"trials":9962,"activeCount":100},[],{"trials":9964,"activeCount":100},[9965],{"nctId":9966,"briefTitle":9967,"status":119,"phases":9968,"primaryCompletion":9969,"completion":9970,"start":9971,"enrollment":487,"conditions":9972,"interventions":9974},"NCT04960384","Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations",[90],"2025-09-30","2025-10-27","2022-05-27",[9973],"Tympanic Membrane Perforation",[9957],{"trials":9976,"activeCount":100},[],{"trials":9978,"activeCount":100},[],{"trials":9980,"activeCount":100},[],{"intervention":1829,"totalTrials":190,"cells":9982},{"EARLY_PHASE1":9983,"PHASE1":9985,"PHASE2":9987,"PHASE3":9993,"PHASE4":9995,"NA":9997},{"trials":9984,"activeCount":100},[],{"trials":9986,"activeCount":100},[],{"trials":9988,"activeCount":100},[9989],{"nctId":1823,"briefTitle":1824,"status":108,"phases":9990,"primaryCompletion":1714,"completion":1714,"start":919,"enrollment":1826,"conditions":9991,"interventions":9992},[90],[923],[1829,1291,1830],{"trials":9994,"activeCount":100},[],{"trials":9996,"activeCount":100},[],{"trials":9998,"activeCount":100},[],{"intervention":1830,"totalTrials":190,"cells":10000},{"EARLY_PHASE1":10001,"PHASE1":10003,"PHASE2":10005,"PHASE3":10011,"PHASE4":10013,"NA":10015},{"trials":10002,"activeCount":100},[],{"trials":10004,"activeCount":100},[],{"trials":10006,"activeCount":100},[10007],{"nctId":1823,"briefTitle":1824,"status":108,"phases":10008,"primaryCompletion":1714,"completion":1714,"start":919,"enrollment":1826,"conditions":10009,"interventions":10010},[90],[923],[1829,1291,1830],{"trials":10012,"activeCount":100},[],{"trials":10014,"activeCount":100},[],{"trials":10016,"activeCount":100},[],{"intervention":10018,"totalTrials":190,"cells":10019},"Extended-Release Tacrolimus",{"EARLY_PHASE1":10020,"PHASE1":10022,"PHASE2":10024,"PHASE3":10036,"PHASE4":10038,"NA":10040},{"trials":10021,"activeCount":100},[],{"trials":10023,"activeCount":100},[],{"trials":10025,"activeCount":100},[10026],{"nctId":10027,"briefTitle":10028,"status":119,"phases":10029,"primaryCompletion":10030,"completion":10030,"start":10031,"enrollment":5457,"conditions":10032,"interventions":10034},"NCT04420195","Envarsus XR in Lung Transplant",[90],"2022-11-30","2020-10-23",[10033],"Lung Transplant",[10018,10035],"Immediate-Release Tacrolimus",{"trials":10037,"activeCount":100},[],{"trials":10039,"activeCount":100},[],{"trials":10041,"activeCount":100},[],{"intervention":10035,"totalTrials":190,"cells":10043},{"EARLY_PHASE1":10044,"PHASE1":10046,"PHASE2":10048,"PHASE3":10054,"PHASE4":10056,"NA":10058},{"trials":10045,"activeCount":100},[],{"trials":10047,"activeCount":100},[],{"trials":10049,"activeCount":100},[10050],{"nctId":10027,"briefTitle":10028,"status":119,"phases":10051,"primaryCompletion":10030,"completion":10030,"start":10031,"enrollment":5457,"conditions":10052,"interventions":10053},[90],[10033],[10018,10035],{"trials":10055,"activeCount":100},[],{"trials":10057,"activeCount":100},[],{"trials":10059,"activeCount":100},[],{"intervention":10061,"totalTrials":190,"cells":10062},"synovial fluid biomarker concentrations",{"EARLY_PHASE1":10063,"PHASE1":10065,"PHASE2":10075,"PHASE3":10077,"PHASE4":10079,"NA":10081},{"trials":10064,"activeCount":100},[],{"trials":10066,"activeCount":100},[10067],{"nctId":10068,"briefTitle":10069,"status":119,"phases":10070,"primaryCompletion":10071,"completion":10071,"start":10072,"enrollment":262,"conditions":10073,"interventions":10074},"NCT03656575","Reduction of Pro-Inflammatory Synovial Fluid Biomarkers in Osteoarthritis of the Knee With Alpha-2 Macroglobulin",[89],"2019-04-20","2017-11-01",[3077],[10061],{"trials":10076,"activeCount":100},[],{"trials":10078,"activeCount":100},[],{"trials":10080,"activeCount":100},[],{"trials":10082,"activeCount":100},[],{"intervention":10084,"totalTrials":190,"cells":10085},"Romidepsin",{"EARLY_PHASE1":10086,"PHASE1":10088,"PHASE2":10099,"PHASE3":10101,"PHASE4":10103,"NA":10105},{"trials":10087,"activeCount":100},[],{"trials":10089,"activeCount":100},[10090],{"nctId":10091,"briefTitle":10092,"status":108,"phases":10093,"primaryCompletion":10094,"completion":10094,"start":1506,"enrollment":195,"conditions":10095,"interventions":10097},"NCT02061449","Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma",[89],"2018-11-05",[10096],"Cutaneous T-cell Lymphoma",[10084,10098],"Poly ICLC",{"trials":10100,"activeCount":100},[],{"trials":10102,"activeCount":100},[],{"trials":10104,"activeCount":100},[],{"trials":10106,"activeCount":100},[],{"intervention":10098,"totalTrials":190,"cells":10108},{"EARLY_PHASE1":10109,"PHASE1":10111,"PHASE2":10117,"PHASE3":10119,"PHASE4":10121,"NA":10123},{"trials":10110,"activeCount":100},[],{"trials":10112,"activeCount":100},[10113],{"nctId":10091,"briefTitle":10092,"status":108,"phases":10114,"primaryCompletion":10094,"completion":10094,"start":1506,"enrollment":195,"conditions":10115,"interventions":10116},[89],[10096],[10084,10098],{"trials":10118,"activeCount":100},[],{"trials":10120,"activeCount":100},[],{"trials":10122,"activeCount":100},[],{"trials":10124,"activeCount":100},[],{"intervention":1739,"totalTrials":190,"cells":10126},{"EARLY_PHASE1":10127,"PHASE1":10129,"PHASE2":10135,"PHASE3":10137,"PHASE4":10139,"NA":10141},{"trials":10128,"activeCount":100},[],{"trials":10130,"activeCount":100},[10131],{"nctId":1730,"briefTitle":1731,"status":119,"phases":10132,"primaryCompletion":1733,"start":1734,"conditions":10133,"interventions":10134},[89],[15],[1737,1738,1739,1740,1741],{"trials":10136,"activeCount":100},[],{"trials":10138,"activeCount":100},[],{"trials":10140,"activeCount":100},[],{"trials":10142,"activeCount":100},[],{"intervention":1741,"totalTrials":190,"cells":10144},{"EARLY_PHASE1":10145,"PHASE1":10147,"PHASE2":10153,"PHASE3":10155,"PHASE4":10157,"NA":10159},{"trials":10146,"activeCount":100},[],{"trials":10148,"activeCount":100},[10149],{"nctId":1730,"briefTitle":1731,"status":119,"phases":10150,"primaryCompletion":1733,"start":1734,"conditions":10151,"interventions":10152},[89],[15],[1737,1738,1739,1740,1741],{"trials":10154,"activeCount":100},[],{"trials":10156,"activeCount":100},[],{"trials":10158,"activeCount":100},[],{"trials":10160,"activeCount":100},[],{"intervention":10162,"totalTrials":190,"cells":10163},"UB-312",{"EARLY_PHASE1":10164,"PHASE1":10166,"PHASE2":10177,"PHASE3":10179,"PHASE4":10181,"NA":10183},{"trials":10165,"activeCount":100},[],{"trials":10167,"activeCount":100},[10168],{"nctId":10169,"briefTitle":10170,"status":119,"phases":10171,"primaryCompletion":10172,"completion":10172,"start":10173,"enrollment":921,"conditions":10174,"interventions":10176},"NCT05634876","UB-312 in Patients With Synucleinopathies",[89],"2025-02-11","2023-05-31",[9284,10175],"Parkinson Disease",[10162],{"trials":10178,"activeCount":100},[],{"trials":10180,"activeCount":100},[],{"trials":10182,"activeCount":100},[],{"trials":10184,"activeCount":100},[],{"intervention":6879,"totalTrials":190,"cells":10186},{"EARLY_PHASE1":10187,"PHASE1":10189,"PHASE2":10195,"PHASE3":10197,"PHASE4":10199,"NA":10201},{"trials":10188,"activeCount":100},[],{"trials":10190,"activeCount":100},[10191],{"nctId":6873,"briefTitle":6874,"status":119,"phases":10192,"primaryCompletion":6876,"completion":1419,"start":3060,"enrollment":1589,"conditions":10193,"interventions":10194},[89],[6549],[6879,2858],{"trials":10196,"activeCount":100},[],{"trials":10198,"activeCount":100},[],{"trials":10200,"activeCount":100},[],{"trials":10202,"activeCount":100},[],{"intervention":10204,"totalTrials":190,"cells":10205},"Povidone iodine",{"EARLY_PHASE1":10206,"PHASE1":10208,"PHASE2":10220,"PHASE3":10222,"PHASE4":10224,"NA":10226},{"trials":10207,"activeCount":100},[],{"trials":10209,"activeCount":100},[10210],{"nctId":10211,"briefTitle":10212,"status":119,"phases":10213,"primaryCompletion":10214,"completion":10215,"start":1333,"enrollment":10216,"conditions":10217,"interventions":10218},"NCT04075526","Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty",[89],"2024-01-01","2025-12-13",2129,[3077],[10204,10219],"Vancomycin powder",{"trials":10221,"activeCount":100},[],{"trials":10223,"activeCount":100},[],{"trials":10225,"activeCount":100},[],{"trials":10227,"activeCount":100},[],{"intervention":10219,"totalTrials":190,"cells":10229},{"EARLY_PHASE1":10230,"PHASE1":10232,"PHASE2":10238,"PHASE3":10240,"PHASE4":10242,"NA":10244},{"trials":10231,"activeCount":100},[],{"trials":10233,"activeCount":100},[10234],{"nctId":10211,"briefTitle":10212,"status":119,"phases":10235,"primaryCompletion":10214,"completion":10215,"start":1333,"enrollment":10216,"conditions":10236,"interventions":10237},[89],[3077],[10204,10219],{"trials":10239,"activeCount":100},[],{"trials":10241,"activeCount":100},[],{"trials":10243,"activeCount":100},[],{"trials":10245,"activeCount":100},[],{"intervention":10247,"totalTrials":190,"cells":10248},"aminocamptothecin colloidal dispersion",{"EARLY_PHASE1":10249,"PHASE1":10251,"PHASE2":10260,"PHASE3":10262,"PHASE4":10264,"NA":10266},{"trials":10250,"activeCount":100},[],{"trials":10252,"activeCount":100},[10253],{"nctId":10254,"briefTitle":10255,"status":119,"phases":10256,"primaryCompletion":6728,"start":10257,"enrollment":2797,"conditions":10258,"interventions":10259},"NCT00003548","Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity",[89],"1998-08",[1205],[10247],{"trials":10261,"activeCount":100},[],{"trials":10263,"activeCount":100},[],{"trials":10265,"activeCount":100},[],{"trials":10267,"activeCount":100},[],{"intervention":10269,"totalTrials":190,"cells":10270},"Packed Red Blood Cells",{"EARLY_PHASE1":10271,"PHASE1":10273,"PHASE2":10283,"PHASE3":10285,"PHASE4":10287,"NA":10289},{"trials":10272,"activeCount":100},[],{"trials":10274,"activeCount":100},[10275],{"nctId":10276,"briefTitle":10277,"status":10278,"phases":10279,"primaryCompletion":706,"completion":1587,"start":10280,"enrollment":632,"conditions":10281,"interventions":10282},"NCT06462027","Packed Red Blood Cell Transfusion During Cardiac Arrest","SUSPENDED",[89],"2026-06-01",[337],[10269,10269],{"trials":10284,"activeCount":100},[],{"trials":10286,"activeCount":100},[],{"trials":10288,"activeCount":100},[],{"trials":10290,"activeCount":100},[],{"intervention":10292,"totalTrials":190,"cells":10293},"Autologous cytokines",{"EARLY_PHASE1":10294,"PHASE1":10296,"PHASE2":10308,"PHASE3":10310,"PHASE4":10312,"NA":10314},{"trials":10295,"activeCount":100},[],{"trials":10297,"activeCount":100},[10298],{"nctId":10299,"briefTitle":10300,"status":119,"phases":10301,"primaryCompletion":10302,"completion":10302,"start":10303,"enrollment":10304,"conditions":10305,"interventions":10307},"NCT02350972","Inducing Systemic Immunity and Regressions in Metastatic Melanoma",[89],"2002-05","1978-07",88,[10306],"Metastatic Malignant Melanoma",[10292],{"trials":10309,"activeCount":100},[],{"trials":10311,"activeCount":100},[],{"trials":10313,"activeCount":100},[],{"trials":10315,"activeCount":100},[],{"intervention":10317,"totalTrials":190,"cells":10318},"AMD3100 injection + rhPDGF-BB topical",{"EARLY_PHASE1":10319,"PHASE1":10321,"PHASE2":10331,"PHASE3":10333,"PHASE4":10335,"NA":10337},{"trials":10320,"activeCount":100},[],{"trials":10322,"activeCount":100},[10323],{"nctId":10324,"briefTitle":10325,"status":294,"phases":10326,"primaryCompletion":10327,"completion":4462,"start":2853,"enrollment":100,"conditions":10328,"interventions":10330},"NCT01353937","Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers",[89],"2016-03",[10329],"Diabetic Ulcer",[10317],{"trials":10332,"activeCount":100},[],{"trials":10334,"activeCount":100},[],{"trials":10336,"activeCount":100},[],{"trials":10338,"activeCount":100},[],{"intervention":10340,"totalTrials":190,"cells":10341},"Fondaparinux",{"EARLY_PHASE1":10342,"PHASE1":10344,"PHASE2":10353,"PHASE3":10355,"PHASE4":10357,"NA":10359},{"trials":10343,"activeCount":100},[],{"trials":10345,"activeCount":100},[10346],{"nctId":10347,"briefTitle":10348,"status":294,"phases":10349,"primaryCompletion":6876,"completion":1475,"start":3060,"enrollment":100,"conditions":10350,"interventions":10352},"NCT00659399","Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression",[89],[10351],"Ovarian Carcinoma",[10340],{"trials":10354,"activeCount":100},[],{"trials":10356,"activeCount":100},[],{"trials":10358,"activeCount":100},[],{"trials":10360,"activeCount":100},[],{"intervention":10362,"totalTrials":190,"cells":10363},"Pomaglumetad Methionil 160mg",{"EARLY_PHASE1":10364,"PHASE1":10366,"PHASE2":10379,"PHASE3":10381,"PHASE4":10383,"NA":10385},{"trials":10365,"activeCount":100},[],{"trials":10367,"activeCount":100},[10368],{"nctId":10369,"briefTitle":10370,"status":108,"phases":10371,"primaryCompletion":10372,"completion":10373,"start":10374,"enrollment":112,"conditions":10375,"interventions":10377},"NCT02234687","A mGlu2\u002F3 Agonist in the Treatment of PTSD",[89],"2016-02-11","2016-09-11","2014-09",[10376],"Post-traumatic Stress Disorder",[10362,10378],"Pomaglumetad Methionil 40mg",{"trials":10380,"activeCount":100},[],{"trials":10382,"activeCount":100},[],{"trials":10384,"activeCount":100},[],{"trials":10386,"activeCount":100},[],{"intervention":10378,"totalTrials":190,"cells":10388},{"EARLY_PHASE1":10389,"PHASE1":10391,"PHASE2":10397,"PHASE3":10399,"PHASE4":10401,"NA":10403},{"trials":10390,"activeCount":100},[],{"trials":10392,"activeCount":100},[10393],{"nctId":10369,"briefTitle":10370,"status":108,"phases":10394,"primaryCompletion":10372,"completion":10373,"start":10374,"enrollment":112,"conditions":10395,"interventions":10396},[89],[10376],[10362,10378],{"trials":10398,"activeCount":100},[],{"trials":10400,"activeCount":100},[],{"trials":10402,"activeCount":100},[],{"trials":10404,"activeCount":100},[],{"intervention":10406,"totalTrials":190,"cells":10407},"Bupropion",{"EARLY_PHASE1":10408,"PHASE1":10410,"PHASE2":10422,"PHASE3":10424,"PHASE4":10426,"NA":10428},{"trials":10409,"activeCount":100},[],{"trials":10411,"activeCount":100},[10412],{"nctId":10413,"briefTitle":10414,"status":119,"phases":10415,"primaryCompletion":10416,"completion":10417,"start":10418,"enrollment":5457,"conditions":10419,"interventions":10421},"NCT00285584","Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)",[89],"2004-03","2004-09","2002-09",[10420,3606],"HIV Infections",[10406],{"trials":10423,"activeCount":100},[],{"trials":10425,"activeCount":100},[],{"trials":10427,"activeCount":100},[],{"trials":10429,"activeCount":100},[],{"intervention":6926,"totalTrials":190,"cells":10431},{"EARLY_PHASE1":10432,"PHASE1":10434,"PHASE2":10440,"PHASE3":10442,"PHASE4":10444,"NA":10446},{"trials":10433,"activeCount":100},[],{"trials":10435,"activeCount":100},[10436],{"nctId":6919,"briefTitle":6920,"status":119,"phases":10437,"primaryCompletion":6922,"completion":6922,"start":4462,"enrollment":96,"conditions":10438,"interventions":10439},[89],[6924],[6926,6594],{"trials":10441,"activeCount":100},[],{"trials":10443,"activeCount":100},[],{"trials":10445,"activeCount":100},[],{"trials":10447,"activeCount":100},[],{"intervention":10449,"totalTrials":190,"cells":10450},"Pitavastatin",{"EARLY_PHASE1":10451,"PHASE1":10453,"PHASE2":10466,"PHASE3":10468,"PHASE4":10470,"NA":10472},{"trials":10452,"activeCount":100},[],{"trials":10454,"activeCount":100},[10455],{"nctId":10456,"briefTitle":10457,"status":119,"phases":10458,"primaryCompletion":111,"completion":111,"start":10459,"enrollment":19,"conditions":10460,"interventions":10462},"NCT01695954","Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz",[89],"2012-05",[10461,3112],"Hyperlipidemia",[10449,10463,10464,10465],"Darunavir","Ritonavir","Efavirenz",{"trials":10467,"activeCount":100},[],{"trials":10469,"activeCount":100},[],{"trials":10471,"activeCount":100},[],{"trials":10473,"activeCount":100},[],{"intervention":10463,"totalTrials":190,"cells":10475},{"EARLY_PHASE1":10476,"PHASE1":10478,"PHASE2":10484,"PHASE3":10486,"PHASE4":10488,"NA":10490},{"trials":10477,"activeCount":100},[],{"trials":10479,"activeCount":100},[10480],{"nctId":10456,"briefTitle":10457,"status":119,"phases":10481,"primaryCompletion":111,"completion":111,"start":10459,"enrollment":19,"conditions":10482,"interventions":10483},[89],[10461,3112],[10449,10463,10464,10465],{"trials":10485,"activeCount":100},[],{"trials":10487,"activeCount":100},[],{"trials":10489,"activeCount":100},[],{"trials":10491,"activeCount":100},[],{"intervention":10464,"totalTrials":190,"cells":10493},{"EARLY_PHASE1":10494,"PHASE1":10496,"PHASE2":10502,"PHASE3":10504,"PHASE4":10506,"NA":10508},{"trials":10495,"activeCount":100},[],{"trials":10497,"activeCount":100},[10498],{"nctId":10456,"briefTitle":10457,"status":119,"phases":10499,"primaryCompletion":111,"completion":111,"start":10459,"enrollment":19,"conditions":10500,"interventions":10501},[89],[10461,3112],[10449,10463,10464,10465],{"trials":10503,"activeCount":100},[],{"trials":10505,"activeCount":100},[],{"trials":10507,"activeCount":100},[],{"trials":10509,"activeCount":100},[],{"intervention":10465,"totalTrials":190,"cells":10511},{"EARLY_PHASE1":10512,"PHASE1":10514,"PHASE2":10520,"PHASE3":10522,"PHASE4":10524,"NA":10526},{"trials":10513,"activeCount":100},[],{"trials":10515,"activeCount":100},[10516],{"nctId":10456,"briefTitle":10457,"status":119,"phases":10517,"primaryCompletion":111,"completion":111,"start":10459,"enrollment":19,"conditions":10518,"interventions":10519},[89],[10461,3112],[10449,10463,10464,10465],{"trials":10521,"activeCount":100},[],{"trials":10523,"activeCount":100},[],{"trials":10525,"activeCount":100},[],{"trials":10527,"activeCount":100},[],{"intervention":284,"totalTrials":190,"cells":10529},{"EARLY_PHASE1":10530,"PHASE1":10532,"PHASE2":10538,"PHASE3":10540,"PHASE4":10542,"NA":10544},{"trials":10531,"activeCount":100},[],{"trials":10533,"activeCount":100},[10534],{"nctId":275,"briefTitle":276,"status":119,"phases":10535,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":10536,"interventions":10537},[89],[126],[284,128],{"trials":10539,"activeCount":100},[],{"trials":10541,"activeCount":100},[],{"trials":10543,"activeCount":100},[],{"trials":10545,"activeCount":100},[],{"intervention":10547,"totalTrials":190,"cells":10548},"MEDI4736",{"EARLY_PHASE1":10549,"PHASE1":10551,"PHASE2":10562,"PHASE3":10564,"PHASE4":10566,"NA":10568},{"trials":10550,"activeCount":100},[],{"trials":10552,"activeCount":100},[10553],{"nctId":10554,"briefTitle":10555,"status":294,"phases":10556,"primaryCompletion":10557,"completion":10557,"start":10558,"enrollment":100,"conditions":10559,"interventions":10560},"NCT02868632","Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer",[89],"2019-03-04","2016-08-07",[1404],[10547,10561],"Tremelimumab",{"trials":10563,"activeCount":100},[],{"trials":10565,"activeCount":100},[],{"trials":10567,"activeCount":100},[],{"trials":10569,"activeCount":100},[],{"intervention":10561,"totalTrials":190,"cells":10571},{"EARLY_PHASE1":10572,"PHASE1":10574,"PHASE2":10580,"PHASE3":10582,"PHASE4":10584,"NA":10586},{"trials":10573,"activeCount":100},[],{"trials":10575,"activeCount":100},[10576],{"nctId":10554,"briefTitle":10555,"status":294,"phases":10577,"primaryCompletion":10557,"completion":10557,"start":10558,"enrollment":100,"conditions":10578,"interventions":10579},[89],[1404],[10547,10561],{"trials":10581,"activeCount":100},[],{"trials":10583,"activeCount":100},[],{"trials":10585,"activeCount":100},[],{"trials":10587,"activeCount":100},[],{"intervention":6521,"totalTrials":190,"cells":10589},{"EARLY_PHASE1":10590,"PHASE1":10592,"PHASE2":10598,"PHASE3":10600,"PHASE4":10602,"NA":10604},{"trials":10591,"activeCount":100},[],{"trials":10593,"activeCount":100},[10594],{"nctId":6513,"briefTitle":6514,"status":119,"phases":10595,"primaryCompletion":6516,"start":6517,"conditions":10596,"interventions":10597},[89],[6519],[6521,1782],{"trials":10599,"activeCount":100},[],{"trials":10601,"activeCount":100},[],{"trials":10603,"activeCount":100},[],{"trials":10605,"activeCount":100},[],{"intervention":6531,"totalTrials":190,"cells":10607},{"EARLY_PHASE1":10608,"PHASE1":10610,"PHASE2":10616,"PHASE3":10618,"PHASE4":10620,"NA":10622},{"trials":10609,"activeCount":100},[],{"trials":10611,"activeCount":100},[10612],{"nctId":6523,"briefTitle":6524,"status":119,"phases":10613,"primaryCompletion":6526,"start":6527,"enrollment":1855,"conditions":10614,"interventions":10615},[89],[6529,6519],[6531,1782,6532],{"trials":10617,"activeCount":100},[],{"trials":10619,"activeCount":100},[],{"trials":10621,"activeCount":100},[],{"trials":10623,"activeCount":100},[],{"intervention":10625,"totalTrials":190,"cells":10626},"Ethyl chloride spray",{"EARLY_PHASE1":10627,"PHASE1":10629,"PHASE2":10637,"PHASE3":10639,"PHASE4":10641,"NA":10643},{"trials":10628,"activeCount":100},[],{"trials":10630,"activeCount":100},[10631],{"nctId":10632,"briefTitle":10633,"status":294,"phases":10634,"primaryCompletion":9366,"completion":9366,"start":3311,"enrollment":100,"conditions":10635,"interventions":10636},"NCT03445780","Comparison of Distraction Methods for Pain Relief of Trigger Finger Injection",[89],[961],[10625],{"trials":10638,"activeCount":100},[],{"trials":10640,"activeCount":100},[],{"trials":10642,"activeCount":100},[],{"trials":10644,"activeCount":100},[],{"intervention":6701,"totalTrials":190,"cells":10646},{"EARLY_PHASE1":10647,"PHASE1":10649,"PHASE2":10655,"PHASE3":10657,"PHASE4":10659,"NA":10661},{"trials":10648,"activeCount":100},[],{"trials":10650,"activeCount":100},[10651],{"nctId":6695,"briefTitle":6696,"status":119,"phases":10652,"primaryCompletion":5859,"completion":5859,"start":6698,"enrollment":1750,"conditions":10653,"interventions":10654},[89],[21],[6701,1860],{"trials":10656,"activeCount":100},[],{"trials":10658,"activeCount":100},[],{"trials":10660,"activeCount":100},[],{"trials":10662,"activeCount":100},[],{"intervention":10664,"totalTrials":190,"cells":10665},"Escitalopram Pill",{"EARLY_PHASE1":10666,"PHASE1":10668,"PHASE2":10679,"PHASE3":10681,"PHASE4":10683,"NA":10685},{"trials":10667,"activeCount":100},[],{"trials":10669,"activeCount":100},[10670],{"nctId":10671,"briefTitle":10672,"status":108,"phases":10673,"primaryCompletion":10674,"completion":10674,"start":10675,"enrollment":772,"conditions":10676,"interventions":10677},"NCT03274817","A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol",[89],"2019-09-25","2009-06-18",[684],[10664,10678],"Venlafaxine Pill",{"trials":10680,"activeCount":100},[],{"trials":10682,"activeCount":100},[],{"trials":10684,"activeCount":100},[],{"trials":10686,"activeCount":100},[],{"intervention":10678,"totalTrials":190,"cells":10688},{"EARLY_PHASE1":10689,"PHASE1":10691,"PHASE2":10697,"PHASE3":10699,"PHASE4":10701,"NA":10703},{"trials":10690,"activeCount":100},[],{"trials":10692,"activeCount":100},[10693],{"nctId":10671,"briefTitle":10672,"status":108,"phases":10694,"primaryCompletion":10674,"completion":10674,"start":10675,"enrollment":772,"conditions":10695,"interventions":10696},[89],[684],[10664,10678],{"trials":10698,"activeCount":100},[],{"trials":10700,"activeCount":100},[],{"trials":10702,"activeCount":100},[],{"trials":10704,"activeCount":100},[],{"intervention":10706,"totalTrials":190,"cells":10707},"Montanide",{"EARLY_PHASE1":10708,"PHASE1":10710,"PHASE2":10719,"PHASE3":10721,"PHASE4":10723,"NA":10725},{"trials":10709,"activeCount":100},[],{"trials":10711,"activeCount":100},[10712],{"nctId":10713,"briefTitle":10714,"status":119,"phases":10715,"primaryCompletion":3313,"completion":3313,"start":3747,"enrollment":1589,"conditions":10716,"interventions":10718},"NCT00935545","Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors",[89],[10717],"Tumors, Central Nervous System",[10706],{"trials":10720,"activeCount":100},[],{"trials":10722,"activeCount":100},[],{"trials":10724,"activeCount":100},[],{"trials":10726,"activeCount":100},[],{"intervention":10728,"totalTrials":190,"cells":10729},"KD019",{"EARLY_PHASE1":10730,"PHASE1":10732,"PHASE2":10740,"PHASE3":10742,"PHASE4":10744,"NA":10746},{"trials":10731,"activeCount":100},[],{"trials":10733,"activeCount":100},[10734],{"nctId":10735,"briefTitle":10736,"status":294,"phases":10737,"primaryCompletion":9495,"completion":9495,"start":4325,"enrollment":100,"conditions":10738,"interventions":10739},"NCT02205463","KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer",[89],[6604,6591],[10728],{"trials":10741,"activeCount":100},[],{"trials":10743,"activeCount":100},[],{"trials":10745,"activeCount":100},[],{"trials":10747,"activeCount":100},[],{"intervention":10749,"totalTrials":190,"cells":10750},"Thalidomide",{"EARLY_PHASE1":10751,"PHASE1":10753,"PHASE2":10762,"PHASE3":10764,"PHASE4":10766,"NA":10768},{"trials":10752,"activeCount":100},[],{"trials":10754,"activeCount":100},[10755],{"nctId":10756,"briefTitle":10757,"status":108,"phases":10758,"completion":6255,"start":6508,"enrollment":632,"conditions":10759,"interventions":10761},"NCT00418132","Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis",[89],[10760],"Scleroderma, Systemic",[10749],{"trials":10763,"activeCount":100},[],{"trials":10765,"activeCount":100},[],{"trials":10767,"activeCount":100},[],{"trials":10769,"activeCount":100},[],{"intervention":10771,"totalTrials":190,"cells":10772},"Mocetinostat Induction Phase + Ipilimumab + Nivolumab",{"EARLY_PHASE1":10773,"PHASE1":10775,"PHASE2":10786,"PHASE3":10788,"PHASE4":10790,"NA":10792},{"trials":10774,"activeCount":100},[],{"trials":10776,"activeCount":100},[10777],{"nctId":10778,"briefTitle":10779,"status":108,"phases":10780,"primaryCompletion":10781,"completion":10781,"start":10782,"enrollment":1826,"conditions":10783,"interventions":10784},"NCT03565406","A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma",[89],"2020-01-13","2018-04-25",[126],[10771,10785],"Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab",{"trials":10787,"activeCount":100},[],{"trials":10789,"activeCount":100},[],{"trials":10791,"activeCount":100},[],{"trials":10793,"activeCount":100},[],{"intervention":10785,"totalTrials":190,"cells":10795},{"EARLY_PHASE1":10796,"PHASE1":10798,"PHASE2":10804,"PHASE3":10806,"PHASE4":10808,"NA":10810},{"trials":10797,"activeCount":100},[],{"trials":10799,"activeCount":100},[10800],{"nctId":10778,"briefTitle":10779,"status":108,"phases":10801,"primaryCompletion":10781,"completion":10781,"start":10782,"enrollment":1826,"conditions":10802,"interventions":10803},[89],[126],[10771,10785],{"trials":10805,"activeCount":100},[],{"trials":10807,"activeCount":100},[],{"trials":10809,"activeCount":100},[],{"trials":10811,"activeCount":100},[],{"intervention":10813,"totalTrials":190,"cells":10814},"phenethyl isothiocyanate",{"EARLY_PHASE1":10815,"PHASE1":10817,"PHASE2":10825,"PHASE3":10827,"PHASE4":10829,"NA":10831},{"trials":10816,"activeCount":100},[],{"trials":10818,"activeCount":100},[10819],{"nctId":10820,"briefTitle":10821,"status":119,"phases":10822,"primaryCompletion":6526,"conditions":10823,"interventions":10824},"NCT00005883","Phenethyl Isothiocyanate in Preventing Lung Cancer in People Who Smoke",[89],[7335],[10813],{"trials":10826,"activeCount":100},[],{"trials":10828,"activeCount":100},[],{"trials":10830,"activeCount":100},[],{"trials":10832,"activeCount":100},[],{"intervention":10834,"totalTrials":190,"cells":10835},"Estradiol 2Mg",{"EARLY_PHASE1":10836,"PHASE1":10838,"PHASE2":10851,"PHASE3":10853,"PHASE4":10855,"NA":10857},{"trials":10837,"activeCount":100},[],{"trials":10839,"activeCount":100},[10840],{"nctId":10841,"briefTitle":10842,"status":119,"phases":10843,"primaryCompletion":10844,"completion":10844,"start":111,"enrollment":10845,"conditions":10846,"interventions":10849},"NCT02673606","Impact of Estrogen on Fear Extinction R61",[89],"2019-04-15",136,[10847,10848],"Fear","Fear; Examination, Phobic",[10834,10850],"Estradiol 4Mg",{"trials":10852,"activeCount":100},[],{"trials":10854,"activeCount":100},[],{"trials":10856,"activeCount":100},[],{"trials":10858,"activeCount":100},[],{"intervention":10850,"totalTrials":190,"cells":10860},{"EARLY_PHASE1":10861,"PHASE1":10863,"PHASE2":10869,"PHASE3":10871,"PHASE4":10873,"NA":10875},{"trials":10862,"activeCount":100},[],{"trials":10864,"activeCount":100},[10865],{"nctId":10841,"briefTitle":10842,"status":119,"phases":10866,"primaryCompletion":10844,"completion":10844,"start":111,"enrollment":10845,"conditions":10867,"interventions":10868},[89],[10847,10848],[10834,10850],{"trials":10870,"activeCount":100},[],{"trials":10872,"activeCount":100},[],{"trials":10874,"activeCount":100},[],{"trials":10876,"activeCount":100},[],{"intervention":10878,"totalTrials":190,"cells":10879},"efalizumab",{"EARLY_PHASE1":10880,"PHASE1":10882,"PHASE2":10892,"PHASE3":10894,"PHASE4":10896,"NA":10898},{"trials":10881,"activeCount":100},[],{"trials":10883,"activeCount":100},[10884],{"nctId":10885,"briefTitle":10886,"status":119,"phases":10887,"completion":3738,"start":10888,"enrollment":772,"conditions":10889,"interventions":10891},"NCT00134134","Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa",[89],"2005-02",[10890],"Hidradenitis Suppurativa",[10878],{"trials":10893,"activeCount":100},[],{"trials":10895,"activeCount":100},[],{"trials":10897,"activeCount":100},[],{"trials":10899,"activeCount":100},[],{"intervention":10901,"totalTrials":190,"cells":10902},"Melatonin 5 mg",{"EARLY_PHASE1":10903,"PHASE1":10905,"PHASE2":10916,"PHASE3":10918,"PHASE4":10920,"NA":10922},{"trials":10904,"activeCount":100},[],{"trials":10906,"activeCount":100},[10907],{"nctId":10908,"briefTitle":10909,"status":119,"phases":10910,"primaryCompletion":2812,"completion":10911,"start":10912,"enrollment":10913,"conditions":10914,"interventions":10915},"NCT04795336","Melatonin Use After Primary Total Joint Arthroplasty",[89],"2024-04-18","2021-07-12",294,[3936],[10901],{"trials":10917,"activeCount":100},[],{"trials":10919,"activeCount":100},[],{"trials":10921,"activeCount":100},[],{"trials":10923,"activeCount":100},[],{"intervention":10925,"totalTrials":190,"cells":10926},"Inhaled Furosemide",{"EARLY_PHASE1":10927,"PHASE1":10939,"PHASE2":10941,"PHASE3":10943,"PHASE4":10945,"NA":10947},{"trials":10928,"activeCount":100},[10929],{"nctId":10930,"briefTitle":10931,"status":294,"phases":10932,"primaryCompletion":10933,"completion":10933,"start":1367,"enrollment":100,"conditions":10934,"interventions":10937},"NCT03946891","Nebulized Furosemide in Premature Infants With Bronchopulmonary Dysplasia - A Cross Over Pilot Study of Its Efficacy and Safety",[88],"2023-06",[10935,10936],"Premature Birth","Premature Infant",[10925,10938],"Intravenous Furosemide",{"trials":10940,"activeCount":100},[],{"trials":10942,"activeCount":100},[],{"trials":10944,"activeCount":100},[],{"trials":10946,"activeCount":100},[],{"trials":10948,"activeCount":100},[],{"intervention":10938,"totalTrials":190,"cells":10950},{"EARLY_PHASE1":10951,"PHASE1":10957,"PHASE2":10959,"PHASE3":10961,"PHASE4":10963,"NA":10965},{"trials":10952,"activeCount":100},[10953],{"nctId":10930,"briefTitle":10931,"status":294,"phases":10954,"primaryCompletion":10933,"completion":10933,"start":1367,"enrollment":100,"conditions":10955,"interventions":10956},[88],[10935,10936],[10925,10938],{"trials":10958,"activeCount":100},[],{"trials":10960,"activeCount":100},[],{"trials":10962,"activeCount":100},[],{"trials":10964,"activeCount":100},[],{"trials":10966,"activeCount":100},[],{"intervention":10968,"totalTrials":190,"cells":10969},"Isatuximab",{"EARLY_PHASE1":10970,"PHASE1":10980,"PHASE2":10982,"PHASE3":10984,"PHASE4":10986,"NA":10988},{"trials":10971,"activeCount":100},[10972],{"nctId":10973,"briefTitle":10974,"status":294,"phases":10975,"primaryCompletion":3714,"completion":1118,"start":8759,"enrollment":100,"conditions":10976,"interventions":10979},"NCT05862766","Isatuximab in Lung Transplant Recipients",[88],[10977,10978],"Antibody-mediated Rejection","Allosensitization",[10968],{"trials":10981,"activeCount":100},[],{"trials":10983,"activeCount":100},[],{"trials":10985,"activeCount":100},[],{"trials":10987,"activeCount":100},[],{"trials":10989,"activeCount":100},[],{"intervention":10991,"totalTrials":190,"cells":10992},"Azithromycin",{"EARLY_PHASE1":10993,"PHASE1":11002,"PHASE2":11004,"PHASE3":11006,"PHASE4":11008,"NA":11010},{"trials":10994,"activeCount":100},[10995],{"nctId":10996,"briefTitle":10997,"status":119,"phases":10998,"primaryCompletion":5882,"completion":5882,"start":5569,"enrollment":34,"conditions":10999,"interventions":11001},"NCT02557958","Chronic Obstructive Pulmonary Disease Transcription Factor and Cytokine Study",[88],[11000],"Chronic Obstructive Pulmonary Disease",[10991],{"trials":11003,"activeCount":100},[],{"trials":11005,"activeCount":100},[],{"trials":11007,"activeCount":100},[],{"trials":11009,"activeCount":100},[],{"trials":11011,"activeCount":100},[],{"intervention":11013,"totalTrials":190,"cells":11014},"Oral Corticosteroids",{"EARLY_PHASE1":11015,"PHASE1":11027,"PHASE2":11029,"PHASE3":11031,"PHASE4":11033,"NA":11035},{"trials":11016,"activeCount":100},[11017],{"nctId":11018,"briefTitle":11019,"status":294,"phases":11020,"primaryCompletion":11021,"completion":11021,"start":11022,"enrollment":100,"conditions":11023,"interventions":11025},"NCT03457025","Effect of Adjuvant Hyperbaric Oxygen Therapy on Bells Palsy Outcome",[88],"2020-06","2019-08",[11024],"Bell Palsy",[11013,11026],"Oral antivirals",{"trials":11028,"activeCount":100},[],{"trials":11030,"activeCount":100},[],{"trials":11032,"activeCount":100},[],{"trials":11034,"activeCount":100},[],{"trials":11036,"activeCount":100},[],{"intervention":11026,"totalTrials":190,"cells":11038},{"EARLY_PHASE1":11039,"PHASE1":11045,"PHASE2":11047,"PHASE3":11049,"PHASE4":11051,"NA":11053},{"trials":11040,"activeCount":100},[11041],{"nctId":11018,"briefTitle":11019,"status":294,"phases":11042,"primaryCompletion":11021,"completion":11021,"start":11022,"enrollment":100,"conditions":11043,"interventions":11044},[88],[11024],[11013,11026],{"trials":11046,"activeCount":100},[],{"trials":11048,"activeCount":100},[],{"trials":11050,"activeCount":100},[],{"trials":11052,"activeCount":100},[],{"trials":11054,"activeCount":100},[],{"intervention":11056,"totalTrials":190,"cells":11057},"denosumab",{"EARLY_PHASE1":11058,"PHASE1":11068,"PHASE2":11070,"PHASE3":11072,"PHASE4":11074,"NA":11076},{"trials":11059,"activeCount":100},[11060],{"nctId":11061,"briefTitle":11062,"status":119,"phases":11063,"primaryCompletion":11064,"completion":11065,"start":280,"enrollment":1855,"conditions":11066,"interventions":11067},"NCT02900469","Presurgical Trial of Denosumab in Breast Cancer",[88],"2019-12-03","2020-01-03",[15],[11056],{"trials":11069,"activeCount":100},[],{"trials":11071,"activeCount":100},[],{"trials":11073,"activeCount":100},[],{"trials":11075,"activeCount":100},[],{"trials":11077,"activeCount":100},[],{"intervention":11079,"totalTrials":190,"cells":11080},"Nusinersen Treatments",{"EARLY_PHASE1":11081,"PHASE1":11091,"PHASE2":11093,"PHASE3":11095,"PHASE4":11097,"NA":11099},{"trials":11082,"activeCount":100},[11083],{"nctId":11084,"briefTitle":11085,"status":294,"phases":11086,"primaryCompletion":784,"completion":784,"start":11087,"enrollment":100,"conditions":11088,"interventions":11090},"NCT04050852","Pulmonary Function Test Changes and Respiratory Muscle Strength Trends in Spinal Muscular Atrophy Patients Receiving Nusinersen Treatments",[88],"2019-07-17",[11089],"Spinal Muscular Atrophy",[11079],{"trials":11092,"activeCount":100},[],{"trials":11094,"activeCount":100},[],{"trials":11096,"activeCount":100},[],{"trials":11098,"activeCount":100},[],{"trials":11100,"activeCount":100},[],{"intervention":1207,"totalTrials":190,"cells":11102},{"EARLY_PHASE1":11103,"PHASE1":11109,"PHASE2":11111,"PHASE3":11113,"PHASE4":11115,"NA":11117},{"trials":11104,"activeCount":100},[11105],{"nctId":1198,"briefTitle":1199,"status":119,"phases":11106,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":1203,"conditions":11107,"interventions":11108},[88],[1205],[1193,1207],{"trials":11110,"activeCount":100},[],{"trials":11112,"activeCount":100},[],{"trials":11114,"activeCount":100},[],{"trials":11116,"activeCount":100},[],{"trials":11118,"activeCount":100},[],{"intervention":11120,"totalTrials":190,"cells":11121},"Glecaprevir\u002Fpibrentasvir",{"EARLY_PHASE1":11122,"PHASE1":11133,"PHASE2":11135,"PHASE3":11137,"PHASE4":11139,"NA":11141},{"trials":11123,"activeCount":100},[11124],{"nctId":11125,"briefTitle":11126,"status":119,"phases":11127,"primaryCompletion":9519,"completion":11128,"start":11129,"enrollment":2797,"conditions":11130,"interventions":11132},"NCT04682509","A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir\u002FPibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation",[88],"2024-02-28","2022-03-20",[11131],"ESRD",[11120],{"trials":11134,"activeCount":100},[],{"trials":11136,"activeCount":100},[],{"trials":11138,"activeCount":100},[],{"trials":11140,"activeCount":100},[],{"trials":11142,"activeCount":100},[],{"intervention":11144,"totalTrials":190,"cells":11145},"intravenous immune globulin",{"EARLY_PHASE1":11146,"PHASE1":11155,"PHASE2":11157,"PHASE3":11159,"PHASE4":11161,"NA":11163},{"trials":11147,"activeCount":100},[11148],{"nctId":11149,"briefTitle":11150,"status":119,"phases":11151,"primaryCompletion":6567,"completion":6567,"start":1808,"enrollment":2797,"conditions":11152,"interventions":11154},"NCT00460928","Preventive IVIG Therapy for Congenital Heart Block",[88],[808,809,11153],"Autoantibody-associated Heart Block",[11144],{"trials":11156,"activeCount":100},[],{"trials":11158,"activeCount":100},[],{"trials":11160,"activeCount":100},[],{"trials":11162,"activeCount":100},[],{"trials":11164,"activeCount":100},[],{"intervention":11166,"totalTrials":173,"cells":11167},"Aprepitant",{"EARLY_PHASE1":11168,"PHASE1":11170,"PHASE2":11180,"PHASE3":11182,"PHASE4":11184,"NA":11186},{"trials":11169,"activeCount":100},[],{"trials":11171,"activeCount":100},[11172],{"nctId":11173,"briefTitle":11174,"status":119,"phases":11175,"primaryCompletion":1262,"completion":3109,"start":11176,"enrollment":11177,"conditions":11178,"interventions":11179},"NCT01527994","Aprepitant Effects in Intravenous Heroin Dependence",[89],"2012-01",64,[489],[11166],{"trials":11181,"activeCount":100},[],{"trials":11183,"activeCount":100},[],{"trials":11185,"activeCount":100},[],{"trials":11187,"activeCount":100},[11188],{"nctId":11189,"briefTitle":11190,"status":294,"phases":11191,"primaryCompletion":7538,"completion":3604,"start":7354,"enrollment":100,"conditions":11192,"interventions":11193},"NCT01017809","Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer",[93],[6549],[11166],{"intervention":11195,"totalTrials":173,"cells":11196},"Nicotine Replacement Therapy",{"EARLY_PHASE1":11197,"PHASE1":11199,"PHASE2":11201,"PHASE3":11203,"PHASE4":11205,"NA":11218},{"trials":11198,"activeCount":100},[],{"trials":11200,"activeCount":100},[],{"trials":11202,"activeCount":100},[],{"trials":11204,"activeCount":100},[],{"trials":11206,"activeCount":100},[11207],{"nctId":11208,"briefTitle":11209,"status":119,"phases":11210,"primaryCompletion":11211,"completion":11212,"start":11213,"enrollment":11214,"conditions":11215,"interventions":11217},"NCT03187730","Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants",[92],"2019-04-30","2021-04-30","2017-09-22",410,[11216],"Smoking Cessation",[11195],{"trials":11219,"activeCount":100},[11220],{"nctId":11221,"briefTitle":11222,"status":119,"phases":11223,"primaryCompletion":11224,"completion":11224,"start":11225,"enrollment":31,"conditions":11226,"interventions":11227},"NCT03673228","Preventing Smoking Relapse After Total Joint Replacement Surgery",[93],"2021-01-28","2019-01-15",[1000,11216],[11195],{"intervention":3080,"totalTrials":173,"cells":11229},{"EARLY_PHASE1":11230,"PHASE1":11232,"PHASE2":11234,"PHASE3":11236,"PHASE4":11238,"NA":11244},{"trials":11231,"activeCount":100},[],{"trials":11233,"activeCount":100},[],{"trials":11235,"activeCount":100},[],{"trials":11237,"activeCount":100},[],{"trials":11239,"activeCount":100},[11240],{"nctId":3071,"briefTitle":3072,"status":108,"phases":11241,"primaryCompletion":3074,"completion":3074,"start":1714,"enrollment":3075,"conditions":11242,"interventions":11243},[92],[3077,3078],[3080,3081,3038],{"trials":11245,"activeCount":100},[11246],{"nctId":11247,"briefTitle":11248,"status":108,"phases":11249,"primaryCompletion":11250,"completion":3705,"start":10912,"enrollment":1900,"conditions":11251,"interventions":11253},"NCT05031520","PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease",[],"2024-09-01",[11252],"Non-Obstructive Coronary Atherosclerosis",[11254,11255,3080],"Isovue","Nitroglycerin",{"intervention":11257,"totalTrials":173,"cells":11258},"Lidocaine",{"EARLY_PHASE1":11259,"PHASE1":11261,"PHASE2":11272,"PHASE3":11274,"PHASE4":11276,"NA":11278},{"trials":11260,"activeCount":100},[],{"trials":11262,"activeCount":100},[11263],{"nctId":11264,"briefTitle":11265,"status":119,"phases":11266,"primaryCompletion":11267,"completion":11267,"start":7064,"enrollment":173,"conditions":11268,"interventions":11270},"NCT02733393","Sphenopalatine Ganglion Block to Treat Shoulder Pain After Thoracotomy",[89],"2017-09-05",[11269],"Ipsilateral Shoulder Pain",[11271],"lidocaine",{"trials":11273,"activeCount":100},[],{"trials":11275,"activeCount":100},[],{"trials":11277,"activeCount":100},[],{"trials":11279,"activeCount":100},[11280],{"nctId":11281,"briefTitle":11282,"status":119,"phases":11283,"primaryCompletion":7355,"completion":11284,"start":6566,"enrollment":2733,"conditions":11285,"interventions":11286},"NCT00681902","Jet Lidocaine for Pain Relief During Needle Insertion in a Pediatric Emergency Department",[93],"2008-07",[3617],[11257],{"intervention":11288,"totalTrials":173,"cells":11289},"Vancomycin",{"EARLY_PHASE1":11290,"PHASE1":11292,"PHASE2":11294,"PHASE3":11304,"PHASE4":11306,"NA":11308},{"trials":11291,"activeCount":100},[],{"trials":11293,"activeCount":100},[],{"trials":11295,"activeCount":100},[11296],{"nctId":11297,"briefTitle":11298,"status":119,"phases":11299,"primaryCompletion":11300,"completion":11300,"start":11301,"enrollment":1589,"conditions":11302,"interventions":11303},"NCT03452189","The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome",[90],"2018-08-18","2017-11-27",[2003],[11288],{"trials":11305,"activeCount":100},[],{"trials":11307,"activeCount":100},[],{"trials":11309,"activeCount":100},[11310],{"nctId":11311,"briefTitle":11312,"status":119,"phases":11313,"primaryCompletion":111,"completion":111,"start":4327,"enrollment":335,"conditions":11314,"interventions":11317},"NCT01198509","Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)",[93],[1446,11315,11316],"Psoriatic Arthritis","Periodontal Disease",[11318,11319],"doxycycline","vancomycin",{"intervention":11321,"totalTrials":190,"cells":11322},"Tolvaptan in euvolemic hyponatremia",{"EARLY_PHASE1":11323,"PHASE1":11325,"PHASE2":11327,"PHASE3":11329,"PHASE4":11331,"NA":11333},{"trials":11324,"activeCount":100},[],{"trials":11326,"activeCount":100},[],{"trials":11328,"activeCount":100},[],{"trials":11330,"activeCount":100},[],{"trials":11332,"activeCount":100},[],{"trials":11334,"activeCount":100},[11335],{"nctId":11336,"briefTitle":11337,"status":294,"phases":11338,"primaryCompletion":4325,"completion":4325,"start":3737,"enrollment":100,"conditions":11339,"interventions":11344},"NCT01425125","Fractional Urate Excretion in Nonedematous Hyponatremia",[93],[11340,11341,11342,11343],"Cerebral Hyponatremia","SIADH","Cerebral Salt-wasting Syndrome","Reset Hypothalamic Osmostat",[11321],{"intervention":11254,"totalTrials":190,"cells":11346},{"EARLY_PHASE1":11347,"PHASE1":11349,"PHASE2":11351,"PHASE3":11353,"PHASE4":11355,"NA":11357},{"trials":11348,"activeCount":100},[],{"trials":11350,"activeCount":100},[],{"trials":11352,"activeCount":100},[],{"trials":11354,"activeCount":100},[],{"trials":11356,"activeCount":100},[],{"trials":11358,"activeCount":100},[11359],{"nctId":11247,"briefTitle":11248,"status":108,"phases":11360,"primaryCompletion":11250,"completion":3705,"start":10912,"enrollment":1900,"conditions":11361,"interventions":11362},[],[11252],[11254,11255,3080],{"intervention":11255,"totalTrials":190,"cells":11364},{"EARLY_PHASE1":11365,"PHASE1":11367,"PHASE2":11369,"PHASE3":11371,"PHASE4":11373,"NA":11375},{"trials":11366,"activeCount":100},[],{"trials":11368,"activeCount":100},[],{"trials":11370,"activeCount":100},[],{"trials":11372,"activeCount":100},[],{"trials":11374,"activeCount":100},[],{"trials":11376,"activeCount":100},[11377],{"nctId":11247,"briefTitle":11248,"status":108,"phases":11378,"primaryCompletion":11250,"completion":3705,"start":10912,"enrollment":1900,"conditions":11379,"interventions":11380},[],[11252],[11254,11255,3080],{"intervention":11382,"totalTrials":190,"cells":11383},"Neutrogena ® Light Therapy Acne Mask",{"EARLY_PHASE1":11384,"PHASE1":11386,"PHASE2":11388,"PHASE3":11390,"PHASE4":11392,"NA":11394},{"trials":11385,"activeCount":100},[],{"trials":11387,"activeCount":100},[],{"trials":11389,"activeCount":100},[],{"trials":11391,"activeCount":100},[],{"trials":11393,"activeCount":100},[],{"trials":11395,"activeCount":100},[11396],{"nctId":11397,"briefTitle":11398,"status":294,"phases":11399,"primaryCompletion":11400,"completion":11400,"start":11401,"enrollment":100,"conditions":11402,"interventions":11404},"NCT03650881","The Comparative Efficacy of an Over the Counter Light Therapy Mask vs Over the Counter Topical Benzoyl Peroxide 2.5% and Used in Combination With Over the Counter Adapalene Gel 0.1% for Mild to Moderate Acne",[93],"2020-02-05","2018-08-07",[11403],"Acne",[11382,11405],"Topical OTC benzoyl peroxide 2.5% gel and OTC adapalene",{"intervention":11405,"totalTrials":190,"cells":11407},{"EARLY_PHASE1":11408,"PHASE1":11410,"PHASE2":11412,"PHASE3":11414,"PHASE4":11416,"NA":11418},{"trials":11409,"activeCount":100},[],{"trials":11411,"activeCount":100},[],{"trials":11413,"activeCount":100},[],{"trials":11415,"activeCount":100},[],{"trials":11417,"activeCount":100},[],{"trials":11419,"activeCount":100},[11420],{"nctId":11397,"briefTitle":11398,"status":294,"phases":11421,"primaryCompletion":11400,"completion":11400,"start":11401,"enrollment":100,"conditions":11422,"interventions":11423},[93],[11403],[11382,11405],{"intervention":11425,"totalTrials":190,"cells":11426},"SARS-COV-2 mRNA Vaccine",{"EARLY_PHASE1":11427,"PHASE1":11429,"PHASE2":11431,"PHASE3":11433,"PHASE4":11435,"NA":11437},{"trials":11428,"activeCount":100},[],{"trials":11430,"activeCount":100},[],{"trials":11432,"activeCount":100},[],{"trials":11434,"activeCount":100},[],{"trials":11436,"activeCount":100},[],{"trials":11438,"activeCount":100},[11439],{"nctId":11440,"briefTitle":11441,"status":119,"phases":11442,"primaryCompletion":11443,"completion":11443,"start":11444,"enrollment":11177,"conditions":11445,"interventions":11446},"NCT04843774","Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)",[],"2023-04-18","2021-04-20",[24],[11425],{"intervention":11448,"totalTrials":190,"cells":11449},"Varenicline",{"EARLY_PHASE1":11450,"PHASE1":11452,"PHASE2":11454,"PHASE3":11456,"PHASE4":11458,"NA":11460},{"trials":11451,"activeCount":100},[],{"trials":11453,"activeCount":100},[],{"trials":11455,"activeCount":100},[],{"trials":11457,"activeCount":100},[],{"trials":11459,"activeCount":100},[],{"trials":11461,"activeCount":100},[11462],{"nctId":11463,"briefTitle":11464,"status":119,"phases":11465,"primaryCompletion":4325,"completion":4325,"start":6032,"enrollment":11466,"conditions":11467,"interventions":11469},"NCT01898195","Improving Adherence to Smoking Cessation Medication Among PLWHA",[93],158,[11468],"Tobacco Use Cessation",[11448],{"intervention":11471,"totalTrials":190,"cells":11472},"Trichuris suis ova",{"EARLY_PHASE1":11473,"PHASE1":11475,"PHASE2":11477,"PHASE3":11479,"PHASE4":11481,"NA":11483},{"trials":11474,"activeCount":100},[],{"trials":11476,"activeCount":100},[],{"trials":11478,"activeCount":100},[],{"trials":11480,"activeCount":100},[],{"trials":11482,"activeCount":100},[],{"trials":11484,"activeCount":100},[11485],{"nctId":11486,"briefTitle":11487,"status":119,"phases":11488,"primaryCompletion":6886,"completion":6886,"start":955,"enrollment":946,"conditions":11489,"interventions":11491},"NCT01433471","Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova",[93],[11490],"Ulcerative Colitis",[11471],{"intervention":11493,"totalTrials":190,"cells":11494},"isosulfan blue",{"EARLY_PHASE1":11495,"PHASE1":11497,"PHASE2":11499,"PHASE3":11501,"PHASE4":11503,"NA":11505},{"trials":11496,"activeCount":100},[],{"trials":11498,"activeCount":100},[],{"trials":11500,"activeCount":100},[],{"trials":11502,"activeCount":100},[],{"trials":11504,"activeCount":100},[],{"trials":11506,"activeCount":100},[11507],{"nctId":11508,"briefTitle":11509,"status":119,"phases":11510,"primaryCompletion":6167,"start":6650,"conditions":11511,"interventions":11513},"NCT00012168","Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat",[93],[11512],"Head and Neck Cancer",[11493,11514],"polymerase chain reaction",{"intervention":11514,"totalTrials":190,"cells":11516},{"EARLY_PHASE1":11517,"PHASE1":11519,"PHASE2":11521,"PHASE3":11523,"PHASE4":11525,"NA":11527},{"trials":11518,"activeCount":100},[],{"trials":11520,"activeCount":100},[],{"trials":11522,"activeCount":100},[],{"trials":11524,"activeCount":100},[],{"trials":11526,"activeCount":100},[],{"trials":11528,"activeCount":100},[11529],{"nctId":11508,"briefTitle":11509,"status":119,"phases":11530,"primaryCompletion":6167,"start":6650,"conditions":11531,"interventions":11532},[93],[11512],[11493,11514],{"intervention":11534,"totalTrials":190,"cells":11535},"Initiate BUP (SL-BUP or XR-BUP) in the ED",{"EARLY_PHASE1":11536,"PHASE1":11538,"PHASE2":11540,"PHASE3":11542,"PHASE4":11544,"NA":11546},{"trials":11537,"activeCount":100},[],{"trials":11539,"activeCount":100},[],{"trials":11541,"activeCount":100},[],{"trials":11543,"activeCount":100},[],{"trials":11545,"activeCount":100},[],{"trials":11547,"activeCount":100},[11548],{"nctId":11549,"briefTitle":11550,"status":119,"phases":11551,"primaryCompletion":11552,"completion":11552,"start":11553,"enrollment":11554,"conditions":11555,"interventions":11556},"NCT03544112","Emergency Department Connection to Care With Buprenorphine for Opioid Use Disorder",[],"2019-05-29","2018-06-11",390,[1655],[11534],{"intervention":11558,"totalTrials":190,"cells":11559},"Acetazolamide",{"EARLY_PHASE1":11560,"PHASE1":11562,"PHASE2":11564,"PHASE3":11566,"PHASE4":11568,"NA":11570},{"trials":11561,"activeCount":100},[],{"trials":11563,"activeCount":100},[],{"trials":11565,"activeCount":100},[],{"trials":11567,"activeCount":100},[],{"trials":11569,"activeCount":100},[],{"trials":11571,"activeCount":100},[11572],{"nctId":11573,"briefTitle":11574,"status":294,"phases":11575,"primaryCompletion":5859,"completion":3603,"start":3626,"enrollment":100,"conditions":11576,"interventions":11578},"NCT02670096","A Single-center Pilot Study Evaluating the Immediate Effects of Low-dose Acetazolamide on Respiratory Control in Subjects With Treatment Emergent Sleep Disordered Breathing",[93],[11577],"Sleep Apnea",[11558],{"intervention":11580,"totalTrials":190,"cells":11581},"Nicotine Replacement Therapies",{"EARLY_PHASE1":11582,"PHASE1":11584,"PHASE2":11586,"PHASE3":11588,"PHASE4":11590,"NA":11592},{"trials":11583,"activeCount":100},[],{"trials":11585,"activeCount":100},[],{"trials":11587,"activeCount":100},[],{"trials":11589,"activeCount":100},[],{"trials":11591,"activeCount":100},[],{"trials":11593,"activeCount":100},[11594],{"nctId":11595,"briefTitle":11596,"status":119,"phases":11597,"primaryCompletion":7064,"completion":348,"start":110,"enrollment":11598,"conditions":11599,"interventions":11600},"NCT02665208","A Pilot Text Messaging Intervention to Reduce Smoking in Office-based Buprenorphine and Inpatient Detoxification Patients",[93],203,[11216],[11580],{"intervention":11602,"totalTrials":190,"cells":11603},"Isoproterenol",{"EARLY_PHASE1":11604,"PHASE1":11606,"PHASE2":11608,"PHASE3":11610,"PHASE4":11612,"NA":11614},{"trials":11605,"activeCount":100},[],{"trials":11607,"activeCount":100},[],{"trials":11609,"activeCount":100},[],{"trials":11611,"activeCount":100},[],{"trials":11613,"activeCount":100},[],{"trials":11615,"activeCount":100},[11616],{"nctId":11617,"briefTitle":11618,"status":119,"phases":11619,"primaryCompletion":3746,"completion":919,"start":7539,"enrollment":2797,"conditions":11620,"interventions":11622},"NCT01377636","Measurement of Bispectral Index and Awareness in Patients Undergoing Electrophysiology Studies With Isoproterenol",[93],[11621],"Intraoperative Awareness",[11602],{"intervention":11624,"totalTrials":190,"cells":11625},"Gadolinium-based Contrast Agent (GBCA) for MRI",{"EARLY_PHASE1":11626,"PHASE1":11628,"PHASE2":11630,"PHASE3":11632,"PHASE4":11634,"NA":11636},{"trials":11627,"activeCount":100},[],{"trials":11629,"activeCount":100},[],{"trials":11631,"activeCount":100},[],{"trials":11633,"activeCount":100},[],{"trials":11635,"activeCount":100},[],{"trials":11637,"activeCount":100},[11638],{"nctId":11639,"briefTitle":11640,"status":119,"phases":11641,"primaryCompletion":11642,"completion":11643,"start":1817,"enrollment":1287,"conditions":11644,"interventions":11645},"NCT03389698","Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD",[],"2022-01-28","2023-07-11",[684],[11624],{"intervention":11647,"totalTrials":190,"cells":11648},"flecainide iv",{"EARLY_PHASE1":11649,"PHASE1":11651,"PHASE2":11653,"PHASE3":11655,"PHASE4":11657,"NA":11659},{"trials":11650,"activeCount":100},[],{"trials":11652,"activeCount":100},[],{"trials":11654,"activeCount":100},[],{"trials":11656,"activeCount":100},[],{"trials":11658,"activeCount":100},[],{"trials":11660,"activeCount":100},[11661],{"nctId":11662,"briefTitle":11663,"status":119,"phases":11664,"primaryCompletion":11665,"completion":11665,"start":11666,"enrollment":11667,"conditions":11668,"interventions":11671},"NCT02302274","Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome",[],"2017-07-26","2010-07-01",209,[11669,11670],"Brugada Syndrome","Arrhythmogenic Right Ventricular Cardiomyopathy",[11647],{"intervention":11673,"totalTrials":190,"cells":11674},"PiB",{"EARLY_PHASE1":11675,"PHASE1":11677,"PHASE2":11679,"PHASE3":11681,"PHASE4":11683,"NA":11685},{"trials":11676,"activeCount":100},[],{"trials":11678,"activeCount":100},[],{"trials":11680,"activeCount":100},[],{"trials":11682,"activeCount":100},[],{"trials":11684,"activeCount":100},[],{"trials":11686,"activeCount":100},[11687],{"nctId":11688,"briefTitle":11689,"status":119,"phases":11690,"primaryCompletion":11691,"completion":11691,"start":11692,"enrollment":11693,"conditions":11694,"interventions":11695},"NCT03814603","The Sleep Amyloid, Slow WAve Race and Ethnicity Study",[],"2025-05-31","2018-11-21",210,[684],[11673],{"intervention":11697,"totalTrials":190,"cells":11698},"Ocrelizumab",{"EARLY_PHASE1":11699,"PHASE1":11701,"PHASE2":11703,"PHASE3":11705,"PHASE4":11707,"NA":11709},{"trials":11700,"activeCount":100},[],{"trials":11702,"activeCount":100},[],{"trials":11704,"activeCount":100},[],{"trials":11706,"activeCount":100},[],{"trials":11708,"activeCount":100},[],{"trials":11710,"activeCount":100},[11711],{"nctId":11712,"briefTitle":11713,"status":119,"phases":11714,"primaryCompletion":11715,"completion":11715,"start":11716,"enrollment":11717,"conditions":11718,"interventions":11719},"NCT04855617","Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis",[],"2022-10-01","2020-10-26",122,[24],[11697],{"intervention":11721,"totalTrials":190,"cells":11722},"Vaginal estrogen",{"EARLY_PHASE1":11723,"PHASE1":11725,"PHASE2":11727,"PHASE3":11729,"PHASE4":11731,"NA":11733},{"trials":11724,"activeCount":100},[],{"trials":11726,"activeCount":100},[],{"trials":11728,"activeCount":100},[],{"trials":11730,"activeCount":100},[],{"trials":11732,"activeCount":100},[],{"trials":11734,"activeCount":100},[11735],{"nctId":11736,"briefTitle":11737,"status":294,"phases":11738,"primaryCompletion":3289,"completion":3289,"start":11739,"enrollment":100,"conditions":11740,"interventions":11742},"NCT07038070","Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study",[93],"2025-07-01",[11741],"Genitourinary Syndrome of Menopause (GSM)",[11721],{"intervention":11744,"totalTrials":190,"cells":11745},"Colchicine Pill",{"EARLY_PHASE1":11746,"PHASE1":11748,"PHASE2":11750,"PHASE3":11752,"PHASE4":11754,"NA":11756},{"trials":11747,"activeCount":100},[],{"trials":11749,"activeCount":100},[],{"trials":11751,"activeCount":100},[],{"trials":11753,"activeCount":100},[],{"trials":11755,"activeCount":100},[],{"trials":11757,"activeCount":100},[11758],{"nctId":11759,"briefTitle":11760,"status":119,"phases":11761,"primaryCompletion":11762,"completion":11763,"start":10557,"enrollment":11764,"conditions":11765,"interventions":11768},"NCT03874338","CLEAR SYNERGY Neutrophil Substudy",[],"2023-02-20","2024-08-09",322,[11766,11767],"Neutrophils.Hypersegmented | Bld-Ser-Plas","STEMI - ST Elevation Myocardial Infarction",[11744],{"intervention":11770,"totalTrials":190,"cells":11771},"Standard Care",{"EARLY_PHASE1":11772,"PHASE1":11774,"PHASE2":11776,"PHASE3":11778,"PHASE4":11780,"NA":11782},{"trials":11773,"activeCount":100},[],{"trials":11775,"activeCount":100},[],{"trials":11777,"activeCount":100},[],{"trials":11779,"activeCount":100},[],{"trials":11781,"activeCount":100},[],{"trials":11783,"activeCount":100},[11784],{"nctId":11785,"briefTitle":11786,"status":108,"phases":11787,"primaryCompletion":3804,"completion":3804,"start":6876,"enrollment":173,"conditions":11788,"interventions":11790},"NCT02528097","A Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis",[93],[11789],"Spontaneous Bacterial Peritonitis",[11770,11791],"Experimental",{"intervention":11791,"totalTrials":190,"cells":11793},{"EARLY_PHASE1":11794,"PHASE1":11796,"PHASE2":11798,"PHASE3":11800,"PHASE4":11802,"NA":11804},{"trials":11795,"activeCount":100},[],{"trials":11797,"activeCount":100},[],{"trials":11799,"activeCount":100},[],{"trials":11801,"activeCount":100},[],{"trials":11803,"activeCount":100},[],{"trials":11805,"activeCount":100},[11806],{"nctId":11785,"briefTitle":11786,"status":108,"phases":11807,"primaryCompletion":3804,"completion":3804,"start":6876,"enrollment":173,"conditions":11808,"interventions":11809},[93],[11789],[11770,11791],{"intervention":11811,"totalTrials":190,"cells":11812},"Ropivacaine 0.5% Injectable Solution",{"EARLY_PHASE1":11813,"PHASE1":11815,"PHASE2":11817,"PHASE3":11819,"PHASE4":11821,"NA":11823},{"trials":11814,"activeCount":100},[],{"trials":11816,"activeCount":100},[],{"trials":11818,"activeCount":100},[],{"trials":11820,"activeCount":100},[],{"trials":11822,"activeCount":100},[],{"trials":11824,"activeCount":100},[11825],{"nctId":11826,"briefTitle":11827,"status":294,"phases":11828,"primaryCompletion":1377,"completion":11829,"start":5432,"enrollment":100,"conditions":11830,"interventions":11832},"NCT04282239","Pectoral Nerves Block to Relieve Post-sternotomy Pain After Cardiac Surgery",[93],"2022-07",[5750,11831],"Cardiac Surgery",[11811,11833,11834],"Lidocaine Epinephrine","Dexmedetomidine 0.004 MG\u002FML",{"intervention":11833,"totalTrials":190,"cells":11836},{"EARLY_PHASE1":11837,"PHASE1":11839,"PHASE2":11841,"PHASE3":11843,"PHASE4":11845,"NA":11847},{"trials":11838,"activeCount":100},[],{"trials":11840,"activeCount":100},[],{"trials":11842,"activeCount":100},[],{"trials":11844,"activeCount":100},[],{"trials":11846,"activeCount":100},[],{"trials":11848,"activeCount":100},[11849],{"nctId":11826,"briefTitle":11827,"status":294,"phases":11850,"primaryCompletion":1377,"completion":11829,"start":5432,"enrollment":100,"conditions":11851,"interventions":11852},[93],[5750,11831],[11811,11833,11834],{"intervention":11834,"totalTrials":190,"cells":11854},{"EARLY_PHASE1":11855,"PHASE1":11857,"PHASE2":11859,"PHASE3":11861,"PHASE4":11863,"NA":11865},{"trials":11856,"activeCount":100},[],{"trials":11858,"activeCount":100},[],{"trials":11860,"activeCount":100},[],{"trials":11862,"activeCount":100},[],{"trials":11864,"activeCount":100},[],{"trials":11866,"activeCount":100},[11867],{"nctId":11826,"briefTitle":11827,"status":294,"phases":11868,"primaryCompletion":1377,"completion":11829,"start":5432,"enrollment":100,"conditions":11869,"interventions":11870},[93],[5750,11831],[11811,11833,11834],{"intervention":11872,"totalTrials":190,"cells":11873},"Omega-3 Fatty Acids",{"EARLY_PHASE1":11874,"PHASE1":11876,"PHASE2":11878,"PHASE3":11880,"PHASE4":11882,"NA":11884},{"trials":11875,"activeCount":100},[],{"trials":11877,"activeCount":100},[],{"trials":11879,"activeCount":100},[],{"trials":11881,"activeCount":100},[],{"trials":11883,"activeCount":100},[],{"trials":11885,"activeCount":100},[11886],{"nctId":11887,"briefTitle":11888,"status":119,"phases":11889,"primaryCompletion":11890,"completion":10459,"start":11891,"enrollment":3770,"conditions":11892,"interventions":11894},"NCT01315327","Omega-3 Fatty Acids in Tourette's Disorder",[93],"2006-02","2003-05",[11893],"Tourette's Disorder",[11872,11895],"Olive oil",{"intervention":11895,"totalTrials":190,"cells":11897},{"EARLY_PHASE1":11898,"PHASE1":11900,"PHASE2":11902,"PHASE3":11904,"PHASE4":11906,"NA":11908},{"trials":11899,"activeCount":100},[],{"trials":11901,"activeCount":100},[],{"trials":11903,"activeCount":100},[],{"trials":11905,"activeCount":100},[],{"trials":11907,"activeCount":100},[],{"trials":11909,"activeCount":100},[11910],{"nctId":11887,"briefTitle":11888,"status":119,"phases":11911,"primaryCompletion":11890,"completion":10459,"start":11891,"enrollment":3770,"conditions":11912,"interventions":11913},[93],[11893],[11872,11895],{"intervention":2751,"totalTrials":190,"cells":11915},{"EARLY_PHASE1":11916,"PHASE1":11918,"PHASE2":11920,"PHASE3":11922,"PHASE4":11924,"NA":11926},{"trials":11917,"activeCount":100},[],{"trials":11919,"activeCount":100},[],{"trials":11921,"activeCount":100},[],{"trials":11923,"activeCount":100},[],{"trials":11925,"activeCount":100},[],{"trials":11927,"activeCount":100},[11928],{"nctId":2743,"briefTitle":2744,"status":294,"phases":11929,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":100,"conditions":11930,"interventions":11931},[93],[2749],[77,2751,2752],{"intervention":2752,"totalTrials":190,"cells":11933},{"EARLY_PHASE1":11934,"PHASE1":11936,"PHASE2":11938,"PHASE3":11940,"PHASE4":11942,"NA":11944},{"trials":11935,"activeCount":100},[],{"trials":11937,"activeCount":100},[],{"trials":11939,"activeCount":100},[],{"trials":11941,"activeCount":100},[],{"trials":11943,"activeCount":100},[],{"trials":11945,"activeCount":100},[11946],{"nctId":2743,"briefTitle":2744,"status":294,"phases":11947,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":100,"conditions":11948,"interventions":11949},[93],[2749],[77,2751,2752],{"intervention":11951,"totalTrials":190,"cells":11952},"Technology based monitoring and behavioral participation",{"EARLY_PHASE1":11953,"PHASE1":11955,"PHASE2":11957,"PHASE3":11959,"PHASE4":11961,"NA":11963},{"trials":11954,"activeCount":100},[],{"trials":11956,"activeCount":100},[],{"trials":11958,"activeCount":100},[],{"trials":11960,"activeCount":100},[],{"trials":11962,"activeCount":100},[],{"trials":11964,"activeCount":100},[11965],{"nctId":11966,"briefTitle":11967,"status":119,"phases":11968,"primaryCompletion":11969,"completion":11969,"start":11970,"enrollment":461,"conditions":11971,"interventions":11974},"NCT03581006","Food Intake REstriction for Health OUtcome Support and Education (FIREHOUSE) Trial",[],"2021-03-04","2018-11-12",[11972,11973],"Lung Injury","Particulate Matter Inhalation Injury",[11951],{"intervention":11976,"totalTrials":190,"cells":11977},"Ibuprofen 600 mg",{"EARLY_PHASE1":11978,"PHASE1":11980,"PHASE2":11982,"PHASE3":11984,"PHASE4":11986,"NA":11988},{"trials":11979,"activeCount":100},[],{"trials":11981,"activeCount":100},[],{"trials":11983,"activeCount":100},[],{"trials":11985,"activeCount":100},[],{"trials":11987,"activeCount":100},[],{"trials":11989,"activeCount":100},[11990],{"nctId":11991,"briefTitle":11992,"status":119,"phases":11993,"primaryCompletion":4112,"completion":4112,"start":11994,"enrollment":11995,"conditions":11996,"interventions":11999},"NCT02915055","NSAID vs. Narcotics",[],"2016-09-01",77,[11997,11998],"Multimodal Analgesia","Nonsteroidal Anti-inflammatory Drugs",[11976,12000],"standard oxycodone\u002Facetaminophen",{"intervention":12000,"totalTrials":190,"cells":12002},{"EARLY_PHASE1":12003,"PHASE1":12005,"PHASE2":12007,"PHASE3":12009,"PHASE4":12011,"NA":12013},{"trials":12004,"activeCount":100},[],{"trials":12006,"activeCount":100},[],{"trials":12008,"activeCount":100},[],{"trials":12010,"activeCount":100},[],{"trials":12012,"activeCount":100},[],{"trials":12014,"activeCount":100},[12015],{"nctId":11991,"briefTitle":11992,"status":119,"phases":12016,"primaryCompletion":4112,"completion":4112,"start":11994,"enrollment":11995,"conditions":12017,"interventions":12018},[],[11997,11998],[11976,12000],{"intervention":12020,"totalTrials":190,"cells":12021},"aldesleukin",{"EARLY_PHASE1":12022,"PHASE1":12024,"PHASE2":12026,"PHASE3":12028,"PHASE4":12030,"NA":12032},{"trials":12023,"activeCount":100},[],{"trials":12025,"activeCount":100},[],{"trials":12027,"activeCount":100},[],{"trials":12029,"activeCount":100},[],{"trials":12031,"activeCount":100},[],{"trials":12033,"activeCount":100},[12034],{"nctId":12035,"briefTitle":12036,"status":119,"phases":12037,"primaryCompletion":12038,"start":7194,"conditions":12039,"interventions":12040},"NCT00899821","Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer",[93],"2004-12",[11512],[12020,12041,12042],"recombinant interleukin-12","sargramostim",{"intervention":12041,"totalTrials":190,"cells":12044},{"EARLY_PHASE1":12045,"PHASE1":12047,"PHASE2":12049,"PHASE3":12051,"PHASE4":12053,"NA":12055},{"trials":12046,"activeCount":100},[],{"trials":12048,"activeCount":100},[],{"trials":12050,"activeCount":100},[],{"trials":12052,"activeCount":100},[],{"trials":12054,"activeCount":100},[],{"trials":12056,"activeCount":100},[12057],{"nctId":12035,"briefTitle":12036,"status":119,"phases":12058,"primaryCompletion":12038,"start":7194,"conditions":12059,"interventions":12060},[93],[11512],[12020,12041,12042],{"intervention":12042,"totalTrials":190,"cells":12062},{"EARLY_PHASE1":12063,"PHASE1":12065,"PHASE2":12067,"PHASE3":12069,"PHASE4":12071,"NA":12073},{"trials":12064,"activeCount":100},[],{"trials":12066,"activeCount":100},[],{"trials":12068,"activeCount":100},[],{"trials":12070,"activeCount":100},[],{"trials":12072,"activeCount":100},[],{"trials":12074,"activeCount":100},[12075],{"nctId":12035,"briefTitle":12036,"status":119,"phases":12076,"primaryCompletion":12038,"start":7194,"conditions":12077,"interventions":12078},[93],[11512],[12020,12041,12042],{"intervention":12080,"totalTrials":190,"cells":12081},"Estrace",{"EARLY_PHASE1":12082,"PHASE1":12084,"PHASE2":12086,"PHASE3":12088,"PHASE4":12090,"NA":12092},{"trials":12083,"activeCount":100},[],{"trials":12085,"activeCount":100},[],{"trials":12087,"activeCount":100},[],{"trials":12089,"activeCount":100},[],{"trials":12091,"activeCount":100},[],{"trials":12093,"activeCount":100},[12094],{"nctId":12095,"briefTitle":12096,"status":119,"phases":12097,"primaryCompletion":12098,"completion":12098,"start":12099,"enrollment":12100,"conditions":12101,"interventions":12102},"NCT04544475","A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause",[93],"2022-10-03","2021-09-01",49,[11741],[12080],{"intervention":12104,"totalTrials":190,"cells":12105},"Atomoxetine",{"EARLY_PHASE1":12106,"PHASE1":12108,"PHASE2":12110,"PHASE3":12112,"PHASE4":12114,"NA":12116},{"trials":12107,"activeCount":100},[],{"trials":12109,"activeCount":100},[],{"trials":12111,"activeCount":100},[],{"trials":12113,"activeCount":100},[],{"trials":12115,"activeCount":100},[],{"trials":12117,"activeCount":100},[12118],{"nctId":12119,"briefTitle":12120,"status":119,"phases":12121,"primaryCompletion":12122,"completion":12122,"start":6589,"enrollment":124,"conditions":12123,"interventions":12124},"NCT00953862","Atomoxetine\u002FAttention Deficit\u002F Hyperactive Disorder (ADHD)\u002FSubstance Use Disorder (SUD)in a Residential Treatment Facility",[93],"2008-04",[5573],[12104],{"intervention":12126,"totalTrials":190,"cells":12127},"NPA radiotracer",{"EARLY_PHASE1":12128,"PHASE1":12130,"PHASE2":12132,"PHASE3":12134,"PHASE4":12136,"NA":12138},{"trials":12129,"activeCount":100},[],{"trials":12131,"activeCount":100},[],{"trials":12133,"activeCount":100},[],{"trials":12135,"activeCount":100},[],{"trials":12137,"activeCount":100},[],{"trials":12139,"activeCount":100},[12140],{"nctId":12141,"briefTitle":12142,"status":294,"phases":12143,"primaryCompletion":12144,"completion":12144,"start":6407,"enrollment":100,"conditions":12145,"interventions":12146},"NCT03999190","Imaging Dopamine D2 Agonist Binding Sites in Schizophrenia",[],"2025-07",[4329],[12126,12147,12148],"Raclopride radiotracer","Dextroamphetamine",{"intervention":12147,"totalTrials":190,"cells":12150},{"EARLY_PHASE1":12151,"PHASE1":12153,"PHASE2":12155,"PHASE3":12157,"PHASE4":12159,"NA":12161},{"trials":12152,"activeCount":100},[],{"trials":12154,"activeCount":100},[],{"trials":12156,"activeCount":100},[],{"trials":12158,"activeCount":100},[],{"trials":12160,"activeCount":100},[],{"trials":12162,"activeCount":100},[12163],{"nctId":12141,"briefTitle":12142,"status":294,"phases":12164,"primaryCompletion":12144,"completion":12144,"start":6407,"enrollment":100,"conditions":12165,"interventions":12166},[],[4329],[12126,12147,12148],{"intervention":12148,"totalTrials":190,"cells":12168},{"EARLY_PHASE1":12169,"PHASE1":12171,"PHASE2":12173,"PHASE3":12175,"PHASE4":12177,"NA":12179},{"trials":12170,"activeCount":100},[],{"trials":12172,"activeCount":100},[],{"trials":12174,"activeCount":100},[],{"trials":12176,"activeCount":100},[],{"trials":12178,"activeCount":100},[],{"trials":12180,"activeCount":100},[12181],{"nctId":12141,"briefTitle":12142,"status":294,"phases":12182,"primaryCompletion":12144,"completion":12144,"start":6407,"enrollment":100,"conditions":12183,"interventions":12184},[],[4329],[12126,12147,12148],{"intervention":12186,"totalTrials":190,"cells":12187},"Phenylephrine",{"EARLY_PHASE1":12188,"PHASE1":12190,"PHASE2":12192,"PHASE3":12194,"PHASE4":12196,"NA":12198},{"trials":12189,"activeCount":100},[],{"trials":12191,"activeCount":100},[],{"trials":12193,"activeCount":100},[],{"trials":12195,"activeCount":100},[],{"trials":12197,"activeCount":100},[],{"trials":12199,"activeCount":100},[12200],{"nctId":12201,"briefTitle":12202,"status":119,"phases":12203,"primaryCompletion":3626,"completion":4462,"start":1506,"enrollment":12204,"conditions":12205,"interventions":12209},"NCT02701582","Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients",[93],66,[12206,12207,3269,12208],"Intracranial Aneurysm","Brain Edema","Surgery",[12186,12210],"Epinephrine",{"intervention":12210,"totalTrials":190,"cells":12212},{"EARLY_PHASE1":12213,"PHASE1":12215,"PHASE2":12217,"PHASE3":12219,"PHASE4":12221,"NA":12223},{"trials":12214,"activeCount":100},[],{"trials":12216,"activeCount":100},[],{"trials":12218,"activeCount":100},[],{"trials":12220,"activeCount":100},[],{"trials":12222,"activeCount":100},[],{"trials":12224,"activeCount":100},[12225],{"nctId":12201,"briefTitle":12202,"status":119,"phases":12226,"primaryCompletion":3626,"completion":4462,"start":1506,"enrollment":12204,"conditions":12227,"interventions":12228},[93],[12206,12207,3269,12208],[12186,12210],{"intervention":12230,"totalTrials":190,"cells":12231},"intravenous continuous infusion of heparin",{"EARLY_PHASE1":12232,"PHASE1":12234,"PHASE2":12236,"PHASE3":12238,"PHASE4":12240,"NA":12242},{"trials":12233,"activeCount":100},[],{"trials":12235,"activeCount":100},[],{"trials":12237,"activeCount":100},[],{"trials":12239,"activeCount":100},[],{"trials":12241,"activeCount":100},[],{"trials":12243,"activeCount":100},[12244],{"nctId":12245,"briefTitle":12246,"status":294,"phases":12247,"primaryCompletion":12248,"completion":12248,"start":10327,"enrollment":100,"conditions":12249,"interventions":12251},"NCT02707263","Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients",[93],"2017-04",[12250],"Venous Thromboembolism",[12230,12252],"Subcutaneous Heparin",{"intervention":12252,"totalTrials":190,"cells":12254},{"EARLY_PHASE1":12255,"PHASE1":12257,"PHASE2":12259,"PHASE3":12261,"PHASE4":12263,"NA":12265},{"trials":12256,"activeCount":100},[],{"trials":12258,"activeCount":100},[],{"trials":12260,"activeCount":100},[],{"trials":12262,"activeCount":100},[],{"trials":12264,"activeCount":100},[],{"trials":12266,"activeCount":100},[12267],{"nctId":12245,"briefTitle":12246,"status":294,"phases":12268,"primaryCompletion":12248,"completion":12248,"start":10327,"enrollment":100,"conditions":12269,"interventions":12270},[93],[12250],[12230,12252],{"intervention":11318,"totalTrials":190,"cells":12272},{"EARLY_PHASE1":12273,"PHASE1":12275,"PHASE2":12277,"PHASE3":12279,"PHASE4":12281,"NA":12283},{"trials":12274,"activeCount":100},[],{"trials":12276,"activeCount":100},[],{"trials":12278,"activeCount":100},[],{"trials":12280,"activeCount":100},[],{"trials":12282,"activeCount":100},[],{"trials":12284,"activeCount":100},[12285],{"nctId":11311,"briefTitle":11312,"status":119,"phases":12286,"primaryCompletion":111,"completion":111,"start":4327,"enrollment":335,"conditions":12287,"interventions":12288},[93],[1446,11315,11316],[11318,11319],{"intervention":12290,"totalTrials":190,"cells":12291},"LCD Intervention",{"EARLY_PHASE1":12292,"PHASE1":12294,"PHASE2":12296,"PHASE3":12298,"PHASE4":12300,"NA":12302},{"trials":12293,"activeCount":100},[],{"trials":12295,"activeCount":100},[],{"trials":12297,"activeCount":100},[],{"trials":12299,"activeCount":100},[],{"trials":12301,"activeCount":100},[],{"trials":12303,"activeCount":100},[12304],{"nctId":12305,"briefTitle":12306,"status":108,"phases":12307,"primaryCompletion":12308,"completion":12309,"start":12310,"enrollment":8277,"conditions":12311,"interventions":12312},"NCT04015011","Effects of a Three-Month Low Calorie Diet Weight Loss Intervention on Knee Replacement Outcomes",[93],"2020-06-30","2021-09-30","2019-07-25",[27],[12290],{"intervention":12314,"totalTrials":190,"cells":12315},"Enoxaparin",{"EARLY_PHASE1":12316,"PHASE1":12318,"PHASE2":12320,"PHASE3":12322,"PHASE4":12324,"NA":12326},{"trials":12317,"activeCount":100},[],{"trials":12319,"activeCount":100},[],{"trials":12321,"activeCount":100},[],{"trials":12323,"activeCount":100},[],{"trials":12325,"activeCount":100},[],{"trials":12327,"activeCount":100},[12328],{"nctId":12329,"briefTitle":12330,"status":108,"phases":12331,"primaryCompletion":4064,"completion":4327,"start":12332,"enrollment":268,"conditions":12333,"interventions":12335},"NCT00836355","Enoxaparin and\u002For Minocycline in Acute Stroke",[93],"2009-04",[12334],"Acute Ischemic Stroke",[12314,12336],"Minocycline",{"intervention":12336,"totalTrials":190,"cells":12338},{"EARLY_PHASE1":12339,"PHASE1":12341,"PHASE2":12343,"PHASE3":12345,"PHASE4":12347,"NA":12349},{"trials":12340,"activeCount":100},[],{"trials":12342,"activeCount":100},[],{"trials":12344,"activeCount":100},[],{"trials":12346,"activeCount":100},[],{"trials":12348,"activeCount":100},[],{"trials":12350,"activeCount":100},[12351],{"nctId":12329,"briefTitle":12330,"status":108,"phases":12352,"primaryCompletion":4064,"completion":4327,"start":12332,"enrollment":268,"conditions":12353,"interventions":12354},[93],[12334],[12314,12336],{"intervention":12356,"totalTrials":190,"cells":12357},"Dexmedetomidine group",{"EARLY_PHASE1":12358,"PHASE1":12360,"PHASE2":12362,"PHASE3":12364,"PHASE4":12366,"NA":12368},{"trials":12359,"activeCount":100},[],{"trials":12361,"activeCount":100},[],{"trials":12363,"activeCount":100},[],{"trials":12365,"activeCount":100},[],{"trials":12367,"activeCount":100},[],{"trials":12369,"activeCount":100},[12370],{"nctId":12371,"briefTitle":12372,"status":108,"phases":12373,"primaryCompletion":11176,"completion":11176,"start":6876,"enrollment":12204,"conditions":12374,"interventions":12376},"NCT01377623","Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion",[93],[12375,3113],"Spinal Stenosis",[12356],{"intervention":12378,"totalTrials":190,"cells":12379},"Armodafinil",{"EARLY_PHASE1":12380,"PHASE1":12382,"PHASE2":12384,"PHASE3":12386,"PHASE4":12388,"NA":12390},{"trials":12381,"activeCount":100},[],{"trials":12383,"activeCount":100},[],{"trials":12385,"activeCount":100},[],{"trials":12387,"activeCount":100},[],{"trials":12389,"activeCount":100},[],{"trials":12391,"activeCount":100},[12392],{"nctId":12393,"briefTitle":12394,"status":294,"phases":12395,"primaryCompletion":12396,"completion":12396,"start":805,"enrollment":100,"conditions":12397,"interventions":12400},"NCT01256905","Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies",[93],"2011-08-08",[12398,12399],"Parkinsons Disease","Lewy Bodies Disease",[12378],{"intervention":12402,"totalTrials":190,"cells":12403},"Low bicarbonate dialysate First",{"EARLY_PHASE1":12404,"PHASE1":12406,"PHASE2":12408,"PHASE3":12410,"PHASE4":12412,"NA":12414},{"trials":12405,"activeCount":100},[],{"trials":12407,"activeCount":100},[],{"trials":12409,"activeCount":100},[],{"trials":12411,"activeCount":100},[],{"trials":12413,"activeCount":100},[],{"trials":12415,"activeCount":100},[12416],{"nctId":12417,"briefTitle":12418,"status":294,"phases":12419,"primaryCompletion":12420,"completion":12420,"start":3626,"enrollment":100,"conditions":12421,"interventions":12424},"NCT02639624","Altering Bicarbonate Delivery During Hemodialysis to Affect Filtration of Indoxyl Sulfate",[93],"2017-07-01",[12422,12423],"Renal Dialysis","Hemodialysis",[12402,12425,12426,12427],"Normal bicarbonate dialysate First","Normal bicarbonate dialysate","Low bicarbonate dialysate",{"intervention":12425,"totalTrials":190,"cells":12429},{"EARLY_PHASE1":12430,"PHASE1":12432,"PHASE2":12434,"PHASE3":12436,"PHASE4":12438,"NA":12440},{"trials":12431,"activeCount":100},[],{"trials":12433,"activeCount":100},[],{"trials":12435,"activeCount":100},[],{"trials":12437,"activeCount":100},[],{"trials":12439,"activeCount":100},[],{"trials":12441,"activeCount":100},[12442],{"nctId":12417,"briefTitle":12418,"status":294,"phases":12443,"primaryCompletion":12420,"completion":12420,"start":3626,"enrollment":100,"conditions":12444,"interventions":12445},[93],[12422,12423],[12402,12425,12426,12427],{"intervention":12426,"totalTrials":190,"cells":12447},{"EARLY_PHASE1":12448,"PHASE1":12450,"PHASE2":12452,"PHASE3":12454,"PHASE4":12456,"NA":12458},{"trials":12449,"activeCount":100},[],{"trials":12451,"activeCount":100},[],{"trials":12453,"activeCount":100},[],{"trials":12455,"activeCount":100},[],{"trials":12457,"activeCount":100},[],{"trials":12459,"activeCount":100},[12460],{"nctId":12417,"briefTitle":12418,"status":294,"phases":12461,"primaryCompletion":12420,"completion":12420,"start":3626,"enrollment":100,"conditions":12462,"interventions":12463},[93],[12422,12423],[12402,12425,12426,12427],{"intervention":12427,"totalTrials":190,"cells":12465},{"EARLY_PHASE1":12466,"PHASE1":12468,"PHASE2":12470,"PHASE3":12472,"PHASE4":12474,"NA":12476},{"trials":12467,"activeCount":100},[],{"trials":12469,"activeCount":100},[],{"trials":12471,"activeCount":100},[],{"trials":12473,"activeCount":100},[],{"trials":12475,"activeCount":100},[],{"trials":12477,"activeCount":100},[12478],{"nctId":12417,"briefTitle":12418,"status":294,"phases":12479,"primaryCompletion":12420,"completion":12420,"start":3626,"enrollment":100,"conditions":12480,"interventions":12481},[93],[12422,12423],[12402,12425,12426,12427],{"intervention":12483,"totalTrials":190,"cells":12484},"Dexamethasone or other corticosteroid",{"EARLY_PHASE1":12485,"PHASE1":12487,"PHASE2":12489,"PHASE3":12491,"PHASE4":12493,"NA":12495},{"trials":12486,"activeCount":100},[],{"trials":12488,"activeCount":100},[],{"trials":12490,"activeCount":100},[],{"trials":12492,"activeCount":100},[],{"trials":12494,"activeCount":100},[],{"trials":12496,"activeCount":100},[12497],{"nctId":12498,"briefTitle":12499,"status":119,"phases":12500,"primaryCompletion":1808,"completion":12501,"start":2840,"enrollment":2733,"conditions":12502,"interventions":12505},"NCT00007358","Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus",[93],"2008-10",[808,809,12503,12504],"Atrioventricular Nodal Dysfunction","Myocardial Injury",[12483],{"intervention":12507,"totalTrials":190,"cells":12508},"Vitamin D2",{"EARLY_PHASE1":12509,"PHASE1":12511,"PHASE2":12513,"PHASE3":12515,"PHASE4":12517,"NA":12519},{"trials":12510,"activeCount":100},[],{"trials":12512,"activeCount":100},[],{"trials":12514,"activeCount":100},[],{"trials":12516,"activeCount":100},[],{"trials":12518,"activeCount":100},[],{"trials":12520,"activeCount":100},[12521],{"nctId":12522,"briefTitle":12523,"status":119,"phases":12524,"primaryCompletion":6118,"completion":6118,"start":945,"enrollment":2797,"conditions":12525,"interventions":12527},"NCT02414529","Efficacy of Vitamin D Therapy on Glucose Homeostasis in Obese Adolescents",[93],[12526],"Vitamin D Deficiency",[12507],{"intervention":12529,"totalTrials":190,"cells":12530},"Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges",{"EARLY_PHASE1":12531,"PHASE1":12533,"PHASE2":12535,"PHASE3":12537,"PHASE4":12539,"NA":12541},{"trials":12532,"activeCount":100},[],{"trials":12534,"activeCount":100},[],{"trials":12536,"activeCount":100},[],{"trials":12538,"activeCount":100},[],{"trials":12540,"activeCount":100},[],{"trials":12542,"activeCount":100},[12543],{"nctId":12544,"briefTitle":12545,"status":119,"phases":12546,"primaryCompletion":12547,"completion":12547,"start":12548,"enrollment":2733,"conditions":12549,"interventions":12550},"NCT05130788","WeChat Quit Coach Pilot Study",[93],"2025-01-15","2022-02-10",[11216],[12529],{"intervention":12552,"totalTrials":190,"cells":12553},"Fluticasone propionate 230mcg for 3 Months",{"EARLY_PHASE1":12554,"PHASE1":12556,"PHASE2":12558,"PHASE3":12560,"PHASE4":12562,"NA":12564},{"trials":12555,"activeCount":100},[],{"trials":12557,"activeCount":100},[],{"trials":12559,"activeCount":100},[],{"trials":12561,"activeCount":100},[],{"trials":12563,"activeCount":100},[],{"trials":12565,"activeCount":100},[12566],{"nctId":12567,"briefTitle":12568,"status":119,"phases":12569,"primaryCompletion":12570,"completion":12570,"start":12571,"enrollment":682,"conditions":12572,"interventions":12575},"NCT02024204","Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program",[93],"2017-05-17","2014-04-09",[12573,12574],"Lung Diseases","Medication Compliance",[12552,12576,12577],"Current Treatment or no treatment","Salmeterol 21mcg for 3 Months",{"intervention":12576,"totalTrials":190,"cells":12579},{"EARLY_PHASE1":12580,"PHASE1":12582,"PHASE2":12584,"PHASE3":12586,"PHASE4":12588,"NA":12590},{"trials":12581,"activeCount":100},[],{"trials":12583,"activeCount":100},[],{"trials":12585,"activeCount":100},[],{"trials":12587,"activeCount":100},[],{"trials":12589,"activeCount":100},[],{"trials":12591,"activeCount":100},[12592],{"nctId":12567,"briefTitle":12568,"status":119,"phases":12593,"primaryCompletion":12570,"completion":12570,"start":12571,"enrollment":682,"conditions":12594,"interventions":12595},[93],[12573,12574],[12552,12576,12577],{"intervention":12577,"totalTrials":190,"cells":12597},{"EARLY_PHASE1":12598,"PHASE1":12600,"PHASE2":12602,"PHASE3":12604,"PHASE4":12606,"NA":12608},{"trials":12599,"activeCount":100},[],{"trials":12601,"activeCount":100},[],{"trials":12603,"activeCount":100},[],{"trials":12605,"activeCount":100},[],{"trials":12607,"activeCount":100},[],{"trials":12609,"activeCount":100},[12610],{"nctId":12567,"briefTitle":12568,"status":119,"phases":12611,"primaryCompletion":12570,"completion":12570,"start":12571,"enrollment":682,"conditions":12612,"interventions":12613},[93],[12573,12574],[12552,12576,12577],{"intervention":12615,"totalTrials":190,"cells":12616},"Rocuronium Bromide, Cisatracurium Besylate",{"EARLY_PHASE1":12617,"PHASE1":12619,"PHASE2":12621,"PHASE3":12623,"PHASE4":12625,"NA":12627},{"trials":12618,"activeCount":100},[],{"trials":12620,"activeCount":100},[],{"trials":12622,"activeCount":100},[],{"trials":12624,"activeCount":100},[],{"trials":12626,"activeCount":100},[],{"trials":12628,"activeCount":100},[12629],{"nctId":12630,"briefTitle":12631,"status":119,"phases":12632,"primaryCompletion":12633,"completion":12633,"start":12634,"enrollment":3244,"conditions":12635,"interventions":12637},"NCT02285829","Determination of TOF Test Threshold for Obtaining Reliable Pedicle Screw Stimulation Test During Lumbar Spine Surgery",[],"2018-01-08","2015-02-11",[12636],"Neuromuscular Blockade",[12615]]